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Abstract 
 
The VGF neurosecretory protein, first identified as a nerve growth factor (NGF) 
inducible gene product, is selectively synthesised predominantly in neuronal and 
neuroendocrine cells. The ~68 kDa VGF protein sequence is rich in paired basic 
amino acids, and thus the protein undergoes endoproteolytic cleavage to produce 
smaller peptides, which are stored in dense core vesicles and released upon 
stimulation via the regulated secretory pathway both in vitro and in vivo. Several of 
these VGF-derived peptides have been characterised and are involved in energy 
homeostasis, reproductive processes, synaptic plasticity as well as pain modulation. A 
number of studies have observed an increase in VGF gene expression in various pain 
models and more recently the VGF-derived peptides, TLQP-21, LQEQ-19 and 
TLQP-62 showed direct modulation of inflammatory and neuropathic pain when 
applied in vivo. The molecular mechanisms of action of VGF-derived peptides are not 
well understood and were investigated in this study.  The TLQP-21 peptide, but not 
LQEQ-19, was shown to dose-dependently induce an increase in intracellular Ca2+ 
levels from cellular internal stores in brain- and spinal cord-derived primary 
microglia, in >65 % of the cell population in vitro. Three hour treatment of primary 
microglia with TLQP-21 (100 nM) induced a 2.78 fold increase in Ccl11 and a 2.28 
fold decrease in Cxcl9 gene expression levels relative to the vehicle control (Student's 
t-test; p ≤ 0.05). Biochemical analysis using affinity chromatography and LC-MS/MS 
techniques identified the gC1q-R protein as a potential binding partner / receptor for 
TLQP-21. The gC1q-R protein is a ubiquitously expressed, multi-compartmental 
protein involved in complement activation, inflammatory processes and the plasma 
bradykinin formation pathway. These results tentatively suggest that TLQP-21 may 
contribute to the modulation of pain through activation of primary microglia and 
potentially involve interactions with components of the complement system. The 
findings highlight the importance of VGF-derived peptides in pain research and could 
lead to new perspectives and targets for pain therapeutics. 
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Introduction 
 
Pain 
 
Definitions and classification 
  
Pain is defined as an unpleasant, subjective sensory and emotional experience 
resulting from actual or potential tissue damage.  It is a protective mechanism that 
allows us to remove ourselves from potentially harmful situations and noxious 
stimuli, thus preventing further damage and allowing the healing process to proceed. 
Pain is a perception, which is both urgent and primitive, thus it must also be 
considered in the emotional context and so can be highly subjective. This emotional 
dimension, combined with the complex interplay of neuronal and non-neuronal cells 
and tissues following noxious stimulation, make pain difficult to define as well as 
treat clinically (Kandel et al., 2000).  
Pain can very broadly be classed as acute and chronic. Acute pain occurs in response 
to an intense or noxious stimulus resulting in a rapid response, which is resolved 
following removal of the stimuli (e.g. withdrawal following contact with a hot 
surface). Chronic pain, however, is more persistent and can last from months to years 
(often exceeding resolution of tissue damage) and does not serve a biological 
function. Generally chronic pain is characterised by allodynia (pain evoked by a 
normally innocuous stimulus) and hyperalgesia (an increased response to a noxious 
stimulus) and has a significant impact on the quality of life of patients by inducing 
depression and anxiety. Hyperalgesia and allodynia are a result of sensitisation events, 
which involve increased responsiveness of nociceptors by decreasing activation 
thresholds (sub-threshold response) and/or increased firing after stimulation.  
As well as classification by temporal features, pain states are also designated by the 
cause. Nociceptive pain occurs after detection of noxious stimuli by a particular 
subset of sensory neurons known as nociceptors. These sensory receptors can detect 
thermal, mechanical or chemical stimuli, which is followed by a transfer of action 
potentials to the spinal cord via dorsal root ganglia (DRG) and onward to the brain. 
Minor tissue damage, as well as infections and burns can lead to inflammatory pain, 
which is mediated by a mixture of inflammatory chemicals such as IL-6, TNFα and 
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cyclooygenase enzymes. Neuropathic pain results from malfunction or damage (by 
lesions or disease) to the nervous system and involves sensitisation of neurons in the 
PNS and CNS and is often associated with hyperalgesia and allodynia. Some 
conditions that induce neuropathic pain include spinal cord injury, diabetic 
neuropathies, viral infections and cancer (direct actions of tumour on nerves or side 
effects of chemotherapy).  
Acute nociceptive and inflammatory pain normally respond well to treatments with 
pain killers such as opioids, paracetamol and NSAIDs. However, treatment of chronic 
pain represents a major challenge and thus far drugs and medication (e.g. gabapentin, 
pregabalin and opioids) are unable to abolish severe persistent pain, they can only 
alleviate symptoms in some of the patients (O'Connor and Dworkin, 2009). One of the 
challenges for clinicians as well as researchers is that chronic pain can involve both 
neuropathic and inflammatory elements. For example, nerve injury can induce an 
inflammatory reaction causing both neuropathic and inflammatory pain. Inflammatory 
nociceptive pain, moreover, could cause damage to neurons by inflammation, leading 
to neuropathic pain. An increased understanding of the molecular mechanisms of 
action of pain and its mediators (e.g. inflammatory cytokines, neuropeptides, etc.) will 
greatly aid development of treatments for these, often debilitating, chronic pain 
conditions.  
 
Dorsal Root Ganglia (DRG)- neurons and nociception 
 
Following tissue or peripheral nerve damage, nociceptors are activated and action 
potentials are transmitted along sensory (afferent) neurons, whose cell bodies are 
located in dorsal root ganglia (DRG). Sensory information transmitted along DRG 
neuron axons travels to the dorsal horn of the spinal cord, where the nociceptive 
message is relayed from the peripheral nervous system (PNS) to the central nervous 
system (CNS). This occurs through synaptic transmission between pre-synaptic 
nociceptor neurons and post-synaptic dorsal horn nerve fibres using neurotransmitters, 
in particular glutamate and neuropeptides (Kandel et al., 2000). From here, the 
nociceptive signal is conveyed from the spinal cord to the thalamus and sensory areas 
of the cerebral cortex via five major ascending pathways, allowing for the perception 
of pain in the brain. As well as transduction of acute nociceptive pain signals, DRG 
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neurons contribute to the development and/or maintenance of allodynia and 
hyperalgesia in chronic pain conditions.  
The peripheral axonal branches of DRG neurons mostly have free nerve endings 
(nociceptors), which are located just below the skin, subcutaneous tissue such as 
joints and muscle or viscera, whereas the central axonal branches of DRG neurons 
enter the spinal cord. Thus, DRG neurons are pseudo-unipolar as they have one axon 
with two branches: a peripheral branch as well as a central branch.  
Two types of DRG sensory neurons are responsible for nociception in the PNS. 
Thinly myelinated, medium diameter Aδ fibre neurons are responsible for acute pain, 
and with conduction speeds of about 5-35 m/s, are responsible for the first, sharp pain 
felt after thermal and mechanical insult. In contrast, small diameter, unmyelinated C 
fibres are responsible for chronic pain, with conduction velocities of 0.5-2 m/s and are 
responsible for the secondary burning sensations felt after noxious thermal, 
mechanical and chemical stimuli. Myelinated, large diameter Aβ fibres, on the other 
hand, are responsible for low-threshold mechanosensitivity, i.e. touch (Kandel et al., 
2000).  
The conversion of thermal, mechanical and chemical energy from noxious insults into 
a change in excitability in the membranes of nociceptor terminals is thought to be due 
to receptors and channels located in these neurons. Receptors and channels localised 
on primary afferent fibres include the transient receptor potential (TRP) channel 
family, the ATP gated P2X receptor family and the voltage gated potassium, calcium 
and sodium channel families. At the site of injury or tissue damage, a number of 
inflammatory mediators are released, including ATP, nerve growth factor (NGF) and 
brain derived neurotrophic factor (BDNF), TNFα and IL-1β. These can directly act on 
neurons and nociceptors as well as stimulate the release of natural chemicals and 
neuropeptides (e.g. substance P, CGRP, histamine, etc.) that activate or increase the 
sensitivity of nociceptors and neurons to painful stimuli (McMahon, 1996).  
 
Glia, immune cells and pain 
 
Neuropathic pain management currently is focused on reducing neuron excitability 
through modulation of ion channel activity (e.g. gabapentin, lidocaine) or mimicking 
inhibitory mechanism (e.g. tricyclic antidepressants, opioids), which mainly aim at 
reducing symptoms (Dworkin et al., 2003). Pain is often regarded as a consequence of 
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changes in neuronal activity and sensitivity, and while this is true for acute 
nociceptive pain, it is becoming increasingly clear that non-neuronal cells (immune 
and glial cells) also play a part in the establishment and maintenance of common 
chronic neuropathic pain states. In the periphery, neuropathic pain development 
involves Schwann cells, satellite cells in the DRG and peripheral immune cells 
including macrophages, neutrophils, T lymphocytes and mast cells. At the level of the 
central nervous system (CNS), microglia and astrocytes take over this role in neuro-
glial interactions (Scholz and Woolf, 2007). As well as contributing to the generation 
of neuropathic pain, some immune cells secrete analgesic mediators, including anti-
inflammatory mediators and immune-derived opioids, which help alleviate 
neuropathic pain (Machelska, 2011). Thus modulation of glial and particularly 
immune cell responses in chronic pain conditions represent a viable target for pain 
management. 
Following peripheral nerve injury, neutrophils and macrophages are the first cells to 
participate in the immune response. These immune cells are attracted to the site of 
nerve injury by various chemical mediators, which are thought to be released by 
primary afferent fibres. After nerve injury, as well as transmitting information to the 
CNS, primary afferent fibres also release neurotransmitters and other chemical 
mediators in peripheral sites, including NGF, BDNF, ATP, substance P and calcitonin 
gene-related peptide (CGRP), which help promote vascular leakage and infiltration of 
immune cells (Wall et al., 2006). Neutrophils have been shown to accumulate at the 
site of nerve injury and are important in the early generation of hyperalgesia. The 
neutrophils are also depleted quite early on (8 days post-sciatic nerve transection), and 
this depletion does not alleviate hyperalgesia, suggesting that these cells play a role in 
generation, but not persistence of chronic pain (Perkins and Tracey, 2000). These 
neutrophils release chemokines and cytokines, which may enhance the recruitment of 
macrophages to the site of injury, something already initiated by injured nerve 
signalling.  
Macrophages are recruited to the site of peripheral nerve injury almost immediately, 
with resident macrophages being the first to access the lesion site (Mueller et al., 
2001). A number of chemical mediators have been identified, which recruit and 
activate macrophages including (but not limited to) the chemokines CCL2 and CCL3 
(Perrin et al., 2005), fractalkine (Zhuang et al., 2007), bradykinin, substance P, nitric 
oxide and CGRP, and are released from injured axons (Zochodne et al., 1999). Many 
 18
of these mediators also cause vascular changes, which cause the invasion of other 
immune cells (including more macrophages, mast cells and T cells) from the blood 
vessels to the lesion site. Once activated, these macrophages, along with Schwann 
cell, take part in Wallerian degeneration of damaged nerves. However, macrophages, 
neutrophils and other recruited immune cells release prostaglandins, some anti-
inflammatory cytokines such as IL-10 and TGF-β1 and pro-inflammatory cytokines 
including IL-1β, IL-6, interferon γ (IFNγ) and TNFα. These chemical mediators 
further recruit and activate more immune cells in a positive feedback mechanism, 
however, pro-inflammatory cytokines can also increase nociceptor sensitivity as well 
as contribute to further axonal damage. Additionally, some cytokines, such as LIF and 
IL-6, can modulate expression and synthesis of neuropeptide transmitters in sensory 
neurons (Scholz and Woolf, 2007). Signalling pathways between primary sensory 
neurons and peripheral immune cells are highly interconnected, with cytokines, 
chemokines, neurotrophins and neuropeptides as central components in this complex 
network.  
Following peripheral nerve injury, microglia and astrocyte activation and proliferation 
are observed in the CNS, particularly in the spinal cord. Astrocytes have been 
observed to increase in numbers and alter their phenotype to an activated form, in the 
ipsilateral spinal cord following nerve injury (Zhang and De Koninck, 2006). The 
signals that trigger as well as sustain astrocyte activation are not as well understood as 
those of microglia, however, glycoproteins such as fractalkine are thought to mediate 
neuro-glial communication as astrocytes were observed to express the receptor for 
fractalkine, CX3CR1 (Dorf et al., 2000). The activation and proliferation of astrocytes 
occurs after microglia, which are the first to respond to nerve injury in the CNS (and 
are discussed below), and although the astrocyte response is slower, it is sustained 
over long periods, sometimes more than 5 months after nerve injury (Echeverry et al., 
2008; Zhuang et al., 2005). It has been suggested that both activated microglia as well 
as dorsal horn neurons induce the astrocyte responses, due to their slower activation, 
and even that the astrocyte response is secondary to microglial activation (Scholz and 
Woolf, 2007). More recent data has observed that astrocytes may be involved in direct 
cross-talk with dorsal horn neurons, and contribute to the maintenance of neuropathic 
pain states. Following nerve injury, dorsal horn neurons activate astrocytes by 
secreting ATP and substance P, which in turn express and secrete neuroexcitatory 
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substances such as IL-1β and NO and thus facilitate neuropathic pain in a feedback 
circuit between astrocytes and spinal neurons (Wang et al., 2009).  
 
i. Microglia and pain modulation 
Microglia cells have received a great deal more attention in pain research than other 
central glial cells, particularly with the observation that a large recruitment and 
activation of spinal microglia in the dorsal horn was apparent, and that this occurred 
at the site of the central terminals of injured sensory nerve fibres (Watkins and Maier, 
2002). Microglia are distributed throughout the CNS and function as immune cells in 
an otherwise immune-privileged environment, and it has been suggested that they 
constitute up to 15 % of the total cell population in the CNS. Under normal 
physiological conditions, microglia are considered to be in their "resting" state in vivo, 
however, it has been observed that microglia are still highly active and motile in the 
brain even under these conditions (Nimmerjahn et al., 2005).  
Activation of microglia is a highly regulated process, and involves morphological 
changes such as thickening and retraction of processes, increases in intracellular Ca2+ 
levels (Farber and Kettenmann, 2006), changes in protein phosphorylation states of 
cell kinases such as p38 MAPK, ERK and JNK (Ji and Suter, 2007) and expression 
and secretion of key inflammatory mediators, all shown to exacerbate local 
inflammatory and neuropathic pain conditions.  
There appears to be a feedback mechanism involving neurons and microglia 
communication in neuropathic pain states, as damaged neurons (e.g. peripheral 
nociceptors) can secrete molecules such as ATP, MCP-1 / CCR2, MMP-9, 
Neuregulin-1 and fractalkine (Calvo et al., 2010; Inoue and Tsuda, 2009), which 
ultimately change the microglia phenotype into the activated state. The activated 
microglia move to the site of neural injury, by chemotaxis, and have been observed in 
their activated forms within 24 h following nerve injury, in various models of 
neuropathic pain and there is also an observation of microglia proliferation. These 
activated microglia then secrete diffusible factors, including, but not limited to, IL-1β, 
TNFα, PGE2, BDNF, etc. It is these inflammatory mediators which then recruit and 
activate more microglia and other immune cells, as well as increasing the sensitivity 
of local neurons (e.g. dorsal horn neurons), inducing greater depolarisation events, 
hyperexcitability and ultimately a neuropathic pain phenotype (i.e. hyperalgesia and 
allodynia). The current research strongly suggests that excessive microglia activation 
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contributes to persistent pain states, indeed several studies have shown that inhibition 
of these activation states of microglia decreased pain responses, for example, 
inhibiting microglial ERK protein, was found to decrease PGE2 production and 
decrease hyper-responsiveness of dorsal horn neurons in the spinal cord of injured rats 
(Zhao et al., 2007).  
Microglia have been implicated in the maintenance of some persistent pain models, 
including both inflammatory and neuropathic pain states. Whilst the involvement of 
microglia in neuropathic pain is better understood and studied (as discussed above), 
the data showing microglia activation in inflammatory pain models is sparse and less 
convincing. For example, in one study intraplantar injection of Complete Freund's 
Adjuvant (CFA) was found to increase microglia activation in the spinal cord, which 
correlated with the enhancement of pain in rats (Raghavendra et al., 2004). However, 
several other studies found that CFA did not activate microglia (Clark et al., 2007; 
Zhang et al., 2003) and additionally, other inflammatory chemicals, such as mustard 
oil, failed to elicit microglia activation (Molander et al., 1997). With this seemingly 
contradictory data, the link between inflammatory pain and microglia activation 
appears tenuous at best.  
However, the formalin model of pain, which is used both as an acute nociceptive pain 
model (Tjolsen et al., 1992) as well as for analysis of long-term inflammation and 
hyperalgesia (Fu et al., 2001), consistently shows microglia activation in several 
studies. Peripheral formalin application activated spinal microglia and when suramin 
(a P2 receptor antagonist) was applied, microglia activation and long-term 
hyperalgesia were blocked (Wu et al., 2004). Several other studies have shown 
increases in microglia activation, following peripheral formalin application, using 
various microglia activation markers, such as ED1, EMAP-II (Guo et al., 2005), 
COX-1 (Zhang et al., 2007) and OX-42 (Cho et al., 2006). This activation of 
microglia has been strongly associated with increased thermal and mechanical 
hyperalgesia, following formalin injection. More recent data suggests that peripheral 
formalin injury may induce two stages of microglia activation in the spinal cord. 
Minutes after 5 % formalin injection, activated p38 MAPK was observed in spinal 
microglia and persisted for 1 hour. A secondary increase in phospho-p38 MAPK in 
spinal microglia occurred 3-7 days after formalin injection. Interestingly, application 
of the p38 inhibitor, SB203580, was found to reduce formalin-induced acute 
nociceptive behaviour as well as long-term hyperalgesia (Li et al., 2010). Another 
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inducer of inflammatory pain, zymosan, was found to significantly increase dorsal 
horn microglia activation, which was associated with hind paw mechanical 
hyperalgesia (Clark et al., 2007). Indeed, intrathecal application of fluorocitrate (a 
glial metabolic inactivator) reversed zymosan-induced hyperalgesia, again 
highlighting the importance of microglia activation in some models of inflammatory 
pain.   
A greater understanding of the molecular mechanisms of microglia activation, 
particularly the microglia-activating molecules/chemicals (both known and novel) 
could provide useful insights into the molecular mechanisms of pain development and 
persistence. As such, they are the focus of much study in pain research, as targeting 
and modulating the activity of these "activators" could lead to novel therapeutics in 
the management of pain.  
 
Calcium (Ca2+) signalling 
 
Calcium (Ca2+) is a simple ion, yet is a highly versatile and ubiquitous intracellular 
signalling molecule, which is responsible for a wide variety of processes, including 
fertilisation, proliferation, learning and memory and pain pathways. Ca2+ signalling is 
driven by the large electrochemical gradients caused by high concentrations of Ca2+ in 
the extracellular environment (mM range) and lower cytoplasmic Ca2+ concentrations 
(nM range). Ca2+ can regulate so many processes by changes (often subtle) in 
magnitude, duration and location of these alterations in intracellular Ca2+ levels and is 
usually initiated by an extracellular ligand binding its plasma membrane receptor.  
The source of the Ca2+, which increases intracellular cytosolic Ca2+ levels, can be due 
to influx of Ca2+ from the extracellular medium or release of Ca2+ from internal stores 
(held within the ER, SR or mitochondria). In fact Ca2+ signals are induced by the 
interplay of four main processes: (1) Ca2+ influx from the extracellular environment; 
(2) Ca2+ release from internal cellular stores; (3) Ca2+ removal from the cytosol; and 
(4) Ca2+ sequestration into intracellular stores (Moller, 2002). Increase in intracellular 
Ca2+ occurs via the first two mechanisms, whereas a return to the baseline Ca2+ levels 
is mediated by the latter two.  
As well as Ca2+ binding directly to proteins and inducing changes in charge and 
shape, and thus modulating protein behaviour this way, it is the steep Ca2+ gradients 
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which are maintained by Ca2+ homeostatic molecular cascades that form the basis for 
Ca2+ signalling (Verkhratsky and Petersen, 2010). One of the foremost questions 
asked with Ca2+ signalling, is how can an increase of intracellular Ca2+ levels regulate 
so many processes? The question of course is not yet fully answerable, as Ca2+ 
signalling mechanisms are not completely understood, however, in recent years great 
progress has been made, and part of the answer to the regulation of many processes 
appears to be due to this versatility of Ca2+ signalling mechanisms involving speed, 
amplitude and the spatio-temporal patterning (Berridge et al., 2000). Increasing 
variations are also produced through interactions of Ca2+ with other signalling 
pathways (crosstalk), and essentially all these features create a cellular Ca2+ signalling 
toolkit, with many molecular components which are mixed and matched to produce 
the multitude of downstream processes controlled by Ca2+ signalling.  
This Ca2+ signalling toolkit contains/utilises Ca2+ channels and transporters, which are 
located on cell plasma membranes and intracellular membranes (e.g. on the ER and 
mitochondria), and thus form a highly organised and compartmentalised cytosolic 
Ca2+ system, and many Ca2+-dependent proteins (which can act as Ca2+ sensors and/or 
Ca2+ buffers) become regulators and effectors in this signalling system. At high 
concentrations, Ca2+ induces aggregation of nucleic acids and proteins, and damages 
lipid membrane integrity by inducing phosphate precipitation. Thus, long-lasting and 
very large increases in cytosolic Ca2+ are cytotoxic, and thus must be carefully 
regulated.  
 
Ca2+ cell compartments 
 
Cellular compartments all have different modes of Ca2+ handling and so create Ca2+ 
concentration gradients within the cell itself as well as between the cell and its 
extracellular environment (Berridge et al., 2003). The movement of Ca2+ between 
these compartments, either passively or by active transport, induces rapid and 
segregated changes in free Ca2+ concentrations. This free Ca2+ is then free to interact 
with Ca2+-sensing proteins/enzymes, which regulate diverse biochemical processes 
(Carafoli et al., 2001). These Ca2+ sensors have different cellular locations and 
affinities to Ca2+, which account for some of the amplitude, specificity and spatial 
aspects of the Ca2+ signalling network. The 3 main compartments in the intracellular 
environment, where Ca2+ signal homeostasis occurs are the cytoplasm/cytosol, the 
 23
endoplasmic reticulum (ER) and the mitochondria, although it must be noted that 
other intracellular organelles, such as the Golgi complex, lysosomes and secretory 
granules have also been implicated in intracellular Ca2+ homeostasis (Michelangeli et 
al., 2005). The ER and mitochondria are often referred to as Ca2+ stores, due to their 
capacity to store and modulate Ca2+ movement in cells.  
Cytosolic Ca2+ levels are kept low, ~50-100 nM and this results in a constant Ca2+ 
gradient from both the extracellular space and intracellular organelles. Stimulation of 
cells, which can be greatly varied, opens channels on the plasma membrane or 
intracellular organelles and produces a rapid and substantial increase in intracellular 
Ca2+ levels. These increases can be global or localised and depend on the type of 
stimulus, degree of Ca2+ channel activation and the buffering in the cytosol, which is 
due to specialised proteins (EF-hand proteins) that have a high affinity for Ca2+ 
(Lewit-Bentley and Rety, 2000).  The types of Ca2+ buffers and their concentrations 
vary between different cells, and due to their high affinity for Ca2+, they are essential 
for creating microdomains of high Ca2+ concentrations within the cell and thus control 
many rapid and spatially restricted cell reactions, such as exocytosis.  
The ER organelle is involved in many vital cell functions, including protein synthesis 
and maturation, intracellular transport mechanisms and cell survival regulation. The 
ER is also the largest dynamic Ca2+ store, and this provides some spatial and temporal 
organisation to Ca2+ signalling events. A complement of pumps and channels on the 
ER membrane, such as the IP3 receptors (IP3Rs), ryanodine receptors (RyRs) and 
sarco/endoplasmic reticulum Ca2+-ATPase (SERCAs), as well as resident Ca2+ buffer 
proteins in the ER lumen (e.g. calreticulin or calumenin), control entry and exit of 
Ca2+ and thus the signalling functions of Ca2+ in the ER (Verkhratsky, 2005). The 
concentration of Ca2+ in the ER can vary between 200 and ~1000 µM, which creates a 
steep gradient between the ER lumen and the cell cytoplasm. The ER acts as the 
major Ca2+ source for cytosolic Ca2+ signals, in many cells, particularly in electrically 
non-excitable cells (such as microglia), and can provide between 90-95 % of the Ca2+ 
required for muscle contraction.  
The mitochondrion is another important Ca2+ store in cells, which can store and 
release accumulated Ca2+. The electronegativity of the mitochondrial matrix, relative 
to the cytosol, creates an electro-driving force when cytosolic Ca2+ levels rise; 
inducing an influx of Ca2+ into the mitochondria and subsequently, this Ca2+ influx 
induces ATP production in mitochondria. However, too much Ca2+ into mitochondria 
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can trigger apoptosis and thus must be carefully regulated. The complement of 
channels and transporters in mitochondria, which control Ca2+ entry and exit is less 
well understood, although the Na+/Ca2+ exchanger and permeability transition pore 
(PTP) are thought to play a role in this (Berridge et al., 2000).  
 
Ca2+ channels and transporters 
 
The movement of Ca2+ through cellular membranes forms the core of the Ca2+ 
homeostatic and signalling system (or "toolkit"). Ca2+ channels are transmembrane 
proteins with aqueous pores, which have selective filters and gating mechanisms and 
allow movement of Ca2+ due to electro-chemical gradients. These channels can be 
broadly characterised as plasma membrane channels and intracellular channels. 
On the plasma membrane there are voltage-gated channels, ligand-gated channels 
(also known as ionotropic receptors), store-operated channels and non-selective (and 
only partially Ca2+-permeable) cationic channels (Verkhratsky and Petersen, 2010). 
Whilst the classic voltage-gated and store-operated (ICRAC) channels are almost 
exclusively Ca2+-permeable, the permeability to Ca2+ through other types of channels 
is quite varied. For ionotropic receptors, the highest Ca2+-permeability is reported for 
certain P2X purinoreceptors, NMDA-type glutamate receptors and some brain 
acetylcholine receptors (Pankratov et al., 2009). The activation of plasma membrane 
channels varies greatly depending on cell types. However, the opening of these 
channels allows entry of a large amount of Ca2+ into the cytosol from the extracellular 
space and can induce a number of physiological and pathophysiological responses, 
depending on duration and amplitude of Ca2+ movement. In excitable cells, such as 
nerve and endocrine cells, the predominant mechanism of plasma membrane Ca2+ 
entry is the result of depolarisation and opening of voltage-gated channels or direct 
activation of ionotropic receptors by relevant transmitters, particularly in neurons. In 
cells that are non-excitable electrically, Ca2+ entry is mainly a result of the opening of 
store-operated and/or cationic channels, which usually involves activation of 
metabotropic receptors (predominantly G-protein coupled receptors; GPCR) and 
subsequent intracellular signalling cascades (Verkhratsky and Petersen, 2010). For 
example, ligand activated GPCRs or receptor tyrosine kinases induce phospholipase C 
(PLC) activation, which in turn hydrolyses PIP2 to form DAG and IP3, and then the 
IP3 goes on to bind the IP3R.  
 25
Thus far, the two confirmed intracellular Ca2+ channels located on the ER membrane 
are the ryanodine receptors (RyRs), which are Ca2+-gated Ca2+ channels and the 
inositol 1,4,5-triphosphate receptors (IP3Rs) and each of the two families have 3 
subtypes of receptors. Other potential channels appear to be present, although their 
molecular identities are not yet clear (Galione and Petersen, 2005). IP3Rs are ligand-
gated channels, the soluble IP3 ligand, which is a secondary messenger produced by 
initial activation of plasma membrane metabotropic receptors (as mentioned above). 
This signalling cascade is almost ubiquitous in electrically non-excitable cells, as well 
as operating in endocrine cells, neurons and some types of muscle cells. Both RyRs 
and IP3Rs may co-exist in the same cell, for example both have been shown to be 
present in microglia cells (Moller, 2002), and depending on their location and protein 
interactions, are involved in the fine-tuning of Ca2+ signals.  
Mitochondrial Ca2+ channels are not well characterised, although Ca2+ uptake was 
shown to occur through a very selective Ca2+ channel, dubbed the uniporter (Kirichok 
et al., 2004). The molecular identity of this channel remains unknown, although a 
number of potential protein candidates have been proposed, including calciphorin, 
calvectin and gC1q-R (Starkov, 2010). Two distinct mechanisms have been identified 
for the outward transport of Ca2+ from mitochondria, the Na+-dependent and the Na+-
independent Ca2+ efflux. In recent years a greater insight into the regulation and 
function of these mitochondrial Ca2+ transport mechanisms has been obtained, 
however, the precise physiological and molecular features of these systems have yet 
to be elucidated (Hoppe, 2010).  
There are also a number of energy-dependent Ca2+ transporters, which move Ca2+ 
against the concentration gradients, and are essential for Ca2+ homeostasis and 
signalling as they balance the diffusion-based movements of Ca2+ between the 
intracellular compartments (Verkhratsky and Petersen, 2010). There are two types of 
ATP-dependent Ca2+ pumps, the plasma membrane Ca2+ ATPases (PMCAs), which 
transport Ca2+ from the cytosol to the extracellular space and the sarco/endoplasmic 
reticulum Ca2+-ATPases (SERCAs), which transport Ca2+ from the cytosol to the ER 
lumen (Berridge et al., 2003). Additionally, Ca2+ is transported across cell and 
mitochondrial membranes using the sodium-calcium exchanger (NCX), this uses 
stored energy from the Na+ transmembrane gradient (Guerini et al., 2005).  
It must be noted that all components of the Ca2+ signalling toolkit operate under tight 
control of Ca2+ concentrations, with a number of feedback loops established that 
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maintain the balance of Ca2+ movements. For example, most plasma membrane Ca2+ 
channels display a strong intracellular Ca2+ concentration-dependent inactivation 
(Fryer and Zucker, 1993; Kasai and Aosaki, 1988). These feedback loops ensure the 
versatility and durability of the cellular Ca2+ homeostasis system.  
 
Ca2+ signalling in neurons and glia 
 
Neurons and glia (e.g. microglia and astrocytes) form inter-dependent and continually 
communicating cellular networks. While neurons and glia do possess distinct 
mechanisms for information transfer, they also work in concert to provide a functional 
and powerful nexus. The integration of these neuronal-glial circuits depends on 
cellular Ca2+ signalling. In neuronal networks, Ca2+ signals can induce exocytotic 
release of neurotransmitters (Barclay et al., 2005), as well as regulate neurotransmitter 
release. Additionally, Ca2+ has an essential role in post-synaptic integration by 
controlling membrane excitability, gene expression and synaptic plasticity and 
sensitivity, including pain modulation (Cao, 2006). Neurons have many different 
types of Ca2+ channels, in different parts of the cell, which carry out numerous 
functions. For example, N- and P/Q-type voltage-operated channels (VOCs), located 
at synaptic endings, trigger release of neurotransmitters. On the other hand, L-type 
VOCs, which are situated on proximal dendrites and the cell body, are positioned to 
provide the Ca2+ signals that induce gene activation (Berridge et al., 2000).  
Ca2+ signalling is even more important for glial cells, as it produces a special form of 
glial excitability. Glial cells in close proximity to neurons and synaptic terminals 
possess many different receptors, which enable them to perceive neuronal activity, as 
well as other glial cell activity (Verkhratsky and Steinhauser, 2000). In most cases, 
these, mostly metabotropic, receptors are coupled to the IP3 signalling events 
controlling Ca2+ release from ER stores (Verkhratsky and Kettenmann, 1996), and 
trigger both Ca2+ oscillations and intracellular Ca2+ waves, which can then spread to 
surrounding glial cells, for example in astrocytes (Cornell-Bell et al., 1990).  
In microglia, purinergic receptors are the most prominent ligand-gated Ca2+-
permeable channels, and control many microglial functions, including cytokine 
release, in a Ca2+ dependent manner. There are also many metabotropic receptors 
expressed by microglia, which are linked to release of Ca2+ from intracellular stores. 
Microglia are activated by many types of CNS injury, and this activation affects many 
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properties, including migration, proliferation, a chronic increase in intracellular Ca2+ 
and the subsequent release of nitric oxide (NO) and inflammatory cytokines, 
including TNFα, IL-1β and IFNγ- all of which can further regulate intracellular Ca2+ 
of more glial cells (Farber and Kettenmann, 2006).  
Ca2+ signalling is instrumental for acquisition and processing of information between 
neuronal-glial communications. Ca2+ signalling is also a universal feature, essential 
for life, which regulates a diverse array of cellular processes. Processes such as 
exocytosis and muscle contraction are very fast and are regulated by Ca2+ signalling 
within the microsecond to millisecond range, whereas processes such as transcription, 
fertilisation, differentiation and proliferation are slower and Ca2+ signals regulate 
these events in the scale of minutes and hours (Berridge et al., 2003).  
Thus Ca2+ signals, which occur in response to cell stimulation and activation, can be 
used as universal reporters of cellular activity. The study of Ca2+ signalling has aided 
in our understanding of many molecular mechanisms of action of various chemicals 
and biological molecules (e.g. neuropeptides), in different systems of the living 
organism. For example, Ca2+ assays provide a means of checking the functionality of 
peptides as well as elucidating the molecular mechanisms of actions of various 
physiological conditions, such as pain pathways.  
 
VGF: An inducible gene product 
 
Identification of an NGF inducible gene 
 
In response to NGF binding, PC12 cells (a rat pheochromocytoma cell line) 
differentiate into mature sympathetic neurons in vitro, through a transcription 
dependent process, and so the cell line has been used extensively to investigate the 
mechanisms of action of the neurotrophins and as a model system for neuronal 
differentiation (Greene and Tischler, 1976; Levi et al., 2004). The delayed early vgf 
gene was identified independently as VGF8a (Levi et al., 1985), a2 (Cho et al., 1989) 
and NGF33.1 (Salton et al., 1991) on the basis of its rapid induction in vitro after 
NGF application in PC12 cells using differential hybridisation techniques. The name 
VGF was agreed upon based on the selection of this clone from plate V of a nerve 
Growth Factor-induced PC12 cell cDNA library (Levi et al., 1985).  
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Among gene products that are regulated with immediate early or delayed early 
kinetics, such as c-fos, VGF is unusual in that it is induced robustly and selectively by 
neurotrophic growth factors (Salton et al., 2000). It was observed that vgf was 
upregulated by brain-derived neurotrophic factor (BDNF) and neurotrophin 3 (NT-3) 
in responsive neuronal targets such as cortical or hippocampal neurons (Bonni et al., 
1995). In concordance with this selectivity to neurotrophin treatment, VGF mRNA 
levels only increase marginally after exposure to epidermal growth factor (EGF), 
fibroblast growth factor (FGF), interleukin-6 (IL-6) and insulin; despite the ability of 
these proteins to induce transcription of immediate early genes in the same PC12 cells 
(Hawley et al., 1992; Levi et al., 2004; Possenti et al., 1992; Salton, 1991; Salton et 
al., 1991). After about two hours treatment with NGF, VGF mRNA levels increased 
up to a maximal 50-fold above basal levels, plateauing at approximately 20-fold 
above basal levels, as long as cells were exposed to NGF. However, following EGF 
treatment, only a two- to three-fold increase of vgf was observed.  It is possible that 
altered RNA stability could contribute to the overall increase observed in VGF 
mRNA; however, experimental evidence suggests that NGF-treatment may actually 
decrease VGF mRNA stability. Following NGF treatment for 9-25 h, VGF mRNA 
half-life was found to substantially decrease in treated PC12 cells (Baybis and Salton, 
1992). However, nuclear run-on analysis, clearly shows induction of vgf transcription 
by NGF (Baybis and Salton, 1992). This method of analysis is a direct and accurate 
measure of the level of transcription for a particular gene, which is used to 
quantitatively measure differences in transgene transcription as a consequence of 
tissue-specific, developmental or physiological regulation. Fusion of the vgf gene 
promoter to various reporter genes, such as β-globulin or chloramphenicol 
acetyltransferase (CAT), also results in NGF-inducibility after transfection into PC12 
cells (D'Arcangelo et al., 1996; Hawley et al., 1992; Possenti et al., 1992). Increased 
levels of VGF mRNA observed in NGF treated PC12 cells is likely due to the 
induction of VGF transcription, which supplement the decreased VGF mRNA 
stability by NGF.  
 
Structure of the vgf gene 
 
After identification and cloning of the rat vgf cDNA and genomic sequences (Salton 
et al., 1991), the human and mouse homologues were isolated. Chromosomal 
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mapping has assigned the vgf gene in humans to chromosome 7q22 and in mice to 
chromosome 5 (Canu et al., 1997a; Canu et al., 1997b; Hahm et al., 1999). All of the 
genomic clones from the three species exhibit extended evolutionary conservation not 
only in the coding region, but also within the promoter and flanking 5’ regulatory 
sequences (Levi et al., 2004). It has been confirmed that vgf is a single copy gene, 
which spans only a few kilobase pairs and has a relatively simple organisation 
(Figure 1.1). It has been observed, in rat, that two different mature mRNAs are 
produced by alternate splicing events, where the second exon is skipped, however, the 
open reading frame remains unaffected (Hawley et al., 1992). The functional 
consequences for this differential splicing are unknown since the entire protein 
sequence is encoded by a single exon with the 5’ untranslated region (UTR) 
containing two small introns (Salton et al., 1991).  
 
Figure 1.1. The relatively simple organisation of the vgf gene. The compact 
structure of the vgf gene shared by human, mice and rat, including two small introns 
in the 5’ UTR, and the entire VGF coding sequence within a single exon (Exon 3) is 
shown.  
 
The VGF precursor and VGF-derived peptides 
 
i. The VGF precursor protein 
The vgf gene encodes a 615 (human) or 617 (mouse and rat) amino acid protein, with 
a typical secretory leader sequence of 23 amino acids, which promotes translocation 
into the lumen of the endoplasmic reticulum (ER). Early studies showed that the VGF 
protein is routed to the secretory compartment of the cell and released in response to 
depolarising stimuli (Possenti et al., 1989). No significant homology of the VGF 
protein is shown with known sequences (Salton et al., 1991). Following cleavage of 
the signal peptide (23 residues), a protein with a predicted mass of 68 kDa is 
generated. However, VGF in PC12 cell extracts is detected by Western blot analysis 
as a doublet of 80 kDa and 90 kDa. Pulse-chase experiments showed that limited 
VGF coding sequence 
Exon 1 Exon 2 Exon 3 
Intron 1 Intron 2 
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proteolysis occurred, resulting in the lower band. Thus far no post-translational 
modifications have been discovered, which would account for the molecular weight 
being higher than predicted, the in vitro translated VGF polypeptide also shows a 
similar mass (Levi et al., 1985). It has been proposed that the unusually high proline 
residue content of the protein may account for the unexpected electrophoretic 
mobility (Salton et al., 2000).  
A major feature of the VGF sequence is the presence of paired basic amino acid 
residues (R – Arginine, and K – Lysine), which represent potential cleavage sites for 
proprotein (or prohormone) convertases of the serine proteinase family (Steiner, 
1998), as discussed below. VGF contains at least 10 pairs of these residues that are 
highly conserved between rat, mouse and human (Figure 1.2).  
 
Figure 1.2. Primary sequence of the rat VGF protein showing adjacent basic 
amino acids. The signal peptide is shown in bold italics at the start of the sequence. 
Stretches of basic amino acids (K/R) are shown in bold, underlined. They represent 
potential cleavage sites where the VGF precursor is/may be processed to smaller 
fragments. A glycine residue (G310) precedes one such cleavage site, and it allows 
the C-terminal amidation of the neuroendocrine regulatory peptides (NERPs), 
discussed below.  
 
ii. VGF-derived peptides 
Generation of a polyclonal anti-serum against the N- and C-terminal of the precursor 
peptide has been particularly beneficial in the study of VGF proteolytic processing. 
Anti-serum to an N-terminal domain of VGF (residues 4 to 240) showed the 
80/90 kDa doublet (referred to as the VGF precursor or simply VGF) after Western 
blot analysis of neuronal cell extracts (Trani et al., 1995). Antibodies raised against 
the C-terminal of rat VGF showed a number of smaller peptides (collectively referred 
to as VGF peptides) in rat brain homogenates, as well as in extracts of primary 
cultures of cerebellar granule cells and of neuronal, endocrine and pancreatic beta cell 
lines (Possenti et al., 1999; Trani et al., 1995). The most prominent VGF peptides had 
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apparent molecular masses of 20 and 10 kDa (named VGF 20 and VGF 10, 
respectively), with a less prominent band at 18 kDa (VGF 18) also detected. These 
VGF peptides were shown to be generated by endoproteolytic cleavage in a late 
compartment of the secretory pathway, and to be enriched in secretory granules to be 
released upon depolarisation; indicating that they are likely to be secreted products  
(Trani et al., 1995). This antibody-mediated method of detection, however, is rather 
limited due to the fact that peptides generated without the C-terminal region of VGF 
would not be detected, and other small molecular weight species would not be 
resolved or retained by Western blot analysis.  
Later work allowed additional VGF peptides to be identified, in rat brain 
homogenates, by mass spectrometry. The VGF peptides were isolated from 
homogenate by affinity purification using the C-terminal anti-serum (Trani et al., 
2002). Some of the presently known VGF-derived peptides are summarised in 
Table 1.1, with a schematic diagram of the most studied peptides to date also shown 
(Figure 1.3). Due to the available antibodies, the majority of VGF derived peptides 
identified so far are C-terminally derived, with only a few N-terminal fragments 
(amino acids 23-62, 23-59 and 26-62) identified thus far, in human cerebrospinal fluid 
(Stark et al., 2001), although this number is slowly increasing (see ahead).  
Some of the endoproteases involved in producing the observed spectrum of VGF 
peptides have been identified. The best characterised of these are the prohormone 
convertases (PCs), members of the family of subtilisin/kexin-like serine proteinases 
(Seidah and Chretien, 1999; Steiner, 1998). The VGF precursor protein, as discussed 
earlier (Figure 1.2), contains numerous short stretches of basic amino acid residues, 
which are potential targets for endoprotease cleavage by enzymes such as the PCs. 
While the cleavage pattern of many of the observed peptides correspond to PC 
cleavage, there are other VGF fragments, such as the N-terminal VGF peptides 
identified in humans, that do not comply with known consensus motifs required by 
the PCs. Thus it is possible that VGF peptides are produced by other, as of yet 
unidentified endoproteases, and the actual number of VGF peptides may prove to be 
significantly greater than presently recognised (Levi et al., 2004).   
The nomenclature of the peptides which has been proposed, is to use the first four (N-
terminal) amino acids (in single letter code) and the peptide length. Thus, for 
TLQP-21, the amino acids at the N-terminus are Thr-Leu-Gln-Pro, with a total length 
of 21 amino acids. However, a number of VGF-derived peptides have been given 
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alternate names, such as the newly identified neuroendocrine regulatory peptides, 
NERP-1 and NERP-2 (Yamaguchi et al., 2007).  
 
 
Table 1.1. List of some currently known VGF peptides. The table shows some of 
the VGF derived peptides that have been observed so far, using C-terminal derived 
antibodies to purify and mass spectrometry to identify them, with the peptides thus far 
shown to have biological functions labelled. The majority of peptides which have 
been observed are at the C-terminal of VGF, however, an increasing number of N-
terminal peptides are being observed in proteomic analyses from CSF. Names are 
based on the first four amino acids in the sequence and number of amino acids in the 
fragments, except the NERPs; which is an acronym for neuroendocrine regulatory 
peptides. Some fragment names are also based on their apparent molecular weights 
observed by Western blot analysis (e.g. VGF 20 = 20 kDa).  
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Figure 1.3. Some of the major VGF derived peptides with known functions. 
Using the prohormone convertases PC1/3 and PC2, the 617 amino acid VGF 
precursor protein is cleaved at residue 417, to form the 20 kDa NAPP-129 peptide, 
this is further cleaved into the remaining peptide fragments. Most of the fragments 
shown in the figure have known biological functions, as discussed later (Figure 
adapted from Jethwa and Ebling, 2008).  
 
Different lines of evidence suggest that the VGF-derived peptides are the biologically 
active agents, stored in dense core vesicles and secreted in order to play a role in inter 
cellular communication, and responsible for the diverse range of functions associated 
with VGF (Jethwa and Ebling, 2008). The major challenge for the future 
characterisation of VGF will be to understand the individual contributions of the large 
number of VGF peptide products to the physiological functions of VGF, as discussed 
later.   
 
Expression and distribution of VGF and VGF-derived peptides 
 
Initial localisation data analysing expression of VGF mRNA and proteins, suggested a 
broad distribution throughout the nervous system, particularly in neurons in the 
central nervous system (CNS) and the peripheral (dorsal root and sympathetic 
ganglia) and enteric nervous systems. Additionally, it is widely expressed in cells of 
neuroendocrine tissue, including the pituitary and adrenal medulla as well as in 
various gastrointestinal and pancreatic endocrine cell types (Salton et al., 2000). 
VGF coding sequence 
Translation 
VGF precursor 
1 617 Enzyme cleavage sites 
617 417 
556 617 
617 
617 
617 
556 576 
588 
599 
NAPP-129 (VGF 20) 
TLQP-62 (VGF 10) 
TLQP-21 HHPD-41 
AQEE-30 
LQEQ-19 
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Whilst VGF has traditionally been classed as a neuro-endocrine specific protein, 
recent data has shown its gene expression in astrocytes treated with the SSRI anti-
depressants, fluoxetine and paroxetine (Allaman et al., 2011), as well being highly 
expressed in oligodendrocyte precursors, although it disappeared upon differentiation 
of these cells (Dugas et al., 2006).  
VGF mRNA appears quite early on in development, and was observed as early as 
embryonic day 11.5 (E11.5). This early expression occurred in the peripheral nervous 
system (PNS) as maturing neurons cluster to form ganglia. VGF mRNA expression 
then occurs in regions of the brain, pituitary, adrenal medulla and myenteric plexus, in 
later stages of embryogenesis. A potential role for VGF in coordination of neuronal 
migration and differentiation was proposed when VGF mRNA was observed in 
neurons in the brain that were undergoing axonal outgrowth and synaptogenesis, but 
not in dividing cells of the CNS (Snyder et al., 1998b). VGF mRNA was detected in 
the olfactory bulb, cerebral cortex, retina, skin and pancreas towards the end of 
gestation, and by post-natal day 10 (P=10), VGF distribution in the brain closely 
resembled adult expression levels and localisations.  
In the adult, VGF mRNA is widely expressed throughout the rodent brain, its 
abundance is highest in the neurons of the hypothalamus, primarily within the arcuate, 
paraventricular, supraoptic, and suprachiasmatic nuclei of the medial hypothalamus 
(Snyder and Salton, 1998). A major function of the hypothalamus is to control feeding 
and metabolism, and to regulate body fat stores, thus suggesting a role of VGF in 
control of energy homeostasis (see below). Interestingly, VGF is found within the 
pituitary gland, mainly within the gonadotropes and lactotropes, suggesting that VGF 
has functions in controlling reproduction (Ferri et al., 1995).  
VGF levels were increased in both primary sensory and sympathetic neuronal 
populations in transgenic mice over-expressing NGF in their skin (Levi et al., 2004). 
Interestingly these sympathetic baskets appeared de novo around primary sensory 
neurons in these animals, which also showed a significant degree of spontaneous 
hyperalgesia (Davis et al., 1994), suggesting a potential role for VGF-derived peptides 
in the regulation of pain transmission. In addition to this, VGF expression in the brain 
was found to be induced rapidly by neuronal activity (Lombardo et al., 1995; Snyder 
et al., 1998a), injury (Mahata et al., 1993a; Snyder et al., 1998a) and by light and the 
circadian clock (Wisor and Takahashi, 1997).  
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More recently, it was observed that VGF was expressed in motor neurons in the 
anterior horn of the spinal cord, with a decrease in expression observed in these 
neurons and in the cerebrospinal fluid (CSF) of SOD1 G93A transgenic mice, an 
amyotrophic lateral sclerosis (ALS) model in mice (Zhao et al., 2008). VGF was also 
shown to co-localise with substance P and partially with CGRP in dorsal root 
ganglion (DRG) neuron cultures in vitro (Rizzi et al., 2008), as well as being up-
regulated in DRG neurons, central terminals and their target dorsal horn neurons 
following peripheral nerve injury (Moss et al., 2008). Additionally, VGF levels 
increased in DRG neurons following 24 hour culture, which was used as a model of 
axotomised neurons in vitro in this study, and this increase persisted for at least 7 days 
(Riedl et al., 2009).  
By examining expression and distribution of VGF and VGF-derived peptides, 
important clues about the functional roles of VGF can thus be elucidated. 
 
Functions of VGF 
 
i. VGF knockout mice 
Studies of regulation, structure and distribution of VGF suggest that it plays an 
important role in the developing as well as the adult nervous and neuroendocrine 
systems. To more directly investigate the function(s) of VGF, the mouse Vgf gene was 
targeted by homologous recombination in embryonic stem cells and the entire VGF 
coding sequence was removed. VGF deficient mice were found to be lean and small, 
with reduced abdominal fat stores and low leptin levels, hypermetabolic, hyperactive 
and infertile (Hahm et al., 1999).  
At birth the homozygous VGF mutant mice were indistinguishable from wild-type 
and heterozygous mice. However, by P=3, the pups showed a lack of body weight 
gain compared to wild-type mice (10-20 % less), with 40-60 % less at 3 weeks of age, 
and after weaning, they were found to plateau at about 50-70 % of the weight of wild-
type mice. Body composition analysis revealed a dramatic decrease in body fat in the 
VGF-deficient mice, as well as elevated basal metabolic rate, measured by O2 
consumption and CO2 output. Circulating leptin, a satiety hormone, was found to be 
extremely low, whereas elevated hypothalamic expression of agouti-related peptide 
and neuropeptide Y mRNA (both normally involved in increased food intake and 
decreased metabolism) was observed. Thus the neuropeptide gene expression profile 
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normally observed in fasted mice, was detected. However, unlike fasted mice, VGF 
mutant mice were found to be hyperactive and feed relatively normally.  
The VGF-deficient mice were also found to be infertile in 85-90 % of cases, as a 
consequence of the VGF mutation or secondary to low circulating leptin. The start of 
puberty and sexual maturation were delayed, sexual behaviour was abnormal and the 
reproductive end organs were significantly smaller in VGF-deficient mice compared 
to control mice. The mutant females were also unable to nurse their offspring, perhaps 
due to incomplete mammary gland development and low sex steroid hormone levels; 
the deficient mice were found to have decreased pituitary stores of FSH and LH. The 
mutant females were found to have abnormal, immature ovaries and a lack of oestrus 
cyclicity. It has been observed that signals reflecting energy balance and stores have 
profound effects on hypothalamic control of reproductive maturation and function 
(Schneider, 2004), thus the infertility and altered energy metabolism observed in the 
VGF knock-out mice are most likely linked. The data indicate that VGF plays an 
important role in the regulation of energy balance and reproduction, with effects 
observed both within the brain and on peripheral tissues.  
In behavioural studies, heterozygous (vgf +/-) mice were found to have increased 
immobility in both tail-suspension tests and the forced-swim test, compared with their 
wild-type litter mates, indicating a depressed state in mice (Hunsberger et al., 2007). 
Hippocampal slices of homozygous knock-out (vgf -/-) mice showed normal long-
term potentiation (LTP), but long-term depression (LTD) could not be induced. The 
VGF mutant mice were found to have impaired hippocampal-dependent spatial 
learning , as well as in contextual fear conditioning tasks (Bozdagi et al., 2008). Thus, 
VGF knockout studies in mice have shown that the protein is involved in learning, 
memory and depression.  
 
ii. Role(s) of VGF in energy homeostasis 
The discovery of high VGF expression in the hypothalamus, as discussed earlier, 
provided the initial pointer to the importance of VGF-derived peptides in energy 
balance (Jethwa and Ebling, 2008). VGF mRNA was found to increase during fasting, 
a state generally associated with reduced leptin levels (Hahm et al., 2002; Hahm et al., 
1999), whereas administration of leptin prevented the fasting induced increases in 
VGF mRNA in mice. Also, in chronically altered states of energy balance, consistent 
changes in VGF expression were observed. For example, in leptin deficient ob/ob and 
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leptin-unresponsive db/db mice, VGF mRNA levels in the arcuate nucleus (ARC) 
resembled those in fasted wild-type mice (Hahm et al., 2002). Further evidence for the 
role of VGF in the regulation of energy balance came from the VGF deficient mice, as 
described earlier, with the major phenotypic feature of these transgenic mice being 
excessive, inappropriate energy expenditure and resistance to obesity, resulting in a 
reduction in body weight.  
It has been observed, so far, that the VGF-derived peptide, TLQP-21 (Figure 1.3), 
regulates energy balance (Bartolomucci et al., 2006; Jethwa et al., 2007). Chronic 
intracerebroventricular (i.c.v.) injection of the TLQP-21 peptide into mice did not 
affect their food intake or body weight, but increased their resting energy expenditure 
and rectal temperature (Bartolomucci et al., 2006). Furthermore, in mice fed on a 
high-fat diet for 14 days, the TLQP-21 prevented increase in body and white adipose 
tissue (WAT) weight, and blocked the hormonal changes associated with a high fat 
diet. Biochemical and molecular analyses indicated that TLQP-21 exerts its effects by 
stimulating autonomic activation of the adrenal medulla and adipose tissues. The 
work indicated that i.c.v. administration of the TLQP-21 peptide limited the early 
phase of diet-induced obesity (Bartolomucci et al., 2006).  
Further work in Siberian hamsters confirmed that the primary action of TLQP-21 was 
to decrease food-intake, rather than increase energy expenditure (Jethwa et al., 2007). 
Thus, in contrast to observations in the VGF knockout mice suggesting that VGF 
signalling constitutes an anabolic drive, studies on the TLQP-21 peptide suggest the 
opposite- that the VGF-derived peptide exerts a catabolic drive (Bartolomucci et al., 
2006; Jethwa et al., 2007). A possible explanation for the contradiction between 
functional in vivo studies of effects of VGF-derived peptides and studies where all 
VGF production is ablated, may be that the multiple peptides, derived from the full 
length VGF, could have opposing biological effects to those described for TLQP-21. 
Preliminary studies by Bartolomucci et al., reported that administration of HHPD-41 
(see Figure 1.3) to fasted mice increased food intake (Bartolomucci et al., 2007).  
VGF-derived peptides have also been observed to have a role in seasonal models of 
energy balance. Under the control of photoperiod, Siberian hamsters naturally become 
obese in the summer, but then enter a catabolic stage during winter where they 
catabolise abdominal fat reserves such that they lose up to a third of their body weight 
(Bartness et al., 1989; Klingenspor et al., 1996; Mercer et al., 2001). It was observed 
that VGF mRNA expression is dramatically regulated in relation to this body weight 
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cycle, with higher hypothalamic expression in the winter catabolic state compared to 
the summer anabolic state (Barrett et al., 2005).  
Additionally, the neuroendocrine regulatory peptide 2 (NERP-2), was reported to 
increase food intake, locomotor activity, body temperature and oxygen consumption 
following i.c.v. injection in rats and appeared to do this via the orexin pathway 
(Toshinai et al., 2010).  
 
iii. VGF peptides and water balance 
The role of VGF in water homeostasis was suggested when VGF mRNA was induced 
following salt loading in the brain of rats (Mahata et al., 1993b). Two novel C-
terminally amidated VGF peptides were identified in the secretome of human 
medullary thyroid carcinoma TT cells. They were named neuroendocrine regulatory 
peptide 1 and 2 (NERP-1 and NERP-2), and their presence was confirmed in the rat 
brain, particularly in the hypothalamus. Hypertonic NaCl application via i.c.v. 
injection normally induces vasopressin release (an anti-diurectic), however, following 
i.c.v. application of both NERPs, the NaCl-induced vasopressin release was 
suppressed. Additionally, NERP antibodies prevented the reduction of plasma 
vasopressin following water loading, thus suggesting a role in physiological 
regulation of water homeostasis (Yamaguchi et al., 2007).  
 
iv. Role of VGF peptides in reproduction 
As described earlier, VGF knockout mice (both male and female) were observed to be 
infertile, thus suggesting a role of VGF in reproduction (Hahm et al., 2002; Hahm et 
al., 1999). As well as the endocrine control of reproduction by VGF, such as the 
altered anterior pituitary function in VGF deficient mice, VGF also affects the 
sympathetic control of reproductive function (Jethwa and Ebling, 2008). C-terminal 
derived peptides, from the VGF precursor, have been shown to induce penile erection 
upon injection into the rat PVN (Succu et al., 2004).  The VGF-derived peptides 
HHPD-41, AQEE-30, LQEQ-19 and to a lesser extent AQEE-11 (see Figure 1.3), 
were all found to induce penile erection in male rats in a dose dependent manner, 
whereas the TLQP-21 peptide had no effect (Succu et al., 2004). This suggests that 
pro-erectile amino acid sequences are found in the last 30 amino acids of the VGF 
precursor C-terminal. The peptides increased nitric oxide (NO) production in the 
PVN, which stimulates sympathetic outflow by activating PVN oxytocinergic neurons 
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projecting to extra-hypothalmic brain areas and mediating penile erection (Succu et 
al., 2005).  
More recently, TLQP-21 was shown to induce multiple actions, at different levels of 
the rat male reproductive axis. When TLQP-21 was centrally applied, it induced a 
gonadotropin response, most likely via secretion of the gonadotropin releasing 
hormone (GnRH). Additionally, this peptide induced the secretion of luteinizing 
hormone (LH) from male pubertal (but not adult) rat pituitaries. Following repeated 
central administration of TLQP-21 on pubertal males, subjected to chronic under-
nutrition, the peptide was found to reduce the hypo-gonadotropic state induced by 
food deprivation, although in fed males at puberty it delayed puberty (Pinilla et al., 
2011).  
 
v. VGF functions in the gastrointestinal tract 
The TLQP-21 peptide was found to induce contraction of gastric fundic strips ex vivo, 
which was mediated by mucosal release of prostaglandins. Additionally, i.c.v. 
injection of the peptide decreased gastric emptying by ~40 % (Severini et al., 2009). 
When the TLQP-21 was applied via i.c.v. injection (but not peripherally), it prevented 
ethanol induced gastric ulceration via a mechanism involving constitutive nitric oxide 
synthase and prostaglandin E2, as well as reducing gastric acid secretion via 
somatostatin and prostaglandins (Sibilia et al., 2010a; Sibilia et al., 2010b).  
 
vi. VGF in hippocampal function and behaviour 
As observed in VGF localisation studies, VGF mRNA was found to be strongly 
labelled in the hippocampal formation, thus suggesting a role for the VGF or VGF-
derived peptides here (Snyder and Salton, 1998). The hippocampus, which has roles 
in learning and memory, has been shown to undergo synaptic strengthening induced 
by BDNF (Tyler et al., 2002). The synaptic strengthening by BDNF is associated with 
learning and is coupled to transcriptional activation. It was observed that, in cultured 
hippocampal neurons treated with BDNF, there was an increased expression of VGF 
mRNA after 3 h, as measured by real time RT-PCR, and the VGF protein was also 
up-regulated. VGF mRNA was also found to increase after trace eye-blink 
conditioning, a hippocampal-dependent learning paradigm (Alder et al., 2003). Two 
C-terminally derived VGF peptides, TLQP-62 and AQEE-30 (see Figure 1.3) were 
found to increase synaptic activity in the hippocampal neurons in a dose-dependent 
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manner, whereas N-terminal peptides had no effect (Alder et al., 2003). This suggests 
that VGF-derived peptides may have a role in long-term maintenance of synaptic 
plasticity associated with learning and memory.  
A role for VGF in mediating anti-depressant actions was independently discovered by 
two research groups, through expression profiling in microarray studies. BDNF is 
up-regulated in the hippocampus by antidepressant treatments and produces anti-
depressant like effects in behavioural models of depression (Nibuya et al., 1995). Due 
to BDNF inducing VGF expression, the effects of depression on VGF were thus 
investigated in animal models of depression. It was observed that VGF was down-
regulated in the hippocampus after both the learned helplessness and forced swim test 
(FST) paradigms (Thakker-Varia et al., 2007). When the VGF-derived peptide, 
TLQP-62 (see Figure 1.3), was infused into the hippocampus of mice subjected to 
FST, it was found that VGF acted as an anti-depressant-like agent by reducing the 
time spent immobile for up to 6 days (Thakker-Varia et al., 2007). Recent evidence 
suggests that anti-depressants increase neurogenesis in the hippocampus, and that 
neurogenesis is required for the behavioural effects of anti-depressants (Dranovsky 
and Hen, 2006). It was found that chronic TLQP-62 treatment enhanced proliferation 
of hippocampal progenitor cells both in vitro and in vivo (Thakker-Varia et al., 2007). 
Thus VGF may act downstream of BDNF and exert its effects as an anti-depressant-
like agent by enhancing neurogenesis in the hippocampus.  
Another study used microarray analysis to identify exercise regulated genes in the 
mouse hippocampus. Exercise produces anti-depressant responses in rodent models 
(Greenwood et al., 2003), and it was observed that one of the most highly regulated 
target genes of exercise was VGF. When the VGF-derived peptide, AQEE-30, was 
administered, a robust anti-depressant response was observed in mice and conversely, 
mutation of VGF in mice (using heterozygous Vgf +/- null mice) produced the opposite 
effects (Hunsberger et al., 2007). Additionally, in cultured astrocytes treated with 
anti-depressants (fluoxetine and paroxetine), the mRNA for VGF was found to be up-
regulated (Allaman et al., 2011).  Thus VGF signalling could be a potential target for 
anti-depressant drug development. 
 
vii. VGF as a neuroprotective agent 
More recently, the VGF derived peptide, TLQP-21, was shown to have a role in 
protecting rat cerebellar granule cells (CGCs) from serum and potassium deprivation-
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induced cell death. It appeared to promote the survival of CGCs via pathways 
involving, within a few minutes, modulation of kinases associated with CGC survival 
(such as extracellular signal-regulated kinase 1/2; ERK1/2), and by increasing 
intracellular Ca2+ levels in these cells, which can contribute to the neuroprotective 
effect of the TLQP-21 peptide. The TLQP-21 increased survival of CGCs in a dose-
dependent manner (Severini et al., 2008).  
Additionally, a small molecule inducer of VGF mRNA (SUN N8075), was found to 
protect cells from endoplasmic reticulum (ER) stress induced cell death. This small 
molecule prevented a reduction in VGF mRNA levels in spinal cords of SOD1 
transgenic mice (ALS models), as well as slowing disease progression and prolonging 
animal survival (Shimazawa et al., 2010).  
 
viii. VGF as a biomarker in disease states 
VGF-derived peptides have more recently been observed to be produced at altered 
levels in various disease states, particularly in human disease conditions. Using a 
number of different human neuroendocrine cells, various VGF-derived peptides were 
observed to increase their protein levels during hyperplasia and tumour development 
of these cells, relative to their corresponding normal cell types, thus it was proposed 
that VGF-derived peptides may be novel diagnostic tools for endocrine cell lesions 
and tumours (Rindi et al., 2007). VGF mRNA and peptide products (in the secreted 
proteome) were found to be reduced in breast cancer cell lines (Hernandez-Vargas et 
al., 2007; Mitra et al., 2008).  
Additionally, VGF mRNA levels in the hippocampus (CA region) and prefrontal 
cortex (Brodmann's area 9) were found to decrease in human bipolar disorder patients 
(Thakker-Varia et al., 2010). VGF immuno-reactivity was also found to be reduced in 
the spinal motor neurons of patients suffering from sporadic amyotrophic lateral 
sclerosis (Shimazawa et al., 2010).  
A number of VGF-derived peptides have been identified (using proteomic techniques) 
in the cerebro-spinal fluid (CSF) of patients with various neurodegenerative and 
psychiatric disorders, which are well summarised in a recent review (Ferri et al., 
2011). However, this research is quite novel and these peptides and their correlation 
with cells and tissues, as well as functions, are yet to be investigated. Although it does 
highlight the potential of VGF-derived peptides as disease biomarkers, by measuring 
their levels in CSF and plasma of patients.  
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ix. VGF in pain signalling and modulation  
 As described earlier, VGF is highly expressed in the PNS, in both sympathetic 
ganglia and primary sensory neurons. Positive immunostaining for VGF was also 
observed in the spinal cord (Ferri et al., 1992). VGF expression appeared to increase 
in sensory neurons in transgenic mice expressing NGF in their skin, which suggested 
a possible role for the VGF-derived peptides in regulation of pain transmission (Levi 
et al., 2004). Recently, increases of VGF mRNA in the DRG after sciatic nerve 
transection were observed (Costigan et al., 2002; Valder et al., 2003), while a 3.5 fold 
induction of VGF after spinal cord injury in the surrounding spinal cord area was 
determined (Song et al., 2001). This was confirmed in a study where gene expression 
profiles were measured in two different neuropathic pain models. The L5 spinal nerve 
transection (SNT) model and the gp120 + ddC model (in which the rat sciatic nerve is 
exposed to HIV gp120 and the anti-retroviral agent ddC) were tested, followed by 
measuring gene expression in the DRG. It was found that in the SNT model, there 
was a 3.5 fold increase of VGF expression, whereas a 1.3 fold increase was observed 
in the gp120 + ddC model (Maratou et al., 2009). Prolonged up-regulation of VGF 
mRNA and protein levels were observed following another pain model, the spared 
nerve injury (SNI) model, in injured DRG neurons (in L4/5 DRG), central terminals 
and their target dorsal horn neurons (Moss et al., 2008). 
It was observed that the VGF-derived peptide, TLQP-21, is a modulatory peptide for 
inflammatory pain (Rizzi et al., 2008). VGF immunostaining in cultured neurons of 
DRG was observed in secretory granule varicosities, where it co-localised with 
Substance P, a neuropeptide with an established involvement in nociception 
(perception of pain). Additionally, the TLQP-21 peptide was shown to have effects on 
inflammatory pain in the formalin test. The formalin test is biphasic, where the first 
phase (early phase) is caused predominantly by nociceptor activation, with data 
suggesting formalin evokes activity mainly in C-fibres and not in Aδ afferents (Heapy 
et al., 1987; Porro and Cavazzuti, 1993; Tjolsen et al., 1992). In fact, more recent data 
has shown that formalin activates primary afferent sensory neurons via TRPA1 
channels, in a direct and specific manner (McNamara et al., 2007). Thus this early 
phase is typically characterised with a local response due to direct chemical 
stimulation of nociceptors, which typically starts immediately after injection of the 
formalin and lasts for 5-10 minutes. The second phase starts approximately 
15-20 minutes following formalin injection and typically lasts for 30-60 minutes. This 
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phase is dependent on a combination of the inflammatory reaction in the peripheral 
tissue as well as functional changes in the dorsal horn of the spinal cord. These 
functional changes appears to be initiated by the C-fibre activity (e.g. TRPA1 
activation) during the early phase, leading to activity-dependent sensitisation of the 
CNS neurons (i.e. central sensitisation) in the dorsal horn (Tjolsen et al., 1992). A 
significant increase of pain-related licking response following peripheral injection of 
TLQP-21 was observed in the second phase of the test. Also, an increase in licking 
response was detected when 4 mM of the peptide was injected alone, without 
formalin. However, when the peptide was administered centrally (via i.c.v. injection), 
there was an analgesic (without pain) effect during the second phase (Rizzi et al., 
2008). This study showed that the VGF-derived peptide may be involved in 
inflammatory pain in vivo and also demonstrates that TLQP-21 acts differently at the 
peripheral and central levels of the nociceptive pathways.  
More recently, intrathecal injection of TLQP-62 was shown to induce a long-lasting 
mechanical and cold behavioural allodynia in vivo, as well increasing dorsal horn 
neuron excitability in whole cell patch recordings of spinal cord slices (Moss et al., 
2008). The LQEQ-19 peptide was found to induce a dose-dependent hyperalgesia in 
mice, using the in vivo tail-flick latency test in response to water (49 °C) immersion. 
Interestingly, immunohistochemical analysis revealed that this response was mediated 
by p38 MAPK phosphorylation in microglia cells in the spinal cord, and the 
LQEQ-19-induced thermal hyperalgesia was inhibited by the p38 MAPK 
phosphorylation inhibitor, SB202190 (Riedl et al., 2009).  
 
VGF has roles in regulation of energy balance, reproduction, and hippocampal 
synaptic plasticity as well as neuropathic and inflammatory pain. The identification of 
its receptor(s), however, remains elusive. Most of the research on VGF has focused on 
the in vivo functional characterisation of VGF peptides, and as of yet there is no 
information on the receptors which mediate the actions of VGF-derived peptides, with 
little emphasis on the molecular mechanisms of action of the peptides on the 
cells/tissues both in vivo and in vitro. Treatment of pain, in particular, pain associated 
with damage to the nervous system, is inadequate at present (Okuse, 2007), and it is 
therefore very important to identify new targets for neuropathic pain. Identification of 
the VGF receptor(s), and elucidation of the downstream molecular consequences of 
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peptide application could help improve current treatments and possibly lead to novel 
discoveries in pain therapeutics.  
 
 
Aims 
 
The role of VGF-derived peptides in certain pain models has been demonstrated, 
however, the underlying molecular mechanisms involved have yet to be clarified. 
This investigation aims to elucidate the molecular mechanisms of action of VGF-
derived peptides in the nervous system, with a particular emphasis on cells and tissues 
known to be involved in pain modulation.  
 
 
The aims of this study are to: 
  
1. Investigate the effects of VGF-derived peptides on intracellular Ca2+ levels on 
cells involved in pain pathways (DRG neurons, microglia), and thus develop 
an in vitro functional assay for the peptide(s). 
2. Identify potential VGF receptors in the nervous system using various 
biochemical techniques. 
3. Investigate some of the downstream signalling events after VGF-derived 
peptide application on cells using quantitative real time reverse transcription 
PCR (qRT-PCR) and Western blot analysis for kinase phosphorylation events 
in vitro. 
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Chapter 2: Investigating the effects 
of VGF-derived peptides on 
intracellular Ca2+ levels 
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Introduction 
 
Methods for studying Ca2+ signalling 
 
Due to the highly versatile and ubiquitous nature of calcium (Ca2+) as an intracellular 
signalling molecule, which is responsible for a wide variety of processes, methods for 
studying the Ca2+ status of cells or tissue are particularly important. A number of 
techniques are available, the choice of which depends on a multitude of factors 
including whether you are performing in vivo or in vitro analysis, length of 
experimental set-up, cell and tissue type, available equipment and costs, etc. The most 
common method for measuring intracellular Ca2+ levels is the use of fluorescent 
chemical indicators, which chelate calcium (Ca2+) ions, however, other less common 
techniques will be briefly discussed before reviewing these fluorescent indicators.  
The use of radio-isotopic 45Ca2+ to study extracellular Ca2+ entry into the cell was a 
widely employed technique, prior to the development of high sensitivity 
electrophysiological and fluorescent indicator techniques. One of the earliest studies 
using this technique measured the rate at which radio-labelled calcium ions (45Ca2+) 
crossed the surface membrane of resting squid axons and compared this to the rate 
during nervous activity (Hodgkin and Keynes, 1957). There are a number of 
advantages of using 45Ca2+ to study Ca2+ signalling: (1) cells can be plated at different 
densities on multi-well plates, and systematically screened for the effects of drugs and 
toxins (or peptides) on 45Ca2+ entry; (2) direct measurement of 45Ca2+ entry into cells 
can be measured chemically; and (3) it is relatively simple to distinguish extracellular 
Ca2+ entry from intracellular buffering systems, as all the 45Ca2+ inside the cell at the 
end of the experiment is from the extracellular environment, this is in contrast to 
fluorescent dyes, such as Fura-2, that do not differentiate between extracellular and 
intracellular Ca2+ mobilisation by direct measurement (Lambert, 1999). With the 
development of advanced patch-clamp techniques, the use of 45Ca2+ became less 
useful, particularly given the expense of isotopes and scintillation fluids, the 
complexities of manipulation and disposal of isotopes and the temporal resolution of 
45Ca2+ measurement being in the range of seconds rather than milliseconds (as with 
electrophysiological techniques).  
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Electrophysiological techniques (in particular the patch clamp technique) have greatly 
advanced our understanding of Ca2+ signalling, as they allow the study of single or 
multiple ion channels in cells, particularly excitable cells such as neurons. Thus it is 
possible to analyse currents through Ca2+ channels, both in resting and excited states, 
in cells of many sizes with high temporal resolution (millisecond range). These 
techniques also provide greater understanding of receptor binding events, ion channel 
functions, secondary messenger signalling as well as excitation propagation. When 
studying very large cells, such as oocytes, single cell recording using 
electrophysiological techniques is often the method of choice due to optical 
limitations conferred by cell thickness, rather than fluorescent Ca2+ dyes (Lambert, 
1999). While electrophysiological techniques confer a number of advantages for Ca2+ 
signalling analysis, due to the highly specialised nature of the experimental set up and 
the potentially expensive equipment involved, electrophysiology is limited to labs 
which specialise in this technique. This is especially relevant with the wide diversity 
of fluorescent Ca2+ indicators, as well as fluorescent indicator proteins now available.  
Fluorescent indicator proteins are genetically encoded reporter constructs, which 
allow fusion of fluorescent proteins to functional proteins that are involved in cell 
signalling and allow real-time visualisation and tracking of various cellular events 
(Miyawaki, 2005). Fluorescent Ca2+ indicator proteins (FCIPs) are encoded to enable 
high-resolution analysis of intracellular Ca2+ events and can be targeted to specific 
tissues and/or subcellular compartments allowing for both in vitro and in vivo 
visualisation and analysis (Heim et al., 2007). The green fluorescent protein (GFP) 
and its variants yellow and cyan fluorescent proteins (YFP and CFP, respectiviely), 
are modified by inserting specific mutations into the chromophore or barrel structure 
of GFP/YFP/CFP. The best characterised FCIP is the insertion of the calmodulin gene 
at Tyr145 of YFP, this results in a Ca2+ sensor that increases its fluorescence up to 
seven fold upon binding Ca2+ (Griesbeck et al., 2001). Another form of FCIPs makes 
use of fluorescence resonance energy transfer (FRET), from a CFP to a YFP. A 
FRET-based probe consists of two proteins (e.g. calmodulin and M13 peptide) 
labelled with CFP and YFP- when the two proteins interact, the CFP and YFP 
fluorophores are brought into close proximity, thus increasing FRET efficiency. In the 
presence of intracellular  Ca2+, the affinity of calmodulin for the M13 peptide 
increases, which results in a change in orientation or distance between YFP and CFP 
resulting in a subsequent increase in FRET (Miyawaki et al., 1997). It is also possible 
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to use transgenic animals which systemically express apoaequorin (a photoprotein 
derived from jellyfish, used as a Ca2+ indicator) and to analyse various tissues ex vivo, 
rather than in vivo. This is particularly useful when performing Ca2+ assays on cell 
types which are not amenable to in vitro culture. For example, various VGF-derived 
peptides were tested in apoaequorin-expressing pituitary and hypothalamic tissue, to 
test their bioactivity (to evoke a Ca2+ response). This approach identified several 
novel VGF-derived bioactive peptides using the fluorescent indicator protein 
apoaequorin (Sasaki et al., 2010).  
A revolution in the study of intracellular Ca2+ signalling occurred when fluorescent 
dyes for Ca2+ were developed, which could be readily introduced into living cells 
(Grynkiewicz et al., 1985). In the present day, there are a huge variety of fluorescent 
Ca2+ indicators and an ever increasing range of detection equipment available to 
observe resting and non-resting states of cells, the choice of which depends on the 
cells being investigated, the objectives of the experiment and the available equipment 
(Lambert, 1999). The fundamental properties of these indicators are based on the fact 
that binding of Ca2+ causes a wavelength shift in the excitation spectra. The 
fluorescent dyes can be excited by near ultraviolet (UV) wavelengths 340-380 nm 
(e.g. quin2 and fura-2) or by visible light at 450 nm and above (e.g. fluo-3 and fluo-
4). The use of visible light-excited fluorophores is advantageous as a lot of 
fluorescence measurement equipment available is designed for use at these 
wavelengths.  
The Ca2+ indicators can be divided into two types, the single excitation indicators and 
the dual excitation indicators. The single excitation indicators are excited at a single 
wavelength, as the name suggests, and the emitted signal intensity increases upon 
Ca2+ binding. The newer indicators (such as fluo-3 and fluo-4) show up to 200-fold 
increases in fluorescence upon Ca2+ binding and have excitation spectra at or close to 
490 nm, thus they are readily used with argon-ion lasers (with excitation at 488 nm). 
Indicators are also available that can be excited at longer wavelengths (e.g. Rhod-3 at 
550 nm), thus allowing use of two different indicators (or an indicator and fluorescent 
protein) in the same experimental set-up. Dual excitation indicators (e.g. fura-2) show 
a shift in their excitation/emission spectra when bound to Ca2+, producing a 
ratiometric emission signal of bound and unbound indicator. These ratiometric 
measurements are advantageous as the ratio signal is not dependent on dye 
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concentration, strength of the excitation signal (e.g. laser) and optical path length, 
which are all common sources of experimental error.  
There are a variety of techniques available for detecting fluorescent signals, from 
basic fluorescent microscopes with the correct filters in place, to fluorometric imaging 
plate readers (FLIPR), which allow high-throughput screening of Ca2+ signalling 
events. With conventional imaging techniques, such as basic fluorescent microscopy, 
one of the major limitations is the collection of light from out-of-focus planes 
resulting in a blurry image. Confocal microscopy overcomes this problem by 
collecting emitted light via a pinhole, which does not allow light from out-of-focus 
planes to pass, and is now widely used to study Ca2+ signalling events in excitable and 
non-excitable cells (Schild, 1996).  
Of course the selection of the fluorescent indicators and detection techniques depends 
on the equipment available as well as the experimental set up, such as cell types being 
investigated. Ultimately the goal is the same, to gain a better understanding of the 
Ca2+ signalling events unfolding. For example, a fluorescent microscope and the 
ratiometric fura-2 dye were used to investigate the effects of the VGF-derived 
peptide, TLQP-21, on intracellular Ca2+ levels in cerebellar granule cells (CGCs). In 
this instance, it was found that the increase in intracellular Ca2+ levels in these cells, 
induced by TLQP-21 contributed to the neuroprotective effect of the peptide (Severini 
et al., 2008).  
 
VGF and pain modulation 
 
VGF mRNA and protein levels in DRG has been reported to increase significantly in 
a number a studies following experimental nerve injury (Costigan et al., 2002; Griffin 
et al., 2007; Lacroix-Fralish et al., 2011; Maratou et al., 2009; Moss et al., 2008; Riedl 
et al., 2009; Song et al., 2001; Valder et al., 2003; Xiao et al., 2002). All these studies, 
using a range of pain models, suggest that VGF (and VGF-derived peptides) have a 
role in pain modulation.  
Most of the studies mentioned thus far only report an up-regulation of VGF mRNA 
and protein following peripheral nerve injuries; however, only recently has data 
shown the direct action of VGF-derived peptides in neuropathic as well as 
inflammatory pain. Direct intrathecal application of TLQP-62 (5-50 nM) caused a 
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long-lasting mechanical and cold behavioural allodynia. The TLQP-62 (50 nM) also 
increased dorsal horn neuron excitability, using whole patch recordings both in vivo 
and on rat spinal cord slices ex vivo (Moss et al., 2008). This data suggests that VGF 
has a role in neuropathic pain.  
Another study assessed the role of TLQP-21 in the formalin test, by investigating its 
peripheral and central effects on inflammatory pain. After peripheral injection of 
TLQP-21, an increased pain-related licking response was observed in the second 
inflammatory phase of the formalin test. When the same peptide (2 mM) was applied 
centrally, however, there was an analgesic response during this second phase. This 
shows that TLQP-21 is a modulator of inflammatory pain and that it acts differently at 
the central and peripheral levels of nociceptive pathways (Rizzi et al., 2008).  
It was observed that another VGF-derived peptide, LQEQ-19, evoked dose-dependent 
thermal hyperalgesia in mice in vivo using the baseline tail-flick latency test in 
response to water immersion (49 °C). Immunohistochemical analysis of the spinal 
cord sections, obtained at the time of peak hyperalgesia, showed that the VGF-derived 
peptide activated microglia via p38 MAPK phosphorylation and the thermal 
hyperalgesia was inhibited in the presence of the p38 MAPK inhibitor SB202190 in 
vivo. This study also showed that LQEQ-19 induced p38 MAPK phosphorylation in 
the BV-2 microglial cell line in vitro as well as implicating VGF-derived peptides as 
potential neuro-glial messengers following nerve injury and inflammation, and as 
important modulators in pain pathways (Riedl et al., 2009).  
Interestingly, these data suggest that both LQEQ-19 (Riedl et al., 2009) and TLQP-21 
(Rizzi et al., 2008) have a role in pain modulation, as well as TLQP-62 (Moss et al., 
2008), which is composed of both TLQP-21 and LQEQ-19 (see Figure 1.3 in the 
General Introduction). This implies that the different peptides not only have direct 
actions alone, but may interact with each other to induce a different, bigger 
(synergistic) or smaller (antagonistic) response when combined or undergoing 
differential proteolytic cleavage (Seidah and Chretien, 1999; Trani et al., 2002).  
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Aims 
 
As data is accumulating on the involvement of various VGF-derived peptides on 
modulation of pain pathways at both the central and peripheral levels of the nervous 
system, it is important to investigate the molecular mechanisms of action of these 
peptides on the various cell types (e.g. DRG neurons and microglia) in the PNS and 
CNS that are involved in these pain pathways.  
The aim of the work presented in this chapter was to develop a functional assay for 
VGF-derived peptides using DRG neurons, primary microglia and various cell lines, 
most of which play a role in pain modulation. To better understand the molecular 
mechanisms of action of VGF-derived peptides, an in vitro Ca2+-based assay was 
developed to test this functionality.  
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Materials & Methods 
 
VGF-derived peptides 
 
The VGF-derived peptides TLQP-21 and LQEQ-19, as well as their corresponding 
scrambled (Scr) peptides were synthesised by Peptide Synthetics (Peptide Protein 
Research Ltd.), with >95 % purity confirmed by HPLC and mass spectrometry 
analysis. Peptides were provided as a lyophilised powdered solid and were dissolved 
in 1x phosphate buffered saline (PBS) solution (the "vehicle" control) at stock 
concentrations, and were aliquoted and stored at -20 °C.   
Peptide sequences (wild type and scrambled): 
TLQP-21  TLQPPASSRRRHFHHALPPAR 
Scr TLQP-21  PSFLLPPHHSRAQHRTPRAAR 
LQEQ-19  LQEQEELENYIEHVLLHRP 
Scr LQEQ-19  LIREQYHNEPLQVLELEEH 
 
Primary DRG culture 
 
DRG (40-50 per dissection) were isolated from all spinal levels of female Wistar rats 
(6 weeks old at ~150 grams), which were culled by CO2 asphyxiation. The DRGs 
were placed in ice-cold and sterile Dulbecco's Modified Eagle Medium (DMEM; 
Invitrogen) and excess dorsal roots and spinal nerves were removed using micro-
dissection Vannas scissors (Fine Science Tools) under a stereo microscope. Following 
a brief wash in DMEM, the DRGs were incubated in 0.1 mg/ml DNase II (Sigma) and 
0.125 % Collagenase XI (Sigma) in DMEM for 90 minutes at 37 °C. Following 
enzymatic digestion, the DRGs were triturated gently but thoroughly until an opaque 
cell suspension was obtained. Cells were centrifuged for 3 minutes at 300 x g, and the 
cell pellet gently resuspended in pre-warmed DMEM, followed by filtration through a 
70 µm cell strainer (BD Biosciences). A pure DRG neuron culture was recovered by 
using the BSA (PAA) cushion method. 1 ml fractions of BSA cushions were prepared 
to a final concentration of 10 % BSA in DMEM (sterile). The filtered DRG cell 
suspension was then divided into 1 ml aliquots and gently applied on top of the BSA 
cushions, followed by centrifugation for 8 minutes at 250 x g. Following 
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centrifugation, cellular debris was removed from the interphase and DRG neurons 
recovered from the pellet. The DRG neurons were then combined and washed in pre-
warmed DMEM, and plated at 5, 000 neurons per plate on 35 mm borosilicate glass 
bottom (10 mm glass) dishes (MatTek) coated with poly-L-lysine (Sigma) and 
Laminin (Invitrogen) in complete media. The complete DMEM (C. DMEM) consisted 
of DMEM, 10 % foetal bovine serum (FBS), Penicillin/Streptomycin (penicillin 100 
U/ml and streptomycin 0.1 mg/ml; Sigma), NGF (50 ng/ml; Peprotech) and 
Aphidicolin (10 µM; Sigma). Cells were incubated in a 95 % air / 5 % CO2 
humidified incubator for two days after plating, after which the cells were loaded with 
the Ca2+ dye, Fluo-4AM and analysed by confocal microscopy (see below).  
The cell numbers were calculated by counting cells in a Neubauer haemocytometer. 
Prior to plating, the 10 mm glass coverslips on the glass bottom dishes were treated 
with 0.1 mg/ml poly-L-lysine (Sigma) for 2 hours at room temperature (R.T.). 
Following 3 washes with deionised distilled (and sterile) water, 10 µg/ml Laminin 
(Invitrogen) in DMEM was added to the coverslips for 90 minutes at R.T. Before 
addition of cells, the plates were washed again 3 times, this time with pre-warmed 
DMEM.  
 
Primary microglia culture 
 
Primary microglia cells were obtained from the cerebral hemispheres of post natal day 
4 (P=4) rats, and the protocol was a modified protocol of previously described 
methods (Nakajima et al., 1989; Nakajima et al., 1992).  
Forebrains were removed from the P=4 rats, placed in ice-cold DMEM and cleaned of 
meninges and blood vessels under a stereo microscope. The resulting brain tissue was 
minced with a sterile razor blade and 0.25 % trypsin (Sigma) added, with 0.1 mg/ml 
DNase II (Sigma), in DMEM for 30 minutes at 37 °C. The enzymes were neutralised 
with the addition of FBS (to a final concentration of 10 %) to the cells, which were 
then triturated 6 times using a P1000 pipette and filtered through a 70 µm cell strainer 
(BD Biosciences). The cells were then centrifuged at 397 x g for 5 minutes, the media 
was removed carefully and discarded, followed by resuspension of cells with 5 ml 
pre-warmed DMEM and centrifuged again. This wash step was repeated twice and 
then the cells were resuspended in pre-warmed C. DMEM and plated on poly-L-
 54
lysine coated 25 cm3 flasks (Nunclon; Fisher), so that it was ~1 brain per flask. Cells 
were incubated at 37 °C with 5 % CO2 overnight. The media was changed the 
following day with pre-warmed C. DMEM, and was cultured for 12 days in vitro 
(DIV), with media changes every 3 days. 
On DIV=13, the flasks were shaken in an orbital shaker at 250 rpm for 5 minutes, 
primary microglia were loosely attached and were detached into the media following 
shaking. This media was transferred to a 50 ml tube and centrifuged at 397 x g for 
5 minutes. The pellet was carefully resuspended in pre-warmed C. DMEM, the cells 
counted and plated on the 35 mm glass bottom dishes (mentioned above) pre-coated 
with poly-L-lysine at 35, 000 cells per plate, and allowed to adhere at 37 °C with 5 % 
CO2. After 30 minutes, unattached cells were removed, the cells on the plate were 
gently washed with C. DMEM twice and finally the pre-warmed C. DMEM was 
applied and cells were incubated at 37 °C in a 95 % air / 5 % CO2 humidified 
incubator, with a media change after 24 hours. The resulting cell purity was > 95 % 
microglia (confirmed using Iba1 staining). Primary microglia were incubated until 
ready for confocal analysis at DIV=23 (see below).  
N.B. For spinal cord-derived primary microglia cultures, the spinal cord was removed 
from P=4 rats and placed in ice-cold DMEM- where they were cleaned of meninges 
and blood vessels under a stereo microscope. The spinal cords were then minced with 
a sterile razor blade and the subsequent digestion and culture protocol was identical to 
that used for brain-derived primary microglia, described above. The only other 
difference being that cells were plated in poly-L-lysine coated 25 cm3 flasks so that 
there were ~3 spinal cords per flask.  
 
ND7, BHK and BV-2 cell culture 
 
The ND7/23 clone (Wood et al., 1990), the BHK (baby hamster kidney) cells and the 
murine microglia BV-2 cells were cultured and maintained in C. DMEM in 10 cm 
tissue culture plates (VWR) at 37 °C in a 95 % air / 5 % CO2 humidified incubator. 
When cells reached ~80 % confluency, they were trypsinised and re-plated at lower 
densities (= 1 passage). Cells which were greater than passage = 20 were not used for 
experiments, and frozen aliquots were thawed and cultured (with a lower passage 
number). For confocal analysis, the cells were counted and plated on poly-L-lysine 
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coated 35 mm glass bottom dishes at a density of 30, 000 cells per plate and incubated 
for 24 hours before confocal analysis.  
 
Fluo-4AM cell loading, confocal imaging and analysis 
 
The membrane permeable Ca2+ fluorescent indicator Fluo-4AM (Molecular Probes; 
Invitrogen) was reconstituted in dimethyl sulfoxide (DMSO) to a final concentration 
of 4 mM (1000x stock solution) and stored at -20 °C. The composition of extracellular 
media used for confocal analysis was: 140 mM NaCl, 5 mM KCl, 1.8 mM CaCl2, 
2 mM MgCl2, 10 mM D-Glucose, 10 mM HEPES, pH 7.4. The Ca2+-free extracellular 
media composition was the same except the CaCl2 was excluded and 2 mM EGTA 
was added. All solutions were sterile filtered using a 0.2 µm filter, and all compounds 
and reagents used for extracellular solutions were cell culture grade from Sigma.  
Prior to confocal analysis, the C. DMEM was removed from the cells and cell were 
washed with extracellular solution (at R.T.) three times and 4 µM Fluo-4AM (diluted 
in extracellular solution) was applied for 30 minutes at R.T. in the dark. Following a 
further three washes in extracellular solution, the cells were left in the solution for 
30 minutes at R.T. for the de-esterfication step. After another three washes, cells were 
ready to be analysed on a Leica SP5 inverted confocal microscope with a 20x air 
objective. For the Ca2+-free conditions, the final three washes before imaging were 
performed using the Ca2+-free extracellular media, followed by a 10 minute 
incubation with this solution (for the EGTA to chelate any remaining Ca2+ left in the 
extracellular environment) before live cell imaging. Application of 
peptides/vehicle/ATP/KCl treatments were always in a volume 1/10th the total volume 
of solution in the dish, to minimise displacement induced by solution application (i.e. 
to the 1 ml solution on cell, a 100 µl solution of treatment was applied during the live 
cell imaging).  
The microscope was equipped with a temperature controlled chamber and cells were 
imaged at 37 °C in the extracellular (or Ca2+-free) solution. The Fluo-4 was excited 
with an Argon laser line at 488 nm, set at 10 % of the lasers maximum power, and 
emitted fluorescence was detected in the 500-570 nm range. Gain and offset of the 
photomultipliers was adjusted using the "Smart gain/offset" tool and the "Saturation 
Pseudocolor" on the Leica LAS software.  The fluorescence recordings were taken 
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every 6 seconds (=1 frame) and the pinhole aperture was set at the maximum value 
(9.89 Airy Units or 600 µm, minimal confocality). Post-acquisition processing and 
quantification was performed using the LAS AF Lite software, and data was exported 
to Excel and analysed accordingly.  
 
Statistical analysis 
 
Data was analysed using OriginPro 8.5 software (OriginLab Corporation). The non-
parametric Mann-Whitney U test was used for comparisons between different 
treatments. Statistical significance was set at p ≤ 0.001. Data was expressed with 
± SEM (standard error of the mean) or propagating SEM, where applicable.  
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Results 
 
Investigating the effects of intracellular Ca2+ levels on cells following 
application of VGF-derived peptides 
 
In order to test different cells types that respond to VGF-derived peptides, a Ca2+ 
based assay was used. By using Fluo-4, a Ca2+ indicator, cells were stained and using 
live cell imaging, were observed with application of either LQEQ-19 or TLQP-21. 
DRG neurons were initially used as well as the neuronal cell line, ND7 to test whether 
the VGF-derived peptides have a direct effect on these neurons in the pain pathway. 
Primary brain microglia were also tested in order to determine whether these glia cells 
were affected by the VGF-derived peptides- previous data has already shown that 
both neurons and microglia are affected by VGF-derived peptides in different assays 
(Maratou et al., 2009; Riedl et al., 2009). A negative control cell line, which should 
not respond to the peptides, the BHK cell line, was also used in the assay for 
comparison. Initially the cells were stained with the fluorescent Ca2+ dye, Fluo-4 and 
visualised using confocal microscopy live cell imaging (1 frame = 6 sec). The plate 
could not be moved throughout the recording and thus a field of view with optimal 
cell number was selected (Figure 2.1). The cells were visualised both using the 
fluorescent dye as well as bright field, in order to record possible morphological 
changes as well as the fluorescence levels. The DRG neurons could not be plated as 
densely as the other cells, this was done to avoid too much contamination of non-
neuronal cells, which mask the neurons during analysis. However, with all the other 
cells (both primary and cell lines), it was possible to plate more densely and a 
minimum of 50 cells were always selected for analysis in order to decrease chances of 
non-specific and random cell activity (which can be normal for cell types, in 
particular the primary microglia which respond to subtle changes in the cellular 
environment). For each of the data sets, a minimum of 3 plates were used per 
condition tested, and the data combined and analysed by fluorescence levels recorded 
at each time interval, as shown by the representative plots in Figure 2.1. A cell 
viability test was always performed at the end of each experiment, using either 
60 mM KCl (for DRG neurons) or 1 mM ATP (for ND7, BHK and primary 
microglia). Only cells that were viable (i.e. had a response to a known chemical 
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stimuli, the ATP or KCl) were selected for analysis and quantification, with the 
exception of cells in extracellular Ca2+-free conditions (see further on).  
 
 
Figure 2.1. Representative cell selection and fluorescence profiles. The cells tested 
were stained with the fluorescent Ca2+ dye, Fluo-4 and visualised using confocal 
microscopy and live cell imaging. (A) Image of one of the field of views and cell 
selection on a microglia cell plate, showing an overlay of bright field and fluorescence 
(shown here in red), both of which were measured for each cell type recorded. All the 
cell types were visualised and selected in a similar way, although the DRG cells were 
not plated as densely as the other cells. (B) A representative fluorescence profile of 
responsive cells is shown, indicating the point at which treatments were applied to the 
cells. The data is the average of 3 biological replicate plates, with a minimum of 50 
cells selected from each plate. (C) A representative profile of non-responsive cells is 
shown, the ATP (or KCl) cell viability test always showed a response, and was thus 
used as a point of reference in subsequent data analysis. Error bars represent the 
standard error of the mean (SEM) of each data point. Fluorescence intensity in 
arbitrary units (A.U.).     
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DRG neurons were not responsive (Figure 2.2), using the Ca2+-based assay, to the 
TLQP-21 (10 µM) or the LQEQ-19 (10 µM) peptides (as well as the vehicle, negative 
control). Most, if not all cells were selected in a field of view and the average 
fluorescence intensity (arbitrary unit, A.U.) was plotted against the time (seconds; 
each point corresponded to the recorded time frame taken every 6 seconds). Due to 
the nature of primary cell culture, there were neurons that were morphologically 
different (i.e. flatter or more rounded), which led to a varied baseline. For consistency 
between experimental plates, the baseline response of each individual cell was set 
within +/- 4 fluorescence units (A.U.), so as not to skew the average numbers too 
much. Only cells with a KCl response (i.e. viable cells) were selected, as stated earlier 
and the average profile plotted (Figure 2.2A) as well as calculating the area under the 
curve (Figure 2.2B; this was measured 6 frames after treatment application and is 
shown as a ratio to the corresponding KCl peak). Both TLQP-21 and LQEQ-19 were 
not statistically different from the vehicle control (Mann-Whitney U test; statistical 
significance set at p ≤ 0.001) when comparing the area under the curves of the 
treatments vs. the vehicle control. As well as the cells not responding to the VGF-
derived peptides, no significant changes were observed between the different peptide 
treatments themselves. Following KCl treatments in DRG neurons, the fluorescence 
profile showed a broad peak, suggesting that although the increase in intracellular 
Ca2+ levels was rapid, the subsequent return to baseline levels was slower, something 
that has been shown to occur in previous studies using DRG neurons and KCl 
(Verkhratsky, 2005).   
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Figure 2.2. VGF-derived peptides did not induce changes in intracellular Ca2+ 
levels in primary DRG neurons. (A) Average fluorescence profiles of DRG 
neurons, selecting most cells in a field of view and combining 3 biological replicates. 
KCl was applied as a cell viability test, and only viable cells were selected. Each data 
point represents a fluorescence measurement taken every 6 seconds (1 time frame). 
The points at which the treatments were applied to the cells are indicated. The vehicle 
control, as well as LQEQ-19 (10 µM) and TLQP-21 (10 µM) did not induce a change 
in intracellular Ca2+ levels. Error bars represent the standard error of the mean (SEM) 
of each data point. (B) The area under the curves was calculated for each treatment 
(which included the point of treatment addition and the following 6 time frames) and 
this is shown as a ratio to the corresponding KCl treatment (used as a reference point) 
on the bar graph. Error bars represent the calculated propagating SEM (which 
calculates the combined error bars of both the VGF-derived peptide and KCl 
treatments). This analysis confirmed that no significant change in intracellular Ca2+ 
levels occurred in DRG neurons following VGF-derived peptide treatments, relative 
to the KCl response. Statistical analysis (Mann-Whitney U test; statistical significance 
set at p ≤ 0.001) comparing the area under the curves of treatments vs. vehicle control, 
confirmed that there was no statistical difference between LQEQ-19 and TLQP-21 
application compared to the vehicle.  
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The ND7 cell line, derived from rat DRG and shown to have sensory neuron-like 
properties (Wood et al., 1990), was also tested along with a valid negative control, 
BHK (baby hamster kidney) cells, which are derived from cells not associated with 
any known VGF expression and/or activity (i.e. kidneys). As with the DRG neurons, 
the highest concentration of 10 µM peptide concentration was applied to the cells. 
Previous work using VGF-derived peptides, both in vitro and in vivo have shown that 
these peptides act at concentrations lower than 1 µM (Moss et al., 2008; Riedl et al., 
2009; Rizzi et al., 2008; Severini et al., 2008), thus the highest concentration used in 
this investigation was 10-fold higher than this. To avoid non-specific reactions, higher 
concentrations of the peptides were not applied, although that may be a consideration 
for further analysis.  
It was observed that neither cell line (ND7 and BHK) had any response to either 
TLQP-21 or LQEQ-19 (Figure 2.3). It must be noted that the ATP (viability test) 
response showed a relatively broad peak, similar to that observed using KCl on DRG 
neurons. When the ATP was applied to microglia, the peak was not broad, and 
induced a rapid and transient increase in intracellular Ca2+ levels and a fast return to 
baseline levels (Figure 2.1B). In fact, the ATP response in the cell lines varied both 
between the two cell lines, as well within the same cell line. For example, the ND7 
cells showed a broad ATP peak following TLQP-21 treatments, but an initial sharp 
peak followed by a broader return to baseline following LQEQ-19 treatment (Figure 
2.3A). It must be noted that this was not a consequence of the preceding peptide 
application (i.e. TLQP-21 or LQEQ-19), as individual plate profiles showed that both 
ATP response types (broad peak as well as the initial sharp peak followed by a broad 
return to baseline peak) were observed following either peptide treatment.  
However, in all cases there was no response to either peptide, suggesting that neither 
LQEQ-19 nor TLQP-21 altered the intracellular Ca2+ levels of these cell lines. Both 
TLQP-21 and LQEQ-19 were not statistically different from the vehicle control 
(Mann-Whitney U test; statistical significance set at p ≤ 0.001) when comparing the 
area under the curves of the treatments vs. the vehicle control for each cell line.
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Figure 2.3. VGF-derived peptides did not induce changes in intracellular Ca2+ 
levels in the ND7 and BHK cell lines. (A and B) Average fluorescence profiles of 
ND7 and BHK cells, selecting a minimum of 50 cells in a field of view and 
combining 3 biological replicates for each cell line. ATP was applied as a cell 
viability test, and only viable cells were selected. Each data point represents a 
fluorescence measurement taken every 6 seconds (1 time frame). The points at which 
the treatments were applied to the cells are indicated. The VGF-derived peptides, 
LQEQ-19 (10 µM) and TLQP-21 (10 µM) did not induce any changes in intracellular 
Ca2+ levels in both the ND7 and BHK cells. Error bars represent the standard error of 
the mean (SEM) of each data point. (C) The area under the curves was calculated for 
each treatment (which included the point of treatment addition and the following 6 
time frames) and this was shown as a ratio to the corresponding ATP treatment (used 
as a reference point) on the bar graph. Error bars represent the calculated propagating 
SEM (which calculates the combined error bars of both the VGF-derived peptide and 
ATP treatments). This analysis confirmed that no significant change in intracellular 
Ca2+ levels occurred in ND7 and BHK cells following VGF-derived peptide 
treatments, relative to the ATP response. Statistical analysis (Mann-Whitney U test; 
statistical significance set at p ≤ 0.001) comparing the area under the curves of 
treatments vs. vehicle control, confirmed that there was no statistical difference 
between LQEQ-19 and TLQP-21 application compared to the vehicle for both cell 
lines.  
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Primary microglia cells, which were harvested from post-natal day 4 (P=4) rat 
forebrains and cultured for 23 days before application of peptides, were tested next. It 
was found that the vehicle control and 10 µM LQEQ-19 did not elicit a response in 
the cells, however, when 10 µM TLQP-21 was applied, an increase in intracellular 
Ca2+ levels was observed in >60 % of cells in a field of view (Figure 2.4). Since both 
the vehicle and LQEQ-19 did not elicit a response, the TLQP-21 response may be a 
specific biological response by microglia to this peptide. The transient increase in 
intracellular Ca2+ was observed as soon as the peptide was applied, there was no delay 
observed between application and increase in fluorescence (Figure 2.4A), and it did 
not appear to alter the subsequent ATP response either. The area under the curves also 
show that the TLQP-21 did elicit a response (Figure 2.4B)- almost half (44 %) that 
produced by ATP, which is quite significant, given the magnitude of the ATP 
response on microglia cells (Farber and Kettenmann, 2006). Statistical analysis 
(Mann-Whitney U test; statistical significance set at p ≤ 0.001), comparing the area 
under the curves of treatments vs. the vehicle control, confirmed that there was no 
statistical difference between LQEQ-19 application when compared to the vehicle. 
However, the TLQP-21 (10 µM) was found to be statistically significant (p ≤ 0.001 
vs. vehicle).  
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Figure 2.4. TLQP-21, but not LQEQ-19, induces an increase in intracellular Ca2+ 
levels in primary microglia. (A) Average fluorescence profiles of primary microglia 
cells, selecting a minimum of 50 cells in a field of view and combining 3 biological 
replicates per treatment. ATP was applied as a viability test, and only viable cells 
were selected for analysis. TLQP-21 (10 µM) application induced a rapid and 
transient increase in intracellular Ca2+ levels of >60 % of cells in a field of view, 
whereas the LQEQ-19 (10 µM) peptide and vehicle control did not elicit a Ca2+ 
response in these cells. All cells showed a sharp and transient peak following ATP 
application. Error bars represent the SEM of each fluorescence data point, taken every 
6 seconds. (B) The area under the curves was calculated for each treatment (starting 
from point of treatment and the following 6 time frames) and is shown as a ratio to the 
corresponding ATP treatment (reference point, set as 1 on graph). Error bars represent 
the calculated propagating SEM (which calculates the combined error bars of both the 
VGF-derived peptide and ATP treatments). The area under the curve for the TLQP-21 
treatment corresponded to almost half (0.44 or 44 %) of the ATP response, whereas 
the vehicle and LQEQ-19 showed no significant change in intracellular Ca2+ levels 
relative to the ATP response. Statistical analysis (Mann-Whitney U test; statistical 
significance set at p ≤ 0.001), comparing the area under the curves of treatments vs. 
the vehicle control, confirmed that there was no statistical difference between 
LQEQ-19 application when compared to the vehicle. However, the TLQP-21 (10 µM) 
was found to be statistically significant (* = p ≤ 0.001 vs. vehicle).  
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The TLQP-21 peptide induces an increase in intracellular Ca2+ levels 
in microglia, in a dose dependent manner 
 
To test the specificity of the TLQP-21 response, a scrambled TLQP-21 (Scr 
TLQP-21) peptide was applied to the cells and different concentrations of both wild 
type (WT) and scrambled peptides were tested (Figure 2.5). The responses were 
compared to their corresponding ATP response by calculating the area under the 
curve for each treatment and representing this as a ratio to their subsequent ATP 
treatment. It was found that at 10 µM, both WT TLQP-21 as well as the Scr TLQP-21 
elicited a Ca2+ response in primary microglia. However, at lower concentrations 
(1 µM and below), the scrambled peptide no longer induced an increase in 
intracellular Ca2+ levels, whereas the wild type peptide was functional up to the much 
lower concentration of 100 nM. In fact, the response elicited by TLQP-21 at this 
lower 100 nM concentration appears to be greater than the higher concentrations (both 
10 µM and 1 µM). The area under the curve for TLQP-21 (calculated from the Ca2+ 
fluorescence signals measured) at 100 nM was greater than its corresponding ATP 
response (1.06 or 106 % as a ratio to ATP). This shows that the TLQP-21 peptide has 
a biphasic dose response curve, similar to the biphasic activity of prostaglandins 
observed in various in vitro cell assays (Calabrese, 2001). At 10 nM, the wild type 
peptide stopped eliciting a response, and was thus no longer functional at this lower 
concentration. Statistical analysis (Mann-Whitney U test; statistical significance set at 
p ≤ 0.001), comparing the area under the curves of treatments vs. the vehicle control, 
confirmed that there was no statistical difference between Scr TLQP-21 (at 1 µM, 
100 nM and 10 nM) and WT TLQP-21 (at 10 nM) application when compared to the 
vehicle. However, the Scr TLQP-21 (at 10 µM) as well as WT TLQP-21 (at 10 µM, 
1 µM and 100 nM) were found to be statistically significant 
(* = p ≤ 0.001 vs. vehicle).  
To differentiate a "true" peptide response from a background signal, an arbitrary cut-
off point was selected, again using the ATP response as a point of reference, since 
only ATP responsive cells were selected for analysis. Any cells with a TLQP-21 
response larger than 20 % of the corresponding ATP signal were selected and 
quantified (as a percentage of the total cells on the plate). It must be noted that there 
were always cells that appeared to respond upon application of reagent to the primary 
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microglia, this is to be expected as microglia are cells that respond to even subtle 
changes in their environment (as well as the slight increase in fluorescence observed 
when applying a solution to cells visualised by live cell imaging). In order to 
differentiate the responsive cells from the background signal, the vehicle was used as 
another cut-off (Table 2.1). The vehicle had 24 % of cells with a response greater than 
20 % of the ATP response, thus this was set as a background signal. It was observed 
that responding cells for the wild type (WT) TLQP-21 (for concentrations above 
100 nM) were well above the background signal, thus indicating a real and significant 
response (* = p ≤ 0.001 vs. vehicle; Mann-Whitney U test). For the scrambled (Scr) 
peptide, the 10 µM concentration elicited a real response (76 % cells with a signal 
greater than 20 % of the corresponding ATP signal, and * = p ≤ 0.001 vs. vehicle; 
Mann-Whitney U test), whereas the 1 µM and 100 nM peptides were below the 
background signal (24 % and 8 %, respectively and not statistically different from the 
vehicle control; Mann-Whitney U test, statistical significance set at p ≤ 0.001) and 
thus it can be stated that they did not elicit a response in primary microglia cells. It 
must be noted that the 10 nM scrambled peptide had a value slightly higher than the 
background vehicle response (28 % of cells had a response that was greater than 20 % 
of the ATP response, compared to 24 % with vehicle application). However, given 
that the scrambled peptide concentration that is 100 times greater than this (i.e. 1 µM) 
does not elicit a response, and that the value for the 10 nM peptide is very close to the 
background (24 % for the vehicle), it can be assumed that the 10 nM scrambled TLQP 
response is still within the background range. Statistical analysis confirmed that the 
Scr TLQP-21 (10 nM) was not statistically different from the vehicle control (Mann-
Whitney U test; statistical significance set at p ≤ 0.001). This highlights the 
importance of this second cut-off point, as well as the need to use many cells and 
multiple biological replicates in these sensitive assays. 
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Figure 2.5. Dose response of WT and Scr TLQP-21 peptides in the Ca2+ assay 
used on microglia cells. The area under the curve, from the fluorescence profiles of 
the cells, was calculated (from point of peptide application and the following 6 
frames). This was represented as a ratio to the corresponding ATP response 
(peptide:ATP) and a dose response curve generated, the peptide concentration (x axis) 
is represented using a logarithmic scale. The data shows that the Scr TLQP-21 is only 
active at 10 µM (4 on graph x axis), and does not elicit a Ca2+ response in microglia at 
1 µM (3 on graph x axis) and lower concentrations. The WT TLQP-21 elicits an 
increase in intracellular Ca2+ levels in microglia at 100 nM (2 on graph x axis) and 
higher concentrations, with the largest response observed at 100 nM, showing a 
biphasic dose response. The WT TLQP-21 does not elicit a response at 10 nM (1 on 
graph x axis). Error bars represent the calculated propagating SEM. The x axis is 
represented on a logarithmic (Log10) scale. Statistical analysis (Mann-Whitney U test; 
statistical significance set at p ≤ 0.001), comparing the area under the curves of 
treatments vs. the vehicle control, confirmed that there was no statistical difference 
between Scr TLQP-21 (at 1 µM, 100 nM and 10 nM) and WT TLQP-21 (at 10 nM) 
application when compared to the vehicle. However, the Scr TLQP-21 (at 10 µM) as 
well as WT TLQP-21 (at 10 µM, 1 µM and 100 nM) were found to be statistically 
significant (* = p ≤ 0.001 vs. vehicle).  
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Treatment Concentration 
Number of cells 
>20 % of ATP 
(Total = 150) 
% of cells 
>20 % of ATP 
(± SEM) 
WT TLQP 10 µM 102 68 % (± 1.2) * 
  1 µM 108 72 % (± 2.3) * 
  100 nM 150 100 % (± 0) * 
  10 nM 18 12 % (± 3.1) 
Scr TLQP 10 µM 114 76 % (± 4.2) * 
  1 µM 36 24 % (± 7.2) 
  100 nM 12 8 % (± 1.2) 
  10 nM 42 28 % (± 6.4) 
Vehicle --- 36 24 % (± 2.3) 
 
Table 2.1. Percentage of cells with a response greater than 20 % of the 
corresponding ATP signal. Using the Ca2+ fluorescence profiles generated from the 
live cell confocal analysis of cells (150 cells from a total of 3 biological replicates), 
the response for each cell was compared to its corresponding ATP response as a 
percentage (only ATP responsive cells were selected). The cells with a response lower 
than 20 % of their corresponding ATP response were excluded, the data was 
combined and the average figures are shown in the table as the absolute number of 
cells (total 150 cells per treatment) as well as a percentage of the total cell population 
analysed (± SEM). The vehicle still has 24 % of cells with a response greater than 
20 % of the corresponding ATP response, and thus this value was used as a second 
cut-off point to differentiate a response from a non-response. Using this second cut-
off, it is possible to see that the Scr TLQP-21 induces a response in microglia at 
10 µM, but not at lower peptide concentrations. The WT TLQP-21 induces a Ca2+ 
response as low as 100 nM peptide concentration; interestingly this concentration also 
shows all the cells (100 %) with a response higher than 20 % of the corresponding 
ATP response. Statistical analysis (Mann-Whitney U test; statistical significance set at 
p ≤ 0.001), comparing the treatments vs. the vehicle control, confirmed these 
observations (* = p ≤ 0.001 vs. vehicle).  
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TLQP-21 de-sensitises microglia to further TLQP-21 stimulation, 
and may act synergistically with the LQEQ-19 peptide 
 
To further elucidate the effects of TLQP-21 peptides on primary microglia, a second 
application of peptide was applied to the cells in order to test whether the subsequent 
applications elicited the same response, no response (de-sensitisation) or an increased 
response (sensitisation), using the Ca2+ assay developed here.   
Initially 100 nM TLQP-21 was applied to the cells followed by a second application 
of TLQP-21. It was observed that, while the initial TLQP-21 application did elicit a 
Ca2+ response, the second application no longer induced an increase in intracellular 
Ca2+ levels (Figure 2.6A), and the ATP cell viability test was unaffected. To test 
whether the non-responsiveness of the second application was due to insufficient time 
for the cells to recover from the initial treatment, the time between applications was 
increased from 3 minutes to 6 minutes (Figure 2.6B). With greater time between 
application of peptides, the second dose of TLQP-21 still failed to elicit an increase in 
intracellular Ca2+ levels, suggesting that the microglia were becoming de-sensitised to 
the TLQP-21, even though the ATP response remained unchanged. The number of 
cells responding to the initial TLQP-21 application were consistent with previous 
data, with 60-80 % of cells having a response greater than 20 % of the subsequent 
ATP response, thus confirming that the initial TLQP-21 and final ATP application 
and responses by microglia were unchanged with or without a second application of 
TLQP-21.  
It was previously observed that the higher concentration of 10 µM Scr TLQP-21 
elicited a response in microglia, in order to test whether this peptide still responded 
after an initial WT TLQP-21 (10 µM) application, the scrambled peptide was applied 
3 minutes after the wild type (Figure 2.6C). It was found that the scrambled peptide 
no longer induced an increase in intracellular Ca2+ levels in the primary microglia, 
suggesting that the scrambled peptide may be acting in a similar way to the wild type 
peptide in inducing a Ca2+ response, and the microglia are de-sensitised to the 
scrambled peptides application, just like for the wild type peptide, after an initial 
TLQP-21 application.  
The area under the curve for each treatment (which included the point of treatment 
addition and the following 6 time frames) was calculated (Figure 2.6D). Statistical 
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analysis (Mann-Whitney U test; statistical significance set at p ≤ 0.001), comparing 
the area under the curves of treatments vs. the vehicle control, confirmed that only the 
initial WT TLQP-21 applications (100 nM or 10 µM) were statistically significant 
(* = p ≤ 0.001 vs. vehicle). The second applications (100 nM WT TLQP-21 or 10 µM 
Scr TLQP-21) showed no statistical difference when compared to the vehicle, thus 
confirming that the second treatments did not elicit a significant Ca2+ response, 
relative to the vehicle control.  
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Figure 2.6. TLQP-21 treatment de-sensitises microglia to further TLQP-21 
stimulation. Average fluorescence profiles of primary microglia cells; each 
experiment represents the average of 150 cells over 3 biological replicates. ATP was 
applied as a cell viability test, and only ATP responsive cells were selected for 
analysis. (A) 100 nM TLQP-21 was applied to cells, followed by a second application 
after 3 minutes. While the initial TLQP-21 application elicited an increase in 
intracellular Ca2+ levels in microglia cells, the second TLQP-21 application did not 
produce a response. The ATP viability test was unaffected. (B) Again, TLQP-21 
(100 nM) was applied to the cells successively, except this time the time between 
applications was increased to 6 minutes. The cells were still not responsive to the 
second application of TLQP-21, and again the ATP response was unaffected. These 
data suggest that the TLQP-21 de-sensitises microglia cells to further TLQP-21 
stimulation. (C) The higher concentration of 10 µM Scr TLQP-21 was previously 
shown to induce an increase in intracellular Ca2+ levels in microglia, to test whether 
this peptide was also prone to de-sensitisation events, its application was preceded 
with 10 µM WT TLQP-21. The WT TLQP-21 elicited a response, however, the Scr 
TLQP-21 then failed to elicit a Ca2+ response, suggesting that the mechanism which is 
inducing the de-sensitisation observed in WT TLQP-21 also affects the Scr TLQP-21 
response. Error bars represent the SEM of each fluorescence data point, taken every 6 
seconds. (D) The area under the curves was calculated for each treatment (which 
included the point of treatment addition and the following 6 time frames). Error bars 
represent the calculated SEM. Statistical analysis (Mann-Whitney U test; statistical 
significance set at p ≤ 0.001), comparing the area under the curves of treatments vs. 
the vehicle control, confirmed that only the initial WT TLQP-21 applications 
(100 nM or 10 µM) were statistically significant (* = p ≤ 0.001 vs. vehicle). The 
second applications showed no statistical difference when compared to the vehicle.  
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To further test microglia sensitivity to VGF-derived peptide application, the 
LQEQ-19 (10 µM) peptide was applied before TLQP-21 (10 µM) application in order 
to see whether this had any effect on the TLQP-21 induced increase in intracellular 
Ca2+ levels in the microglia. It was found that, as expected LQEQ-19 application did 
not induce a Ca2+ response, however, the following TLQP-21 did induce an increase 
in intracellular Ca2+ levels (Figure 2.7A). This confirms that the LQEQ-19 does not 
sensitise or de-sensitise the microglia to subsequent treatment with TLQP-21 (and 
does not alter the ATP response).  
Interestingly, when both TLQP-21 and LQEQ-19 were combined/pre-mixed and 
applied to microglia cells (at 10 µM each), the response elicited appeared to be greater 
than the TLQP-21 (10 µM) response on its own, since the TLQP-21+LQEQ-19 
response was greater than the subsequent ATP application (Figure 2.7B).  
The area under the curve for each treatment application was calculated (Figure 2.7C), 
as described earlier, and statistical analysis performed (Mann-Whitney U test; 
statistical significance set at p ≤ 0.001). Comparing the area under the curves of 
treatments vs. the vehicle control, confirmed that the initial WT LQEQ-19 application 
(10 µM) was not statistically different relative to the vehicle. The proceeding 
TLQP-21 application (10 µM), as well as the combined TLQP-21 + LQEQ-19 
(10 µM) treatment were both statistically significant (* = p ≤ 0.001 vs. vehicle). 
Both these data indicate that the interplay of the two peptides (LQEQ-19 and 
TLQP-21) may be far more complex than initially thought, with possible synergistic 
effects previously not documented.  
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Figure 2.7. LQEQ-19 pre-treatment of microglia does not alter the subsequent 
TLQP-21 induced response, but may act synergistically with TLQP-21 to elicit 
an enhanced Ca2+ response. Average fluorescence profiles of primary microglia 
cells; each experiment represents the average of 150 cells over 3 biological replicates. 
ATP was applied as a cell viability test, and only ATP responsive cells were selected 
for analysis. The ATP thus serves as a reference point within each experiment. (A) 
10 µM LQEQ-19 was applied to microglia and did not elicit a Ca2+ response, it did 
not inhibit or de-sensitise the microglia to the subsequent TLQP-21 (10 µM) induced 
increase in intracellular Ca2+ levels. The ATP response was unaffected. (B) The 
LQEQ-19 and TLQP-21 peptides were pre-mixed and applied to the microglia. The 
resultant increase in intracellular Ca2+ levels was larger than the subsequent ATP 
response, suggesting that the two peptides may act synergistically to elicit an 
enhanced increase in intracellular Ca2+ compared to TLQP-21 alone at this 
concentration (10 µM). Error bars represent the SEM of each fluorescence data point, 
taken every 6 seconds.  (C) The area under the curves was calculated for each 
treatment (which included the point of treatment addition and the following 6 time 
frames). Error bars represent the calculated SEM. Statistical analysis (Mann-Whitney 
U test; statistical significance set at p ≤ 0.001), comparing the area under the curves of 
treatments vs. the vehicle control, confirmed that the initial LQEQ-19 (10 µM) 
application was not statistically different from the vehicle. The proceeding TLQP-21 
application (10 µM), as well as the combined TLQP-21 + LQEQ-19 (10 µM) 
treatment were both statistically significant (* = p ≤ 0.001 vs. vehicle).  
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An increase in intracellular Ca2+ levels in microglia is still observed 
when extracellular Ca2+ is excluded 
 
When studying changes in Ca2+ levels in cells, it is important to know from which 
compartments the Ca2+ is moving to and from. The Ca2+ can enter the cytoplasm from 
the extracellular environment, as well as from Ca2+ stores within the cell (such as the 
ER and mitochondria). To test where the Ca2+ is coming from after TLQP-21 
application, the extracellular Ca2+ was depleted, using Ca2+-free media and EGTA (a 
Ca2+ chelator), followed by TLQP-21 treatment.  
It was found that there was still an increase in intracellular Ca2+ levels after TLQP-21 
(100 nM) application, even in Ca2+ free conditions, although the overall/average ATP 
response was greatly reduced (Figure 2.8A). Interestingly, there were many cells that 
responded to TLQP-21 only, but did not respond to ATP (Figure 2.8B). Normally 
cells not responding to ATP are excluded from analysis, however, in Ca2+-free 
conditions it was found that a much larger proportion of cells (47 % of the total cells 
analysed) had a TLQP-21 response, without a subsequent ATP response. Of the 
selected cells, 31 % of these had a TLQP-21 and an ATP response, as well as 22 % of 
cells having only an ATP response (Figure 2.8B). The number of cells with an ATP 
only response is the same as in normal Ca2+ conditions (i.e. in normal conditions 60-
80 % of cells respond to TLQP-21 and ~20 % respond to ATP only). The lack of 
extracellular Ca2+ to replenish intracellular stores may be the reason why so many 
cells responded to TLQP-21 but did not subsequently respond to ATP. The scrambled 
TLQP-21 peptide (100 nM) in Ca2+-free conditions did not elicit a response when 
applied to primary microglia (Figure 2.8C).  
The area under the curve for each treatment application was calculated (Figure 2.8D), 
as described earlier, and statistical analysis performed (Mann-Whitney U test; 
statistical significance set at p ≤ 0.001). Comparing the area under the curves of 
treatments vs. the vehicle control, confirmed that the Scr TLQP-21 (100 nM) 
application was not statistically different relative to the vehicle. The WT TLQP-21 
(100 nM) treatments was found to be statistically significant 
(* = p ≤ 0.001 vs. vehicle) in Ca2+-free conditions.  
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Figure 2.8. TLQP-21 (100 nM) elicited an increase in intracellular Ca2+ levels in 
extracellular Ca2+-free conditions. Average fluorescence profiles of primary 
microglia cells; each experiment represents the average of 150 cells over 3 biological 
replicates. ATP was applied as a cell viability test. (A) 100 nM TLQP-21 was applied 
to microglia cells, in the absence of extracellular Ca2+ and the peptide still elicited an 
increase in intracellular Ca2+ levels in these cells, although the subsequent ATP 
response was greatly reduced (or absent in many TLQP-21 responsive cells). (B) The 
microglia cells tested were quantified, using their ATP response or non-response as a 
marker. It was observed that most of the cells that were responsive to TLQP-21, did 
not have a subsequent ATP response (47 %) and 31 % of the cells analysed had both a 
TLQP-21 and ATP response, although most of these cells had a TLQP-21 response 
which was greater than 20 % of their subsequent ATP response. Only 22 % of the 
cells did not show an increase in intracellular Ca2+ levels induced by TLQP-21, and 
only an ATP response. (C) The scrambled TLQP-21 (100 nM) did not elicit a 
response in Ca2+-free conditions, although the ATP response was unchanged relative 
to microglia in normal Ca2+ conditions. Error bars represent the SEM of each 
fluorescence data point, taken every 6 seconds. (D) The area under the curves was 
calculated for each treatment (which included the point of treatment addition and the 
following 6 time frames). Error bars represent the calculated SEM. Statistical analysis 
(Mann-Whitney U test; statistical significance set at p ≤ 0.001), comparing the area 
under the curves of treatments vs. the vehicle control, confirmed that the TLQP-21 
(100 nM) treatment was statistically significant (* = p ≤ 0.001 vs. vehicle) in 
Ca2+-free conditions. The Scr TLQP-21 (100 nM) was not statistically different from 
the vehicle.  
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The current study has shown that TLQP-21 elicits a Ca2+ response in microglia 
derived from neonatal rat brain. Spinal microglia have been implicated as a major 
player in many pain models and in vivo work, and are responsible for inducing many 
pain states through processes such as release of inflammatory mediators following 
nerve injury (Olson, 2010). To test whether TLQP-21 elicits a similar Ca2+ response 
to brain microglia, the peptide (WT TLQP-21) was applied to spinal microglia, along 
with the scrambled (Scr) TLQP-21. It was observed that the WT TLQP-21 did induce 
an increase in intracellular Ca2+ levels in spinal microglia, just as it did in brain 
microglia, and was functional up to (and including) 100 nM WT TLQP-21 (Figure 
2.9A). At 10 nM, as with brain microglia, there was no response elicited after 
application. It was also found that the response was specific, as the scrambled peptide, 
at 100 nM, did not elicit a response when applied (Figure 2.9B).  
Statistical analysis (Mann-Whitney U test; statistical significance set at p ≤ 0.001) 
confirmed these observations. When comparing the area under the curves of 
treatments vs. the vehicle control, it was observed that there was no statistical 
difference between WT TLQP-21 (at 10 nM) as well as Scr TLQP-21 (100 nM) 
application when compared to the vehicle. However, at 1 µM and 100 nM, the WT 
TLQP-21 was found to be statistically significant (* = p ≤ 0.001 vs. vehicle). 
These data indicate that both brain and spinal microglia are responsive specifically to 
TLQP-21 in a biphasic dose-dependent manner, with the highest response observed at 
100 nM TLQP-21.  
 
 77
 
 
Figure 2.9. TLQP-21 dose-dependently induced an increase in intracellular Ca2+ 
levels in spinal microglia. The Scr TLQP-21 (100 nM) did not elicit a response in 
these cells. (A) The area under the curve, from the fluorescence profiles of the cells, 
was calculated (from point of TLQP-21 application and the following 6 frames). This 
was represented as a ratio to the corresponding ATP response (TLQP-21:ATP) and a 
dose response curve generated, the TLQP-21 concentration (x axis) is represented 
using a logarithmic scale (Log10). The TLQP-21 peptide is functional at 1 µM (3 on 
graph x axis) and at 100 nM (2 on graph x axis), but does not elicit a Ca2+ response at 
10 nM (1 on graph x axis), as observed in the brain-derived microglia previously. 
Again, the maximal response is observed at 100 nM. Error bars represent the 
calculated propagating SEM. Statistical analysis (Mann-Whitney U test; statistical 
significance set at p ≤ 0.001), comparing the area under the curves of treatments vs. 
the vehicle control, confirmed that there was no statistical difference between WT 
TLQP-21 (at 10 nM) application when compared to the vehicle. However, at 1 µM 
and 100 nM, the WT TLQP-21 was found to be statistically significant 
(* = p ≤ 0.001 vs. vehicle). (B) Average fluorescence profile of primary microglia 
cells; this experiment represents the average of 150 cells over 3 biological replicates. 
ATP was applied as a cell viability test. The Scr TLQP-21 (100 nM) failed to elicit a 
response in spinal microglia and did not alter the subsequent ATP response, thus 
spinal microglia showed the same responses as brain-derived microglia. Error bars 
represent the SEM of each fluorescence data point, taken every 6 seconds (i.e. 
1 frame = 6 seconds). Statistical analysis (Mann-Whitney U test; statistical 
significance set at p ≤ 0.001), comparing the area under the curves of treatment vs. the 
vehicle control, confirmed that there was no statistical difference between 
Scr TLQP-21 (at 100 nM) application when compared to the vehicle.  
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The VGF-derived peptides elicited a Ca2+ response in BV-2 cells, 
albeit in an inconsistent manner 
 
The murine microglia cell line (BV-2) was tested to see whether the effects of VGF-
derived peptides on these cells were similar to primary microglia. Both the LQEQ-19 
and TLQP-21 peptide sequences are identical in both mouse and rats (Jethwa and 
Ebling, 2008), thus the same peptides can be tested on both murine and rat cells.  
The BV-2 cells showed a transient response to TLQP-21, again at 100 nM, but not at 
10 nM (Figures 2.10A and 2.10B). The scrambled TLQP-21 peptide, also at 100 nM, 
did not elicit an increase in intracellular Ca2+ levels in BV-2 cells either, suggesting 
that the response was specific (Figure 2.10C). When analysing the average 
fluorescence profiles of the cells, there are times when a small increase is sometimes 
observed after application (Figure 2.10C), this is due to the addition of a solution, 
rather than a specific response. In order to separate this background noise from a 
specific response, the ATP response was used as a reference point and as before a cut-
off of 20 % of the ATP signal was applied. Any cells with a response greater than 
20 % of the ATP response were included in the analysis. Even with this cut-off, the 
vehicle application showed 26 % of cells above this threshold, thus this second 
reference and cut-off point was applied. Thus, the only cells which showed a specific 
response, above the two cut-off points, were BV-2 cells treated with 100 nM 
TLQP-21 (Figure 2.10D). This was confirmed by statistical analysis (Mann-Whitney 
U test; statistical significance set at p ≤ 0.001), which found that only the WT 
TLQP-21 (100 nM) was statistically different relative to the vehicle control 
(* = p ≤ 0.001 vs. vehicle). There was no statistical difference between WT TLQP-21 
(at 10 nM) as well as Scr TLQP-21 (100 nM) application when compared to the 
vehicle (Figure 2.10D).  
Previous data has shown that the LQEQ-19 peptide induced p-38 phosphorylation in 
the BV-2 cell line (Riedl et al., 2009), thus the BV-2 cells were also treated with this 
peptide. It was observed that the cells do respond to 10 µM LQEQ-19 and is similar to 
the transient TLQP-21 response (Figure 2.10E). Statistical analysis (Mann-Whitney U 
test; statistical significance set at p ≤ 0.001), confirmed that the WT LQEQ-19 
(10 µM) was statistically different relative to the vehicle control (Figure 2.10D; 
* = p ≤ 0.001 vs. vehicle). The scrambled LQEQ-19 peptide, as well as lower 
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concentrations of LQEQ-19 were not tested in this investigation, thus it is difficult to 
conclude the specificity of this peptide.  
The BV-2 cells were quite difficult to use, as their Ca2+ fluorescence signal fluctuated 
a lot more than primary microglia, but perhaps the biggest problem with these cells 
was the inconsistency with the results, when performed on different days. It was 
found that, although the ATP response was always constant and consistent, there were 
times when the VGF-derived peptides had no effect on the intracellular Ca2+ levels 
after application (Figure 2.10F). Due to this inherent inconsistency with these cells in 
this Ca2+ assay system, they were not used for further analysis.  
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Figure 2.10. Both TLQP-21 and LQEQ-19 elicit an increase in intracellular Ca2+ 
levels in the BV-2 cell line, albeit in an inconsistent manner. Average fluorescence 
profiles of BV-2 cells; each experiment represents the average of 150 cells over 3 
biological replicates. ATP was applied as a cell viability test after each treatment, and 
only viable cells were selected. (A) 100 nM TLQP-21 induced a rapid and transient 
increase in intracellular Ca2+ levels in BV-2 cells. (B) The lowest concentration of 
10 nM TLQP-21 failed to elicit a Ca2+ response in these cells and did not affect the 
subsequent ATP response. (C) The scrambled (Scr) TLQP-21 peptide, at 100 nM, did 
not elicit an increase in intracellular Ca2+ levels either. (D) The responses for the cells 
tested were compared to their corresponding ATP responses (only ATP responsive 
cells were selected). The cells with a response lower than 20 % of their corresponding 
ATP response were excluded, the data was combined and the average figures are 
shown in the table as the absolute number of cells (total 150 cells per treatment) as 
well as a percentage of the total cell population analysed (± SEM). The vehicle still 
has 26 % of cells with a response >20 % of the corresponding ATP response, and thus 
this value was used as a second cut-off point to differentiate a response from a non-
response. Using this second cut-off, it is possible to see that only 100 nM WT 
TLQP-21 induces an increase in intracellular Ca2+ levels (92 %) above the cut-off 
points, and the WT TLQP-21 at 10 nM as well as the Scr TLQP-21 at 100 nM do not 
elicit a significant Ca2+ response. Statistical analysis (Mann-Whitney U test; statistical 
significance set at p ≤ 0.001), comparing the treatments vs. the vehicle control, 
confirmed these observations (* = p ≤ 0.001 vs. vehicle). The LQEQ-19 peptide was 
also found to be statistically different from the vehicle control. (E) The LQEQ-19 
peptide (10 µM) was shown to induce a rapid and transient increase in intracellular 
Ca2+ levels. (F) The BV-2 cells did not consistently show responses to VGF-derived 
peptides when tested on different days; this is highlighted in the average fluorescence 
profile shown here. The BV-2 cells are not responding to TLQP-21 (100 nM) in this 
instance, even though the ATP response is normal.  
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Discussion 
 
DRG neurons and the ND7 cell line 
 
Previous published data has shown that VGF is up-regulated in DRG after peripheral 
nerve injury in vivo (Costigan et al., 2002; Maratou et al., 2009), as well as in DRG 
neurons in vitro (Riedl et al., 2009). Thus far no work has investigated the effects of 
VGF-derived peptides on DRG neurons (or the sensory neuron based cell line, ND7 
cells) following direct application of the peptides.  
The data presented here confirms that the VGF-derived peptides (LQEQ-19 and 
TLQP-21) do not induce an increase in intracellular Ca2+ levels, within the technical 
limitations of the assay. Ca2+ imaging assays, like the methods employed in this 
investigation, have been used extensively when analysing neuron behaviour (Smetters 
et al., 1999; Yuste et al., 2011). However, the measurements are usually taken in 
millisecond frames, rather than in seconds (or every 6 seconds per frame, as 
performed in this investigation), thus the sensitivity of the readings allows more 
subtle and quicker events to be captured, something that may have been missed in the 
work presented here (which is one of the main technical limitations mentioned 
earlier). Further work using higher resolution cameras and increased temporal 
resolution (such as a high speed resonant scanner system) may pick up subtle changes 
in fluorescent signals that may be occurring upon addition of VGF-derived peptides. 
There is of course the likelihood that these VGF-derived peptides do not in fact affect 
DRG neurons by a Ca2+-based mechanism or even at all. Negative data sets can 
sometimes bring up more questions and hypotheses than positive data, thus the fact 
that LQEQ-19 and TLQP-21 did not elicit a Ca2+ response (one of many possible 
assays available) in DRG neurons opens up a plethora of further questions. It may be 
that the VGF-derived peptides act only on a small subset of DRG neurons, which 
need to be further expanded for analysis or they induce another response in these 
cells, such as protein phosphorylation or alter the depolarisation status (or sensitivity 
of the neurons to further stimuli) due to the fact that VGF-derived peptide application 
modulate inflammatory pain (Rizzi et al., 2008), as well as neuropathic pain (Moss et 
al., 2008). This could be verified using voltage sensitive dyes, such as DiBAC 
(Invitrogen) combined with increased temporal resolution, although it should be noted 
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that the Ca2+ response measured in this investigation is indicative of neuronal action 
potential activity (Yuste et al., 2011). VGF-derived peptides may be synthesised and 
released by DRG neurons following depolarisation, which then act on other cell types 
such as microglia and dorsal horn neurons, something that has been observed in vitro 
(Moss et al., 2008), without any autocrine activities of the peptides on DRG neurons. 
With the increase in intracellular Ca2+ levels not observed in DRG neurons, but only 
in primary microglia in this investigation, it could be argued that TLQP-21 only acts 
on glial cells (at least in a mechanism involving Ca2+ movement). However, TLQP-21 
(at 10 µM) was previously shown to induce an increase in the intracellular Ca2+ levels 
of cerebellar granule neurons in vitro, a mechanism through which the peptide acted 
to induce a neuroprotective role from potassium and serum deprivation (Severini et 
al., 2008).  
The fact that the ND7 cells, a cell line with sensory neuron-like properties derived 
from rat DRG neurons (Wood et al., 1990), also do not show any responses to the 
VGF-derived peptides, further confirms that these peptides may not act on DRG 
neurons at all or at least not by altering their intracellular Ca2+ levels. However, there 
is a possibility that DRG neurons (and also ND7 cells) may be de-sensitised by 
TLQP-21 that they produce and secrete themselves in the cell culture conditions 
tested, especially as it has been observed in this investigation that TLQP-21 
application leads to de-sensitisation to further peptide stimulation in microglia. VGF 
is synthesised almost exclusively in neuronal and neuroendocrine cells (Jethwa and 
Ebling, 2008; Snyder and Salton, 1998), and has not been shown to be expressed by 
microglia, excluding the possibility of de-sensitisation by endogenously produced 
VGF-derived peptides in these cells.  
The BHK cells were used as a negative control, as no published work has revealed the 
expression or function of the VGF-derived peptides LQEQ-19 and TLQP-21 in 
kidney cells (and in baby hamster kidney cells). As expected they did not show any 
cells responding to the VGF-derived peptides, further highlighting the specificity of 
the Ca2+ assay developed here to test the functionality of the TLQP-21 peptide. 
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Modulation of intracellular Ca2+ levels in primary microglia by 
TLQP-21 
 
Ca2+ signalling and its functional significance in microglia is still not understood very 
well, although there is a general consensus that an increase in intracellular Ca2+ levels 
in these cells is one of the markers of activated microglia (Farber and Kettenmann, 
2006; Hoffmann et al., 2003). However, one issue that must be raised here is that of 
the problem of studying microglia in their resting state or near-resting in vivo state. 
Isolation of microglia in most cell culture techniques represent cells in their activated 
state already and do not represent the resting state of these cells often seen in the 
healthy brain, although it must be noted that in vivo imaging has revealed that 
microglial cells are continually surveying their CNS environment and have motile 
protrusions even in their resting state (Nimmerjahn et al., 2005). Additionally, 
isolation of microglia from early neonatal brains, which is the most common 
procedure for these cells, actually are microglia that haven't yet transformed to their 
resting form (Farber and Kettenmann, 2006). Thus the study of microglia Ca2+ 
signalling and activation in vitro is actually the study of further activation of 
microglia after isolation from their healthy brain state and there is a possibility that 
VGF-induced changes in intracellular Ca2+ levels in vitro may not represent in vivo 
activity of the peptides. Further analysis using in vivo fluorescent Ca2+ sensors and 
VGF-derived peptide application would help overcome this issue, although these 
techniques are not without their technical difficulties either (Heim et al., 2007; 
Whitaker, 2010). Recently, transgenic mice systemically expressing apoaequorin were 
used in a tissue-based Ca2+ assay to test various VGF-derived peptides. Interestingly, 
the five peptides tested (NERP-1, NERP-2, NERP-3, NERP-4 and AQEE-30, but not 
any scrambled versions of the peptides) at 1 µM all induced a transient increase in 
intracellular Ca2+ levels in pituitary and hypothalamic tissues ex vivo and this assay 
was used to test the bioactivity of the peptides (Sasaki et al., 2010). However, the cell 
types in these tissues were not identified; it is possible that the peptides elicited a 
response in the microglia in these tissues.  
The data presented here shows that the VGF-derived peptide, TLQP-21, induces a 
dose-dependent transient and rapid increase in intracellular Ca2+ levels, this rapidity 
could indicate that the peptide may function by binding a receptor on the cell surface 
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or by entering the cell and directly initiating signalling events inside the cell. There is 
always the possibility that the multiple arginine residues in TLQP-21 (4 total, 3 
consecutive residues; sequences shown below) allow the peptide to cross the cell 
membrane freely and induce the intracellular Ca2+ response internally, especially as 
the addition of multiple arginine residues is a common modification used to increase 
cell permeability of biological and chemical agents (Futaki, 2005; Wu et al., 2003). 
However, it has been observed that a minimum of 6 or more consecutive arginine 
residues are required for increased efficiency of cell permeability (Mitchell et al., 
2000), although this does not exclude the possibility that TLQP-21 is able to enter the 
cells freely and effectively in the time frame of the experimental observations.  
 
Wild-type TLQP-21 sequence  TLQPPASSRRRHFHHALPPAR 
Scrambled TLQP-21 sequence  PSFLLPPHHSRAQHRTPRAAR 
 
The scrambled TLQP-21 peptide is only functional at 10 µM, whereas the wild type 
peptide is functional up to 100 nM, even though both have the same overall charge 
due to the amino acid residues being identical. This precludes the possibility that the 
functionality of the peptides is solely due to the charge, rather it suggests that the 
positions of amino acid residues of the peptides are responsible for the induction of 
Ca2+ changes in microglia and that the effect is a specific biological response (as the 3 
arginine residues are no longer consecutive in the scrambled TLQP-21). There is 
always the possibility that the sequence change in the scrambled peptide could induce 
a different conformational change in any secondary structures, such as random coil or 
α helix structures, that small peptides can have (Simmons et al., 1994), which in turn 
can alter the local environment of the charged residues and decrease the activity of the 
scrambled peptide relative to the wild type peptide. The likelihood of a charge-based 
response is reduced, however, by the fact that various other VGF-derived peptides, 
with different charges were able to elicit an increase in intracellular Ca2+ levels in 
pituitary and hypothalamic tissue ex vivo (Sasaki et al., 2010).  
The functionality of the scrambled TLQP-21 peptide at the higher concentration of 
10 µM could also be due to a number of other possible reasons, for example the 
scrambled peptide sequence may not be sufficiently different from the wild type to 
completely attenuate the effects of the peptide and thus only the efficiency of the 
scrambled peptide is reduced. There is also the possibility that the scrambled 
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TLQP-21 may be acting in a different way to the wild type peptide, using a different 
pathway to elicit a similar Ca2+ response. Although this is less likely due to the fact 
that initial treatment of cells with wild type TLQP-21 de-sensitises the cells so that a 
subsequent scrambled peptide application no longer elicits an increase in intracellular 
Ca2+ (Figure 2.6C), in a similar fashion to multiple wild type TLQP-21 treatments 
(de-sensitisation events are discussed below).  
The higher concentration of 10 µM, used for the scrambled peptide, may be enough to 
elicit non-specific events in the microglia, thus effects seen at this concentration may 
not represent any significant specific cellular response. However, it must be noted that 
this higher concentration of 10 µM was used to test the LQEQ-19 peptide, and it did 
not elicit a Ca2+ response, thus just using a higher concentration isn’t sufficient to 
induce an increase in intracellular Ca2+ levels by itself and some other factor (such as 
peptide charge or conformation) may be necessary for this.  
Higher concentrations than 10 µM were not tested for any of the peptides (TLQP-21 
and LQEQ-19, wild type and scrambled). Previously published data using various 
VGF-derived peptides were not used at concentrations higher than 10 µM both in vivo 
and in vitro. Additionally other neuroendocrine peptides, such as NPY are applied at 
and functional in similar in vitro assays at concentrations less than 10 µM (Prieto et 
al., 2000; Wiley et al., 1993). As the LQEQ-19 did not induce any changes in 
intracellular Ca2+ levels in microglia (as well as DRG and ND7 cells), it may be 
possible that at higher concentrations the peptide may be functional, although there is 
always the possibility of non-specific events occurring at these peptide 
concentrations. There is also the possibility that LQEQ-19, alone at least, does not 
elicit a Ca2+ response in microglia at all, nor was it shown to induce sensitisation/de-
sensitisation to subsequent TLQP-21 treatments on these cells. However, the data 
presented in this investigation does suggest that the LQEQ-19 may be having some 
functional response on microglia. Normally at the higher concentrations of 10 µM and 
1 µM, TLQP-21 has a lower increase in intracellular Ca2+ levels relative to the 
increase observed at 100 nM (discussed below). However, when combined, LQEQ-19 
and TLQP-21 (both at the higher 10 µM concentrations) showed an enhanced Ca2+ 
response, similar to that observed for 100 nM TLQP-21- where the Ca2+ response is 
equal to or larger than the subsequent ATP response. This suggests that the two 
peptides may be working synergistically, and that the larger TLQP-62 peptide may 
also induce a similar increase in intracellular Ca2+ levels in microglia. As TLQP-62 
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has already been shown to modulate neuropathic pain in vivo, as well as increase 
dorsal horn neuron excitability (Moss et al., 2008), further work would involve testing 
this longer peptide (which consists of both TLQP-21 at the N-terminal and LQEQ-19 
at the C-terminal, as well as some extra residues in between) and its effect(s) on 
primary microglia. The possibility of a synergistic effect of two peptides to modulate 
responses, such as substance P and CGRP acting on nociceptive input (Woolf and 
Wiesenfeld-Hallin, 1986) is nothing novel, although the effect observed with 
LQEQ-19 and TLQP-21 is interesting as it involves different peptides derived from 
the same pro-protein. However, there is a possibility that, rather than showing an 
enhanced response, the TLQP-21+LQEQ-19 peptide mix are reducing the cell 
viability, and thus the ATP (a viability test) response has been reduced, which appears 
to enhance the Ca2+ response observed with the peptide combination mix. Without 
further work, such as alternate cell viability tests (e.g. MTS assay), it is not possible to 
firmly conclude whether the response observed here is a reduction in cell viability or a 
possible synergistic mechanism of the VGF-derived peptides.  
 
The biphasic dose response curve and de-sensitisation 
 
To ensure a more specific and unbiased analysis of the Ca2+ imaging data, an arbitrary 
cut-off point was set up. ATP was applied at the end of every experiment to show cell 
viability, and only cells with an ATP response were analysed (with the exception of 
cells in Ca2+-free conditions, which will be discussed further). Due to this constant 
internal control for each cell, it was possible to use the ATP response as a reference 
point for subsequent analysis. Any cells with a response greater than 20 % of the 
subsequent ATP response were classed as being responsive to the applied treatment. 
Live cell imaging using confocal microscopy is particularly sensitive to changes in 
fluid levels (i.e. addition of solution volume). When solutions were applied to the 
plates, there was always a slight shift in fluorescence on the confocal microscope set-
up. This was classed as the background noise level and was removed with the 
aforementioned cut-off point, using the ATP signal as the reference point.  
Even after this cut-off point, there were still some background signals coming from 
cells that had only the vehicle added to them (~24 % of cells). This means that 24 % 
of cells appeared to increase their fluorescence signal, above the background, by just 
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adding the same solution ("vehicle") the cells were already present in, thus showing 
just how sensitive this Ca2+ based assay is. In order to ensure objectivity with the data 
analysis, this second figure of 24 % was used as a second cut-off point. If, upon 
peptide addition, it was found that there were 24 % or fewer cells with a signal 20 % 
greater than the subsequent ATP signal, then this was classed as the "vehicle noise" of 
the experiment. Using these highly stringent cut-off points makes the analysis more 
reliable; however, any subtle biological activity that may have been occurring within 
this background noise would not be picked up. Due to the nature of the TLQP-21 “all 
or nothing” response, it is better to have more stringency, which misses out any subtle 
responses that may be occurring, than a broader range of responding cells that may 
pick up non-specific background.  
Interestingly, it was found that the lower concentration of 100 nM TLQP-21 elicited a 
more enhanced increase in intracellular Ca2+ levels in cells, compared to the higher 
concentrations of the peptide (10 µM and 1 µM), when comparing the ratio of the 
TLQP-21 peak with the internal control, ATP peak. In fact at 100 nM TLQP, all the 
cells analysed (100 %) showed a response greater than 20 % of the subsequent ATP 
response for each cell. This biphasic dose response is often observed with 
pharmacological, as well as biological agents both in vitro and in vivo. For example, 
prostaglandins were observed to show a biphasic response using various endpoint 
assays in vitro, including neutrophil migration, fibroblast proliferation and DNA 
synthesis (Calabrese, 2001). At the lower concentrations of 1 µM and 100 nM, the 
scrambled TLQP-21 peptide was not functional, whereas the wild type peptide 
elicited the highest Ca2+ response at 100 nM TLQP-21 (at 10 nM the wild type 
peptide was no longer functional).  
As well as inducing an increase in intracellular Ca2+ levels in a dose dependent 
manner, TLQP-21 treatment induced de-sensitisation to subsequent TLQP-21 
treatments, without affecting the ATP viability test at the end of each experiment. A 
possible explanation for this could be the depletion of intracellular Ca2+ levels 
following the first TLQP-21 application, with insufficient time to recover and 
replenish the Ca2+. In order to test this explanation, a longer "recovery" time of 6 
minutes (rather than 3 minutes) between TLQP-21 treatments was applied. This did 
not alter the outcome, and even after 6 minutes, the subsequent TLQP-21 application 
failed to elicit a response and again the ATP response (always 3 minutes after 
TLQP-21 application) was unaffected. It could be argued that since the ATP response 
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was unaltered, the issue of Ca2+ depletion is not valid, however, ATP induces an 
increase in intracellular Ca2+ levels by acting on both P2X receptors (ligand gated ion 
channels) and P2Y receptors (G protein-coupled receptors), thus the Ca2+ enters from 
outside the cell (extracellularly via P2X receptors) as well as from Ca2+ release from 
internal stores into the cytoplasm, through P2Y signalling (Moller, 2002). The source 
of Ca2+ after TLQP-21 application appears to be from internal stores only, as an 
increase in intracellular Ca2+ is still apparent when extracellular Ca2+ is removed 
(Ca2+-free conditions, discussed below) and it may be that the internal stores are 
unable to replenish their Ca2+ in the 3-6 minutes allowed, even in normal conditions 
where extracellular Ca2+ is not limited. As the ATP allows Ca2+ from the extracellular 
environment as well as internal stores, it's affect on intracellular Ca2+ levels is 
unaffected/minimal in normal conditions following TLQP-21 pre-treatment of the 
cells. The idea that the apparent de-sensitisation of microglia to subsequent TLQP-21 
treatments is due to depletion of internal stores of Ca2+, with insufficient time to be 
replenished, is given further credence by the observation that in Ca2+-free conditions 
(removal of extracellular Ca2+), the ATP response is actually reduced or minimised 
relative to the ATP response in normal conditions. In some cases, it was found that 
most cells that responded to TLQP-21 in Ca2+-free conditions, did not have a 
corresponding ATP response. This suggests that under normal conditions, the Ca2+ 
response observed after ATP application is mostly due to entry of Ca2+ 
extracellularly, and is replenished more rapidly (within 3 minutes), but the increase in 
intracellular Ca2+ observed after TLQP-21 application (which appears to originate 
from internal stores) is not replenished within 3-6 minutes.  
The other possibility for the absence of a Ca2+ response from a second application of 
TLQP-21, is that there is a biological de-sensitisation occurring. This normally occurs 
when a ligand induces an event, which causes the receptor not to respond to further 
stimulation from the same ligand and sometimes other stimuli. A classic example of 
this is capsaicin, which can de-sensitises nociceptive neurons to further capsaicin 
stimulation when applied at low concentrations, but at high concentrations it also 
leads to a reduction or loss of responsiveness to other stimuli, which is why it is often 
used as an analgesic and anti-inflammatory agent (Winter et al., 1995). The 
neuropeptide substance P also causes de-sensitisation to further substance P 
stimulation by acting on and inducing endocytosis of its receptor, neurokinin-1 
(NK-1) in various tissues, including neurons (Jenkinson et al., 2000) and cutaneous 
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vasculature (Wong et al., 2005). The TLQP-21 neuropeptide could be acting in a 
similar fashion, and inducing de-sensitisation to further stimuli through a receptor-
mediated process. Interestingly, the TLQP-21 peptide (at 10 µM) elicited an increase 
in intracellular Ca2+ levels in cerebellar granule cells in vitro and a second TLQP-21 
application failed to elicit another response, suggesting a de-sensitisation of these 
cells to TLQP-21 (Severini et al., 2008).  
The data presented in this investigation cannot unfortunately distinguish and fully 
explain the de-sensitisation event without some further work. To evaluate whether this 
is caused by the Ca2+ levels not being replenished, a longer time period between 
peptide applications would need to be tested, where the initial TLQP-21 application 
would also be washed out using extracellular solution. Identification of a VGF-
derived peptide receptor would also help clarify some of the molecular mechanisms 
downstream of TLQP-21 treatments, and allow pharmacological analyses to verify or 
dispute the biological de-sensitisation hypothesis.    
Taken together, these data suggest that the TLQP-21 induced increase in intracellular 
Ca2+ levels in primary microglia is a robust and specific response, which acts dose-
dependently and appears to be de-sensitised to subsequent TLQP-21 treatments.  
 
Exclusion of Ca2+ from the extracellular medium 
 
Having established that TLQP-21 induces an increase in intracellular Ca2+ levels in 
primary microglia, it was important to determine whether the Ca2+ is entering the 
cytoplasm from outside the cell, or from Ca2+ released from internal stores into the 
cytoplasm. To test this, Ca2+ was removed from the extracellular medium using Ca2+-
free media containing the Ca2+-specific chelator EGTA at 2 mM (a 10 minute pre-
incubation before TLQP-21 application was included to ensure chelation of any 
residual Ca2+ in the media). Even in these conditions, the TLQP-21 peptide (100 nM) 
induced an increase in intracellular Ca2+ levels, suggesting that the Ca2+ increase is 
independent of extracellular Ca2+ and is released from internal stores into the 
cytoplasm. The scrambled peptide (100 nM) did not elicit a response as expected. It is 
possible that the conditions in which the cells were tested were not completely free of 
extracellular Ca2+, and even a fraction of the normal Ca2+ concentration (1.8 mM) is 
sufficiently larger than the resting cytoplasmic Ca2+ concentration (50-150 nM) in 
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microglia (Moller, 2002). Thus even a 100-fold dilution of extracellular Ca2+ would 
still produce a steep Ca2+ gradient between extracellular and intracellular Ca2+ levels, 
sufficient for Ca2+ entry and microglial activation. The Ca2+-free conditions used in 
this investigation are fairly standardised conditions similar to those used in a wide 
variety of published materials, however, a validation of Ca2+-free conditions would 
have further confirmed this work, using an agent known to only induce an 
intracellular increase in Ca2+ from the internal stores of microglia, such as BDNF 
(Mizoguchi et al., 2009).  
Another potential indicator that the conditions tested were actually free of 
extracellular Ca2+, is the observation that the ATP cell viability test showed a reduced 
Ca2+ signal after the TLQP-21 treatments, in some cases there was a definite Ca2+ 
signal for the TLQP-21 application and no response for the ATP application. In 
normal conditions, non-ATP responsive cells were excluded from analysis (and the 
ATP response was used as a reference point), however, it was necessary in these Ca2+-
free conditions to include the ATP non-responsive cells in the analysis, due to the 
observation that the majority of cells were responsive to TLQP-21 but not to ATP. In 
these conditions, 47 % of cells showed an increase in intracellular Ca2+ levels after 
application of TLQP-21, without a subsequent increase after application of ATP, 
additionally only 31 % of the cells in the field of view showed a response to both 
TLQP-21 and ATP (thus a total of 78 % TLQP-21 responsive cells). This could in fact 
be used as a confirmation of Ca2+-free conditions in the extracellular medium, as ATP 
causes Ca2+ from both the extracellular medium and internal stores to enter the cell 
cytoplasm, via P2X and P2Y receptor signalling, respectively. As the larger 
extracellular pool of Ca2+ has been removed, ATP can only induce a Ca2+ response 
from the internal stores, which may not have been completely replenished from the 
preceding TLQP-21 application, thus a greatly reduced ATP response was observed.  
All analysis of these cells involves comparison of TLQP-21 responses relative to the 
subsequent ATP response, with no reference to absolute Ca2+ concentrations. Given 
the variability in primary microglia responses to ATP from experiment to experiment, 
use of absolute Ca2+ concentrations may make the results more consistent and reliable 
between the different data sets. It is possible to convert fluorescent Ca2+ signals into 
Ca2+ concentrations, although this is often done using the Fura-2 dye (Invitrogen), 
which allows conversion of the 340/380 nm values to Ca2+ concentrations using 
calibrations kits (Mizoguchi et al., 2009). However, as the ATP application and 
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subsequent response are indicators of cell viability, it may be possible that in Ca2+-
free conditions, the TLQP-21 induced increase in Ca2+ levels is causing a reduction in 
cell viability and this could be the cause of the loss of the ATP (viability test) 
response. This could be tested by using other cell viability assays (such as the MTS or 
caspase assay) to test what effects (if any) the TLQP-21 is having on primary 
microglia cell viability/survival in Ca2+-free conditions. 
The data presented here suggests that the TLQP-21 induced increase in intracellular 
Ca2+ is due to the release of Ca2+ from internal stores in the microglia, which can be 
from either the endoplasmic reticulum (ER) or from mitochondria (Moller, 2002). To 
further elucidate the source of Ca2+ and pathways used (e.g. receptor-mediated) to 
increase intracellular Ca2+ levels, a variety of pharmacological agents would need to 
be applied, which are commonly used to block various routes of Ca2+ entry into the 
cytoplasm and analyse Ca2+ signalling events. The PLC inhibitor, U73122, is 
commonly used to check whether the signalling pathways downstream of agent 
application involves the classical G protein coupled receptors/PLC/IP3 generation 
pathway, which ultimately leads to increases in intracellular Ca2+ levels from internal 
stores (Berridge et al., 2000; Takenouchi et al., 2005). Thapsigargin is another 
commonly used drug, as it depletes intracellular Ca2+ stores by inhibiting the ER 
Ca2+-ATPase, thus inhibiting any signalling that normally occurs by movement of 
Ca2+ from the ER to the cytoplasm (Inesi et al., 2005). Studies involving Ca2+ entry 
into the cytoplasm from mitochondria are less well developed due to the little 
information known about the exact mechanisms of Ca2+ signalling in these organelles, 
although progress is being made in this field (Carafoli, 2010).  
As well as providing data on the source of Ca2+, the drugs would give a clue about the 
nature of any potential receptors for VGF-derived peptides, now that a reliable and 
consistent functional assay has been developed.  
 
Spinal microglia and TLQP-21 
 
Most of the data in this study has focused on the effects of VGF-derived peptides on 
microglia derived from the brain, however, much of the research for microglia and 
their involvement in pain states (e.g. inflammatory and neuropathic pain) focuses on 
microglia in the spinal cord (Inoue and Tsuda, 2009). This may be because of the fact 
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that less is known about pain perception and processing in the brain and with the huge 
number of different cell types present, it is still extremely difficult to separate cellular 
events related to pain from other pathways and cellular processes. However, given the 
technical difficulties of isolating large numbers of primary microglia from the spinal 
cord, the favoured method for isolation of large microglia numbers involves 
extraction from the brain of neonatal animals and is a very common practice, using a 
fairly standardised cell culture process (Giulian and Baker, 1986; Nakajima et al., 
1992). Thus it is often considered acceptable to use brain microglia in place of spinal 
microglia, with little difference seen in responses to various ligands. However, more 
recent data has suggested that spinal microglia may in fact have different/enhanced 
immune reactivity compared to the microglia in the brain (Batchelor et al., 2008; 
Olson, 2010). To test whether there was any difference in Ca2+ response to TLQP-21, 
spinal microglia were cultured and tested. It was found that TLQP-21 induced an 
increase in intracellular Ca2+ levels, in a dose dependent manner in spinal microglia, 
and identical to that observed in brain-derived microglia. Again, the maximal 
response was observed using 100 nM of TLQP-21, with greater than 65 % of cells in 
the field of view showing this increase in intracellular Ca2+, suggesting that the brain-
derived microglia are a suitable alternative to spinal microglia in this assay. If there 
are any differences between the brain and spinal microglia responses to TLQP-21, 
they are not observable using the Ca2+ assay developed here and differences may 
emerge further downstream of the microglial activation pathway (such as in the 
expression and secretion of inflammatory mediators, levels of proliferation and 
chemotaxis).  
 
The BV-2 cells and their inconsistencies 
 
Cell lines are extremely useful tools in research as they accelerate research and reduce 
the necessity to continuously culture primary cells and perform animal 
experimentation. However, as well as reproducing results obtained in primary 
microglia with high fidelity, they must also produce repeatable and consistent data. 
The murine BV-2 cell line is often used as a substitute for primary microglia (even 
when the primary cells are obtained from rats), and have recently been shown to be 
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suitable alternatives to primary microglia in a number of in vitro assays (Henn et al., 
2009).  
The data presented in this investigation, however, suggests otherwise. TLQP-21 
(100 nM) appeared to induce an increase in intracellular Ca2+ levels in the BV-2 cells, 
in a dose dependent manner (with no response using 10 nM TLQP-21). Interestingly, 
LQEQ-19 (10 µM) also induced a transient increase in intracellular Ca2+ levels. 
However, when tested on different days, the cells no longer responded, and this 
inconsistency made the cells unsuitable to study the effects of VGF-derived peptides 
on intracellular Ca2+ levels.  
The BV-2 cells are rapidly proliferating cells, thus they are continuously going 
through different points in the cell cycle. The different results on different days may 
be a symptom of this cell cycle irregularity. To test whether this is the cause of the 
inconsistent data, it would be possible to synchronise the cells and test them at 
different time points in order to determine whether cell cycle is the cause of the 
inconsistent data (Merrill, 1998).  
Cell lines often suffer from a number of problems, which can alter their behaviour and 
sensitivity with time. For immortalised cells, such as BV-2, ND7 and BHK cells, a 
common problem is genetic instability, which can arise with increased passaging of 
cells (splitting cells once 85 % confluency reached). When cells are cultured for long 
periods of times, they naturally tend to change the number of chromosomes or have 
increasing mutations (a normal feature of cells derived from cancer cells), thus 
changing their genotype over time. This also leads to phenotypic drift, which can 
cause the cells to behave differently depending on their passage number or the 
number of times they were frozen and defrosted (as well as the length of time they 
were stored at -80 °C or in liquid nitrogen) and so the same cell line in one lab can 
produce very different results from the same cells in another lab (Masramon et al., 
2006). As well as this inherent genetic and phenotypic instability in cell lines, there is 
also a problem of cross-contamination of different cell lines, which is unfortunately 
more widespread when the cell lines are transferred from lab to lab. For decades many 
scientists have worked with contaminated or mis-identified cells, wasting both money 
and time and it has been observed that very few scientists confirm the identity of cell 
lines through techniques such as DNA fingerprinting (Chatterjee, 2007). This of 
course further confounds the problem of experimental repeatability and makes data 
analysis a lot more complicated, for example, any negative (as well as positive) 
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results need to be tested thoroughly to ensure the lack of response is real rather than 
due to problems of genetic instability, passage number or cross-contamination of the 
cell line.  
 
The VGF-derived peptide, TLQP-21 may elicit pain responses observed in previous 
investigations (Moss et al., 2008; Rizzi et al., 2008), by being expressed and secreted 
by neurons upon depolarisation (Riedl et al., 2009) and activating microglia in the 
central nervous system (either in the spinal cord, or even possibly in the brain), 
through an increase in intracellular Ca2+ levels in these cells. A recent publication 
showed that neuronal damage caused a highly localised activation of cortical 
microglia, shown by an increase in intracellular Ca2+ levels from internal stores using 
in vivo two-photon imaging techniques, giving further credence to this neuro-glial 
activation mechanism (Eichhoff et al., 2011). Microglia activation is now known to 
play a significant part in the development of chronic pain states, such as neuropathic 
pain (Inoue and Tsuda, 2009; Machelska, 2011). In fact, several pain models have 
shown that VGF can be expressed in neurons long after nerve injury (Valder et al., 
2003; Xiao et al., 2002), thus allowing long-term changes in neuro-glia signalling and 
chronic pain development, with VGF-derived peptides potentially being part of the 
cohort of signalling molecules involved in the development and maintenance of this 
disease state.  
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Chapter 3: The search for receptors 
of VGF-derived peptides 
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Introduction 
 
VGF expression and tissue distribution 
 
Detailed localisation studies of the VGF mRNA and protein, show that it is widely 
distributed throughout the nervous system, selectively in neurons in the brain and 
spinal cord, and in the peripheral (dorsal root and sympathetic ganglia) and enteric 
nervous systems. It is also expressed in a number of neuroendocrine tissues, including 
the pituitary and adrenal medulla as well as in various gastrointestinal and pancreatic 
endocrine cell types (Salton et al., 2000). Important clues as to the function of VGF 
can be obtained by examining these in vivo localisation studies.  
VGF mRNA has been detected in rats as early as embryonic day 11.5 (E11.5), with 
the earliest VGF expression occurring in the peripheral nervous system (PNS) as 
maturing neurons cluster to form ganglia. In later stages of embryogenesis, VGF 
mRNA is also expressed in regions of the brain, pituitary, adrenal medulla and 
myenteric plexus. Interestingly, VGF mRNA synthesis in the brain tends to appear in 
neurons as they complete migration and begin to differentiate, suggesting a role of 
VGF in coordinating these processes (Snyder et al., 1998b). By the end of gestation, 
VGF mRNA can also be detected in the olfactory bulb and cerebral cortex, as well as 
in the retina, skin and pancreas. By postnatal day 10 (P10), the pattern of VGF mRNA 
hybridisation in the brain closely resembles that found in the adult.  
In the adult, VGF mRNA is widely expressed throughout the rodent brain, its 
abundance is highest in the neurons of the hypothalamus, primarily within the arcuate, 
paraventricular, supraoptic, and suprachiasmatic nuclei of the medial hypothalamus 
(Snyder and Salton, 1998). A major function of the hypothalamus is to control feeding 
and metabolism, and to regulate body fat stores, thus suggesting a role of VGF in 
control of energy homeostasis. Interestingly, VGF is found within the pituitary gland, 
mainly within the gonadotropes and lactotropes, suggesting that VGF has functions in 
controlling reproduction (Ferri et al., 1995).  
VGF levels were increased in both primary sensory and sympathetic neuronal 
populations in transgenic mice over-expressing NGF in their skin (Levi et al., 2004). 
Interestingly these sympathetic baskets appeared de novo around primary sensory 
neurons in these animals, which also show a significant degree of spontaneous 
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hyperalgesia (Davis et al., 1994), an early indication for the potential role for VGF-
derived peptides in the regulation of pain transmission. In addition to this, VGF 
expression in the brain was found to be induced rapidly by neuronal activity 
(Lombardo et al., 1995; Snyder et al., 1998a), injury (Mahata et al., 1993a; Snyder et 
al., 1998a) and by light and the circadian clock (Wisor and Takahashi, 1997). Much of 
the VGF (and VGF-derived peptide) expression and functional data suggests that the 
yet to be identified receptor(s) may be expressed in the brain and spinal cord (CNS) 
tissue.  
 
Methods for receptor identification 
 
A receptor is defined as an entity on target cells, which upon binding a ligand 
(agonist), initiates a biological response. These receptors can be localised on the cell 
surface or intracellularly, they can be membrane bound or soluble cytosolic proteins. 
With such a wide variety of receptors, a number of methodologies have been 
developed in order to identify these ligand binding proteins, some of which will be 
described here. Receptor-ligand interactions are not only important to academics, but 
also to the pharmaceutical industry as many of their best selling drugs target 
receptors, particularly membrane receptors.  
 
Biological activity 
 
The initial step in receptor identification is to establish that there is some form of 
biological activity occurring upon ligand application. A biological system, such as an 
in vitro cell preparation, is required and an assay system for measuring this biological 
activity (e.g. measuring changes in intracellular Ca2+ levels), which gives 
reproducible data. This biological validation step is necessary in order to isolate the 
correct tissue/cells to purify the receptor, as well as providing a useful insight into the 
potential affinities between ligand and receptor to aid in this search (i.e. concentration 
ranges of biological activity).  
It is optimal to use a pure cell preparation (e.g. microglia cells), however, the process 
of fractionation and purification often does not provide sufficient receptor 
concentrations for downstream study. To isolate and identify a receptor from a 
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complex protein mixture, such as whole tissue (e.g. brain), one must therefore have a 
sufficient starting material. Due to the nature of searching for unknown receptors 
(often aptly termed "fishing"), the biological mechanism of action may not provide a 
clear-cut cell or tissue type for receptor identification, in this case it is best to analyse 
the ligand and its cell and tissue expression and distribution patterns. This is often 
indicative of the tissue distribution of the receptor(s).  
 
Receptor solubilisation 
 
Receptor solubilisation is the next hurdle in identifying receptors, as it is necessary to 
maintain functional receptor-ligand interactions and allows one to analyse the 
biochemical properties and ideally purify the receptor enough to determine at least a 
portion of its amino acid sequence. Membrane receptors are particularly difficult to 
solubilise as functional moieties of the receptor-ligand complex, due to their highly 
hydrophobic properties. For this reason, plasma membranes are prepared from the 
tissue of interest and are solubilised in the appropriate buffer with a suitable detergent. 
Several factors need to be optimised when solubilising functional receptors, including 
the type and concentration of detergent used, the buffers and their pH and ionic 
strengths as well as the temperature and duration for the binding of ligands to their 
solubilised receptors (Vinayek and Gardner, 1990).  
 
Ligand labelling 
 
To follow the progress of any ligand-receptor complex, and ultimately identify the 
receptor, the known ligand(s) can be chemically, biologically or radiologically 
labelled. The most common form of labelling is radio-labelling ligands, using a 
radioisotope (generally 3H or 125I). Identification and characterisation of receptor 
pharmacology has been aided immensely by the radioligand binding technique, 
particularly neurotransmitter and hormone receptor systems (Bylund and Toews, 
1993). The choice of radioisotope depends greatly on the radioligand-receptor 
relationship. The advantage of 3H is that the radioligand remains chemically unaltered 
and thus biologically identical from the unlabelled ligand as well as having a long 
half-life (12 years vs. 60 days for 125I). An advantage of the iodinated ligands is their 
higher specific activity, which is useful when receptor concentrations are low. 
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However, use of radioligands requires specialist equipment and training, which are 
not always available, limiting the general usefulness of this assay.  
Fluorescently labelled ligands are an attractive alternative to radioligands, as there are 
far fewer safety considerations and no costly waste disposal issues that are necessary 
when using radioligands. Fluorescent ligands also enable techniques that are not 
applicable to radioligands, for example, by combining multiple dyes with distinct 
emission spectra, multiparametric assays become possible (Burchiel et al., 2000). It is 
also possible to do live cell imaging (at the single cell level) with fluorescently 
labelled peptides, using high resolution light and confocal microscopy- providing 
greater detail than electron microscope autoradiography used for radioligands. One of 
the major challenges of fluorescently labelling ligands is retaining their binding 
affinity, particularly if attaching a bulky fluorophore to a small peptide ligand. 
Fluorescence signals are also highly dependent on the environment, with interactions 
between fluorophores and other species (as well as other fluorophores) in the 
surrounding environment producing environment-sensitive fluorescence. However, 
increased demand has led to many fluorescent ligands becoming available in the last 
few years (Middleton and Kellam, 2005).  
Biotinylated peptides are now routinely used to study peptide-receptor and peptide-
antibody interactions. They can help localise cells expressing ligand receptors, as well 
as analyse ligand-receptor binding properties. Modification of proteins and peptides 
with a biotin label has been successfully applied for multiple studies. For example, 
biotinylated insulin-like peptide 3 (INSL3) was shown to have full biological activity 
and introduction of the N-terminal biotin even promoted conformational stability and 
improved receptor activation (Fu et al., 2004). Also, biotinylated relaxin was used to 
identify the specific cell types expressing the relaxin receptor (Min and Sherwood, 
1996). Another advantage of the biotinylated peptide is that it can be immobilised on 
a streptavidin-coated surface and used to isolate potential receptors using affinity 
chromatography techniques. However, elution of biotinylated peptides from 
streptavidin-coated surfaces is a major challenge, due to the extremely high stability 
of the complex (Kd ~ 10-15 M). This has led to the development of monomeric avidin, 
which has a much lower binding affinity to biotin and is thus ideal for affinity 
chromatography using biotinylated peptides. The biotinylated molecules are also 
easily detected with derivatives of streptavidin (e.g. fluorophore- or horseradish 
peroxidase-conjugates). 
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The selection of ligand labels are entirely dependent on the work being done and the 
properties of the ligand and receptor(s), as well as the associated costs and availability 
of specialist equipment all contribute to the label(s) used in an investigation. All this 
must be taken into account, as well as the fact that any labelling can modify the ligand 
and thus alter its biological specificity.  
 
Affinity chromatography 
 
Affinity chromatography is a diverse and powerful method for purification of a 
specific molecule or group of molecules from a protein mixture. The method, when 
originally developed, referred to the use of an immobilised natural ligand that 
interacted with a target protein. It is based on the highly specific, biological 
interactions between two molecules, such as receptors and ligands, or antibody and 
antigen. These typically reversible interactions are used for purification by attaching 
an affinity ligand to a solid matrix to create a "stationary phase", whereas the target 
molecule (e.g. receptor) that is applied is in the "mobile phase". The most successful 
affinity purifications require some prior knowledge of the ligand-receptor interaction 
in order to help determine appropriate affinity chromatography conditions (Urh et al., 
2009). The strict definition of "affinity" techniques is the use of biospecific 
interactions, which result in the change of properties of a protein (e.g. receptor) so it 
can be separated from a complex protein mixture (Scopes, 1994).  
 
Covalent crosslinking 
 
Protein-protein interactions form the basis for most complex biological processes. 
These interactions can be transient or stable, and often form elaborate interaction 
networks. Chemical crosslinking provides a method of identifying both types of these 
interactions, by chemically joining two or more molecules by a covalent bond. There 
are now a huge array of chemical crosslinking reagents, which are used for a wide 
variety of applications. They can be used to determine the geometric configuration of 
subunits within a protein or complex, as well as near-neighbour relationships. It is 
also possible, using this technique, to study protein-protein and receptor-ligand 
interactions. For example, the NPY receptor in rat brain membrane preparations was 
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identified using radiolabelled NPY and several different crosslinkers (Mannon et al., 
1989).  
Receptor-ligand complexes can be isolated and purified, using both labelled 
crosslinkers and/or labelled ligands. Crosslinking reagents are classified on the 
following characteristics: (1) chemical specificity; (2) the length of the spacer arm of 
the crosslinker; (3) whether the crosslinker is homobifunctional (identical reactive 
groups at either end of the spacer arms) or heterobifunctional (different reactive 
groups at either end); (4) chemically reactive or photo-reactive groups; (5) does the 
crosslinker have a cleavable bond to separate the two proteins after crosslinking; (6) 
can the crosslinker be labelled (e.g. radiolabelled). When selecting a crosslinker, there 
are numerous factors to consider, thus it is best to have some prior knowledge of the 
interaction. The details of crosslinker selection and varieties available have been 
covered extensively in reviews and will not be covered here, more in-depth 
knowledge can be found in the following literature (Hermanson, 2008; Mattson et al., 
1993). When searching for receptors of ligands, for which little is known, there is 
often no easy way to predict which crosslinker will provide the best chance of 
success.  
 
Mass spectrometry and identification of the receptor 
 
The final step of studying ligand-receptor interactions is to identify the receptor. Once 
the receptor has been solubilised, fractionated and purified (e.g. by affinity 
chromatography) the amino acid sequence can be elucidated using increasingly 
powerful and sensitive mass spectrometry techniques that are becoming available. 
Mass spectrometry (MS) is an indispensable analytical tool in chemistry, 
biochemistry and pharmacy. With the development of powerful methods to produce 
ions in the mass spectrometer, progress in biological mass spectrometry has greatly 
aided protein analysis and tandem MS (MS/MS) has allowed determination of the 
amino acid sequences of identified proteins. This therefore allows identification of 
receptors, in a mostly automated and repeatable manner (Schermann et al., 2005).  
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Aims 
 
The work presented in this chapter was to confirm the functionality of modified VGF-
derived peptides, using the Ca2+ assay developed in the previous chapter. These VGF-
derived peptides were then used to identify any potential receptor(s)/binding partners. 
Two methodologies were employed to achieve this, covalent crosslinking and affinity 
chromatography followed by mass spectrometric analysis of proteins. Protein-specific 
antibodies were used to validate the receptor protein identity, by Western blot 
analysis, immunocytochemistry (ICC) and the Ca2+ assay.  
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Materials & Methods 
 
Modified VGF-derived peptides and in vitro functionality testing 
 
The modified VGF-derived peptides used in the search for VGF-binding 
partners/receptors were synthesised by Peptide Synthetics (Peptide Protein Research 
Ltd.), with >95 % purity (HPLC confirmed). The peptides were provided as a 
lyophilised powdered solid and were dissolved in 1x PBS, aliquoted and stored at 
-20 °C. The peptides were synthesised with the biotin covalently attached via the 
amide bond at the N-terminus, and an extra cysteine residue was included at the C-
terminus. The peptide sequences are: 
Biotin-TLQP-21+Cys  Biotin-TLQPPASSRRRHFHHALPPARC 
Biotin-LQEQ-19+Cys Biotin-LQEQEELENYIEHVLLHRPC 
To test peptide in vitro functionality, primary microglia cultures (DIV=23) and 
confocal analysis were performed (as described in the Materials & Methods section in 
Chapter 2).  
 
Peptide conjugation  
 
The Sulfo-EMCS heterobifunctional crosslinker contains N-hydroxysuccinimide 
(NHS) ester and maleimide groups, which allow covalent conjugation of amine- and 
sulfhydryl-containing molecules, respectively. NHS esters react with primary amines 
at pH 7-9 to form amide bonds, while maleimides react with sulfhydryl groups at pH 
6.5-7.5 to form stable thioether bonds. The Sulfo-EMCS was initially conjugated to 
the VGF-derived peptides, LQEQ-19 and TLQP-21, via the sulphydryl group on the 
C-terminus of the peptides. 1 mM Sulfo-EMCS cross-linker, dissolved in MES buffer 
(pH 6.5) was prepared freshly on the day of the experiment; additionally 2 mM EDTA 
and 2 mM TCEP (Tris [2-carboxyethyl] phosphine; a thiol-free reducing agent) were 
incubated with 0.1 mM peptide (either LQEQ-19 or TLQP-21) in 100 mM MES 
buffer for 2 hours on ice. The conjugated peptides were then used for the following 
MALDI-TOF mass spectrometry (MS) and crosslinking steps, or flash frozen and 
stored at -80 °C.  
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MALDI-TOF mass spectrometry and crosslinking reactions 
 
The conjugated reaction was analysed by MALDI-TOF MS, briefly, this involved 
doing a clean-up reaction using C18 Zip-Tips (Millipore). The Zip-Tips were washed 
with 0.1 % trifluoroacetic acid (TFA) in acetonitrile, followed by washing in 50 % 
acetonitrile (in water), followed by equilibration of the Zip-Tip twice in 0.1 % TFA. 
The conjugated peptides had TFA added to them, to a final concentration of 0.1 %, 
and they were passed through the Zip-Tip repeatedly, by pipetting in and out to bind 
the peptides to the C-18 resin. This was followed by washing three times (by 
pipetting) with 0.1 % TFA. Finally the peptide sample was eluted from the Zip-Tip in 
alpha-cyano-4-hydroxycinnamic acid matrix dissolved in 0.3 % Formic acid and 
100 % acetonitrile solution, directly onto the MALDI-TOF sample plate and analysed 
using the 4800 Plus MALDI-TOF/TOF (Applied Biosystems) apparatus, in both 
linear and reflectron modes and ProteinPilot v4.0 software.  
The in vitro functionality of the conjugated TLQP-21 was tested using primary 
microglia and confocal microscopy, as described in the Materials & Methods section 
in Chapter 2 (as was the testing of anti-gC1q-R antibody on primary microglia and 
live cell confocal imaging).  
Once the conjugation reaction was confirmed by MALDI-TOF MS analysis, the 
crosslinking reaction was set up. The spacer arm on the crosslinker is 9.4 Å, thus any 
protein (i.e. receptor or binding partner) within this space should become covalently 
linked to the VGF-derived peptides. The protein preparation (10 µg; see below for 
preparations) had 10 µM conjugated peptide added in 150 mM NaCl and boric acid 
buffer, pH 8.0. The crosslinking reaction was allowed to proceed for 2 hours on ice. 
The reaction was stopped with the addition of 50 mM Tris buffer (pH 8.0), which has 
primary amines that react with any unconjugated crosslinker. The samples were then 
analysed by Tricine-PAGE and Western blot analysis (see below).  
 
Protein fraction preparations 
 
For the crosslinking experiment, whole brain and spinal cord (CNS) tissue was 
removed from female Wistar rats (6 weeks old; 150 grams), which were culled by 
CO2 asphyxiation. The CNS tissue was flash frozen and prepared as described below. 
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For the monomeric avidin experiments, post-natal day 4 (P=4) rat forebrain was used 
instead and flash frozen. Both sets of tissue (adult CNS and P=4 brain) were ground 
into a fine powder using a pestle and mortar while on dry ice (to prevent thawing). 
For each preparation and experiment, 200 mg of tissue was used and any remaining 
tissue powder was stored at -80 °C. The different protein fractions were then prepared 
from here (N.B. For the crosslinking experiment, only the membrane protein fraction 
was prepared from adult CNS tissue).  
All solutions and tissue preparations (unless otherwise stated) were kept on ice at all 
times throughout the protocol.  
 
Whole cell lysate (WCL) fraction 
 
To the 200 mg ground powder in a 1.5 ml eppendorf, ice-cold PBS solution with 20 % 
glycerol and 0.1 % Triton-X100 was added and gently mixed. The mixture was 
incubated for 1 hour on a rotator at 4 °C. This was followed by sonication for 6 sec 
bursts (15 % amplitude), followed by incubation on ice for ~1 minute, followed by 
another 6 second burst of sonication. This process was repeated until a homogenous 
solution was observed (~6-7 sonication bursts). Mammalian protease inhibitor 
cocktail (Sigma) was added immediately after this at the recommended dilution 
(100 µl per 2 grams tissue). The sample was then stored at 4 °C overnight or used 
immediately for downstream processes (i.e. monomeric avidin column application).  
 
Cytosolic fraction 
 
To the 200 mg ground powder in a 1.5 ml eppendorf, ice-cold PBS solution with 20 % 
glycerol was added and gently mixed. The tissue was then sonicated for 6 sec bursts 
(15 % amplitude), followed by incubation on ice for ~1 minute, followed by another 
6 second burst of sonication. This process was repeated until a homogenous solution 
was observed (~6-7 sonication bursts). Mammalian protease inhibitor cocktail 
(Sigma) was added immediately after this at the recommended dilution (100 µl per 
2 grams tissue). The sample was then centrifuged at 1000 x g for 10 minutes at 4 °C 
and the supernantant transferred to an ultracentrifuge tube. The protein sample was 
then centrifuged for 30 minutes, at 100, 000 x g at 4 °C in a Beckman Optima Max 
ultracentrifuge with a fixed angle TLA-45 rotor. The supernatant was collected and 
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contained the cytosolic protein fraction, and the mammalian protease inhibitor 
cocktail was added again. The cytosolic protein fraction was then stored at 4 °C 
overnight or used immediately for downstream processes (i.e. monomeric avidin 
column application). The pellet obtained after the ultracentrifugation step was used to 
obtain the membrane and associated proteins (M+A) fraction (see below).  
 
Membrane and associated proteins (M+A) fraction 
 
The pellet obtained from the preparation described above was resuspended in 
PBS/Glycerol (20 %) solution and sonicated as described above, until a homogenous 
solution was obtained (~5 sonication bursts). The protein solution was then 
centrifuged at 36, 000 x g for 30 minutes, to remove aggregates. The supernatant was 
removed and centrifuged 30 minutes, at 100, 000 x g at 4 °C. The resulting pellet was 
gently resuspended in PBS/Glycerol with 4 % n-Dodecyl β-D-maltoside (DDM) 
detergent (a non-ionic detergent used to solubilise membrane proteins). The mixture 
was incubated for 1 hour on a rotator at 4 °C, followed by centrifugation for 
30 minutes, at 100, 000 x g at 4 °C. The supernatant was collected and represented the 
solubilised membrane (and associated) proteins, and the mammalian protease 
inhibitor cocktail was added immediately after this at the recommended dilution. The 
M+A fraction was then stored at 4 °C overnight or used immediately for downstream 
processes (i.e. monomeric avidin column application).  
N.B. For the crosslinking experiment and the adult CNS tissue, before the addition of 
DDM, an extra step was included where 100 mM Na2CO3 in the PBS/Glycerol buffer 
was added to the protein mixture and incubated for 1 hour on a rotator at 4 °C, 
followed by an additional sonication step and centrifugation for 30 minutes, at 
100, 000 x g at 4 °C. This Na2CO3 step removed any membrane associated proteins, 
leaving a membrane protein only fraction. The proceeding steps (i.e. with DDM 
buffer addition and onwards) were the same as described above. This extra step 
reduced the protein concentration quite severely, however, due to the specificity and 
covalent attachment of any binding proteins/receptors to VGF-derived peptides, this 
reduction was acceptable (but not for the monomeric avidin protocol).  
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Monomeric avidin agarose affinity chromatography 
 
The monomeric avidin agarose (Thermo Scientific; Pierce) was packed into an empty 
column with a 2 ml resin-bed volume (Thermo Scientific; Pierce) according to 
manufacturer instructions. Briefly, 2 ml monomeric avidin agarose was added to the 
column and washed with 8 ml PBS/glycerol (20 %)/0.1 % DDM. This was followed 
by addition of 6 ml biotin blocking/elution buffer (2 mM D-biotin in PBS/glycerol/ 
DDM) to block the non-reversible biotin binding sites. The resin was then washed 
with 12 ml regeneration buffer (0.1 M glycine, pH 2.8) to remove biotin from the 
reversible binding sites, followed by a wash with PBS/glycerol/DDM buffer (wash 
buffer). The column was now ready to have protein/peptide samples added, and it was 
possible to regenerate the resin a maximum of 10 times for re-use.  
To attach the VGF-derived peptides to the column, a 10 µM peptide solution (2 ml 
total volume) was prepared in wash buffer, with 1 mM TCEP added (a reducing agent 
as VGF-derived peptides can form disulphide bonds due to the extra cysteine residues 
at their C-termini). This solution was applied to the column and left for 30 minutes to 
allow the peptide to completely attach. The column was then washed with 10 ml wash 
buffer and tissue (WCL, cytosolic or M+A) could now be added.  
The 200 mg protein preparations (WCL, cytosolic or M+A) were split into two for 
each experiment, 100 mg for negative control (membrane only, without the peptides 
attached) and the other 100 mg for application to a column with VGF-derived peptide 
(TLQP-21 or LQEQ-19) attached.  
The tissue (100 mg WCL, cytosolic or M+A) was added to the column in a total 
volume of 2 ml (topped up using wash buffer). This was followed by a 12 ml wash 
buffer application, which was performed rapidly, followed by application of 10 ml 
elution buffer, and the elution fractions were collected and stored on ice until SDS-
PAGE analysis and silver staining or Western blot analysis (see below). The column 
was regenerated (using 8 ml regeneration buffer), followed by 10 ml wash buffer 
application. The column could now be re-used (up to a total of 10 regeneration steps 
as mentioned earlier).  
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SDS- or Tricine-PAGE and Western blot analysis 
 
Samples from the crosslinking reaction were analysed by Tricine-PAGE, as this 
allows for better resolution of proteins, particularly those smaller than 30 kDa 
(Schagger, 2006). Samples eluted from the monomeric avidin experiment were 
analysed by SDS-PAGE. All samples were mixed with 5x Laemmli buffer (Sigma), 
incubated for 10 minutes at 50 °C (due to membrane protein precipitation, it is 
recommended not to heat samples to 95 °C) and equally loaded and resolved by SDS- 
or Tricine-PAGE (Bio-Rad apparatus). For the crosslinking experiment, the protein 
gels were then analysed by Western blot analysis (see on). The monoavidin 
experiment sample gels were either silver stained or analysed by Western blot 
analysis. 
For silver staining, the SilverQuestTM Silver Staining kit (Invitrogen; # LC6070) was 
used as this was compatible for subsequent mass spectrometric analysis. All staining 
solutions were filtered (0.2 µm) and everything performed in detergent cleaned 
apparatus and in a keratin- and dust-free laminar flow hood. The "Fast Staining" 
protocol was used as per manufacturer's instructions. Gel images were taken using the 
light-box and Fujifilm LAS-3000 Imaging System, and protein bands of interest were 
cut and analysed by LC-MS/MS (see on).   
For Western blot analysis; following electrophoresis, proteins were transferred onto 
polyvinylidene fluoride (PVDF) membrane (GE Healthcare) using the wet-transfer 
system for 2 hours at 200 mA on ice (Bio-Rad). The membrane was then incubated in 
5 % bovine serum albumin (BSA) block in TBS-T solution (Tris buffered saline with 
0.1 % Tween 20) for 1 hour at room temperature (R.T.), followed by three 10 minute 
washes in TBS-T. For the crosslinking experiment, the biotinylated peptides 
(TLQP-21 and LQEQ-19), and any protein(s) they were crosslinked to, were probed 
with HRP-conjugated Streptavidin (Zymed), at 1:2000 dilution in TBS-T (which 
detected the biotin on the peptides) for 1 hour at R.T. The samples from the 
monomeric avidin experiment were probed with the anti-gC1q-R antibody (Abcam), 
at 1:2000 dilution in TBS-T overnight at 4 °C, followed by three 10 minute washes 
with TBS-T and the secondary, goat anti-mouse-HRP antibody, at 1:1000 dilution in 
TBS-T for 1 hour at R.T.  
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Following the Streptavidin-HRP or goat anti-mouse-HRP antibody incubations, the 
PVDF membranes were washed three times (10 minutes each) with TBS-T. This was 
followed by application of the chemiluminescence detection kit for HRP (AppliChem, 
VWR) and detection with the Fujifilm LAS-3000 Imaging System.  
 
LC-MS/MS 
 
Following monomeric avidin chromatography, protein bands which were found to be 
more intense than the corresponding negative control, after analysis by SDS-PAGE 
and silver staining, were carefully cut from the gel using a clean/sterile razor blade in 
a laminar flow hood (to prevent dust and keratin contamination). The gel pieces were 
placed in a clean Lo-bind (Eppendorf) 1.5 ml tube (cleaned with 100 % acetonitrile, 
and multiple 0.2 µm filtered water washes to remove keratin). The gel pieces were 
then de-stained, as per manufacturer instructions (SilverQuestTM Silver Staining kit; 
Invitrogen), and sent for trypsinisation and LC-MS/MS Orbitrap analysis (University 
of Oxford, Central Proteomics Facility). 
 
Immunocytochemistry (ICC)  
 
For ICC analysis, primary microglia (purified and cultured using the same protocol 
described in Chapter 2) were plated on 13 mm glass coverslips coated with poly-L-
lysine, instead of the glass bottomed dishes used for confocal analysis. For staining, 
cells were initially washed three times with PBS, fixed with 4 % paraformaldehyde 
(PFA; Sigma) in PBS for 10 minutes at R.T., followed by two PBS washes. For cells 
which needed permeabilising, an additional step of applying 0.1 % Triton-X100 in 
PBS for 10 minutes at R.T. was included, followed by another two PBS washes. Cells 
were then blocked for 20 minutes at R.T. in 10 % goat serum (serum raised in the 
same animal as the secondary antibody) in PBS, and another two PBS washes were 
applied. The primary antibody, anti-gC1q-R (Abcam), was used at 1:50 diluted in the 
blocking solution (10 % goat serum in PBS) and incubated overnight at 4 °C, washed 
twice in PBS and the Hoechst 33342 nuclear dye (Invitrogen) applied at 1:10000 
dilution in PBS for 10 minutes at R.T. Cells were then washed twice with PBS and the 
secondary, goat anti-mouse-FITC applied at 1:1000 in blocking solution for 1 hour at 
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R.T. in a dark chamber or wrapped in foil. Cells were then washed three times with 
PBS, twice with deionised water and mounted on glass slides with anti-fade agent 
AF1 (Citifluor Ltd.). Coverslips were sealed to the glass slides with nail varnish 
remover. If samples needed to be stored, they were left at 4 °C in the dark or for long-
term storage, stored at -20 °C. Cells were analysed on a widefield Nikon 80i 
microscope, with pictures taken using a digital Nikon DXM1200F camera and 
Lucia G software. Image analysis was performed using Adobe Photoshop CS.  
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Results 
 
Determining the functionality of modified VGF-derived peptides 
 
To aid with the search for potential VGF receptors, the peptides TLQP-21 and 
LQEQ-19 were synthesised (>95 % purity; Peptide Synthetics, PPR Ltd) with a biotin 
tag at the N-terminal (via the amide bond) and an additional cysteine residue at the C-
terminal. A biotin tag is useful for a multitude of applications, including allowing 
direct detection of the peptide (e.g. using streptavidin-HRP) and thus indirect 
detection of any binding partners, as well as for use in purification and affinity 
columns. The extra cysteine is useful as it allows heterobifunctional crosslinkers to be 
utilised to assist in capturing any receptors, and as there are no cysteine residues 
naturally present in the whole mature VGF sequence, there is no concern of further 
chemical modifications to VGF-derived peptides via any endogenous cysteine 
residues. As a result of the modifications, it was essential to confirm that the peptides 
were still functional in vitro, using the Ca2+ assay developed in the previous chapter. 
It was observed that the modified TLQP-21 peptide (Bio-TLQP-21+Cys) was able to 
induce an increase in intracellular Ca2+ levels in a transient manner similar to the wild 
type peptides (Figure 3.1A and B), and the subsequent ATP application confirmed the 
viability of the cells remained unaffected, even with the addition of biotin and a 
cysteine residue. However, the modifications appeared to reduce the affinity of (or 
microglia sensitivity to) the TLQP-21, as the increase in intracellular Ca2+ was no 
longer induced at 100 nM (Figure 3.1C), as observed with the wild type peptide, 
instead the lowest measured concentration for the induction of the Ca2+ response was 
1 µM, a 10-fold order of magnitude lower than the wild type (Figure 3.1B).  
The Ca2+ assay was performed on the modified TLQP-21, this time conjugated to the 
Sulfo-EMCS cross-linker via the C-terminal cysteine residue (Figure 3.1D). It was 
observed that at 1 µM, the peptide still induced an increase in intracellular Ca2+ levels 
and thus its functionality appeared unaffected, as least using this in vitro assay, with 
the small crosslinker attached. The subsequent ATP response, however, was smaller 
than for the conjugated TLQP-21, suggesting that the conjugated species enhanced the 
Ca2+ response in microglia cells, or more likely the cell viability may have been 
reduced. The conjugated LQEQ-19 could not be tested using this assay. 
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To confirm that the modified TLQP-21 had been conjugated to the Sulfo-EMCS, the 
conjugated peptide was analysed by MALDI-TOF mass spectrometry (MS). The 
predicted monoisotopic mass of the modified TLQP-21 peptide, with the Sulfo-EMCS 
("X-linker") attached is 3147.46 Da (to 2 d.p.), and the major peak observed in the 
MALDI-TOF MS was the [TLQP+X-linker+H]+ form of this peptide conjugate, at 
m/z 3148.4 (Figure 3.2A). In MALDI-TOF MS, ions are nearly always singly charged 
species (where H is a proton), to obtain the exact molecular weight of the species of 
interest, it is a simple matter of subtracting the mass of a single proton (i.e. 1) from 
the mass observed on the spectrum. Thus, the Sulfo-EMCS ("X-linker") was 
successfully conjugated to TLQP-21. Some unconjugated TLQP-21 (again 
protonated) was also present, as represented by the peak at m/z 2764.6, [TLQP+H]+ 
and with ~40 % the intensity of the conjugated peptide. There were also a number of 
other peaks, which represented conjugated TLQP-21 that was doubly protonated, 
[TLQP+X-linker+H]++ at m/z 1572.9 as well as fragmentation products due to the 
MALDI-TOF procedure (e.g. m/z 3104.8 represented conjugated TLQP-21 with the 
loss of CO2).  
The predicted monoisotopic mass of LQEQ-19 conjugated to the Sulfo-EMCS is 
3106.36 (to 2 d.p.), and one of the smaller peaks observed (m/z 3101.5662) represents 
the [LQEQ+X-linker]+ species (Figure 3.2B). In this instance, the MALDI-TOF m/z 
values are all displaced by 4-5 Da, a common occurrence in MALDI-TOF analysis 
when the peptides are analysed in the linear mode. This did not occur for the 
TLQP-21 peptide analysis, and may have been due to differences in ionisation ability 
of the peptides or fluctuations in the mass spectrometry equipment. However, the 
prominent peak observed in the MALDI-TOF analysis was at m/z 2912.46 (to 2 d.p.), 
this corresponds to a doubly charged Sulfo-EMCS cross-linker conjugated to the 
LQEQ-19 peptide. Thus the conjugation reaction was successful, with the main 
species on the MALDI-TOF spectra being the LQEQ-19 + Sulfo-EMCS, but with the 
crosslinker doubly charged [LQEQ+(X-linker+2)/2]+. The conjugation was performed 
at pH 6.5, however, before application onto the MALDI-TOF plate, the conjugation 
reaction was eluted using 100 % acetonitrile and 0.3 % formic acid, while washing 
out the buffer keeping the conjugation mixture at pH 6.5. This elution in acidic 
conditions enhanced the protonation of the Sulfo-EMCS, which was conjugated to the 
LQEQ-19, but not for the Sulfo-EMCS-TLQP-21. A small amount of unconjugated 
LQEQ-19 peptide was also apparent, with a minor peak observed at m/z 2719.31 
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[LQEQ+H]+. These data do, however, suggest that the majority of both the peptides 
were conjugated to the Sulfo-EMCS crosslinker successfully.  
 
 
 
Figure 3.1. Determining the functionality of modified VGF-derived peptides and 
conjugated species. Average fluorescence profiles of primary microglia cells; each 
experiment represents the average of 150 cells over 3 biological replicates. ATP was 
applied as a cell viability test, and only viable cells were selected. (A) 10 µM of the 
modified TLQP-21 (Biotin-TLQP-21+Cys) induced a rapid and transient increase in 
intracellular Ca2+ levels in primary microglia cells. (B) 1 µM of the biotin-TLQP-
21+Cys peptide was also able to induce a Ca2+ response in the microglia. (C) At 
100 nM, the modified TLQP-21 no longer elicited a Ca2+ response in the cells. (D) 
The modified TLQP-21, conjugated to Sulfo-EMCS, induced an increase in 
intracellular Ca2+ levels in microglia, when applied at 1 µM, and this response was 
larger than the subsequent ATP response.  
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Figure 3.2. MALDI-TOF MS confirmed that the major species observed were 
Sulfo-EMCS-conjugated TLQP-21 and LQEQ-19. The VGF-derived peptides were 
conjugated to Sulfo-EMCS, followed by sample clean-up and elution from C18 resin 
Zip Tips (Millipore) and MALDI-TOF MS analysis. (A) The structure of the 
conjugated TLQP-21 with Sulfo-EMCS is shown, with a predicted monoisotopic 
mass of 3147.458151 Da. The major peak at m/z 3148.4 [TLQP-X-linker+H]+ 
represents the TLQP-21 conjugated to Sulfo-EMCS ("X-linker") in it's protonated 
form, with a minor peak representing the double protonated form of this conjugate at 
m/z 1572.9. Another peak at ~40 % the intensity of the major peak represents 
protonated, unconjugated TLQP-21 at m/z 2764.6 [TLQP+H]+. The other peaks 
represent fragmentation of the conjugated peptide during MALDI-TOF MS analysis 
(e.g. m/z 3104.8 represents a loss of CO2). (B) The structure of the conjugated 
LQEQ-19 with Sulfo-EMCS is shown, with a predicted monoisotopic mass of 
3106.360179 Da. The major peak at m/z 2912.4644 represents a doubly protonated 
Sulfo-EMCS conjugated to the LQEQ-19 peptide. Another peak at ~20 % the 
intensity of the major peak represents protonated, unconjugated LQEQ-19 at 
m/z 2719.3098 [TLQP+H]+.  
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Crosslinking of conjugated VGF-derived peptides to CNS tissue  
 
Protein-receptor interactions are the underlying molecular mechanism of a multitude 
of complex biological processes. When searching for the binding partners and 
receptors of proteins and peptides, it is often difficult to predict the affinity and 
kinetics of the interaction. Interactions can be transient, or form stable complexes, 
often in multi-protein assemblies. Chemical crosslinking allows a direct method for 
identifying interactions that are both transient and stable.  
The Sulfo-EMCS crosslinker is heterobifunctional; it has a maleimide group, which 
was used to react with the sulphydryl group of cysteine, of the VGF-derived peptides. 
The second functional group on the crosslinker is the NHS-ester, which reacts with 
primary amines of any proteins in close proximity to the conjugated VGF-derived 
peptides (i.e. receptors and binding proteins). After conjugating the peptide to the 
heterobifunctional crosslinker, via the cysteine on the modified VGF-derived peptides 
(LQEQ-19 or TLQP-21 at 10 µM), this conjugate was applied to a membrane protein 
preparation (10 µg per reaction) from an adult rat brain and spinal cord (total CNS 
tissue from 150 g rat). This tissue was used as a large starting material was necessary, 
and previous data (Ferri et al., 2011), as well as the data presented in this report, 
indicate that VGF-derived peptides act on the cells in the CNS, from neurons in the 
cerebellum (Severini et al., 2008), to microglia. Although it was observed in the 
previous chapter that the TLQP-21 peptide induced an increase in intracellular Ca2+ 
levels in microglia, ideally the receptor search should start here. However, microglia 
are extremely difficult to culture in very large numbers, thus it was decided to start 
from a broader pool of cell types using rat CNS tissue and then refine the tissue 
fractions in later steps. Microglia constitute a large proportion of cells in the CNS, and 
although the precise proportions are still debated, it has been suggested that the 
number of microglia may match the number of neurons in the CNS, although they are 
less numerous than other neuro-glia cells (Graeber, 2010). 
The cross-linking reaction, using the Sulfo-EMCS-conjugated VGF-derived peptides, 
was allowed to proceed on ice for 3 h, with the CNS membrane protein preparation, 
and was terminated by addition of excess Tris buffer (which contains primary 
amines),  followed  by  ethanol  precipitation  and  resolution  by  Tricine-PAGE  and 
Western  blotting.  The peptides had N-terminal biotin tags, thus using Streptavidin-
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HRP, it was possible to detect them using Western blot analysis.  The cross-linking 
experiment showed ~30 kDa bands appear when the conjugated peptides (both 
TLQP-21 and LQEQ-19) were applied to the CNS membrane preparation (Figure 
3.3), but not in the membrane controls. The membrane controls consisted of the same 
amount of CNS protein sample, with unconjugated Sulfo-EMCS crosslinker (i.e. 
identical except for the presence of the VGF-derived peptides). This also allowed 
analysis of proteins that crosslinked non-specifically to Sulfo-EMCS, as well as 
endogenous biotinylated proteins in the CNS membrane protein fractions.  
Application of conjugated TLQP-21 to CNS membrane proteins showed a clear 
~30 kDa species, which was barely visible in the membrane control (Figure 3.3A). 
The weak ~30 kDa band appearing in the membrane control is most likely to be some 
cross-contamination of samples when loading the cell, this highlights the sensitivity of 
the technique. There were a few faint protein bands at higher molecular weights 
(~72 kDa), which appeared to be proteins not apparent in the membrane control. 
However, they were not many orders of magnitude greater than the control well and 
thus it was difficult to differentiate actual crosslinking differences from differences in 
gel loading, unlike the ~30 kDa protein observed.  
The ~30 kDa protein band was also apparent when conjugated LQEQ-19 was applied 
to the CNS membrane proteins, but not the membrane control (Figure 3.3B), although 
the protein band was a lot less prominent than for the TLQP-21 experiment. However, 
some precipitated protein was observed at the top of the LQEQ-19 lane of the 
membrane blot (but not in the membrane control lane), which corresponds to the 
stacking region or well of the SDS-PAGE gel. This suggests that much of the protein 
did not migrate into the gel and thus the overall protein amount observed in the 
resolving region of the resultant Western blot were greatly reduced.  
One thing is clear from both datasets; the ~30 kDa band is prominent for both 
peptides, and is many orders of magnitude greater than in the respective membrane 
control lanes.  
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Figure 3.3. A ~30 kDa protein was observed following chemical crosslinking 
using VGF-derived peptides, TLQP-21 and LQEQ-19. Conjugated peptides 
(TLQP-21 or LQEQ-19 at 10 µM) were applied to CNS membrane protein 
homogenates, under conditions necessary for crosslinking to proceed (boric acid 
buffer, pH 8, with 150 mM NaCl) for 3 h on ice. The membrane controls, using 
unconjugated Sulfo-EMCS crosslinker, were performed at the same time and 
conditions. The reaction was terminated using 50 mM Tris buffer, samples ethanol 
precipitated and resolved using Tricine-PAGE and visualised by Western blot analysis 
by detecting the biotin on the modified peptides. (A) The TLQP-21 crosslinking 
reaction showed a clear band at ~30 kDa (indicated by an arrow), which was many 
orders of magnitude greater than the corresponding band (barely visible) in the 
membrane control lane. (B) The same ~30 kDa band (indicated by an arrow) was 
apparent in the LQEQ-19 reaction (but not in the corresponding membrane control 
lane), although the ~30 kDa band was not as prominent as the TLQP-21 crosslinking 
reaction. Some protein precipitate was observed at the top of the LQEQ-19 lane, 
suggesting that some protein did not enter or resolve in the gel and may account for 
the loss of ~30 kDa band intensity observed.  
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Identification of receptors/binding partners for VGF-derived 
peptides 
 
Another methodology often employed to identify protein-protein interactions (e.g. 
ligand-receptor), is to use affinity chromatography- by attaching a ligand to a column 
and applying a protein mixture to allow binding to occur. This is then followed by 
washing and finally eluting the protein complex from the column, as long as the 
ligand-receptor affinity is high enough to capture and retain the receptor during the 
washing steps. The same principles were applied in this investigation, by taking 
advantage of the biotin tag on the N-terminus of the VGF-derived peptides. Avidin is 
a biotin-binding protein, which forms one of the strongest known non-covalent bonds 
with biotin. This interaction is thus exploited in many biochemical assays; however, 
dissociation of the avidin-biotin complex often proves to be extremely difficult, with 
many step processes, often resulting in reduction of the protein left in the sample. 
Thus a monomeric form of avidin is used in affinity resin, which has a lower affinity 
to biotin and elution from the avidin can be performed under milder conditions.  
A monomeric avidin column was used in this investigation to purify and identify 
potential receptor(s) for the VGF-derived peptides, LQEQ-19 and TLQP-21. These 
peptides (at 10 µM) were attached to monomeric avidin resin, via their biotin tags, 
followed by application of tissue. Any receptor(s) would bind the TLQP-21 or LQEQ-
19, while other proteins would be washed away. Finally, the TLQP-21 or LQEQ-19, 
along with any bound receptor(s) would be eluted and resolved by SDS-PAGE. As a 
control, the same chromatography would be performed, but without the VGF-derived 
peptides attached to the column. Any resulting proteins eluted from the control would 
be non-specific proteins bound by the resin (e.g. endogenously biotinylated proteins).  
Whole brain tissue from post-natal day 4 (P=4) rats was used, as this was the same 
tissue used to extract and culture primary microglia (in the previous chapter) for use 
in Ca2+ imaging using the VGF-derived peptides. As the microglia derived from P=4 
rat brain showed a response to TLQP-21, then it was assumed that, if this response 
was receptor-mediated, it would be logical to use the same tissue in search of the 
receptor(s). Three different protein preparations were used, from P=4 rat brain, in 
order to identify the receptor(s), whole cell lysate (WCL), cytosolic proteins as well 
as  membrane and membrane-associated proteins (M+A). These preparations were 
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then applied to a monomeric avidin column, with or without (negative control) the 
VGF-derived peptides attached. The columns were washed and protein complexes 
were eluted, resolved by SDS-PAGE, silver stained and then visualised. The elutions 
from columns with peptide attached were directly compared to the negative controls 
(tissue put through a column without the peptides attached).  
It was found that, when WCL, cytosolic or M+A proteins were put through a 
monomeric avidin column, a ~30 kDa band was apparent in all of the elutions that had 
TLQP-21 attached (Figure 3.4, indicated by arrows), but was barely visible in the 
associated negative control column (one without TLQP-21 attached). After resolution 
by SDS-PAGE, it was only possible to visualise these bands using silver staining- a 
highly sensitive protein stain that can detect protein concentrations as low as 
picograms (pg) of protein. This suggests that only very little of this ~30 kDa protein 
was isolated following the affinity chromatography purification. As expected, there 
are a lot more overall proteins observed in the WCL preparation, since no prior 
fractionation and purification steps were performed on this tissue. The M+A protein 
mixture had the least proteins present and thus the least background staining. It must 
be noted that the ~30 kDa bands are not due to more protein being loaded in the 
+TLQP lanes of the gels, as equal amounts of protein were loaded, which is apparent 
from the non-specific bands on the gels.  
Other bands were visible in both cytosolic (~50 kDa) and M+A (~75 kDa) TLQP-21 
elution fractions, which were not in the corresponding control lanes, however, these 
proteins did not consistently appear when repeated (indicated by "+?"). This suggests 
that they are artefacts of the chromatography process, or are potential binding proteins 
which do not consistently remain bound to the TLQP-21 and are sometimes washed 
away before elution. Interestingly, some proteins were found to decrease in the 
TLQP-21 elutions relative to their controls (indicated by "-"). This suggested that 
these could potentially be endogenous biotinylated proteins in brain tissue and 
attachment of the TLQP-21 peptide to the column removed potential binding of these 
proteins to the monomeric avidin affinity resin, thus reducing the protein bands in the 
TLQP-21 elutions relative to the control (resin without TLQP-21 attached).  
When the same procedure was used for the LQEQ-19 peptide, however, there were no 
apparent differences between the negative control and LQEQ-19 elutions (Figure 
3.5A). Additionally, purified primary microglia (~2 x 106 cells starting material, again 
derived from P=4 rats) were harvested (at 23 days in vitro; DIV 23) and fractionated 
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into cytosolic as well as M+A protein homogenates. As with the brain tissue, they 
were applied to monomeric avidin columns +/- TLQP-21 peptide, purified and 
resolved using SDS-PAGE. No specific interacting protein bands were apparent; in 
fact there was not much protein content in these samples at all (Figure 3.5B). This 
suggests that a greater amount of starting material was required, hence the reason why 
brain tissue was preferable.  
These data suggest that TLQP-21 interacts with a ~30 kDa protein in the WCL, 
cytosolic and M+A fractions of brain tissue.  
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Figure 3.4. The TLQP-21 peptide specifically interacted with a ~30 kDa protein 
in all brain tissue fractions tested. Monomeric avidin only ("Negative control") or 
with TLQP-21 attached had various P=4 rat brain fractions applied to them (whole 
cell lysate; WCL, cytosolic and membrane and membrane-associated proteins; M+A). 
Following considerable washes, elution buffer was applied and the eluents resolved 
on SDS-PAGE, followed by silver staining. A ~30 kDa band (indicated by "+") was 
apparent in all the elutions with TLQP-21 attached to the column, and was 
significantly greater than the corresponding negative controls (monomeric avidin 
without TLQP-21 attached). Other bands were visible in both cytosolic (~50 kDa) and 
M+A (~75 kDa) TLQP-21 elution fractions, which were not in the corresponding 
control lanes, however, these proteins did not consistently appear when repeated 
(indicated by "+?"). Some proteins were found to decrease in the TLQP-21 elutions 
relative to their controls (indicated by "-"), suggesting that these proteins were 
endogenous biotinylated proteins in brain tissue, which no longer bound the 
monomeric avidin resin due to TLQP-21 occupying their binding sites on the resin. 
All protein bands of interest are indicated by arrows, and "+", "+?" or "-", referring to 
an increase, an inconsistent increase and a decrease in protein levels in the TLQP-21 
elutions relative to the controls, respectively.  
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Figure 3.5. The LQEQ-19 peptide does not specifically bind any proteins in brain 
tissue fractions. The TLQP-21 peptide does not specifically bind any proteins in 
primary microglia cell fractions. (A) Monomeric avidin only ("Negative control") 
or with LQEQ-19 attached had various P=4 rat brain fractions applied to them 
(whole cell lysate; WCL, cytosolic and membrane and membrane-associated proteins; 
M+A). Following considerable washes, elution buffer was applied and the eluents 
resolved on SDS-PAGE, followed by silver staining. No protein band differences 
were observed in LQEQ-19 eluents relative to their corresponding controls. (B) The 
same experiment, except this time using primary microglia cell fractions (cytosolic 
and M+A) and TLQP-21 peptide on the monomeric avidin column, showed no protein 
band differences between TLQP-21 eluents and their controls. For the ~2 x 106 pure 
primary microglia used here, not many proteins were observed in any of the elutions, 
which could indicate a larger starting material is required.  
 123
To elucidate the identity of the ~ 30 kDa bands, which were apparent using two 
different techniques (the crosslinking experiment as well as the monomeric avidin 
affinity chromatography); the protein bands from the monomeric avidin experiment 
were cut out, de-stained, trypsinised and analysed using LC-MS/MS Orbitrap. 
Initially the ~30 kDa protein band from the WCL sample (Figure 3.4) was analysed, 
and over 136 proteins were identified in this single band (see Appendix A1). In order 
to improve the accuracy of the mass spectrometry data, the data was filtered using a 
number of parameters. Since the band was cut out at ~30 kDa, it was reasonable to 
assume that proteins too large or too small could be excluded; in fact the average 
molecular weight from the identified proteins was 30.6 kDa. Any proteins that had a 
mass +/- 20 % of this value (above 36.7 kDa and below 24.5 kDa) were excluded. 
Another important parameter was the number of unique peptides identified in the 
mass spectrometer. Any proteins that were identified with less than 3 unique peptides 
were excluded, this is often used as a standard cut-off parameter (Nesvizhskii, 2007). 
Often, there are homologous proteins that are identified in mass spectrometry data, in 
order to reduce repetition of protein identities, proteins with the most unique peptides 
allocated to them, from a family of homologous proteins, were selected. Finally, using 
the Mascot software, the emPAI scale was applied and proteins with a value less than 
0.5 % were excluded from the analysis. The emPAI scale estimates absolute protein 
contents of a complex protein mixture, thus the protein abundance index (PAI) was 
defined as the number of observed peptides divided by the number of observable 
peptides of a protein (Ishihama et al., 2005).  
After filtering the data, using these stringent parameters, a list of 19 proteins were left 
(Table 3.1). The column representing unique peptides identified is shown in the 
column labelled "Sequences" (i.e. unique peptide sequences). There are a number of 
potential VGF receptor candidates, such as microtubule associated protein, 
complement protein gC1q-R and toll interacting protein. Even with the stringent 
exclusion parameters, the identification process must be repeated, when there are a 
large number of potential protein partners for VGF peptides. The proteins identified 
were from a complex protein mixture, the whole cell lysate (WCL) of rat brain tissue, 
however, the same ~30 kDa protein band was apparent in the M+A fraction. Due to 
the fractionation process, fewer proteins were observed in the gel, thus fewer 
background proteins would be identified in the ~30 kDa band, which was analysed by 
LC-MS/MS again. It was found that, as expected, a lot fewer proteins were present in 
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this band (Table 3.2), however, a lot of keratin was also present (excluded from table). 
Keratin contamination is particularly problematic when performing mass 
spectrometry on low concentrations of protein (such as bands excised from a silver 
stained gel), as their abundance in a sample can overwhelm the analysis capacity of 
LC-MS/MS system and mask the signals for the peptides of interest, particularly if the 
concentration of the keratin contamination is greater than the protein(s) of interest.  
Only 3 proteins were indentified (that were not keratin), in the M+A sample, 
however, only 1 unique peptide ("Sequence") for each protein was used to identify 
them (Table 3.2). This is below the 3 peptide cut-off used previously, as well as 
having an emPAI score less than 0.5 % (all 3 protein identities had emPAI of 0.11 %). 
The 3 identified proteins were gC1q-R, VDAC-1 and VDAC-3, two of which were 
present in the first WCL dataset (Table 3.1; gC1q-R and VDAC-3). However, 
previous data accumulated using LC-MS/MS analysis on CNS tissue (data not 
shown), revealed that VDAC proteins (all isoforms) were always apparent in data 
sets, when analysing protein bands at ~30 kDa, as these voltage-dependent ion 
channels are ubiquitously expressed on mitochondrial outer membranes as well as 
being found on plasma membranes (De Pinto et al., 2010). The complement-binding 
protein, gC1q-R also appeared in both WCL and the M+A protein datasets, in the 
TLQP-21 elutions (Tables 3.1 and 3.2). This highly acidic ~30 kDa protein is also 
ubiquitously expressed and binds to the globular heads of C1q, the first subcomponent 
of the classical pathway for complement activation (Kishore and Reid, 2000). It has 
been observed that gC1q-R is a multiligand-binding, multi-functional protein 
(Ghebrehiwet and Peerschke, 2004), with affinity for a diverse array of ligands, for 
example, high molecular weight kininogen (Herwald et al., 1996), α1B-adrenergic 
receptor (Xu et al., 1999) and β1 integrin (Feng et al., 2002).  
The peptide coverage from both mass spectrometry datasets, showed overlap 
(Figure 3.6), with the single peptide from the M+A fraction being one of the same 
peptides as those observed in the first, WCL, dataset. The fragmentation spectra for 
these peptides showed that the fragment ion assignments corresponded to the major 
peaks of the spectra for the gC1q-R peptides identified (Figure 3.6), which is 
indicative of an accurate mass spectrometric identification.  
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 Score Mass Sequences emPAI 
14-3-3 protein epsilon 1012 29326 24 47.08 
Acidic leucine-rich nuclear phosphoprotein 32 
family member A 
443 28718 13 4.18 
Microtubule-associated protein RP/EB family 
member 1 
311 30156 5 1.08 
gC1q-R protein; Complement component 1 Q 
subcomponent-binding protein. 
228 31320 3 0.66 
Purine nucleoside phosphorylase 227 32566 3 0.63 
F-actin-capping protein subunit beta 214 30952 9 1.5 
Cell division protein kinase 5 214 33689 6 0.93 
V-type proton ATPase subunit E 1 213 26169 6 1.61 
Serine/threonine-protein phosphatase 
PGAM5 
172 32269 7 1.19 
Tropomyosin alpha-3 chain 163 29217 8 1.37 
ATP synthase subunit gamma 157 30229 5 0.87 
Pyridoxal phosphate phosphatase 151 33493 6 0.94 
Prohibitin; 141 29859 5 0.7 
Toll-interacting protein; 141 30523 4 0.68 
ADP/ATP translocase 2 124 33108 5 0.61 
Voltage-dependent anion-selective channel 
protein 3; VDAC-3 
119 31178 5 0.66 
Proteasome subunit alpha type-1 110 29784 4 0.7 
Acidic leucine-rich nuclear phosphoprotein 32 
family member E 
98 29628 4 0.53 
Haloacid dehalogenase-like hydrolase 
domain-containing protein 2 
63 28932 4 0.55 
 
Table 3.1. Following stringent filtering parameters, 19 proteins identities were 
confirmed for the ~30 kDa band analysed from the WCL fraction. List of proteins 
detected using LC-MS/MS for the WCL +TLQP elution at ~30 kDa (see Figure 3.4), 
after filtering parameters were applied. The "Sequences" column defines the number 
of unique peptides measured for the protein (cut-off was set at ≥ 3). The emPAI score 
(represented in %) is the number of observed peptides divided by the number of 
observable/possible peptides, only proteins with a score of 0.5 % or higher were 
included.  
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 Score Mass Sequences emPAI 
Voltage-dependent anion-selective channel 
protein 3; VDAC-3 
52 31178 1 0.11 
gC1q-R protein; Complement component 1 Q 
subcomponent-binding protein  
33 31320 1 0.11 
Voltage-dependent anion-selective channel 
protein 1; VDAC-1 
27 30851 1 0.11 
 
Table 3.2. The LC-MS/MS data from the ~30 kDa band of the M+A fraction 
identified 3 proteins as possible TLQP-21 binding partners. Protein identities from 
LC-MS/MS analysis for the M+A fraction (TLQP-21 elution; see Figure 3.4), again at 
~30 kDa. Due to the heavy keratin contamination (not included in the table), only 3 
proteins were identified and they all had only 1 unique peptide match ("Sequences"), 
with a low emPAI score (represented in %), thus the previous stringent parameters 
could not be applied. The VDAC-3 and gC1q-R protein were apparent in both 
LC-MS/MS datasets (see Table 3.1 and this table).  
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Figure 3.6. Peptide coverage of gC1q-R from LC-MS/MS data. There were 3 
unique peptides identified (in bold red) for this protein from the first LC-MS/MS 
analysis. The second dataset identified a single peptide (underlined), which came up 
for both datasets. The fragmentation spectra for these peptides showed that the 
fragment ion assignments corresponded to the major peaks of the spectra for the 
gC1q-R peptides identified.   
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Validation of the gC1q-R protein identification 
 
To confirm that the gC1q-R protein was purified in the elutions for the monomeric 
avidin (when TLQP-21 was attached), a monoclonal antibody specific for the N-
terminus (amino acids 76-93; Abcam) of gC1q-R was used. The same elution samples 
from the monomeric avidin experiment, including those used for the LC-MS/MS 
analysis (Figures 3.4 and 3.5) were analysed by Western blot analysis. It was found 
that a prominent ~30 kDa band for gC1q-R was apparent in the TLQP-21 elutions of 
all the brain tissue fractions, but was barely visible in the corresponding negative 
control (Figure 3.7A). The most intense band was visible in the WCL sample, as this 
was the least processed/fractionated protein and thus had the highest amount of 
protein in it. Very little of the gC1q-R protein was detected in the M+A fraction 
samples. However, even with little protein in this fraction, the gC1q-R protein band in 
the TLQP-21 elutions was more prominent than in the corresponding negative control.  
Western blot analysis was also performed on the LQEQ-19 monomeric avidin 
elutions (again, using P=4 brain tissue), it was found that there was no difference in 
gC1q-R protein bands at ~30 kDa between the negative control and LQEQ-19 
elutions (Figure 3.7B), thus confirming that the LQEQ-19 does not specifically bind 
and elute with the gC1q-R protein.  
For the samples where primary microglia cell fractions were applied to monomeric 
avidin +/- TLQP-21 peptide (instead of P=4 rat brain), Western blot analysis of the 
eluents showed no protein bands for gC1q-R in both the negative control and the 
TLQP-21 elutions (Figure 3.7C). In fact no protein, not even background proteins, 
were detected on the Western blot, as had been the case for the P=4 brain tissue 
samples (Figure 3.7A and B).  
These data strongly suggest that the TLQP-21 binding protein/receptor is indeed the 
gC1q-R protein identified using the LC-MS/MS technique. Only P=4 brain tissue 
could be used (all fractions) to observe a signal by Western blot analysis using the 
gC1q-R antibody, as there was probably not enough protein in the primary microglia 
samples.  
There was however, the possibility that primary microglia did not express gC1q-R at 
all, thus to test this and further investigate expression of gC1q-R, various cells types 
and media were tested for the presence of the gC1q-R protein, using Western blot 
 129
analysis (Figure 3.8). It was observed that the ~30 kDa band, corresponding to the 
gC1q-R protein, was evident in all the cells tested including primary microglia 
derived from both the brain and spinal cord, BV-2 cells (the murine microglia cell 
line) as well as DRG neurons. This is consistent with the notion that gC1q-R is a 
ubiquitously expressed protein, particularly in the nervous system and cells of the 
immune system (Ghebrehiwet and Peerschke, 2004). The media in which the cells 
were cultured in, complete DMEM (C. DMEM), did not indicate the presence of any 
of the gC1q-R protein, which meant that the gC1q-R detected from the cell 
homogenates was not from the serum (foetal bovine serum) present in the cell culture 
media. Additionally, supernatant removed from primary microglia cells (at DIV=23) 
also showed no ~30 kDa gC1q-R protein.  
The primary microglia were not suitable for biochemical analysis using the 
monomeric avidin chromatography due to low protein concentrations, however, the 
gC1q-R antibody was applicable for use in both immunocytochemistry of primary 
microglia, as well as a neutralising antibody. To further confirm the expression of the 
gC1q-R protein in primary microglia, as well as determine cellular distribution of the 
protein, the cells +/- Triton X-100 permeabilisation, were incubated with the gC1q-R 
antibody and visualised using a FITC-conjugated secondary antibody (Figure 3.9A). 
The cells stained well, with a diffuse staining pattern throughout the individual 
primary microglia cells, which corresponded with published data regarding gC1q-R 
cell distribution (Ghebrehiwet and Peerschke, 2004). It was observed that the 
permeabilisation had no effect on this staining pattern, although it must be noted that 
the 4 % paraformaldehyde (PFA) fixative used has been observed to partially 
permeabilise the cells.  
Primary microglia cells (DIV=23), stained with Fluo-4 (Ca2+-binding) fluorescent 
dye, were pre-incubated with 107 nM of the neutralising gC1q-R monoclonal 
antibody (α-gC1q-R mAb) for 3 minutes. The TLQP-21 (100 nM) peptide was then 
applied and a resultant increase in intracellular Ca2+ levels was still observed (Figure 
3.9B).  
The data presented here appears to validate the LC-MS/MS data, which suggests that 
the TLQP-21 peptide binds the gC1q-R protein. As well as confirmation that the 
gC1q-R protein is eluted many orders of magnitude greater after binding to TLQP-21, 
compared to the negative control (Figure 3.7A), the gC1q-R has been shown to be 
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expressed by cells of the nervous system, including primary brain and spinal 
microglia (Figure 3.8 and 3.9).  
 
Figure 3.7. The gC1q-R protein is eluted with TLQP-21 following monomeric 
avidin-based affinity chromatography. Monomeric avidin only ("Negative control") 
or with TLQP-21 or LQEQ-19 attached (10 µM), had various P=4 rat brain (or 
primary microglia) fractions applied to them (whole cell lysate; WCL, cytosolic and 
membrane and membrane-associated proteins; M+A). Following considerable 
washes, elution buffer was applied and the eluents resolved on SDS-PAGE, followed 
by Western blot analysis using the gC1q-R antibody. (A) Western blot analysis 
confirms that the gC1q-R protein appears at ~30 kDa and is many orders of 
magnitude greater in the elutions for the column with TLQP-21 attached, and not in 
the corresponding negative controls. This is true for all the P=4 brain fractions, with a 
most prominent ~30 kDa band observed in the WCL fraction. (B) The gC1q-R protein 
did not appear prominently in any of the P=4 brain fractions, when using LQEQ-19 as 
the ligand on the monomeric avidin column. The ~30 kDa protein band that did 
appear, albeit weakly, in the WCL and cytosolic fractions, showed no differences in 
intensity between LQEQ-19 and negative control elutions. (C) When primary 
microglia were fractionated and applied to monomeric avidin +/-TLQP, no bands 
were visible on Western blot analysis, not even non-specific background proteins. 
This confirmed that TLQP-21 did not appear to bind or "pull-out" any gC1q-R protein 
from these cells or that the primary microglia were not suitable for analysis in these 
biochemical techniques, as the protein concentrations obtained from the cultures were 
too low (something observed when silver staining total protein content using the same 
samples shown here; Figure 3.5B).  
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Figure 3.8. The gC1q-R protein is expressed by immune and nerve cells in the 
nervous system, but is not observed in the cell culture media or microglia 
supernatant. Whole cell homogenates from various cells and cell culture media were 
tested for gC1q-R expression using Western blot analysis and the gC1q-R monoclonal 
antibody. It was observed that both brain and spinal cord derived primary microglia 
expressed the ~30 kDa gC1q-R protein, the differences in protein expression levels 
are due to the cell numbers being 4-fold fewer in the spinal microglia homogenate. 
Interestingly, the brain derived microglia supernatant did not show expression of the 
gC1q-R protein, and neither did the complete DMEM (C. DMEM) media, used to 
culture all the cell types tested here. The murine microglia cell line, BV-2, showed 
high expression levels of the gC1q-R protein, even though the same cell numbers as 
primary brain derived microglia were used. DRG neuron homogenate also showed 
expression of the gC1q-R protein. 
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Figure 3.9. Primary microglia show diffuse, whole cell distribution of the gC1q-R 
protein, although the gC1q-R neutralising antibody does not attenuate the 
TLQP-21 induced increase in intracellular Ca2+ levels in these cells. (A) Primary 
brain-derived microglia cells, +/- Triton X-100 permeabilisation, were stained with 
the gC1q-R antibody and visualised using a secondary FITC-stained antibody and 
fluorescence microscopy. Both cell treatments showed diffuse whole cell distribution 
in these cells. Scale bar, 10 µm. (B) Average fluorescence profile of primary 
microglia cells; represents the average of 150 cells over 3 biological replicates. ATP 
was applied as a cell viability test after treatment, and only viable cells were selected. 
Pre-incubation (3 minutes) of the cells with the gC1q-R antibody (107 nM) did not 
attenuate the TLQP-21 (100 nM) induced increase in intracellular Ca2+ levels.  
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Discussion 
 
Modified ligands and their in vitro functionality 
 
Protein-protein interactions form the basis for virtually every biological process, and 
thus understanding these events is vital. These interactions often involve a ligand (or 
ligand complexes) binding to a receptor and initiating a signalling event, which in turn 
initiate the characteristic biochemical processes of the specific ligand. The classic 
definition of a receptor is usually a membrane-bound molecule, however, this 
definition can be defined in a broader context- any species that binds a specific ligand 
and causes a change in the cell activity (such as an increase in intracellular Ca2+ 
levels). Identification of receptors is an important step towards understanding and 
explaining biological events and, perhaps more importantly, in exploiting these events 
in order to inhibit and enhance them (for example, developing new and effective 
drugs).  
A number of techniques are applied in order to aid these investigations, from radio-
labelling ligands and following their activity in a complex protein mixture to 
crosslinking ligands to their receptors. Often, the ligand is modified in order to aid the 
tracking of events and isolation of the receptor-ligand complex. In this investigation, 
the VGF-derived peptides were modified with an N-terminal biotin label and a 
C-terminal cysteine residue. The biotin tag is versatile as it can be used for detection 
of the peptide and peptide-receptor complexes, as well as allowing attachment to an 
avidin column for affinity chromatography. The cysteine residue served as a means to 
conjugate a crosslinker (Sulfo-EMCS) to the peptide and subsequently allow covalent 
attachment to any binding partners / receptors.  
In the previous chapter, it was observed that the TLQP-21 peptide induced an increase 
in intracellular Ca2+ levels in primary rat microglia. This same assay was thus useful 
in order to test the in vitro functionality of the modified TLQP-21 peptide. The biotin-
TLQP-21+Cys peptide still induced an increase in intracellular Ca2+ levels in these 
cells, however it was only functional to a lower concentration (1 µM) than the wild 
type TLQP-21, which was functional at 100 nM. This suggests that the modified 
peptide had a lower affinity (or decreased microglia sensitivity to the modified 
peptide) than the wild type TLQP-21, although it was still functional at higher 
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concentrations (i.e. 1µM). The modifications may have altered the affinity of the 
peptides to their receptor(s), thus increasing the concentration required for the Ca2+ 
response to be observed. Chemical and biological modifications to ligands can both 
improve and reduce their affinity and/or specificity to their receptors (Cho et al., 
2007). The LQEQ-19 peptide did not induce an increase in intracellular Ca2+ levels in 
cells at any concentrations tested and thus the in vitro functionality of this modified 
peptide could not be tested using the Ca2+ assay. Nonetheless, both modified 
TLQP-21 and LQEQ-19 were used to identify potential binding partners for VGF-
derived peptides.  
The reduction in affinity of and/or microglia sensitivity to the peptide has important 
implications when searching for the receptor, for example, if the affinity of the 
receptor-ligand complex is already low, then this modification makes it more difficult 
to isolate the receptors with the further reduction in affinity, as well as reducing the 
chance of finding other low affinity binding proteins.  
The modified VGF-derived peptides were conjugated to Sulfo-EMCS, the first step to 
use these peptides to search for any VGF receptor(s). Sulfo-EMCS was selected as the 
crosslinker of choice due to the fact that it has two reactive groups 
(heterobifunctional), which help minimise undesirable polymerisation or self-
conjugation. The maleimide group specifically reacts with sulphydryl groups, in this 
case on the extra cysteine residue on the TLQP-21 and LQEQ-19 peptides, whereas 
the N-Hydroxysuccinimide esters (NHS esters) react with accessible primary amines 
(N-termini and -amines in lysine residues) on any proteins (e.g. receptors) within 
range of the spacer arm length (for the Sulfo-EMCS, this is 9.4 Å). MALDI mass 
spectrometry was used to confirm the conjugation of the Sulfo-EMCS to the VGF-
derived peptides. For the TLQP-21 conjugation, it was observed that the major peak 
corresponded to conjugated Sulfo-EMCS with TLQP-21 in a singly protonated form 
and for the LQEQ-19, the major peak also represented the conjugated peptide 
although the Sulfo-EMCS was found to be doubly charged/protonated, most likely 
due to the acidic conditions in which the conjugates were eluted in for MALDI 
analysis (100 % acetonitrile and 0.3 % formic acid). Both conjugated peptides were 
thus suitable for use in the subsequent crosslinking experiments. 
However, there were a few minor peaks in both spectra, including some unconjugated 
peptide, for the TLQP-21 spectra this peak was ~40 % the intensity of the conjugated 
species, whereas the unconjugated LQEQ-19 peak was ~20 % of the major 
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conjugated species. The un-conjugated peptides which were apparent in the MALDI 
results were not ideal as they could compete with the conjugated peptide for any 
receptor(s), thus reducing the amount of crosslinked and detected receptor(s). The 
reduced affinity of the peptide (due to the modification) and the competition from 
unconjugated peptide may have caused some binding proteins to be excluded from the 
crosslinking results.  
Again, the Ca2+ assay was used to test the functionality of the conjugated TLQP-21, 
and it was found that even with the addition of the Sulfo-EMCS, the peptide was able 
to induce an increase in intracellular Ca2+ levels at 1 µM (the same concentration as 
the modified peptide without the Sulfo-EMCS conjugated). There is of course the 
possibility that the small fraction of unconjugated peptide could have induced this 
increase. If this were the case however, with the reduction in concentration of "free" 
(unconjugated) peptide, it would be expected that a smaller Ca2+ response would be 
observed, or a smaller number of cells would show this effect. As this did not appear 
to be the case, it is possible to suggest that the conjugated TLQP-21 still induced an 
increase in intracellular Ca2+ levels. Further work would involve increasing the 
amount of conjugated peptide, with minimal or no observable MALDI peaks for 
unconjugated species. When setting up the conjugation reaction, the peptides (TLQP-
21 and LQEQ-19) were added to the conjugation reaction at a ratio of 1:10 with the 
Sulfo-EMCS (i.e. 10 times more crosslinker to peptide) as recommended by the 
manufacturer. Altering the ratio of peptide to crosslinker, as well as changing the 
conditions for conjugation to occur (e.g. different buffers, reaction time, temperature, 
etc) and confirmation with MALDI mass spectrometry would improve chances of 
conjugation and ultimately reduce competition and complications from unconjugated 
peptides.  
Another interesting observation from the Ca2+ assay performed on the conjugated 
TLQP-21 showed that the subsequent ATP (viability test) Ca2+ response was reduced. 
In normal conditions the ATP response is larger than the TLQP-21 induced increase 
in intracellular Ca2+ levels, however, the reduced ATP response could be indicative of 
a loss of viability in these cells due to the presence of the crosslinker. It is possible 
that the NHS-ester group of the Sulfo-EMCS was able to react/crosslink with 
microglia surface proteins and induce a reduction in cell viability in this way; the cell 
solution conditions were suitable for this to occur (i.e. solution at pH 7.4 and 
6 minutes incubation time before ATP application). There is also a possibility that the 
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reduced ATP response enhanced the signal from conjugated TLQP-21, and in fact this 
loss of the viability test signal (ATP) masked a reduced response from the conjugated 
TLQP-21. The TLQP-21 response is always compared to the subsequent ATP 
(reference point) response, thus with a reduction in ATP response it is difficult to 
analyse the conjugated TLQP-21 response. Further confirmation is needed on the 
effects of the crosslinker on the cells, for example, Sulfo-EMCS on it own or 
conjugated to an relatively inert protein such as bovine serum albumin (BSA) could 
be applied to the microglia cells and subsequent ATP responses compared to non-
treated (without Sulfo-EMCS) microglia cells.  
 
Chemical crosslinking and the search for receptors 
 
After conjugation with the Sulfo-EMCS crosslinker, and the subsequent confirmation 
by MALDI mass spectrometry, the conjugated peptides were applied to rat CNS 
(brain and spinal cord) tissue. For consistency with the functional assay developed in 
the previous chapter, as well as their central role in pain pathways, using primary 
microglial cells to identify the receptor would have been ideal. However, due to the 
nature of the biochemical fractionation and purification processes, this multi-step 
procedure causes a high amount of protein loss before detection and so the starting 
material must be in large quantities, something that was technically unfeasible with 
pure primary microglia cultures. Since the VGF protein is highly expressed in the 
CNS (Snyder and Salton, 1998; van den Pol et al., 1994) and appears to function by 
acting on the cells in this tissue, including primary microglia and dorsal horn neurons 
(Moss et al., 2008; Riedl et al., 2009), CNS tissue was an appropriate compromise to 
use in order to identify a VGF receptor.  
The crosslinking experiment, using both TLQP-21 and LQEQ-19 peptides, showed a 
~30 kDa species that was apparent on the Western blot (detected using the biotin tag 
on the VGF-derived peptides with streptavidin-HRP), which was not present in the 
membrane only controls. The ~30 kDa band was less prominent for the LQEQ-19 
experiment, and this could possibly be explained by the fact that some protein was 
observed at the top of the gel in the LQEQ-19 crosslinking sample, suggesting that 
some of the protein sample precipitated and thus did not resolve into the gel, reducing 
the overall detected protein. This precipitate was only observed with the LQEQ-19 
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crosslinking reaction and not in the corresponding negative control, suggesting that 
the presence of LQEQ-19 in the reaction may have induced precipitation. However, 
due to the fact that the same ~30 kDa species appeared for both the VGF-derived 
peptides, supports the idea that the protein is not a non-specific band and may in fact 
be a potential VGF receptor, and the confirmation of similar molecular weight 
(~30 kDa) species appearing using the monomeric avidin (and a completely different 
experimental set up) further supported this observation.  
It should be noted, that while different cellular fractions (WCL, cytosolic and M+A) 
were prepared for use in the monomeric avidin experiment, only CNS membrane 
protein homogenate was prepared and used in the crosslinking experiment. Due to the 
nature of the crosslinking experiment, if too many proteins are included in the mixture 
for crosslinking to occur, then too many non-specific (background) reactions can 
occur and hide the "real" receptor signal on the gel. The crosslinking works by 
covalently attaching proteins that are close enough and interact for long enough to the 
conjugated species (in this case the VGF-derived peptides), thus if the protein sample 
is too complex (such as the WCL and cytosolic fractions), this increases the likelihood 
of non-specific, background signals. However, by only using the membrane fraction, 
this excludes the identification of VGF receptors from the cytoplasm and other 
cellular compartments not included in the membrane homogenate.  
Further work would require the investigation of the WCL and cytosolic fractions, 
which could have their background biotinylated protein signal reduced by pre-
incubation with monomeric avidin, before addition of the conjugated VGF-derived 
peptides. By removing the endogenous biotinylated protein in these complex protein 
mixtures, the non-specific signals appearing on the Western blot analysis are reduced 
and it is therefore easier to visualise actual crosslinked species using the biotin tag on 
the VGF-derived peptides. However, the increase in procedures for tissue preparation 
also causes increased loss of tissue at each stage, thus a compromise between the 
starting material (more complex protein fractions such as WCL) and purification steps 
would need to be optimised to improve upon and advance this investigation. 
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Affinity chromatography and identification of a receptor / binding 
partner 
 
Another methodology for investigating protein-protein interactions is affinity 
chromatography. The general principle is to attach a ligand (in this case the VGF-
derived peptides) to an immobilised gel matrix and then apply a protein mixture, so 
the ligand can bind and "trap" any protein(s) that it interacts with, followed by 
washing out of the non-bound proteins and finally elution and analysis of the binding 
proteins/receptors. The biotin tags on the VGF-derived peptides (LQEQ-19 and 
TLQP-21) served the purpose of allowing attachment to the monomeric avidin, which 
allows reversible binding of biotinylated proteins. In this case, various cell fractions 
(WCL, cytosolic and M+A) were prepared from post-natal day 4 rat cortices, as well 
as cytosolic and M+A fractions from primary microglia cells. It must be noted that the 
M+A fraction is named as such, due to the fact that the biochemical fractionation 
process removes most cytosolic proteins, however, those proteins which bind to 
membrane proteins (but which are not inserted in the membrane) are not separated 
from this fraction. Thus the protein fraction contains both integral membrane proteins, 
and those proteins associated with them (i.e. M+A). 
It was found that when using the TLQP-21 peptide, in all fractions of the brain tissue, 
a ~30 kDa protein was observed in the elutions, which was many fold more intense 
than the protein bands at ~30 kDa in the negative control (where no TLQP-21 was 
attached to the resin prior to tissue application). This protein appeared consistently 
when the work was repeated, as well as in all the fractions tested. There were other 
bands which appeared to bind TLQP-21 (at ~55 kDa in the cytosolic fraction and 
~72 kDa in the M+A fraction), but these proteins were not consistently appearing 
from experiment to experiment, suggesting that they may have been non-specific 
artefacts, or possibly low affinity receptors which should be investigated further and 
identified. However, when the primary microglia culture fractions (cytosolic and 
M+A) were applied to the resin +/- TLQP-21, there were no discernible differences 
between the control and +TLQP-21 elutions. In fact, there were very few proteins that 
were detected at all in the primary microglia samples, suggesting that the sample 
protein concentration was too low to use in this biochemical assay. There is also the 
possibility that there was no gC1q-R expressed in these cells; however, Western blot 
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analysis on microglia cell homogenate confirmed that the protein was in microglia. It 
could be that there was very little gC1q-R protein or it was in a modified (e.g. 
glycosylated) form, which does not bind TLQP-21. 
It must be noted that even with many washes before eluting the proteins, a number of 
other protein bands are visible in both control and +TLQP-21 (and +LQEQ-19) lanes, 
suggesting that they were non-specific proteins, which are potentially endogenous 
biotinylated proteins. In fact this is supported by the observation that a number of 
bands that are observed in the control lanes are no longer visible (or are reduced) in 
the elutions for +TLQP-21 (and +LQEQ-19). The most likely explanation of this is 
that the biotin-binding sites in the monomeric avidin were occupied by the 
biotinylated VGF-derived peptides, thus stopping the endogenous biotinylated 
proteins from binding the affinity matrix and being washed away before the elution 
step. To reduce this non-specific biotinylated protein binding, the tissue samples 
could first be pre-incubated with monomeric avidin and the eluent could then be used 
to find VGF-derived peptide receptors, although increasing tissue processing steps 
always results in loss of protein concentration, which is unfavourable in these 
biochemical assays.  
When the LQEQ-19 peptide was attached to the monomeric avidin, there did not 
appear to be any proteins that the peptide bound and eluted, relative to the control. 
The ~30 kDa protein observed in the +TLQP-21 affinity chromatography experiment, 
may be the same protein observed in the crosslinking experiments discussed 
previously, which was apparent for both +TLQP-21 and +LQEQ-19 experiments. If 
the same protein is being detected in the two different experimental systems, then the 
~30 kDa band not appearing in the monomeric avidin experiment for +LQEQ-19 
elutions is not surprising. For the crosslinking experiment, the ~30 kDa band was 
barely visible for the +LQEQ-19, and this is after allowing covalent conjugation of 
proteins. This suggests that the ~30 kDa species may have a lower affinity for the 
LQEQ-19 peptide, which would make it easier for the protein to be washed away in 
the monomeric avidin experiment, where covalent attachment did not occur.  
Ideally, to confirm the specificity of binding of the ~30 kDa species, a simple 
competition assay could be performed, for both the crosslinking experiment as well as 
the monomeric avidin experiment. By applying increasing concentrations of 
unmodified, wild type TLQP-21 in the crosslinking and/or monomeric avidin 
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experiments, decreasing amount of this ~30 kDa protein should be crosslinked and/or 
eluted, if the protein interaction is specific.  
In the biochemical assays discussed, the scrambled peptides were not used. In these 
assays, the high concentration of 10 µM of peptide was used, to ensure that there was 
enough peptide to be detected by Western blot analysis after the various purification 
and processing steps. At this high concentration, it was previously observed that the 
scrambled TLQP-21 peptide was still functional (i.e. induced an increase in 
intracellular Ca2+ levels in primary microglia), thus it was not the ideal control. 
Further work would involve using lower concentrations of the peptides, where the 
scrambled peptides were no longer functional, without reducing the peptide 
concentration so much that any binding proteins and biotinylated peptides were no 
longer detectable.  
The ~30 kDa bands from WCL and M+A elutions (for +TLQP-21) were excised from 
the gels and analysed using LC-MS/MS. For the WCL sample (a complex protein 
mixture from brain homogenate), a total of 136 proteins were initially identified, but 
after application of stringent filtering parameters (such as number of peptides 
identified, mass range, emPAI scores, etc.), 19 proteins were left. However, without 
more datasets, it was not possible to narrow this list down any further. Thus the 
~30 kDa band from the less complex protein mixture, M+A, was excised and 
analysed by LC-MS/MS. Unfortunately, due to high keratin contamination, the 
resultant protein identifications could not be put through the same stringent filtering 
parameters (as well as highlighting the need for keratin-free conditions when using 
highly sensitive mass spectrometric techniques). The total number of proteins, which 
were not keratin, came to 3, all with only 1 unique peptide match and low emPAI 
scores. However, even with low specificity, two proteins were found to be in both 
datasets - the gC1q-R protein and the voltage-dependent anion-selective channel 
protein 3 (VDAC-3). The VDAC-3 protein, as well as other members of the VDAC 
family are ion channels located on the outer mitochondrial membrane (Hoogenboom 
et al., 2007). Unfortunately, the VDACs are a family of proteins that are highly 
prevalent in all datasets obtained in our group at this mass range, without any 
apparent specificity of binding. Due to their ubiquitous nature in all tissues of the 
body, as well as in all the datasets obtained, this particular protein was excluded from 
further analysis in this investigation. However, for completion and confirmation, 
further validation (as carried out for gC1q-R) would be required to see whether this 
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protein does indeed interact specifically with TLQP-21, and would have been 
performed had time permitted. Further information about the gC1q-R protein is 
discussed below. 
The peptide coverage (3 unique peptides) for the gC1q-R protein was sufficient to 
conclude that this protein was present in the +TLQP-21 elution fraction at ~30 kDa, 
as were the fragmentation spectra (Bantscheff et al., 2007). The individual 
fragmentation spectra for each peptide confirmed that the fragment ion assignments 
corresponded to the major peaks of the gC1q-R peptide spectra. In fact the second 
mass spectrometry dataset (M+A sample), with only one peptide, found the same 
peptide fragment identified as that in the first WCL dataset, further corroborating the 
data obtained. This peptide may be easier to generate following trypsinisation of the 
protein sample, or easier to ionise and thus analyse by mass spectrometry.  
Although the high stringency filtering of the WCL mass spectrometry data was 
necessary, there is a possibility that some important binding partners for VGF-derived 
peptides were excluded. Proteins which are not easily fragmented, or those whose 
peptides cannot "fly" easily in the mass spectrometric apparatus (due to ability to 
ionise) would automatically be excluded, as well as low concentration protein signals 
which would be masked by ubiquitous proteins with relatively high concentrations. 
These are all normal factors, which have to be taken into consideration when 
identifying proteins from complex protein mixtures. However, due to the fact that so 
little is known about VGF receptors, these factors must be given more attention, for 
example, proteins not in the correct mass range of 30 kDa (+/- 20 %) were excluded 
from analysis, but the VGF binding proteins could be part of a complex or even 
proteins that were degraded in the experimental conditions. The best method to 
overcome this complexity is to repeat the work as many times as possible and 
accumulate many datasets in order to find proteins that are apparent in all datasets, 
without the need for such high stringency parameters.  
Ideally, to use mass spectrometry to quantitatively compare two protein samples, both 
control and +TLQP-21 samples should be labelled differently, combined and then 
tandem mass spectrometry performed (MS/MS). The isobaric tag for relative and 
absolute quantitation (iTRAQ) method would suit this purpose, as it involves 
covalently labelling different samples with a different charged group (one for the 
control protein mix and a different charged group to label the proteins for the 
+TLQP-21 experiment). The elution samples (both control and +TLQP-21) can then 
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be combined and run in the same lane on a gel, and the same ~30 kDa band cut out 
(Zieske, 2006). Following LC-MS/MS, it would be possible to differentiate between 
the proteins from the control protein mix and those from the +TLQP-21 protein mix, 
as well as quantify the proteins (i.e. is there more of the gC1q-R protein signal in the 
+TLQP-21 than the control elution mix?).  
 
Validation of the identified receptor 
 
To validate the results obtained from the monomeric avidin experiment and the 
proceeding LC-MS/MS analysis, an antibody for gC1q-R was used to confirm its 
presence in a variety of samples. The same elution samples analysed by silver staining 
(and the subsequent mass spectrometric analysis) were analysed by Western blot 
analysis using the gC1q-R antibody. The ~30 kDa gC1q-R protein was apparent in the 
+TLQP-21 elutions and there was significantly more of this protein present than in the 
corresponding control elutions (many-fold difference), for all the cellular fractions 
(WCL, cytosolic and M+A). The most gC1q-R protein was in the WCL fraction, with 
less in the cytosolic fraction and even less in the M+A samples, this can be explained 
by the general loss of total protein content that occurs with increasing steps for the 
biochemical fractionation process (least steps for WCL preparation, and most steps 
for the M+A fraction preparation). Cellular fractionation must find the right balance 
between reducing protein complexity in a mixture and not reducing the concentration 
of the protein of interest too much. There is also the possibility that a modified (e.g. 
glycosylation) or different isoform of gC1q-R is present in the WCL and cytosolic 
fraction, which binds TLQP-21 with greater efficiency and thus more is present in the 
elutions from these samples than in the M+A fraction. However, other bands were 
observed, which were higher than ~30 kDa, these could either be larger multimers of 
the gC1q-R protein, which has previously been observed (Ghebrehiwet et al., 2001) or 
non-specific background proteins. These bands also decrease in intensity from the 
WCL to the M+A fraction, again highlighting the decrease in overall protein 
concentration with increased processing/fractionation of protein samples.  
Western blot analysis of the LQEQ-19 monomeric avidin experiment did not show 
any difference in gC1q-R protein levels between the control and +LQEQ-19 elutions.  
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For the monomeric avidin experiment, where primary microglia cells (~2 x 106) were 
used +/- TLQP-21, analysis of the resultant elution by Western blot revealed no 
proteins at all. This suggested that TLQP-21 was not binding to gC1q-R on microglia 
or that not enough protein was present in the primary microglia cell fractions 
following monomeric avidin chromatography. Due to the lack of background proteins 
appearing by both Western blot analysis and silver staining when using primary 
microglia fractions, it is likely that the protein concentration of the samples was too 
low, and that more starting material is required for the use of primary microglia in 
biochemical assays.  
Overall these Western blot data, using the gC1q-R antibody confirm that the protein 
identified by LC-MS/MS is the gC1q-R, and it does appear to bind TLQP-21 
(although we cannot confirm that this interaction has any physiological response 
here).  
For confirmation that primary microglia expressed gC1q-R, and to further investigate 
the expression of the protein, various cells and media were tested for expression of the 
gC1q-R protein. It was found that the murine microglia cell line, BV-2, as well as 
brain microglia homogenate express the gC1q-R protein at the highest levels (as 
observed by the sharp and intense ~30 kDa band). Spinal microglia and DRG cells 
also express this protein, although the supernatant taken from microglia (DIV=23) 
and the media all the cells are cultured in (complete DMEM; C. DMEM) did not show 
any presence of the 33 kDa protein, indicating that the protein isn't an artefact in the 
media.  
Immunocytochemistry was used to further confirm the presence of gC1q-R in 
cultured primary brain microglia cells, as well analysis of localisation of the protein. 
In both permeabilised and non-permeabilised cells, the gC1q-R protein showed a 
diffuse whole cell distribution, which confirmed previous data suggesting that the 
protein is expressed intracellularly as well as associating with some membrane 
proteins, and is thus described as a multi-compartmental protein (Ghebrehiwet and 
Peerschke, 2004).  
Pre-treatment (3 minutes) of primary microglia cells with the gC1q-R antibody, a 
neutralising antibody used at an approximately equimolar concentration as TLQP-21, 
did not stop the TLQP-21 induced increase in intracellular Ca2+ levels in these cells. 
There is a possibility that the interaction of TLQP-21 with gC1q-R protein is not 
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responsible for the intracellular increase in Ca2+ levels in primary microglia, and the 
TLQP-21 acts via an unrelated protein interaction and mechanism of action.  
The gC1q-R neutralising antibody stops C1q-gC1q-R interactions by binding to 
amino acid residues 76-93 at the N-terminus of gC1q-R (Ghebrehiwet et al., 1994; 
Ghebrehiwet et al., 1997). If the gC1q-R protein interacting with TLQP-21 does 
indeed induce an increase in intracellular Ca2+ levels in primary microglia, then the 
antibody may not be binding and hence blocking the correct region of gC1q-R and 
thus does not stop the gC1q-R-TLQP-21 interaction. There is also the possibility that 
the antibody needs to be used at a higher concentration, or for a longer time period 
than 3 minutes for the gC1q-R-TLQP-21 interaction to be stopped/inhibited. If the 
interaction of gC1q-R and TLQP-21 is occurring inside the cell, then the antibody 
may not be able to enter the cell efficiently and thus inhibit the interaction. Another 
antibody, which recognises and binds the C-terminal amino acids 204-218 of gC1q-R 
(Ghebrehiwet et al., 1996), could also be tested with the Ca2+ assay to assess whether 
this inhibits the increase in intracellular Ca2+ levels in microglia, in case the TLQP-21 
interacts with this gC1q-R domain, rather than the N-terminal domain.   
DRG neurons were shown to express the gC1q-R protein, albeit at very low levels. 
These cells did not show an increase in intracellular Ca2+ levels when TLQP-21 was 
applied and this could be for a number of reasons. If the gC1q-R-TLQP-21 interaction 
is responsible for the Ca2+ response, then DRG neurons may not have the correct 
molecular machinery (such as complement receptors, which recognise complexes 
containing gC1q-R and have been shown to be expressed in microglia) to process this 
interaction (Farber et al., 2009), or the concentration of the gC1q-R protein is too low 
in these cells (as shown by Western blot analysis) for this response to occur. It could 
also be a confirmation that the gC1q-R-TLQP-21 interaction does not induce an 
increase in intracellular Ca2+ levels. Clearly this data has highlighted the need for 
further investigation into the gC1q-R-TLQP-21 interaction and downstream molecular 
consequences of this interaction. 
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The gC1q-R protein 
 
The complement system and C1q 
 
The complement system is part of the innate immune system, which aids 
("complements") the antibodies and phagocytic cells in their removal of pathogens. It 
can also be recruited and activated by components of the adaptive immune system. 
The complement pathways consist primarily of a complex series of proteins, found in 
plasma, that are rapidly and efficiently recruited and activated in an enzymatic 
cascade following initiation, typically induced by detection of pathogenic antigens, 
leading to a greatly amplified response. The proteins and glycoproteins, which 
constitute the complement system are typically designated with the letter "C" (e.g. 
C1q, C3, C4), and include serum proteins and cell membrane receptors.  
There are 3 major pathways with which complement can be described, the classical, 
alternative and lectin pathways, which are differentiated by the proteins/complexes 
that lead to the initiation of the complement system (e.g. the classical pathway is 
initiated by the C1 complex). All the pathways aim to activate the central component 
of the complement system (i.e. the C3 component). However, it is becoming 
increasingly clear that this depiction of a linear cascade of separate pathways is a 
much more complex and inter-connected network, which is tightly regulated and 
connected to other systems. The basic functions of complement are to: (1) attract 
immune cells, such as macrophages and neutrophils, via chemotaxis; (2) enhance 
phagocytosis of antigens, through a process known as opsonisation; and (3) cause cell 
lysis of target cells/organisms through formation of the membrane attack complex 
(MAC).  
The complement system has now been shown to be involved in an array of non-
traditional roles such as eliminating cellular debris and synaptic remodelling, 
angiogenesis, tissue regeneration and pain modulation (Li et al., 2007). The details of 
the complement system have been covered extensively in a number of excellent 
reviews and will not be covered here, for a more in-depth overview, consult the 
following literature: (Carroll, 2004; Dunkelberger and Song, 2010; Le Friec and 
Kemper, 2009; Ricklin et al., 2010; Sarma and Ward, 2011).  
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In the classical complement pathway, the C1 protein is the first component and 
consists of three sub-components, C1q, C1r and C1s, which form a macromolecular 
complex in a Ca2+-dependent manner. The activation of the C1 complex leads to 
activation of the C2-C9 components, culminating in the generation of the membrane 
attack complex and eventual lysis of the target cell/pathogen (Nayak et al., 2010).  
The C1q molecule is a multimeric complex, which has globular "head" domains and 
collagen-like tail domains. The traditional role of C1q is to bind pathogens or 
antibody-pathogen complexes and thus generate a recognition signal to allow 
formation of the C1 complex and subsequent complement activation. C1q is 
predominantly expressed in myeloid cells, including tissue macrophages, dendritic 
cells (Nayak et al., 2010) and microglia (Korotzer et al., 1995).  
The C1q protein can also bind a wide range of cell types, which can result in a wide 
range of cell-specific biological responses being induced, such as modulation of 
chemotaxis and differentiation of immune cells. For example, C1q was shown to 
modulate phagocytosis of the amyloid β-peptide (Aβ) in microglia (Webster et al., 
2000). Interestingly, the C1q protein expression is up-regulated following nerve 
injury, and it has been proposed that C1q enhances the clearance of apoptotic neurons 
and neuronal blebs by activating microglia, as well as modulating subsequent 
microglial inflammatory cytokine production (Fraser et al., 2010). The C1q protein 
was shown to induce an increase in intracellular Ca2+ levels in microglia, thus 
activating the cells to release proinflammatory mediators, including IL-6, TNFα and 
nitric oxide (Farber et al., 2009).  
The interaction of C1q with a wide array of cell types, including lymphocytes, 
platelets, endothelial cells and microglia, and the subsequent specific cellular 
responses are mediated by C1q interacting with C1q-binding proteins or receptors on 
the cell surfaces. A number of binding proteins/receptors have been identified, 
including gC1q-R, a 33 kDa homotrimeric protein.  
 
gC1q-R 
 
The gC1q-R protein (also known as C1QBP, p33, TAP, HABP1 and p32) was 
initially identified and shown to act as a receptor for the C1q protein, by binding the 
globular heads of C1q (Ghebrehiwet et al., 1994). It is a 33 kDa, highly acidic 
(calculated pI = 4.15), ubiquitously expressed protein, and is a multiligand-binding, 
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multicompartmental protein, involved in a variety of ligand-mediated cellular 
responses. It is expressed on a wide range of tissue and cell types, including dendritic 
cells, platelets, endothelial cells and lymphocytes. 
 
i. Cellular distribution 
The gC1q-R protein has been shown to be associated with a number of different 
cellular compartments, including  the cytosol (Peterson et al., 1997), mitochondria 
(Dedio et al., 1998), ER, nucleus (Petersen-Mahrt et al., 1999) and on the cell surface 
(Grace et al., 2002; Peerschke and Ghebrehiwet, 2007). This multicompartmental 
nature of the protein appears to be due to the processing and modifications of the 
gC1q-R pre-protein, which is 282 amino acid residues long (van Leeuwen and 
O'Hare, 2001). Interestingly, although the protein is expressed on the cell surface, the 
translated amino acid sequence of the membrane-associated form of gC1q-R does not 
predict a GPI anchor or transmembrane segment, although it has been suggested that 
it localises to the membrane surfaces via interactions with proteins such as β1-
integrins, which also allow signal transduction across the membrane (Feng et al., 
2002; Ghebrehiwet et al., 2001). This may be due to the methods used to detect the 
gC1q-R protein as was demonstrated, when different antibodies (binding different 
termini of the protein) showed different localisations of the gC1q-R (Peerschke et al., 
2003). There is also the possibility that gC1q-R belongs to a class of proteins initially 
targeted for the mitochondria, but then exported to different compartments of the cell 
via specific and currently unknown mechanisms (Soltys et al., 2000). The cell surface 
localisation on platelets, endothelial cells and T cells, as well as functional studies 
(see further on), support the idea that gC1q-R may serve as a binding site for 
pathogenic proteins, and thus plays a role in inflammation and infection (Ghebrehiwet 
and Peerschke, 2004). The name multicompartmental is therefore a suitable term for 
these types of proteins.  
 
ii. Structure 
The crystal structure of gC1q-R was determined at 2.25 Å resolution, and showed that 
three gC1q-R molecules (trimer) formed a doughnut-shaped quaternary structure, with 
an unusual charge distribution on its surface and a sizeable central channel/pore (Jiang 
et al., 1999). These structural data have allowed predictions of function and 
localisation, with putative sites for zinc and ligand binding, as well as cell-surface 
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association (Ghebrehiwet et al., 2002). Interestingly, it has also been proposed that 
gC1q-R could form pores on mitochondrial membranes and serve as a gateway or 
channel to Ca2+ ions and their movement in and out of the mitochondria (Starkov, 
2010). Thus gC1q-R could modulate intracellular Ca2+ levels in cells, following some 
sort of activation signal (such as peptide binding), which can activate channel 
formation of the gC1q-R protein in mitochondrial membranes, although it must be 
noted that this model is highly speculative and data that directly supports this theory is 
not currently available.   
 
iii. Multi-ligand binding 
There is growing evidence that suggests that gC1q-R is able to interact with a large 
variety of ligands that are of cellular, bacterial or viral origin. As well as binding the 
complement C1q protein, and playing a role in classical complement activation 
(Ghebrehiwet et al., 2006; Peerschke et al., 2006; Yin et al., 2007), the protein is 
known to bind to high molecular weight kininogen (Herwald et al., 1996), factor XII 
(Joseph et al., 1996)- both of which are part of the kinin formation pathway, 
vitronectin (Lim et al., 1996), thrombin and prothrombin (Ghebrehiwet et al., 1996), 
α1B-adrenergic receptor (Xu et al., 1999) and β1 integrin (Feng et al., 2002). While 
most of the functional consequences of these interactions are known (see below), 
some still remain a mystery.  
 
Biological functions of gC1q-R 
 
i. Role in carcinogenesis 
The gC1q-R protein was detected in the breast cancer cell lines MCF7 and SKBr3 
(Ghebrehiwet et al., 2001). It was also shown to be preferentially expressed in 
adenocarcinoma cells of the thyroid, colon, pancreatic, gastric and lung, compared to 
their non-malignant counterparts (Rubinstein et al., 2004). It has been proposed that 
the gC1q-R protein may play a role in metastasis of tumour cells, due to its 
proteolysis by MT1-MMP protein, which is essential for tumour invasion (Rozanov et 
al., 2002) as well as the observation that gC1q-R binds integrin αvβ3 and induces 
melanoma cell migration and tumour growth through NFκB-dependent MMP-2 
activation (Prakash et al., 2011).  
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A study showed that gC1q-R may also have a role in carcingenesis through anti-
apoptotic activities on germ cell tumours (Kitazawa et al., 2006), and the gC1q-R may 
also have an important role in HPV-16 induced cancer immune evasion (Gao et al., 
2011). 
 
ii. Role in bacterial and viral infections 
Previous studies have shown that the C1q protein has an important role in 
phagocytosis or lysis of a number of pathogenic organisms (Ghebrehiwet and 
Peerschke, 2004), however, the C1q receptor proteins that serve as attachement sites 
between pathogenic antigens and the C1q were not known. Increasingly, data is 
suggesting that gC1q-R in the plasma, as well as on the cell surface of various 
immune cells, may bind these pathogen antigens, and subsequently activate immune 
cells and recruit and activate the C1q complement component (Peerschke and 
Ghebrehiwet, 2007).  
The gC1q-R protein on the cell surface of platelets was shown to bind Staphylococcus 
aureus protein A, thus aiding in the pathogenesis of the bacterium (Nguyen et al., 
2000). Further, the blockade of gC1q-R inhibited S. aureus adherence to the 
microvascular endothelium (Sethi et al., 2011). Bacillus cereus, another pathogenic 
bacterium, produces spores which contain a binding site for gC1q-R, and it was 
observed that the gC1q-R protein plays a role in the initial stages of B. cereus spore 
attachment and entry, as an antibody against gC1q-R partially inhibited the uptake of 
spores by monocytes and neutrophils (Ghebrehiwet et al., 2007). Interestingly, gC1q-
R was shown to promote entry of Listeria monocytogenes, by binding its InlB 
invasion protein (Braun et al., 2000).  
The gC1q-R protein has also been observed to have a role in viral infectivity, by 
interacting with a number of viral proteins. For example, the hepatitis C virus (HCV) 
core protein interacts with the gC1q-R protein and inhibits T cell proliferation and 
activation by interfering with the ERK/MEK MAPK activation pathway, and this 
inhibition was reversed after addition of an anti-gC1q-R antibody (Yao et al., 2003; 
Yao et al., 2001). Further to this, HCV core protein-induced IL-8 mRNA and protein 
expression in fibroblasts, was blocked by the addition of the anti-gC1q-R antibody 
(Moorman et al., 2005).  
As well as HCV core protein interactions, application of soluble gC1q-R protein was 
shown to inhibit HIV-1 strains in vitro by blocking CD4 and gp120 interactions 
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(Szabo et al., 2001), gC1q-R was shown to interact with hepatitis B virus protein P22 
in the nucleus and cytoplasm of COS-7 cells (Laine et al., 2003) and gC1q-R 
interaction with Epstein-Barr virus (EBV) nuclear antigen-1 (EBNA-1) induced 
transcriptional activation and thus was observed to play a role in EBV latent cycle 
DNA replication (Van Scoy et al., 2000).  
These data support the idea that gC1q-R has an important role in pathogenic 
infections, and many pathogens appear to hijack the endogenous activities of gC1q-R 
and improve their infectivity and/or evade the host immune system through this 
interaction with the gC1q-R protein.  
 
iii. Immune cell modulation and complement activation  
The gC1q-R protein is expressed by a number of immune cells, including B and T 
lymphocytes, platelets, endothelial cells and macrophages, as mentioned earlier. It has 
also been shown in this investigation that the protein is expressed by both spinal cord- 
and brain-derived primary microglia. Dendritic cells expressing gC1q-R were shown 
to undergo chemotaxis due to the C1q-gC1q-R interaction (Vegh et al., 2006). 
Additionally, activated platelets were shown to have sustained expression gC1q-R 
(Peerschke et al., 2003). In fact, it was shown that blood platelets activate the classical 
pathway of human complement using C1q and gC1q-R (Peerschke et al., 2006). It 
was observed that fibroblasts expressing gC1q-R, after application of the complement 
C1q protein, induced a rapid and transient increase in intracellular Ca2+ levels via an 
IP3-dependent pathway (Bordin et al., 1998). The gC1q-R protein also has a role in 
complement activation in human endothelial cells via its interaction with C1q (Yin et 
al., 2007).  
It is becoming increasingly clear that the gC1q-R protein serves as a molecular bridge 
between complement activation in immune cells and the subsequent inflammatory 
processes and downstream consequences of this inflammation, such as inflammatory 
and neuropathic pain, although it is as of yet a poorly understood relationship 
(Ghebrehiwet et al., 2006; Li et al., 2007).  
 
iv. Bradykinin generation 
The kallikrein/kinin system (KKS), also known as the plasma bradykinin-forming 
cascade, consists of three essential blood plasma proteins that are assembled and 
activated in a complex fashion, ultimately to generate the bradykinin peptide, and the 
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system plays a major role in inflammation, coagulation and pain modulation. The 
three proteins in the KKS are factor XII, prekallikrein (PK) and high molecular 
weight kininogen (HK). The proteins interact in the presence of macromolecular 
complexes formed during inflammatory processes and via highly charged proteins 
along cell structures, in the presence of zinc (Zn2+). Upon binding a negatively 
charged surface, factor XII converts to XIIa due to autocatalytic activation. Factor 
XIIa then generates more factor XIIa from factor XII (positive feedback) as well as 
converting PK to kallikrein. This kallikrein then digests HK to generate bradykinin 
(Kaplan and Ghebrehiwet, 2010), which can then bind to its receptors to induce 
inflammatory responses, vascular permeability in endothelial cells and of course pain 
modulation (Moalem and Tracey, 2006).  
The key initiation step requires the presence of highly charged surface structures to 
allow binding of HK and/or factor XII on cell surfaces. It has been observed that 
gC1q-R, a highly acidic protein, can bind both HK and factor XII (Herwald et al., 
1996; Joseph et al., 1996), and more recently it was observed that the HK-gC1q-R 
interaction plays an important role in KKS complex formation and thus bradykinin 
generation in macrophages (Barbasz et al., 2008).  
Thus, the gC1q-R protein, particularly when on the cell surface, can bind plasma 
proteins such as C1q and HK, which in turn generates an inflammatory response from 
both the complement and kinin/kallikrein systems and initiates a plethora of 
biological responses. The gC1q-R protein highlights the complex inter-relationship 
between the complement and kinin system.  
 
VGF-derived peptides, gC1q-R and pain modulation 
 
The gC1q-R protein is described as a multi-ligand binding, multi-compartmental, 
multi-functional protein, and has been observed to bind the VGF-derived peptide, 
TLQP-21 in this investigation. Of course, this interaction and its specificity must be 
further confirmed with direct binding assays, such as surface plasmon resonance 
(SPR) as well as competition assays using non-biotinylated TLQP-21 (which is not 
attached to the affinity column). However, the interaction between TLQP-21 and 
gC1q-R brings up some intriguing possibilities.  
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For example, the TLQP-21 may modulate the gC1q-R - C1q interaction (after binding 
the gC1q-R), which in turn could activate a whole host of possible cell-specific 
biological responses, including activation of microglia via an increase in intracellular 
Ca2+ levels, similar to the response observed in fibroblasts following C1q-gC1q-R 
interactions (Bordin et al., 1998). The interaction could also modulate cell behaviour 
in other cell types such as neurons and glia cells in the CNS. The subsequent 
inflammatory responses could induce a pain response, already shown to be modulated 
by VGF-derived peptide application in various animal models (Moss et al., 2008; 
Riedl et al., 2009; Rizzi et al., 2008). Interestingly, following spinal nerve ligation 
(SNL), DRG showed an increased expression not only in VGF, but also C1q (Valder 
et al., 2003), highlighting the link between complement activation and neuropathic 
pain, currently a poorly understood field (Li et al., 2007).  
Additionally, TLQP-21 interaction with gC1q-R could promote opening of gC1q-R-
pore structures in mitochondria (Starkov, 2010), or even the ER and plasma 
membrane, thus modulating intracellular Ca2+ levels in the cells. Also, TLQP-21 
interaction with gC1q-R could induce bradykinin formation via the kinin pathway, 
shown to be functionally downstream of gC1q-R. Bradykinin is known to be involved 
in the modulation of pain (Moalem and Tracey, 2006), and cells including microglia 
express bradykinin receptors (Noda et al., 2004; Talbot et al., 2010).  
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Introduction 
 
Molecular mechanisms of action of VGF-derived peptides 
 
VGF is a 617 (rat and mouse) or 615 (human) amino acid precursor protein, which is 
proteolytically cleaved into smaller bioactive peptides. While the regulation and 
selective inducibility of vgf expression is well understood, the downstream molecular 
mechanisms of the bioactive VGF-derived peptides are less clear. Much of the studies 
on VGF have focussed on the in vivo effects of VGF-derived peptides, including, but 
not limited to, energy homeostasis (Bartolomucci et al., 2009; Jethwa et al., 2007; 
Toshinai et al., 2010), water balance (Yamaguchi et al., 2007),  reproduction (Succu 
et al., 2005), depression (Thakker-Varia et al., 2007) and pain (Riedl et al., 2009; 
Rizzi et al., 2008). While in vivo studies are crucial in our understanding of the whole 
organism effects of neuropeptides such as VGF, in vitro analysis allows a greater 
understanding of individual components of molecular signalling events and their basic 
biological functions. The currently known in vitro molecular mechanisms downstream 
of VGF application will be clarified here.  
Whole-cell patch-clamp recordings were performed on hippocampal cells following 
exogenous VGF-derived peptide application.  It was found that two of the VGF-
derived peptides, TLQP-62 and AQEE-30 (also known as peptide V), enhanced 
synaptic activity of rat hippocampal cells within 5 minutes of application. Both these 
peptides are derived from the C-terminal of the full length VGF protein, however, a 
peptide from the N-terminal region of VGF, LEGS-28, did not induce a change in 
synaptic charge after application. Both TLQP-62 and AQEE-30 peptides increased 
synaptic charge in a dose-dependent manner, saturating at 0.1 µM (Alder et al., 2003). 
The electrophysiological profile of the VGF-derived peptides on hippocampal 
neurons was similar to that observed upon BDNF application (Levine et al., 1996). 
This data indicated that VGF-derived peptides had a role in synaptic plasticity in the 
hippocampus. Following this initial data, another study found that TLQP-62 promoted 
cell proliferation in mouse hippocampal cells. Cultured hippocampal cells showed a 
dose-dependent increase in [3H] thymidine incorporation (a marker for DNA 
synthesis), following 48 h TLQP-62 treatment, reaching saturation at 3 µM. In 
addition to this, BrdU incorporation was studied to quantitate cellular proliferation in 
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these cells after TLQP-62 (3 µM) or vehicle treatments. The resulting ~50 % increase 
in DNA synthesis suggested that TLQP-62 promoted proliferation in hippocampal 
cells (Thakker-Varia et al., 2007). This study also showed that mRNA for Cdc2 (also 
known as Cdk1), which promotes cell cycle progression, was up-regulated in these 
cells by 1.43 fold relative to the control after 48 h treatment with TLQP-62. Double 
immunocytochemistry experiments, using BrdU stain and various cell type specific 
markers, confirmed that TLQP-62 application increased the number of dividing cells 
that express neuronal markers (ibidem). These data, taken together with the in vivo 
data (which showed TLQP-62 produced antidepressant-like behavioural effects), 
suggest that VGF-derived peptides may exert their effects as antidepressants by 
enhancing neurogenesis and synaptic strengthening in the hippocampus (Alder et al., 
2003; Thakker-Varia et al., 2007).  
The VGF-derived peptide, TLQP-21, was shown to have neuroprotective effects on 
serum and potassium deprived rat cerebellar granule cells (CGCs) in vitro (Severini et 
al., 2008). This research investigated the molecular mechanisms of action of TLQP-21 
quite extensively in these cells, and in that respect, is the only study to solely analyse 
the in vitro effects of a VGF-derived peptide. It was found that 1 µM TLQP-21 was 
sufficient to significantly prevent potassium deprivation-induced cell death in CGCs, 
shown by an increase in viable cells and decreased DNA fragmentation (using both 
immunocytochemistry and Hoechst 33258 staining as well as an ELISA for cell death, 
which measures histone-associated DNA fragmentation). The study found 1 µM 
TLQP-21, but not scrambled TLQP-21, induced phosphorylation of Erk1/2 within 15 
minutes of application and that this effect was abolished using the MAPK ERK kinase 
(MEK) inhibitor UO126. This VGF-derived peptide was also found to induce 
phosphorylation in Akt and a 44 kDa isoform of JNK, but a decrease in PKC 
phosphorylation- all after 15 minute application of TLQP-21 (1 µM), although the 
scrambled peptide was not included in the study of Akt, JNK and PKC 
phosphorylation. Interestingly, it was found that application of 10 µM TLQP-21 
induced a transient increase in intracellular Ca2+ levels in ~60 % of the CGCs, 
whereas the scrambled peptide did not. Lower concentrations (1 and 3 µM) of 
TLQP-21 failed to induce this Ca2+ response in the cells, and a second application of 
10 µM TLQP-21 did not elicit an increase in intracellular Ca2+ levels, indicating that 
the cells were de-sensitised to the VGF-derived peptide. Thus this study found that the 
TLQP-21 peptide specifically promoted the survival of CGCs via modulation of 
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Erk1/2, Akt, JNK and PKC within 15 minutes of application, and by transiently 
increasing intracellular Ca2+ levels in these cells- which can contribute to the 
neuroprotective effect of the peptide (ibidem).  
The VGF-derived peptides, LQEQ-19 and AQEE-30 evoked dose-dependent thermal 
hyperalgesia in adult mice, using the warm-water (49 °C) tail-immersion in vivo 
assay. Immunohistochemical analysis of spinal cords obtained at the peak of LQEQ-
19-induced hyperalgesia (10 minutes) showed a nearly three-fold increase in 
phosphorylated p38 MAPK immunofluorescence, and this staining showed co-
localisation with CD68, a marker for reactive microglia. The BV-2 murine microglia 
cell line was treated with LQEQ-19 and dose-dependently increased p38 
phosphorylation in these cells (Riedl et al., 2009).  
These data provide an insight into some of the molecular mechanisms of action of a 
few of the VGF-derived peptides, however, they also highlight how little is currently 
known about the signalling mechanisms of VGF.  
 
Microglia, inflammatory cytokines and MAPK signalling 
 
Microglia are the resident immune cells of the central nervous system (CNS) and 
constitute a significant population of the total number of cells in the CNS (~15 %). 
They have important roles in immune surveillance, inflammatory reactions as well as 
various CNS pathologies including neurodegenerative diseases and neuropathic pain. 
This means that these cells can be neuroprotective as well as having detrimental 
effects on CNS tissue, for example in human immuno-deficiency (HIV) infection 
microglia activation can have both neuroprotective and neurotoxic effects on cells 
(Sawada, 2009). Microglia cells are very resilient cells, which undergo an array of 
physiological changes, such as morphology and surface-receptor configuration, 
depending on environmental cues and functional roles. The plasticity of microglia is 
essential for them to fulfil their immunological and homeostatic functions within the 
otherwise immune-privileged environment of the CNS.  
In a normal healthy CNS environment, the microglia have a ramified morphology and 
are said to be in their resting, quiescent state. However, it is now becoming 
increasingly clear that these "resting" cells are in fact actively scanning their 
environment and that microglial activation is better described as occurring in a graded 
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fashion (Kettenmann et al., 2011). Microglial activation is a highly regulated and 
complex process, which is associated with an array of changes in the cell release 
profile as well as changes in morphology, intracellular Ca2+ levels (Farber and 
Kettenmann, 2006; Moller, 2002), altered phosphorylation states of intracellular 
signalling kinases, such as MAPKs (Ji et al., 2009) and ultimately altered expression 
profiles for cytokines and receptors.  
The activation of microglia has been extensively studied and reviewed, both in in 
vitro (Nakamura, 2002), and in vivo models (Banati, 2002, 2003). Neurodegenerative 
diseases, such as Alzheimer's disease (AD), Creutzfeldt-Jakob disease (CJD), 
Parkinson's disease (PD) and multiple sclerosis (MS), have all been widely 
demonstrated to activate microglia cells. The activated cells rapidly proliferate and 
begin to express a plethora of receptor and signalling molecules, such as the 
macrophage antigen complex-1 (MAC-1), nitric oxide (NO), reactive oxygen species 
(ROS) and many proinflammatory cytokines, such as TNFα, IL-6 and IL-1β (Dheen 
et al., 2007).  
Neuropathic pain is a chronic condition, which occurs after nerve damage that can be 
induced by cancer, diabetes, AIDS or physical injury (Inoue and Tsuda, 2009). This 
often leads to hyperalgesia and tactile allodynia, caused by hyperexcitability of 
neurons. This change in neuronal behaviour has increasingly been shown to involve 
microglia in the CNS, which have become activated. Many of the same changes 
mentioned above are observed in these activated microglia in vivo, including (but not 
limited to) changes in cell surface receptor expression, changes in intracellular 
signalling molecules such as phosphorylation to p38 MAPK (Jin et al., 2003) and 
increased expression and secretion of inflammatory cytokines and neurotrophic 
factors such as IL-1β, IL-6, TNFα and BDNF, which can act on neurons to induce 
hyperexcitability as well as act in an autocrine manner (i.e. act on microglia), 
reviewed in (Inoue and Tsuda, 2009; Ji and Suter, 2007).  
For in vitro studies, microglia were shown to be activated by various inflammatory 
stimuli such as lipopolysaccharide (Dheen et al., 2005), proinflammatory cytokines 
such as IFNγ (Smith et al., 1998), and neuropeptides such as substance P (Martin et 
al., 1993) and many other inflammatory mediators (Ji and Suter, 2007).  
Studying gene expression and intracellular signal transduction pathways (e.g. MAPK 
signalling) are extremely important in furthering our understanding of microglial 
physiology, particularly when novel activating agents, such as VGF-derived peptides 
 158
are identified. Understanding the activating stimuli as well as the molecular 
mechanisms of microglial activation and function is an area of extensive research. 
 
Quantitative real-time PCR 
 
Quantitative real-time reverse transcription PCR (real time qRT-PCR) is a highly 
sensitive and specific technique that has dramatically enhanced the field of gene 
expression studies. It is one of the most widely used techniques for gene 
quantification due to its ability to detect often-rare mRNA targets and its large 
dynamic range and is thus preferred to older techniques such as Northern blot 
analysis, which require large quantities of starting RNA material and only provide 
qualitative or semi-quantitative data. Real-time PCR allows amplification and 
detection in a single step, using fluorescent chemistry to correlate PCR product 
concentrations to fluorescence intensities. This technique allows quantitative data to 
be accumulated, can be relatively high-throughput and does not require post-
amplification manipulation (Wong and Medrano, 2005). Real-time PCR assays are 
many fold more sensitive than RNase protection assays (Wang and Brown, 1999), dot 
blot hybridisation (Malinen et al., 2003) and it has been reported that a single copy of 
a specific transcript can even be detected (Palmer et al., 2003). However, real-time 
PCR equipment and reagents are often quite expensive and due to the high sensitivity 
of the technique, small variations in experimental set-up can even be detected. Due to 
this inherent sensitivity in the technique, suitable experimental design and a deep 
understanding of data analysis techniques are necessary for accurate conclusions.  
 
RNA isolation and cDNA synthesis 
 
The collection of samples and careful purification of RNA are the initial step of qRT-
PCR. The quality of this RNA is the most important aspect in order to obtain 
reproducible and biologically relevant results, in fact most problems affecting 
reproducibility normally originate here (Bustin and Nolan, 2004). RNA is extremely 
delicate, unlike DNA, especially once it is removed from the cellular environment. 
Thus the RNA purification techniques need to be optimised to obtain a suitable 
template for the RT-PCR assay. The following criteria are essential for this: 
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(1) RNA must be free of DNA contaminants, particularly if the gene of interest is 
intronless or the PCR primers are not intro-spanning. 
(2) The RNA must be very high quality for quantitative results. This is often 
measured by checking RNA purity using UV spectrophotometry and/or ribosomal 
RNA band integrity (Fleige and Pfaffl, 2006).  
(3) Any inhibitors (e.g. heme compound) of the reverse transcription (RT) step must 
be removed during the purification steps (Akane et al., 1994).  
(4) Nucleases must be removed from the RNA samples, especially for extended 
storage periods.  
Following RNA extraction, a cDNA synthesis reaction must be performed. This can 
be done in a one-step reaction where cDNA synthesis and PCR amplification are 
performed in a single step. A two-step procedure can also be performed, where the 
reverse transcription and PCR amplification are carried out separately. This two-step 
protocol is the method of choice when using DNA binding dyes (e.g. SYBR Green), 
as it is easier to manipulate melting temperatures in the PCR amplification process 
and thus eliminate primer-dimer formation (Vandesompele et al., 2002a).  
 
Detection chemistries 
 
Reactions for real-time qPCR are often defined by the cycle threshold (Ct) value, this 
is where the fluorescence of the target amplification is first detected, and is greater 
than the background fluorescence. The greater the quantity of target DNA, the faster 
the increase in the fluorescent signal and thus the lower the Ct value (Wong and 
Medrano, 2005). Fluorescent detection chemistries can be broadly characterised into 
two groups, non-specific detection and specific detection.  
The non-specific detection methods use DNA binding dyes (e.g. SYBR Green), which 
emit fluorescence when bound to double stranded DNA (dsDNA). As dsDNA 
accumulates, the fluorescence signal intensifies, thus fluorescent intensity is 
proportional to DNA concentration. This non-specific dye method is very flexible, as 
one dye can be used for multiple gene assays. However, the DNA binding dyes are 
not sequence specific and can thus generate false positives. Data must be verified for 
these reactions, using dissociation curve analysis, whereby a single melt-curve is 
generated for a single PCR amplification product and any further melting peaks 
represent different, non-specific PCR products (Ririe et al., 1997).  
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Template specific detection chemistries (e.g. TaqMan) require custom made 
fluorescent probes, which bind a DNA region amplified by specific sets of primers. 
TaqMan probes have both a fluorophore and a quencher attached to them. As the 
polymerase extends the specific primer and generates a new DNA strand, the TaqMan 
probe is degraded. This then separates the quencher from the fluorophore and allows a 
fluorescence signal to be generated, thus the fluorescent intensity is proportional to 
the amount of DNA. In this way, a fluorescent signal is only generated if the amplicon 
specific probe hybridises to its complementary target (Bustin and Nolan, 2004). Given 
its high specificity, the TaqMan method is preferable; however, it is a lot more 
expensive when multiple genes are being studied.  
 
Real-time quantification and data analysis 
 
To quantify data obtained from real-time qPCR, two different methods are often 
employed: absolute quantification or relative quantification. Absolute quantification 
involves generating a standard curve using a sample of known concentration that has 
been serially diluted. The standard curve establishes a linear relationship between Ct 
(this term is defined below) and initial amounts of RNA or cDNA, and then allows 
determination of the concentrations of unknown amounts of sample based on their 
resulting Ct values.  
Relative quantification measures changes in sample gene expression based on either 
an external standard or a reference (housekeeping) sample, also known as a calibrator 
(Wong and Medrano, 2005). A mathematical model is applied to allow calculation of 
the relative gene expressions of different samples, using mean normalised gene 
expression data.  
The comparative Ct (2-∆∆Ct) method is a commonly used model that calculates changes 
in gene expression as a relative fold difference between a housekeeping gene and an 
experimental sample. However, this model assumes the amplification efficiencies of 
target and housekeeping genes are approximately equal, which is not always the case, 
and so different efficiencies will generate errors using this method (Livak and 
Schmittgen, 2001). This comparative method doesn't require a standard curve and is 
thus useful when assaying a large number of samples as more reaction wells can be 
used for the sample reactions, rather than for the standard reactions.  
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Controls and normalisation 
 
There are a number of important controls that are required in all real time qRT-PCR 
experiments, which ensure the integrity and reliability of the procedure. Eliminating 
genomic DNA contamination is essential for obtaining optimal real-time gene 
expression profiling data. As well as enzymatically cleaving genomic DNA when 
extracting RNA from samples, another common method employed is to design a 
target PCR product which spans an exon-exon boundary.  
A passive reference dye, such as ROX, is also often included in the reactions, which 
compensates for subtle changes in master mix volumes as well as non-PCR-related 
fluctuations in the fluorescence signal (Wong and Medrano, 2005).  
Normalisation of gene expression is used to correct for sample to sample variations in 
qRT-PCR efficiencies and errors in sample quantification. It can also correct for 
differences in RNA integrity or quantity, or experimental treatments. The ideal 
control gene should have constant expression levels, regardless of experimental 
conditions, as well as serving as a positive control for the real-time PCR reaction.  
Housekeeping genes, such as GAPDH, β-actin and cyclophilin A, traditionally have 
stable expressions. However, selection of housekeeping gene is dependent on 
experimental conditions, such as tissue/cell type, thus it is imperative to validate the 
stability of the housekeeping gene for the each experimental set-up rather than relying 
on previously published data. Normalisation using multiple housekeeping genes is the 
most accurate method and can overcome these normalisation problems.  
 
Cytokine and receptor gene expression 
 
Cytokines (and their receptors) are regulatory proteins that play a key role in many 
inflammatory responses. Knowing local cytokine patterns of expression is important 
to further our understanding of molecular events that shape many inflammatory 
responses such as infectious diseases, neurodegenerative diseases and neuropathic 
pain. Cytokine protein detection, using techniques such as ELISA and Western blot 
analysis, only allows a limited number of cytokines to be measured from a single 
sample. Real-time qRT-PCR is widely used to quantify cytokine (and their receptor) 
profiles, which are often expressed at very low levels (Giulietti et al., 2001), due to 
the high sensitivity and exponential amplification process of the technique. A 
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potential drawback is the fact that this technique measures mRNA, which is only an 
estimate of cytokine profiles at the protein level. However, this deficiency can be 
partially circumvented by studying the expression of genes involved in cytokine 
signalling and regulation (Peinnequin et al., 2004).  
 
Real-time qRT-PCR is an extremely powerful technique that can generate 
reproducible, reliable and meaningful data and is thus an invaluable tool in 
elucidating the molecular mechanisms of novel agents and peptides. 
 
Aims 
 
It has already been shown in previous chapters of this investigation that the TLQP-21 
peptide dose-dependently elicits an increase in intracellular Ca2+ levels in primary 
microglia. It has also been observed that TLQP-21 binds the gC1q-R protein, a 
complement protein associated with the immune response, among other functions. 
The work presented in this chapter was to investigate molecular events downstream of 
VGF-derived peptide application on microglia cells in vitro. Expression of genes 
encoding inflammatory mediators, cytokines and receptors were analysed after 3 h 
application of TLQP-21 (and scrambled TLQP-21), using quantitative real-time PCR 
analysis. Phosphorylation of p38 MAPK protein, following TLQP-21 application, 
were also analysed in both primary microglia cells, as well as the murine microglia 
BV-2 cell line.  
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Materials & Methods 
 
Primary microglia culture and confirmation of peptide functionality 
in DMEM/F-12 
 
The in vitro functionality of the wild type and scrambled TLQP-21 peptides in 
DMEM/F-12 media was confirmed using primary microglia cultures (DIV=23) and 
confocal live cell imaging as described in the Materials & Methods section of 
Chapter 2. However, instead of using extracellular media to wash and incubate the 
primary microglia cells, DMEM-F-12 media was used instead to replace the 
extracellular media at all steps.  
 
Quantitative real-time reverse transcription PCR analysis 
 
Treatments and RNA extraction 
 
Primary microglia, which were isolated from P=4 rats as described in Chapter 2, were 
plated on 35 mm plastic dishes (BD Falcon) coated with poly-L-lysine at 200, 000 
cells per dish, per condition. At DIV=23 (the same number of days in vitro for the 
cells when analysed using the Ca2+ assay), cells were washed three times with pre-
warmed DMEM/F-12 media and then incubated in the DMEM/F-12 media for 2 hours 
at 37 °C with 5 % CO2 to allow the cells to adjust to the media. The media was 
removed and replaced with pre-warmed DMEM/F-12 media, this time with the 
different treatments (100 nM TLQP-21 and Scr TLQP-21 as well as 1x PBS vehicle 
control). Following 3 hours incubation at 37 °C with 5 % CO2, the cells were washed 
with pre-warmed 1x PBS, followed by use of the RNA extraction kit, as per 
manufacturers instructions (RNeasy Mini kit; Qiagen). Briefly, Buffer RLT (350 µl) 
was applied to each plate and cells were scraped using sterile RNase-free cell scrapers 
(PAA) and collected into clean RNase-free eppendorfs, using RNase-free pipette tips 
(Ambion; all RNase-free pipette tips and conditions were used from this point 
forward). Cells were kept on ice throughout the procedure unless otherwise stated, to 
minimise RNA degradation. Cells were passed through a blunt 20-gauge needle 20 
times and 1 volume of 70 % ethanol was added to the lysate and mixed well. This 
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sample was then applied to the RNeasy spin column placed in a collection tube and 
centrifuged for 15 seconds at 8000 x g. The flow through was discarded, and 350 µl 
Buffer RW1 was added to the column and centrifuged as before. The flow though was 
discarded and on-column DNase digestion was performed, by adding 80 µl DNase I 
solution directly to the spin column membrane and left on the bench at R.T. for 
15 minutes. This was followed by addition of 350 µl of Buffer RW1 to the column 
and centrifugation as above and discarding of the flow through. Buffer RPE (500 µl) 
was then applied and centrifuged as above, again discarding flow through. Another 
500 µl of Buffer RPE was applied, and this time the spin column was centrifuged for 
2 minutes at 8000 x g. The spin column was then removed and placed in a new 
collection column and centrifuged at 17000 x g for 1 minute. Finally the spin column 
was placed in a new 1.5 ml collection tube and 30 µl RNase-free water applied 
directly onto the membrane, followed by centrifugation for 1 minute at 8000 x g to 
elute the RNA.  
RNA  concentration  was  determined  by  spectrophotometric analysis,  using  the  
ND-1000  Spectrophotometer  (Thermo Scientific).  1 µl of each RNA sample was 
loaded onto the spectrophotometer and approximate RNA concentration and purity  of  
samples  was  assessed  by  spectrophotometric  absorbance  at  A260 value, and  by  
the A260:A280 ratio, respectively.  Good quality, pure RNA sample should have 
A260:A280 ratios of 1.8 to 2.1, lower ratios indicate possible protein contamination. All 
RNA samples used in this investigation had A260/A280 ratios higher than 2.09. 
 
Reverse transcription and synthesis of cDNA 
 
The RNA was then reverse transcribed using the SuperScript III First-Strand 
Synthesis System kit (Invitrogen). Briefly, the RNA was mixed with the random 
hexamer primer and dNTPs and incubated at 65 °C for 5 minutes, placed on ice for 
1 minute, and then returned to R.T. The cDNA synthesis mix (reverse transcriptase 
and buffer, MgCl2, DTT and RNaseOUT) was added to the reaction and incubated at 
R.T. for 10 minutes, followed by incubation at 50 °C for 50 minutes. The reaction was 
terminated by heating to 85 °C for 5 minutes, followed by incubation on ice. The 
remaining RNA was then removed by addition of RNase H and incubation at 37 °C 
for 20 minutes.  
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Real time quantitative PCR 
 
Real time PCR was performed using the StepOnePlus System (Applied Biosystems) 
and the 2x Fast SYBR Green Master Mix (Applied Biosystems), to accurately 
determine target gene expression levels. PCR reactions were performed in a total 
reaction volume of 20 µl, containing 10 µl 2x Fast SYBR Green Master Mix, 0.5 µM 
of both forward and reverse primers and cDNA (this concentration could not be 
measured, thus the original 300 ng of the RNA used to synthesise the cDNA was used 
to determine the volume of treatment cDNA added to the reaction mix). Samples were 
loaded in triplicate on the plate for each primer set, and both GAPDH and Cyclophilin 
A were used as housekeeping genes. The PCR was run with an initial step of 95 °C 
for 20 seconds to activate the AmpliTaq Fast DNA polymerase enzyme, followed by 
45 cycles of 95 °C for 3 seconds, 60 °C (annealing) for 15 seconds and 72 °C for 
15 seconds. Fluorescence incorporation of the SYBR Green to double stranded DNA 
was measured after each cycle, to generate an amplification curve. Product 
composition was verified at the end of each reaction with melt curve analysis in 
0.6 °C increments from 60 °C to 95 °C. Primer sequences (5' to 3') are stated below, 
with annealing temperatures of 60 °C and amplicon size < 250 bp, and primer 
efficiency for use with the 2-∆∆Ct method of analysis were previously confirmed and 
validated (Peinnequin et al., 2004): 
GAPDH Forward  GTATTGGGCGCCTGGTCACC 
GAPDH Reverse  CGCTCCTGGAAGATGGTGATGG 
Cyclophilin A Forward TATCTGCACTGCCAAGACTGAGTG 
Cyclophilin A Reverse CTTCTTGCTGGTCTTGCCATTCC 
IL-1β Forward  CACCTCTCAAGCAGAGCACAG 
IL-1β Reverse   GGGTTCCATGGTGAAGTCAAC 
IL-6 Forward   TCCTACCCCAACTTCCAATGCTC 
IL-6 Reverse   TTGGATGGTCTTGGTCCTTAGCC 
TNFα Forward  AAATGGGCTCCCTCTCATCAGTTC 
TNFα Reverse   TCTGCTTGGTGGTTTGCTACGAC 
iNOS Forward  CATTGGAAGTGAAGCGTTTCG 
iNOS Reverse   CAGCTGGGCTGTACAAACCTT 
COX-2 Forward  TGTATGCTACCATCTGGCTTCGG 
COX-2 Reverse  GTTTGGAACAGTCGCTCGTCATC 
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BDNF Forward  AAGGCACTGGAACTCGCAAT 
BDNF Reverse  AACCGCCAGCCAATTCTCTT 
The threshold amplification cycles (CT values) were calculated by the StepOne 
software (v2.2; Applied Biosystems) and then analysed using the 2-∆∆Ct method 
(Livak and Schmittgen, 2001).  
The PCR Arrays (SABiosciences; # PARN-011C) had the primers (for Rat 
Inflammatory Cytokines and Receptors) already added to the wells (96-well format), 
and only the cDNA (from microglia treatments; prepared as above) and SYBR Green 
Master Mix had to be applied. The PCR reactions (25 µl total volume) were run with 
an initial step of 95 °C for 10 minutes to activate the HotStart DNA polymerase 
enzyme, followed by 40 cycles of 95 °C for 15 seconds and 60 °C (annealing and 
extension) for 1 minute. Fluorescence incorporation of the SYBR Green to double 
stranded DNA was measured after each cycle, to generate an amplification curve. 
Product composition was verified at the end of each reaction with melt curve analysis 
in 0.6 °C increments from 60 °C to 95 °C. 
All analysis was carried out using the software and 2-∆∆Ct method. This method 
compares all datasets to both the housekeeping genes and the control in the 
experiment (the vehicle control). All the primers used in the PCR Arrays were 
validated for this method (2-∆∆Ct) of analysis by SABiosciences (personal 
communication with the company).  
For each treatment, three technical replicates were used, and were repeated three or 
four times to obtain biological replicates (n=3 for individual primer sets shown above 
and n=4 for PCR Arrays). These large number of repeats (using 200, 000 cells each 
time, for each treatment) ensured accurate, reliable and repeatable datasets were 
obtained. The Student's t-test was used for statistical analysis of real time qPCR data, 
and statistical significance was set at p ≤ 0.05. Data was expressed with ± SEM where 
applicable.  
 
The p38 MAPK and Western blot analysis 
 
For analysis of p38 MAPK phosphorylation states following VGF-derived peptide 
treatments, primary microglia (DIV=23 on day of treatments) or BV-2 cells were 
plated on 35 mm plastic dishes (BD Falcon) coated with poly-L-lysine at 200, 000 
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cells per dish, per condition. Cells were washed three times with pre-warmed 
DMEM/F-12, followed by a 2 hour incubation with the media to allow the cells to 
adjust. The media was removed and replaced with pre-warmed DMEM/F-12, this 
time with the different treatments for 5 minutes and 30 minutes. Following incubation 
for the appropriate time, cells were quickly, but gently washed with ice-cold PBS 
followed by cell lysis (Lysis Buffer: 2 % SDS, 1x PhosSTOP; Roche, 1x protease 
inhibitor cocktail; Roche) and collected using a sterile cell scraper (PAA). The lysed 
cells were heated at 60 °C for 10 minutes, centrifuged at 17, 000 x g for 5 minutes and 
the pellets stored at -80 °C until ready for SDS-PAGE and Western blot analysis. 
Protein concentration was quantified using the BCA kit and BSA standards (Pierce) 
and 100 µg of protein was loaded to each well, and resolved via SDS-PAGE, 
followed by transfer to PVDF membrane, washing, BSA blocking and incubation 
with antibodies (as described in Chapter 3 Materials & Methods section). The rabbit 
phospho-p38 MAPK monoclonal antibody (Cell Signalling Technology) was used 
and incubated overnight at 4 °C, followed by the secondary goat anti-rabbit-HRP 
antibody for 1 hour at R.T. Both were used at 1:1000 dilution in TBS-T. To detect 
total p38 MAPK protein, the same membranes were stripped and re-probed. The 
stripping buffer (2 % SDS, 50 mM Tris-HCl, pH 6.8, and 100 mM β-mercaptoethanol 
added fresh each time) was incubated with the membrane at 50 °C for 30 minutes 
with gentle shaking in a sealed container. Membranes were then thoroughly washed 
with TBS-T (three times at 15 minutes each) and blocked again with 5 % BSA in 
TBS-T before being washed again and re-probed. The rabbit p38 MAPK antibody 
(Cell Signalling Technology) was used at a dilution of 1:1000 in TBS-T and 
incubated overnight at 4 °C and the same secondary antibody was used- the goat anti-
rabbit-HRP antibody, for 1 hour at R.T. The membranes were washed and detected as 
described in Chapter 3; using the chemiluminescence detection kit for HRP 
(AppliChem, VWR) and detection with the Fujifilm LAS-3000 Imaging System. 
Signal intensities were quantified using freeware image analysis software ImageJ 
(http://rsweb.nih.gov/ij/).  
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Results 
 
Determining the functionality of TLQP-21 peptides in DMEM/F-12 
media 
 
The previous data presented in this investigation suggest that the TLQP-21 peptide 
induces a dose dependent increase in intracellular Ca2+ levels in primary microglia 
cells. When performing the Ca2+ assay on microglia, the cells were placed in 
extracellular media for 1 hour prior to treatment. This media was suitable for the short 
times typically needed for confocal live cell imaging. However, for longer times (such 
as 3 hours), primary microglia cells become unhealthy and start to undergo cell death, 
thus serum-free DMEM/F-12 media (which is nutrient rich), was found to be more 
suitable for the cells and allowed long term survival, without activating the microglia 
cells in the process. However, this media needed to be tested to ensure that the 
TLQP-21 peptide still induced Ca2+ response in primary microglia cells. It was 
observed that TLQP-21 (100 nM) still induced an increase in intracellular Ca2+ levels, 
when the primary microglia cells were in pre-warmed media and analysed by live cell 
imaging (Figure 4.1). The DMEM/F-12 media was therefore suitable to treat cells and 
did not inhibit the TLQP-21 induced Ca2+ response.  
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Figure 4.1. TLQP-21 (100 nM) induced an increase in intracellular Ca2+ levels in 
primary microglia cells using DMEM/F-12 media. Average fluorescence profile of 
primary microglia cells, representing the average of 150 cells over 3 biological 
replicates. ATP was applied as a cell viability test after treatment, and only viable 
cells were selected. 100 nM TLQP-21 was applied to microglia cells, in serum-free 
and nutrient rich DMEM/F-12 media, and the peptide still elicited an increase in 
intracellular Ca2+ levels in these cells. Error bars represent the SEM of each 
fluorescence data point, taken every 6 seconds.  
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Gene expression levels of inflammatory mediators in primary 
microglia cells following 3 hour TLQP-21 treatments 
 
To elucidate some downstream signalling events following TLQP-21 induced 
increases in intracellular Ca2+ levels, quantitative real-time PCR (qRT-PCR) was 
performed on primary microglia cells treated with wild type TLQP-21 (as well as 
vehicle and scrambled TLQP-21 peptides). This technique measures the levels of gene 
expression induced after the treatments. Data has accumulated suggesting the 
importance of the role of inflammatory mediators, released by non-neuronal cells such 
as microglia, in modulating responses of pain signalling neurons (Inoue and Tsuda, 
2009). They can do this by releasing mediators into peripherally damaged tissues as 
well as the central nervous system (CNS). TLQP-21 was shown to be involved in 
inflammatory pain modulation in vivo (Rizzi et al., 2008).  The TLQP-21 peptide may 
act directly on neurons, as well as modulate activity of microglia cells, which can act 
on neurons through the release of inflammatory mediators. Previous data has shown 
that inflammatory mediator gene expression in primary microglia is usually maximal 
between 2 to 6 hours after induction, when analysing the same mediators and qPCR 
techniques used in this investigation (Baker et al., 2010; Dheen et al., 2005; Wang et 
al., 2007). An intermediate time of 3 hours of TLQP-21 treatment was selected, as this 
would allow the inflammatory mediators to have expressed to sufficient amounts, if 
indeed induced by the TLQP-21 peptide, and allows analysis of the downstream 
consequences of TLQP-21-induced increase in intracellular Ca2+ levels. Quantitative 
real-time PCR is a highly sensitive technique, which also means that small changes in 
experimental set up, such as the initial RNA quality, can affect the outcome greatly. 
Thus it is highly recommended to have both technical replicates and biological 
replicates in order to produce reliable datasets (Bustin, 2010). The primary microglia 
for each condition were plated at 200, 000 cells per plate (total DIV=23, like the cells 
used in the live cell imaging and Ca2+ assay). For each dataset (n=1), three plates were 
set up for each treatment (i.e. three technical replicates), the RNA was extracted and 
combined for reverse transcription and qRT-PCR analysis. This was repeated on three 
separate occasions, to obtain biological replicates (n=3). The 3 datasets were then 
analysed using the 2-∆∆Ct method (Livak and Schmittgen, 2001). The wild type TLQP-
21 peptide, at 100 nM, was tested, as well as the scrambled TLQP-21 peptide- and 
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both were compared to the vehicle control. The 2-∆∆Ct method normalises the data for 
each gene with the corresponding data from the vehicle, as well as normalising each 
gene against a housekeeping gene. The housekeeping genes should be expressed at 
relatively constant levels, however, some can vary depending on experimental 
conditions (Greer et al., 2010). Two different housekeeping genes were used in this 
investigation (GAPDH and cyclophilin A), in case one of these housekeeping genes 
changed expression levels in the microglia following peptide application. The six 
genes of interest which were selected for analysis were the inflammatory mediators: 
IL-1β (interleukin-1β), IL-6 (interleukin-6), TNFα (tumour necrosis factor α), iNOS 
(inducible nitric oxide synthase), COX-2 (cyclooxygenase-2) and BDNF (brain-
derived neurotrophic factor), all of which have previously been shown to be up-
regulated after microglia activation following nerve injury, and that induce 
sensitisation of neurons and persistent pain facilitation (Ji and Suter, 2007).  
Primary microglia cells were initially incubated with pre-warmed DMEM/F-12 media 
for 2 hours prior to treatment, to allow cells to adjust to the media. This was followed 
by treatment with the TLQP-21, scrambled TLQP-21 (Scr TLQP-21) or the vehicle 
control for 3 hours at 37 °C, 5 % CO2 before RNA extraction, reverse transcription 
and qRT-PCR. It was found that none of the genes of interest changed expression, 
relative to the vehicle control, when microglia cell were treated with TLQP-21 or Scr 
TLQP-21 for 3 hours (Figure 4.2). This was found to be consistent when using both 
GAPDH and cyclophilin A (CypA) as the housekeeping gene control. In case the 
experimental set-up was the cause of the results, a positive control using LPS was 
performed at the same time. Following 3 hours treatment of primary microglia with 
LPS (1 µg/ml) in DMEM/F-12 media, it was found that all the genes of interest had 
increased (Figure 4.3). The fold increases after LPS treatment, relative to the control 
were quite significant; IL-1β (73 fold), IL-6 (2943 fold), TNFα (55 fold), iNOS (764 
fold), COX-2 (91 fold) and BDNF (5 fold), thus suggesting that the experimental set 
up may not have been responsible for the lack of gene expression modulation 
following 3 h TLQP-21 treatments.  
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Figure 4.2. Both wild type (WT) and scrambled (Scr) TLQP-21 did not induce a 
significant change in expression levels of inflammatory mediators after 3 h 
incubation. When the wild type TLQP-21 (WT TLQP-21) and scrambled TLQP-21 
(Scr TLQP-21) were applied to primary microglia cells for 3 hours, it was found that 
no inflammatory mediator gene expression significantly changed (Student's t-test; 
p ≤ 0.05) from the vehicle control (set at 1.0 on "Fold Change" scale), when using 
both housekeeping genes and the 2-∆∆Ct method of analysis. Error bars represent SEM 
from data over 3 biological replicates.  
 
 
Figure 4.3. LPS (1 µg/ml) induced expression of all inflammatory mediators 
tested, following 3 h incubation with primary microglia cells. Primary microglia 
cells were treated with the positive control, LPS (1 µg/ml) for 3 hours in DMEM/F-12 
media, followed by qRT-PCR analysis. All genes tested (inflammatory mediators) 
showed up-regulated expression levels ("Fold Change" calculated using the 2-∆∆Ct 
analysis method); IL-1β (73 fold), IL-6 (2943 fold), TNFα (55 fold), iNOS (764 fold), 
COX-2 (91 fold) and BDNF (5 fold). This was apparent when using both 
housekeeping genes, which remained constant for treatments.  
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For a larger set of genes (84 genes), PCR arrays (SABiosciences) were used to test 
whether TLQP-21 application induced changes in gene expression of a range of rat 
inflammatory cytokines and receptors (see Appendix A2 for full list of genes). Again, 
three technical replicates of treated cells were combined to obtain one biological 
replicate, and four biological replicates were performed in total (n=4). Each replicate 
cDNA was sufficient for one PCR array, which had five housekeeping genes and its 
own quality control wells (see Appendix A2). All five housekeeping genes were used 
in the analysis, and all the arrays tested passed the quality control tests (which 
included PCR array reproducibility, reverse transcription efficiency and genomic 
DNA contamination).  
A 2-fold (up- or down-) regulation threshold was set to observe gene expression 
changes after peptide incubation for 3 hours with primary microglia cells. It was 
found that the scrambled TLQP-21 peptide (Scr TLQP-21) showed 3 genes up-
regulated and 1 down-regulated relative to the vehicle control group (Figures 4.4A 
and 4.4C). The wild type TLQP-21 peptide induced 4 genes to be up-regulated and 3 
genes to be down-regulated (Figures 4.4B and 4.4D). It was observed that most of the 
84 genes tested did not show any changes to TLQP-21 and Scr TLQP-21 application, 
and Ct values were constant for most over the many replicates, highlighting the 
consistency and reliability of the array data and experimental set up.  
Of the gene changes observed, only two showed statistically significant variance from 
the vehicle control (p ≤ 0.05, Student's t-test) when WT TLQP-21 was applied to the 
cells, Ccl11 and Cxcl9 (Figure 4.4D). The Ccl11 gene was up-regulated by 2.78 fold, 
relative to the vehicle control, whereas the Cxcl9 gene was down-regulated by 2.28 
fold (-2.28). The expression of both these genes was unaltered after scrambled 
TLQP-21 application, suggesting a specific response for WT TLQP-21.  
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Figure 4.4. PCR array data shows that only two gene expression levels are 
significantly different from the vehicle control after 3 h TLQP-21 application.  
Data from the PCR arrays, represented in scatter plots showing a boundary set at a 
2-fold change from vehicle ("Control" group) using the 2-∆∆Ct method of analysis. 
Genes showing greater than a 2-fold increase relative to the control are represented in 
red and those genes showing a greater than 2-fold decrease in expression are 
represented in green. (A) Following application of Scr TLQP-21 on primary microglia 
cells for 3 h, it was observed that 3 genes were up-regulated greater than 2-fold from 
the vehicle control and 1 gene down-regulated. (B) The WT TLQP-21 peptide showed 
4 genes up-regulated and 3 genes down-regulated, relative to the control. The majority 
of the 84 genes tested remained constant (relative to the control) following 3 h 
incubations with both peptides. (C) Statistical analysis, using the Student's t-test, 
showed that none of the genes that showed a greater than 2-fold change following Scr 
TLQP-21 application were significantly different from the vehicle control. (D) 
Analysis of WT TLQP-21 application showed that 2 genes showed statistically 
significant changes relative to the vehicle (p ≤ 0.05) and are indicated in red (up-
regulated) and green (down-regulated). The Ccl11 gene was found to be up-regulated 
by 2.78 fold, whereas the Cxcl9 gene was found to be down-regulated by 2.28 fold 
(-2.28). Four biological replicates were used to generate and analyse this data (n=4). 
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Analysis of p38 MAPK phosphorylation after TLQP-21 application 
 
Previous work has shown that VGF-derived peptides induce phosphorylation of 
signalling proteins inside cells following application. The TLQP-21 peptide was 
found to induce an increase in phosphorylation of Erk1/2, Akt and a 44 kDa isoform 
of JNK, as well as a decrease in phosphorylation in PKC phosphorylation, all after 
15 minutes in cerebellar granule cells in vitro (Severini et al., 2008). The LQEQ-19 
(100 nM) peptide was shown to induce p38 MAPK phosphorylation in spinal 
microglia in vivo, as well as in BV-2 cells in vitro, although the TLQP-21 peptide was 
not tested in this study (Riedl et al., 2009).  
To test whether the TLQP-21 peptide induced phosphorylation of p38 MAPK in 
primary microglia in vitro, cells were treated with 100 nM wild type (WT) TLQP-21 
and scrambled (Scr) TLQP-21 for 5 and 30 minutes. Western blot analysis was carried 
out, using a phosphorylation specific p38 MAPK antibody, and as a loading control; 
total p38 MAPK antibody (Figure 4.5). The vehicle control was included, as well as 
two positive controls, ATP (1 mM) and LPS (1 µg/ml). The phosphorylation bands 
were normalised to total p38 MAPK protein levels and compared to the vehicle 
control. After 5 minutes treatment of cells, it was observed that neither the TLQP-21, 
nor the Scr TLQP-21 induced any changes in phosphorylation of p38 MAPK relative 
to the vehicle control (Figure 4.5A). Interestingly, only the ATP induced an increase 
in p38 MAPK phosphorylation after 5 minutes (~42 % higher than vehicle), the LPS 
did not. After 30 minutes, however, the LPS did induce phosphorylation of p38 
MAPK (~41 % higher than vehicle), whereas the ATP showed levels identical to the 
vehicle control (Figure 4.5B). Both the TLQP-21 and Scr TLQP-21 did not induce 
any changes in p38 MAPK phosphorylation relative to the vehicle control, after 
30 minutes.  
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Figure 4.5. Primary microglia cells did not show an increase in p38 MAPK 
phosphorylation following TLQP-21 (100 nM) treatment for 5 and 30 minutes. 
Primary microglia cells were treated with vehicle, LPS (1 µg/ml), ATP (1 mM), wild 
type (WT) TLQP-21 (100 nM) and scrambled (Scr) TLQP-21 (100 nM) for 5 and 30 
minutes, followed by cell lysis and Western blot analysis. The blots were probed for 
phospho-specific p38 MAPK protein, as well as total p38 MAPK (used as a loading 
control). The protein bands were quantified using ImageJ software, followed by 
normalisation to the total p38 MAPK protein loading control and then compared to 
vehicle control (with the vehicle set at 100 %). (A) After 5 minute treatments, it was 
observed that ATP induced an increase in p38 MAPK phosphorylation (~42 % higher 
than vehicle), whereas all other treatments (including TLQP-21) did not significantly 
change p38 MAPK phosphorylation states relative to the vehicle control. (B) After 
30 minute treatments, ATP p38 MAPK phosphorylation levels returned to baseline 
levels (i.e. same as vehicle), however, the LPS treated cells increased p38 MAPK 
phosphorylation levels (~41 % higher than vehicle control). Both WT TLQP-21 as 
well as Scr TLQP-21 did not significantly induce phosphorylation of p38 MAPK after 
30 minutes treatments of primary microglia in vitro.  
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The BV-2 cells were also tested with the TLQP-21 peptide, as well as LQEQ-19 
(along with their scrambled peptides; all at 100 nM) to check for phosphorylation of 
p38 MAPK. As before, the phosphorylation bands were normalised to total p38 
MAPK protein levels and compared to the vehicle control. It was found that both 
TLQP-21 and LQEQ-19 peptides (and their scrambled peptides), did not induce 
phosphorylation of the p38 MAPK protein after 5 minutes incubation (Figure 4.6). 
 
 
Figure 4.6. BV-2 cells did not show an increase in p38 MAPK phosphorylation 
following TLQP-21 (100 nM) and LQEQ-19 (100 nM) treatments for 5 minutes. 
BV-2 cells were treated with vehicle as well as wild type (WT) and scrambled (Scr) 
VGF-derived peptides, LQEQ-19 and TLQP-21 (all at 100 nM) for 5 minutes, 
followed by cell lysis and Western blot analysis. The blots were probed for phospho-
specific p38 MAPK protein, as well as total p38 MAPK (used as a loading control). 
The protein bands were quantified using ImageJ software, followed by normalisation 
to the total p38 MAPK protein loading control and then compared to vehicle control 
(with the vehicle set at 100 %). It was observed that the VGF-derived peptides (WT 
and Scr) did not induce a significant change in p38 MAPK phosphorylation levels in 
BV-2 cells after 5 minute treatments.  
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Discussion 
 
TLQP-21 peptide application and qRT-PCR analysis 
 
Data in the previous chapters has shown that the TLQP-21 peptide induces an 
increase in intracellular Ca2+ levels, as well as binding the gC1q-R protein in vitro. To 
elucidate downstream signalling events following this, the primary microglia were 
tested for changes in gene expression levels. The extracellular media used for 
confocal analysis was suitable for the Ca2+ assay; however, for more long-term 
incubation with the cells, it lacked necessary nutrients for cell survival. The serum-
free DMEM/F-12 media was a suitable substitute, as it is nutrient rich and does not 
affect cell viability. The TLQP-21 peptide (100 nM) was still able to induce an 
increase in intracellular Ca2+ levels using this media, suggesting that the peptide and 
cell media were suitable to allow qRT-PCR analysis.  
To elucidate downstream signalling events following the initial Ca2+ response, 
previous data regarding VGF-derived peptides as well as microglia in pain pathways 
were used as guidance (Riedl et al., 2009; Tsuda et al., 2005). Thus the genes of 
interest selected for qRT-PCR were inflammatory cytokines and receptors, as Ca2+ 
signalling in microglia is often a marker of microglia activation and can lead to 
release of inflammatory cytokines and ultimately increases in their gene expression 
(Moller, 2002; Sattayaprasert et al., 2005). Due to the unknown nature of downstream 
changes induced by TLQP-21 application to microglia, previous data which tested the 
expression levels of these inflammatory mediators was used as a starting point, with 
the assumption that after 3 hours, maximal gene expression levels would be observed 
(Baker et al., 2010; Dheen et al., 2005; Wang et al., 2007).  
For the individual primer sets (IL-1β, IL-6, TNFα, iNOS, COX-2 and BDNF), after 
3 hours treatment with TLQP-21 (100 nM), the microglia did not change the 
expressions of these genes, relative to the vehicle control. There are a number of 
reasons why no change was observed, these genes may not be downstream of the 
TLQP-21 signalling pathway (if the Ca2+ response is affecting gene expression of 
proteins at all), or after 3 hours, gene expression changes may have already occurred 
and returned to baseline levels. It is also possible that after the rapid and transient 
effects of Ca2+ increase, microglia may have more immediate physiological responses 
 179
such as chemotaxis modulation, and any significant gene expression changes may 
occur after 3 hours. This can be tested further using multiple time points, both longer 
and shorter than 3 hours, for TLQP-21 incubation (along with the scrambled peptide). 
Another possibility is that the DMEM/F-12 media, which is nutrient rich, could have 
activated the cells already (during pre-incubation) and so any further increase 
observed with peptide addition would be masked. Thus the treatments would need to 
be tested in other media, to ensure that this is not the case. However, the LPS positive 
control was used to ensure that the conditions used in the experimental set-up were 
suitable to test gene expression changes. As the LPS induced quite significant changes 
(up to 2943 fold for IL-6) in the DMEM/F-12 media, it could be suggested, therefore, 
that the TLQP-21 indeed did not have any effect on the expression of these genes in 
microglia following 3 hours incubation and that this is a true physiological result. 
However, LPS induced increases in gene expression represent an extreme version of 
microglial activation, and even if the experimental conditions (such as pre-activation 
of microglia with the DMEM/F-12 media) inhibited or concealed TLQP-21 induced 
gene expression, this effect would go almost unobserved with LPS, due to this very 
high gene expression induction. Ideally another positive control, such as the amyloid 
beta (Aβ) peptide, would serve as a suitable control, as it can increase expression of 
various inflammatory mediators, such as iNOS (Rogers and Lue, 2001) and thus 
indicate any subtle experimental inhibitory conditions.  
The subtlety of TLQP-21 induced changes are highlighted by the data obtained in the 
PCR arrays, where only two genes were found to be significantly (Student's t-test; 
p ≤ 0.05) changed relative to vehicle control. The gene expression changes for Ccl11 
and Cxcl9 (both discussed further, see below) were only different from the vehicle 
control by 2.78 and -2.28 fold respectively. Due to the sensitivity of the qRT-PCR 
technique, subtle changes in experimental conditions could easily conceal expression 
changes (Bustin and Nolan, 2004). The need for both biological and technical 
replicates is therefore necessary to obtain reproducible, reliable and biologically 
meaningful data. Four biological replicates (and numerous, combined technical 
replicates) were used to obtain the data from the PCR arrays. The plates checked 84 
different genes representing common inflammatory cytokines and receptors (which 
are by no means exhaustive), as well as quality control wells included for each plate 
(which included positive PCR and reverse transcription controls). Primers to test for 
genomic DNA contamination were included, and it was found that this was removed 
 180
successfully prior to reverse transcription and qPCR analysis. All five housekeeping 
genes represented on the plate (see Appendix A2) were found to be constant from 
plate to plate (and between treatments) and were thus all used in the analysis, 
increasing the accuracy and stringency of data accumulated (Vandesompele et al., 
2002b).   
Whilst the Student's t-test is useful for comparative data analysis (e.g. vehicle vs. 
treatment) of a small number of samples or genes, it does not fully take into account 
the multiple comparisons (or multiple testing problem) arising from the statistical 
analysis of multi-array qPCR. This problem occurs due to the increased number of 
statistical tests and thus the increase in associated errors and statistical inferences. For 
instance, in this investigation the p-value for significance was set at 0.05, which 
means that there is a 5 % chance of obtaining a false positive (i.e. obtaining the 
observed result by chance, with the null hypothesis still being true). This type of error 
is known as a type I error (false positive; often referred to as α) and is particularly 
important to consider when performing multiple statistical tests. On the PCR arrays, 
84 genes were tested for differential expression between treatments (WT or Scr 
TLQP-21) and the vehicle. Using a p-value of 0.05 means that we expect 4 of the 
genes to be significant just due to chance (i.e. false positives).  
There are a number of approaches for dealing with the multiple comparisons problem, 
the most common being the Bonferroni correction. This controls the family-wise error 
rate (FWER; the probability of at least one type of type I error) by dividing the FWER 
(usually 0.05, as in this investigation) by the number of tests being performed. Thus, 
with 84 statistical tests, the error rate (α) would be 0.05 / 84 = 0.000595 and only 
individual tests with p ≤ 0.000595 would be considered significant. However, the 
Bonferroni correction may lead to a very high rate of false negatives (type II errors) 
and only genes with very large differences in expression levels would be significant. 
In this scenario any genes with real, but small or moderate-sized differences would be 
excluded.  
Another approach for dealing with the multiple comparisons problem is to control the 
false discovery rate (FDR; the proportion of type I errors amongst results declared 
significant). For example, if a FDR of 5 % were selected, it would mean that 5 % of 
the genes deemed significant would actually be false positives. Conversely, it means 
that 95 % of genes considered significant do indeed have differential expression 
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levels. Thus setting a FDR results in an enrichment of genes, which are truly 
differentially expressed.  
There is not a universally accepted approach for dealing with the problem of multiple 
comparisons and repeat testing, and it is still an area of active research. Whilst the 
goal of multiple comparison corrections is to reduce the number of false positives 
(type I errors), an inevitable consequence of this is that the number of false negatives 
(type II errors) increases (i.e. where there really is an effect, but it is not detected as 
statistically significant). It is important to be suitably cautious when dealing with 
multiple comparisons, but it must be noted that a false positive can be 
confirmed/validated with a few more experiments (e.g. Northern blot analysis or 
further qPCR for the genes of interest). However, a false negative could mean that an 
important discovery has been overlooked. Thus, in this investigation one would 
ideally further validate the two genes found to be differentially expressed (Ccl11 and 
Cxcl9) using different primers for the same genes (i.e. annealing to different 
sequences on the genes).  
With qPCR analysis, it is important to have specific and efficient primers to ensure 
reproducibility and reliable data sets. The individual primer sets were obtained from a 
previously published source and were shown to be suitable for use by the 2-∆∆Ct 
method (Peinnequin et al., 2004). This method of data analysis compares all datasets 
(i.e. WT TLQP-21 or Scr TLQP-21) to both the housekeeping genes and the vehicle 
control. However, the assumption with this model of data analysis is that the 
amplification efficiencies of the target and housekeeping genes are approximately 
equal, when using the primers. Ideally one would perform real time qPCR on serially 
diluted cDNA from microglia (using similar number of cells and conditions as the 
actual experiments in this investigation) and test amplification efficiency for each and 
every primer. Whilst the individual primer sets were validated in this way, the primers 
on the PCR arrays are propriety data and thus were not revealed. However, 
SABiosciences confirmed that the primer sets were validated for the 2-∆∆Ct method, 
although further details, such as cDNA used, were not provided (personal 
communication with the company). It is important to note that this validation is 
context dependent, as for example, different cells types have differing primer 
efficiencies. Thus, all primers on the PCR arrays and individual primer sets used in 
this investigation require data on primer efficiency, using cDNA similar to that used 
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in this investigation and thus validation of the 2-∆∆Ct method (Livak and Schmittgen, 
2001).  
As well as monitoring gene expression levels downstream of TLQP-21 application, 
analysis of protein levels and secretion of these inflammatory mediators would give a 
more clear and direct indication about modulation by TLQP-21 of inflammatory and 
pain responses (if they do occur). Peptides such as substance P modulate pain 
peripherally and centrally by direct stimulation of cells, such as macrophages and 
microglia, to release inflammatory mediators, for example, IL-1 and TNFα (Martin et 
al., 1993). These released mediators are pre-synthesised, stored and released 
following stimulation and thus analysis of secreted proteins and cytokines, using 
techniques such as ELISA and multiplex arrays, have provided increasingly sensitive 
and specific data on inflammatory modulation events (Leng et al., 2008).  
This does not however, reduce the significance of gene expression data analysis, as 
most inflammatory mediators have short half lives, and thus cannot be stored for too 
long and need to replenished, hence the study of gene expression levels often 
accompanies cytokine release assay data. In fact, it is also possible to increase gene 
expression levels, without the release of soluble cytokines, for example, substance P 
was found to increase expression of a transmembrane form of TNFα (mTNFα), 
without the subsequent release of soluble TNFα from primary microglia cells (Zhou et 
al., 2010). Additionally, COX-2 and iNOS are enzymes that are responsible for the 
formation of inflammatory mediators (prostaglandins and nitric oxide, respectively), 
and are not secreted, thus gene expression studies are more appropriate for these 
important enzymes. An interesting experiment, particularly with the increase in 
powerful mass spectrometric (MS) apparatus available, would be to analyse the 
secretome (secreted proteins) produced following TLQP-21 application, as well as 
proteomic analysis of cell homogenates (i.e. what is changing inside the cells) and 
compare them to the controls (scrambled TLQP-21 and vehicle). This would allow 
analysis of both quantitative and qualitative protein differences, and secretome 
analysis is becoming increasingly attractive, with the availability of these powerful 
MS machines and the wealth of data accumulating from these studies (Skalnikova et 
al., 2011).  
Another signalling event which was tested, following VGF-derived peptide treatment, 
was p38 MAPK phosphorylation. Both LQEQ-19 and TLQP-21 have previously been 
shown to be involved in central and peripheral inflammatory pain (Riedl et al., 2009; 
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Rizzi et al., 2008). It was also observed in vivo that LQEQ-19 induced activation of 
spinal microglia by phosphorylation of p38 MAPK, as well as inducing p38 MAPK 
phosphorylation in BV-2 cells in vitro (Riedl et al., 2009). The TLQP-21 peptide was 
applied to primary microglia and used to test whether a downstream consequence of 
the increase in intracellular Ca2+ levels observed in this investigation, (or in addition 
to this Ca2+ response), also induced a change in phosphorylation of p38 MAPK- an 
event that is commonly associated with activated microglia and modulation of pain (Ji 
and Suter, 2007).   
When the TLQP-21 (and scrambled TLQP-21, both at 100 nM) were applied to 
primary microglia for 5 minutes and 30 minutes, it was observed that the p38 MAPK 
phosphorylation levels did not change relative to the vehicle control, even though the 
positive controls, LPS (1 µg/ml) and ATP (1 mM) did induce increased 
phosphorylation. This also suggests that TLQP-21 induced increase in intracellular 
Ca2+ does not induce phosphorylation of p38 MAPK in microglia, at least in the times 
tested. As the positive controls (LPS and ATP) both showed an increase in p38 
MAPK phosphorylation, this suggested that the experimental set up may not have 
been a problem. However, as with the gene expression analysis, the positive controls 
are known to elicit a large response in primary microglia, thus any experimental 
anomalies would not mask the physiological effects of these positive controls enough 
to be observable, but would mask more subtle responses, which may occur with VGF-
derived peptides. ATP elicits a rapid and transient increase in Ca2+ levels in microglia, 
similarly to TLQP-21; however, the data here has shown that p38 MAPK 
phosphorylation only occurs following ATP application. While this may be due to 
experimental and technical issues, there is a possibility that the response is real, which 
highlights the question of why ATP induced increases in intracellular Ca2+ produce 
different downstream responses to TLQP-21. The answer to this may be due to the 
versatility of Ca2+ signalling events (see General Introduction), and even though the 
data here shows the same rapid and transient response after ATP and TLQP-21 
application, other temporal and spatial changes (more subtle) could induce very 
different physiological downstream responses.   
When the BV-2 cells were tested, it was found that the LQEQ-19 peptide (100 nM), 
previously shown to induce p38 MAPK phosphorylation (Riedl et al., 2009), did not 
elicit this phosphorylation event (nor did the TLQP-21 and both their scrambled 
peptides). This lack of response from BV-2 cells following LQEQ-19 application 
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could suggest a problem with the experimental set-up (even though the same 
conditions were used as those in the published work) and the cells may have become 
activated before, during or after the treatments (including the vehicle control), thus 
any additional (and subtle) changes in p38 MAPK phosphorylation events, induced by 
VGF-derived peptides, would not be observed. As the same experimental set up was 
used for both the BV-2 cell and primary microglia, the same problems may thus 
persist in both experiments. However, BV-2 cell line problems and inconsistencies, 
already shown in this investigation (Ca2+ imaging data in Chapter 2) may be further 
highlighted here, by the lack of p38 MAPK phosphorylation. By repeating the 
experiment exactly as outlined in the published paper (Riedl et al., 2009) and getting 
different data could indicate cell line instability, phenotypic drift, cell line 
contamination or misidentification of cells (Chatterjee, 2007; Masramon et al., 2006).  
Due to the poorly understood molecular mechanisms of action of VGF-derived 
peptides, certain assumptions had to be made in this investigation when planning and 
implementing experimental techniques. For example, there was an assumption that the 
TLQP-21 induced Ca2+ response activated the microglia, and thus may have increased 
gene expression levels of inflammatory mediators as well as inducing changes in 
phosphorylation of p38 MAPK. Using previously published work relating to VGF-
derived peptides and microglia function and activity, these were not unreasonable 
assumptions to make. In fact even Ca2+ signalling in microglia (and indeed in other 
cell types) and downstream consequences of intracellular Ca2+ changes are still a 
relatively poorly understood field. Ca2+ signalling is very versatile and could lead to a 
wide array of other cellular activities not tested here, including chemotaxis, 
proliferation, cell differentiation and phosphorylation changes of other signalling 
proteins and kinases known to occur in activated microglia, including JNK (Dheen et 
al., 2007), ERK and CREB (Dai et al., 2011), and in cerebellar granule cells following 
TLQP-21 application, including Erk1/2, Akt and PKC (Severini et al., 2008). This 
investigation has highlighted the need for further work in the field of downstream 
molecular events following VGF-derived peptide application.  
 
In the PCR array data, 2 significant (p ≤ 0.05) gene changes were observed, relative to 
the vehicle control, following TLQP-21 (100 nM) treatment of primary microglia for 
3 hours: the Ccl11 gene was up-regulated by 2.78 fold and the Cxcl9 gene was down-
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regulated by 2.28 fold (-2.28). Interestingly, both Ccl11 and Cxcl9 are cytokines 
whose main functions are to induce chemotaxis in immune cells.  
 
Ccl11 (Eotaxin-1) 
 
Chemokine C-C motif ligand 11 (Ccl11) is a small cytokine, commonly known as 
eotaxin-1, which was originally isolated from the bronchoalveolar fluid of allergy 
model guinea pigs, where it was shown to be a potent and specific chemoattractant for 
eosinophils, but not neutrophils (Jose et al., 1994).  Murine and human homologues of 
the eotaxin-1 protein were cloned and found to share over 60 % sequence identity 
with the guinea pig eotaxin-1 (Ponath et al., 1996; Rothenberg et al., 1995). 
Expression studies, using Northern blot analysis, have shown constitutive expression 
of eotaxin-1 in the small intestine, heart, kidney, colon and pancreas and it is believed 
that large amounts of this chemokine are produced by epithelial and endothelial cells, 
in addition to eosinophils themselves (Garcia-Zepeda et al., 1996).  
The receptor for Ccl11/eotaxin-1 was initially identified as CCR3, a G-protein 
coupled receptor, which had a high level of expression in human eosinophils 
(Daugherty et al., 1996; Ponath et al., 1996), as well as on basophils and Th2 
lymphocytes. The cytokines, RANTES and MCP-3, in addition to eotaxin-1, were 
shown to bind this CCR3 receptor and eotaxin-1 de-sensitised eosinophils to both 
RANTES- and MCP-3-induced increases in intracellular Ca2+ levels in these cells 
(Ponath et al., 1996). Although it was initially suggested that eotaxin-1 had a great 
deal of selectivity to its CCR3 receptor, due to the eotaxin-1 inactivity on neutrophils 
and monocytes, which do not express CCR3 (Garcia-Zepeda et al., 1996; Ponath et 
al., 1996), more recent data has suggested another two eotaxin-1 receptors, CCR2 and 
CCR5. Using various assays, including Ca2+ imaging, chemotaxis, and cell binding 
assays, it was determined that eotaxin-1 acted as an antagonist for CCR2 and as an 
agonist for CCR5 (Ogilvie et al., 2001). Additionally, eotaxin-1 was shown to dose-
dependently induce chemotaxis and degranulation of eosinophils through activation 
(by phosphorylation) of p38 MAPK and ERK2 kinases (Kampen et al., 2000). Thus it 
has been suggested that Ccl11/eotaxin-1 may have a role in the fine-tuning of cellular 
responses at sites of inflammation.  
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Cxcl9 (monokine induced by gamma interferon; MIG) 
 
Chemokine (C-X-C motif) ligand 9 (Cxcl9), is another small cytokine, which is also 
known as monokine induced by gamma interferon (MIG). It is a chemoattractant, 
whose expression, as its name suggests, is induced by interferon gamma (IFNγ) and is 
closely related to Cxcl10 and Cxcl11. Under normal physiological conditions, these 
chemokines are not generally detectable, however, during infection, injury or 
inflammatory states, their expression is strongly induced by IFNγ, an inflammatory 
mediator whose production is largely restricted to activated T cells and NK cells 
(Farrar and Schreiber, 1993; Muller et al., 2010). The Cxcl9 cytokine, as well as 
Cxcl10 and Cxcl11, are known for their role in leukocyte trafficking, particularly on 
activated CD4+ Th1 cells, CD8+ T cells and Natural Killer (NK) cells (Gustafsson et 
al., 2008; Muller et al., 2010). Additionally, all three of these chemokines are ligands 
to the CXCR3 receptor (Tensen et al., 1999). While much of the data on Cxcl9 is 
often contradictory, the role of this chemokine on chemotaxis on activated T cells and 
NK cells, particularly during neuroinflammation is fairly consistent (Muller et al., 
2010).  
 
Interestingly, Cxcl9 is a natural antagonist to eotaxin-1 receptor CCR3 (Loetscher et 
al., 2001), which could explain why the two genes were differentially regulated by 
TLQP-21 in this investigation, with Ccl11/eotaxin-1 up-regulated 2.78 fold and the 
Cxcl9/MIG down-regulated by 2.28 (-2.28). The data presented here highlight the 
complexity of the VGF-derived peptide responses on primary microglia cells, which 
require further analysis. The TLQP-21 peptide appears to be involved in modulation 
of microglia activity, by altering expression of genes involved in the chemotaxis of 
different immune cells (e.g. eosinophils and T cells), as well as modulation of 
inflammatory responses that appears to occur following TLQP-21 application in vivo 
(Rizzi et al., 2008), ultimately these complex interactions may indicate the 
mechanisms of action of VGF-derived peptides and their roles in pain pathways.  
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Chapter 5: General Discussion 
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Overview 
 
The field of pain research and the study of the chemical and biological modulators of 
pain is an ever expanding topic. While modulators such as neurotrophins, like NGF 
and BDNF (Pezet and McMahon, 2006), and neuropeptides, like substance P and 
CGRP (Kandel et al., 2000; Wall et al., 2006; Wiesenfeld-Hallin et al., 1991), are 
relatively well established, the list of pain and inflammatory mediators is far from 
comprehensive. The role of VGF-derived peptides in pain modulation is a relatively 
novel field of research.  The fact that different research groups, using various in vivo 
pain models, all revealed the up-regulation of VGF gene expression, suggested that 
this gene has a role to play in pain (Costigan et al., 2002; Griffin et al., 2007; Lacroix-
Fralish et al., 2011; Maratou et al., 2009; Song et al., 2001; Valder et al., 2003; Xiao 
et al., 2002). More recently, the direct application and in vivo actions of three VGF-
derived peptides, LQEQ-19, TLQP-21 and TLQP-62, appeared to implicate VGF-
derived peptides in modulation of inflammatory and neuropathic pain (Moss et al., 
2008; Riedl et al., 2009; Rizzi et al., 2008). While the role of VGF-derived peptides in 
pain modulation may not be particularly well established, this investigation intended 
to elucidate some of the molecular mechanisms of actions of VGF-derived peptides in 
the nervous system, with a particular emphasis on cells involved in pain pathways (i.e. 
DRG neurons and microglia).  
 
Summary of data 
 
In this investigation, a number of novel and original contributions to the field of VGF-
derived peptide molecular research have been made, and are discussed in detail in the 
relevant chapters; briefly this investigation has shown: 
 
1. The VGF-derived peptide TLQP-21, but not LQEQ-19, was shown to induce a 
dose dependent increase in intracellular Ca2+ levels in primary microglia, 
derived from the brain and the spinal cord, but not in DRG neurons. At 
100 nM, WT TLQP-21, but not Scr TLQP-21, induced an increase in 
intracellular Ca2+ levels even when Ca2+ was excluded from the extracellular 
environment, suggesting that Ca2+ was released from internal Ca2+ stores, such 
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as the ER or mitochondria, following TLQP-21 application. The TLQP-21 
application appeared to de-sensitise the microglia cells to subsequent TLQP-
21-induced increases in intracellular Ca2+ levels, although it is unclear from 
the work presented here whether this is a receptor-mediated de-sensitisation 
event or merely a consequence of the depletion of intracellular Ca2+ levels. 
Although LQEQ-19 application alone did not elicit a response in microglia, 
the combination of LQEQ-19 with TLQP-21 appeared to attenuate the Ca2+ 
response, suggesting a possible synergistic mechanism of action. The murine 
microglial cell line, BV-2, responded to TLQP-21 as well as LQEQ-19 by 
elevating intracellular Ca2+ levels following application of the peptides, 
although this response was inconsistent and thus the data presented here can 
only be considered preliminary for BV-2 cells.  
2. Modified VGF-derived peptides, with an N-terminal biotin tag and additional 
cysteine residue at the C-terminus, were conjugated to the Sulfo-EMCS 
crosslinker to aid in the search for VGF receptors/binding proteins, and 
conjugated TLQP-21 was still able to induce an increase in intracellular Ca2+ 
levels in primary microglia. The conjugated peptides (LQEQ-19 or TLQP-21) 
were applied to rat CNS tissue (membrane fraction homogenate), crosslinking 
was allowed to proceed and a ~30 kDa band was observed for both LQEQ-19 
and TLQP-21 reactions. A different approach, using TLQP-21 attached to a 
monomeric avidin column, showed a ~30 kDa protein band eluted when rat 
brain tissue was applied, relative to the control (without TLQP-21 attached). 
This band was not apparent when LQEQ-19 was attached to the column and 
brain tissue applied, nor did it appear when primary microglia cell homogenate 
was applied to the column with TLQP-21 attached. The ~30 kDa protein was 
analysed using LC-MS/MS Orbitrap and the gC1q-R protein was identified in 
both the WCL and M+A fraction mass spectrometry results, with good peptide 
coverage of the protein and peptide overlap between two different samples and 
mass spectrometry runs. The gC1q-R protein identity was validated by 
Western blot analysis of the same monomeric avidin experiment samples used 
for LC-MS/MS analysis, and the presence of the gC1q-R protein was 
confirmed in various cell types, including primary rat microglia. However, 
3 minute pre-incubation of the antibody for gC1q-R with primary microglia 
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failed to inhibit the TLQP-21-induced increase in intracellular Ca2+ levels in 
these cells.  
3. Following 3 hour peptide treatments, the WT TLQP-21 induced a 2.78 fold 
increase in Ccl11 and a 2.28 fold decrease (-2.28) in Cxcl9 expression levels 
relative to the vehicle control (Student's t-test; p ≤ 0.05), and this was not 
observed with Scr TLQP-21 treatments.  
 
TLQP-21 and microglia activation through Ca2+ signalling 
 
The TLQP-21-induced increase in intracellular Ca2+ levels in primary microglia, 
observed in this investigation, indicates the in vitro functionality of the VGF-derived 
peptide in this assay. While the work presented here does suggest that the Ca2+ 
originates from internal stores, and for microglia there are at least two types of 
dynamic Ca2+ stores, the ER and mitochondria (Kettenmann et al., 2011), it highlights 
the need to elucidate the mechanisms of this increase in intracellular Ca2+ levels, 
which may or may not involve the gC1q-R protein (which will be discussed below). 
As already mentioned, nerve injury has been shown to increase gene expression of 
VGF (Lacroix-Fralish et al., 2011), and it has been observed that VGF is stored in 
dense core vesicle and secreted from neurons following depolarisation, via the 
regulated secretory pathway (Salton et al., 2000; Tschernitz et al., 1995). Thus, 
following nerve injury, neurons (e.g. DRG neurons) may secrete VGF-derived 
peptides, including TLQP-21 (as well as LQEQ-19 and TLQP-62, which includes 
both TLQP-21 and LQEQ-19 in its sequence as described in previous chapters) both 
centrally and peripherally. The TLQP-21 peptide may then bind a cell surface 
receptor, such as a G-protein coupled receptor, and follow the classical IP3 mediated 
release of Ca2+ from internal stores such as the ER, or an alternate intracellular 
pathway to release Ca2+ from the mitochondria and/or the ER (Figure 5.1A).  
Another potential method of Ca2+ modulation by TLQP-21 could be by its direct entry 
into the cell cytoplasm by crossing the microglia plasma membrane (Figure 5.1B), 
due to its multiple positively charged arginine residues (Futaki, 2005), and induce an 
increase in intracellular Ca2+ levels in microglia, either by directly acting on the ER 
and/or mitochondria, or via interactions with other proteins (e.g. gC1q-R, discussed 
below). It has previously been observed that ammonium, a positively charged species 
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(NH4+), elicits an increase in intracellular Ca2+ levels in primary microglia from 
internal stores, by directly entering the cells and activating the PLC/IP3 pathway, and 
TLQP-21 may act by a similar mechanism of action. Interestingly, the NH4+-induced 
microglia activation event is not associated with release of the inflammatory 
mediators, TNFα and NO (Minelli et al., 2000).  
The implications of this Ca2+ response in microglia still remains elusive, especially as 
Ca2+ signalling and its functional significance in microglia is still not clearly 
understood, and the fact that cultured microglia (currently the most prevalent mode of 
study of these cells) actually represent already activated microglia (Farber and 
Kettenmann, 2006). Although there appears to be a general consensus that an increase 
in intracellular Ca2+ levels is a marker of activated (or further activated) microglia, the 
downstream consequences of this can be greatly varied in these cells. For example, in 
response to various stimuli such as ATP release from nerve damage or bacterial LPS, 
activated microglia release proinflammatory mediators, such as TNFα and NO 
following a Ca2+ response (Duan et al., 2009; Hoffmann et al., 2003). In fact, 
microglia activation and subsequent BDNF release, goes so far as to shift the dorsal 
horn neuron anion gradient, inducing their hyperexcitability and shifting to a 
neuropathic pain phenotype (Coull et al., 2005; Inoue and Tsuda, 2009). Whilst this is 
the "classical" microglia activation response to be expected, releasing agents which 
exacerbate neuronal hyperexcitability, degeneration and/or inflammation, it is 
becoming increasingly clear that microglia-neuronal interactions are far more 
complex.  
Microglia can elicit both neurotoxic and neuroprotective effects on neurons. For 
example, the two neuropeptides, pituitary adenylate cyclase activating polypeptide 
(PACAP) and vasoactive intestinal peptide (VIP) function by inhibiting the 
production of inflammatory mediators by activated microglia, responsible for 
neurodegenerative processes in the brain (Dejda et al., 2005). Thus, the modulation or 
activation of microglia by neuropeptides, does not always elicit harmful or toxic 
responses. The role of microglia in the development and maintenance of the 
neuropathic pain phenotype is a current "hot topic" of interest, and there is much data 
which suggests that neuron-microglia signalling is crucial in this pathological state, 
and a potential target for future treatments of chronic pain states (Inoue and Tsuda, 
2009). The current in vivo data on TLQP-21 suggests that it may be a modulator of 
inflammatory pain, potentially with different mechanisms of action at the peripheral 
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and central levels of the nociceptive pathways, with potential analgesic effects when 
administered centrally, by intracerebroventricular (i.c.v.) application at certain 
concentrations (Rizzi et al., 2008). From the data found in this investigation, it is 
possible that these effects occur via the interaction of TLQP-21 with microglia. The 
inflammatory mediators, whose expression levels were tested by qRT-PCR, did not 
show any changes after 3 hour TLQP-21 application. While this may be due to the 
experimental set up (including time points tested or inhibitory effects of the media 
used), there is a possibility that TLQP-21 does not in fact elicit an inflammatory 
response, particularly in light of the analgesic effects observed in vivo (Rizzi et al., 
2008) and that different downstream effects occur after microglia activation, 
including supportive and neuroprotective effects elicited by microglia (Nakajima and 
Kohsaka, 2004; Streit, 2002). It should be noted that TLQP-21 has already been 
observed to have a direct role in neuroprotection of cerebellar granule cells, which it 
does by eliciting an increase in intracellular Ca2+ levels in these neuronal cells 
(Severini et al., 2008).  
Whilst the direct actions of TLQP-21-activated microglia on neurons is one possible 
mechanism of action in pain modulation, another possibility to be considered is that 
microglia mediate activity of other cell types such as other glia, including astrocytes, 
as well as other immune cells. This is highlighted by the results in this investigation, 
which show that 3 hour TLQP-21 incubation induced significant (Student's t-test; 
p ≤ 0.05) changes in expression of two genes in microglia (Ccl11 and Cxcl9), both of 
which are chemokines that regulate chemotaxis in immune cells. Ccl11, or eotaxin-1 
as it is more commonly known, is a chemoattractant for eosinophils, basophils and 
Th2 lymphocytes (Baggiolini et al., 1997), and TLQP-21 induced an increase in gene 
expression of 2.78 fold for this particular gene, relative to the vehicle. The Cxcl9 
chemokine, a chemokine for activated NK and T cells, also acts as an antagonist to 
the Ccl11 receptor (Loetscher et al., 2001; Xanthou et al., 2003) and accordingly, its 
gene expression was down-regulated (-2.28 fold) following TLQP-21 application. 
This suggests that TLQP-21 induces microglia to recruit other immune cells, such as 
eosinophils, potentially to a site of nerve injury, in order to modulate inflammatory 
responses or even modulate neurotransmission at the synaptic level (Vallejo et al., 
2010).  
The downstream consequences of TLQP-21-induced increase in intracellular Ca2+ 
levels in microglia may not have been fully elucidated here, however it is possible to 
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state that the TLQP-21 induction was specific, due to the inactivity of the scrambled 
peptide (and vehicle) at lower concentrations. Also the Ca2+ appears to originate from 
internal stores (ER or mitochondria), either through (A) a plasma membrane receptor-
mediated mechanism; (B) entry of TLQP-21 into microglia through the plasma 
membrane and direct modulation of the Ca2+ machinery; or (C) interaction with 
another protein (such as gC1q-R) and intracellular Ca2+ modulation this way (Figure 
5.1). Of course, there is the possibility that the TLQP-21 could be acting through a 
novel mechanism of action, not mentioned here, thus highlighting the need for further 
elucidation of the mechanisms of action of VGF-derived peptides.  
 
TLQP-21 and gC1q-R: complement and kinins 
 
This study found that TLQP-21 was able to bind the gC1q-R protein. More recent 
data has since been accumulated in investigations in our laboratory (Alva Chen, Kenji 
Okuse; currently unpublished observations), including a TLQP-21-induced increase in 
intracellular Ca2+ levels in macrophages, which the scrambled TLQP-21 and 
LQEQ-19 failed to induce. Additionally, in the macrophages, when two antibodies 
(Abcam) against gC1q-R were combined and applied to the cells, the TLQP-21 
showed a reduced Ca2+ response, although individually the antibodies failed to inhibit 
the TLQP-21-induced Ca2+ response (one recognising the amino terminus residues 
76-93 and used in this investigation, the other antibody recognising the carboxyl 
terminus residues 204-218 of gC1q-R). This gives increasing credence to the 
interaction of TLQP-21 and gC1q-R eliciting or at least taking part in the TLQP-21-
induced increase in intracellular Ca2+ levels in microglia (the resident "CNS 
macrophages"). The data may also explain why application of a single anti-gC1q-R 
antibody to microglia failed to inhibit the TLQP-21 induced Ca2+ response in this 
investigation; the interaction may be occurring in a more complex form than simply 
binding one terminus of the protein and this is particularly relevant for the gC1q-R, 
which forms a unique quaternary structure (Jiang et al., 1999). It is also possible that 
this interaction with gC1q-R could have roles in other functions, currently associated 
with TLQP-21 activity, including energy homeostasis and reproduction as well as 
pain modulation- although it must be noted that no published data has thus far 
observed functions of gC1q-R outside of those mentioned already (i.e. complement 
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activation, kinin formation, etc.), and this is conjecture at this point and requires 
further investigation.  
The gC1q-R protein is ubiquitously expressed, and is described as a multiligand-
binding and multi-compartmental protein, observed in the cytosol, mitochondria, ER 
and the cell surface (Peerschke and Ghebrehiwet, 2007). Following pre-incubation of 
primary microglia (3 minutes) with an anti-gC1q-R antibody (107 nM), TLQP-21 
(100 nM) was still able to elicit an increase in intracellular Ca2+ levels in the cells. 
This suggests that the interaction with gC1q-R is not necessary for the TLQP-21-
induced Ca2+ response in microglia, or that the antibody incubation was not sufficient 
to inhibit the potential gC1q-R-TLQP-21-induced Ca2+ response in microglia, thus 
further investigation into this interaction and its consequences must be carried out.   
Whilst the possibility of a Ca2+ response independent of gC1q-R has been discussed 
above, the possibility of the gC1q-R-TLQP-21 interaction activating microglia is an 
intriguing one. The gC1q-R protein was initially identified as a C1q-binding protein, 
and its involvement in complement activation via this interaction has been observed in 
a number of cell types, including blood platelets (Peerschke et al., 2006) and 
endothelial cells (Yin et al., 2007). Interestingly, the gC1q-R interaction with C1q 
induced a rapid and transient increase in intracellular Ca2+ levels in fibroblasts 
(Bordin et al., 1998). Thus, introduction of TLQP-21 could potentially trigger 
complement activation at sites of injury where VGF-derived peptides are secreted, 
which could ultimately alter neuronal hyperexcitability (Figure 5.1F). Although the 
link between complement proteins and chronic pain conditions is currently poorly 
understood, more recent research does appear to suggest that the inflammatory 
processes associated with complement activation could contribute to neuropathic pain 
(Li et al., 2007). In fact, the C5a complement component was shown to have up-
regulated gene expression in three in vivo neuropathic pain models, and interestingly 
VGF gene expression was shown to be up-regulated in the same study (although deep 
in the supplementary data), suggesting a tenuous link between VGF, complement and 
chronic pain (Griffin et al., 2007). Additionally, another study showed up-regulation 
of VGF and C1q gene expression following spinal nerve ligation in rats, a chronic 
pain model (Valder et al., 2003). Thus, the gC1q-R-TLQP-21 interaction could induce 
complement activation, potentially involving an increase in intracellular Ca2+ levels in 
primary microglia (Figure 5.1F). Application of C1q protein to microglia, and 
examination of the effects of this to the subsequent TLQP-21 Ca2+ response (if any) 
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would shed some light onto this relationship between complement proteins and 
TLQP-21.  
Following the elucidation of the gC1q-R structure (Jiang et al., 1999), it has been 
postulated that gC1q-R could form pores in the mitochondrial membrane and 
modulate movement of Ca2+ ions in and out of mitochondria (Starkov, 2010). Due to 
the unique charge distribution and doughnut-shaped quaternary structure of gC1q-R, 
it could also be postulated that this pore structure could form on microglia 
endoplasmic reticulum (ER) and plasma membranes as well, and modulate Ca2+ 
movement here. The interaction with TLQP-21 could further modulate this activity, 
and lead to microglia activation and subsequent downstream effects (Figure 5.1D). It 
must be noted that the idea of gC1q-R pore formation is highly speculative and 
currently no data is available to substantiate this theory.  
In addition to its role in complement activation, gC1q-R can bind proteins in the 
kallikrein/kinin system (KKS; a bradykinin forming pathway). It was shown to bind 
the high molecular weight kininogen (HK) protein and factor XII (Herwald et al., 
1996; Joseph et al., 1996), and more recently gC1q-R was shown to play a role in 
bradykinin formation on macrophages, in the presence of Zn2+ (Barbasz et al., 2008). 
As microglia are often described as the macrophages of the central nervous system, it 
is possible that this bradykinin formation may occur on the cell surface of microglia 
and that the TLQP-21-gC1q-R complex may modulate these processes. Bradykinin is 
a key signalling molecule in pain pathways, and contributes to inflammatory 
processes and pain modulation by interactions with cells which express its receptors, 
including sensory neurons (Steranka et al., 1988) and microglia (Noda et al., 2003). 
Thus, a downstream consequence of the TLQP-21-gC1q-R interaction could be 
formation of bradykinin and modulation of both microglia and neuronal cell 
behaviours and ultimately chronic pain modulation (Figure 5.1E).  
Further work would involve using the increasingly powerful mass spectrometric 
equipment now available and checking the microglia secretome following TLQP-21 
application (Skalnikova et al., 2011). This work would allow a greater understanding 
of the proteins being secreted by microglia (both quantitative and qualitative) and give 
clues as to the types of downstream and intracellular molecular mechanisms of action 
of TLQP-21 peptides. Additionally, use of neuropathic pain models on VGF knock 
out (KO) mice would give an idea about the importance of the VGF-derived peptides 
in pain modulation, although as VGF KO mice tend have other phenotypes, such as 
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hyperactivity (Hahm et al., 1999), this could make behavioural studies more 
complicated. A potential solution to this is tissue specific KO of VGF expression (or 
even gC1q-R) using siRNA techniques or Cre-Lox recombination and analysis of 
changes in neuropathic pain development in vivo.  
The role of VGF-derived peptides in chronic pain modulation is a novel and 
expanding field of research, and the underlying molecular mechanisms are not well 
understood. The work presented here suggests that TLQP-21 could be in the 
inflammatory soup of molecules which include bradykinin, PGE2, NGF, ATP and 
NO, all associated with pain modulation and may act through activation of microglia 
and potentially involve components of the complement system. Thus this data could 
lead to new perspectives in pain research and novel painkillers could be developed to 
disrupt these molecular events.  
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Figure 5.1. Proposed model for some TLQP-21-mediated mechanisms of action 
in chronic pain modulation. Following nerve injury, VGF gene expression is up-
regulated and VGF-derived peptides could be secreted, upon depolarisation, from 
neuronal cells (e.g. DRG neurons) via a regulated secretory pathway (Salton et al., 
2000). As well as TLQP-21, the LQEQ-19 and TLQP-62 (which includes both TLQP-
21 and LQEQ-19 in its sequence) could be secreted both peripherally and centrally (as 
represented here). (A) The TLQP-21 could bind receptors on the cell surface, and 
through them induce increases in intracellular cytosolic Ca2+ levels in primary 
microglia from internal ER and mitochondrial stores, through a variety of pathways 
(e.g. G-protein coupled receptor and IP3 generation) which are yet to be elucidated. 
(B) The TLQP-21 may also be able to traverse the plasma membrane of microglia, 
without receptors, and directly modulate intracellular Ca2+ levels by a variety of 
protein-protein interactions. (C) The TLQP-21 could interact with the gC1q-R protein 
on the plasma membrane, and through an as of yet unknown mechanism of action, 
elicit an increase in intracellular Ca2+ levels in microglia, or induce microglia 
activation via a Ca2+-independent pathway. (D) The TLQP-21-gC1q-R interaction 
could potentially induce Ca2+ release from mitochondria and/or the ER, through 
modulation of the pore structure formed by trimeric gC1q-R (Jiang et al., 1999; 
Starkov, 2010). (E) The TLQP-21-gC1q-R interaction could induce formation of 
bradykinin at the surface of microglia, which in turn could modulate neuronal 
hyperexcitability and chronic pain. (F) The TLQP-21-gC1q-R interaction could also 
modulate the interaction with C1q, and either directly induce a Ca2+ response in 
microglia, or induce complement activation. All pathways shown could ultimately 
activate microglia and thus shift the microglial phenotype to either a neuroprotective 
one, or induce neuronal (e.g. dorsal horn neuron) hyperexcitability and thus a 
modulation of chronic pain states. Organelles are not drawn to scale.   
 198
Bibliography 
 
Akane, A., Matsubara, K., Nakamura, H., Takahashi, S., and Kimura, K. (1994). Identification of the 
heme compound copurified with deoxyribonucleic acid (DNA) from bloodstains, a major inhibitor of 
polymerase chain reaction (PCR) amplification. J Forensic Sci 39, 362-372. 
Alder, J., Thakker-Varia, S., Bangasser, D.A., Kuroiwa, M., Plummer, M.R., Shors, T.J., and Black, 
I.B. (2003). Brain-derived neurotrophic factor-induced gene expression reveals novel actions of VGF 
in hippocampal synaptic plasticity. J Neurosci 23, 10800-10808. 
Allaman, I., Fiumelli, H., Magistretti, P.J., and Martin, J.L. (2011). Fluoxetine regulates the expression 
of neurotrophic/growth factors and glucose metabolism in astrocytes. Psychopharmacology (Berl) 216, 
75-84. 
Baggiolini, M., Dewald, B., and Moser, B. (1997). Human chemokines: an update. Annu Rev Immunol 
15, 675-705. 
Baker, B.J., Park, K.W., Qin, H., Ma, X., and Benveniste, E.N. (2010). IL-27 inhibits OSM-mediated 
TNF-alpha and iNOS gene expression in microglia. Glia 58, 1082-1093. 
Banati, R.B. (2002). Visualising microglial activation in vivo. Glia 40, 206-217. 
Banati, R.B. (2003). Neuropathological imaging: in vivo detection of glial activation as a measure of 
disease and adaptive change in the brain. Br Med Bull 65, 121-131. 
Bantscheff, M., Schirle, M., Sweetman, G., Rick, J., and Kuster, B. (2007). Quantitative mass 
spectrometry in proteomics: a critical review. Anal Bioanal Chem 389, 1017-1031. 
Barbasz, A., Guevara-Lora, I., Rapala-Kozik, M., and Kozik, A. (2008). Kininogen binding to the 
surfaces of macrophages. Int Immunopharmacol 8, 211-216. 
Barclay, J.W., Morgan, A., and Burgoyne, R.D. (2005). Calcium-dependent regulation of exocytosis. 
Cell Calcium 38, 343-353. 
Barrett, P., Ross, A.W., Balik, A., Littlewood, P.A., Mercer, J.G., Moar, K.M., Sallmen, T., Kaslin, J., 
Panula, P., Schuhler, S., et al. (2005). Photoperiodic regulation of histamine H3 receptor and VGF 
messenger ribonucleic acid in the arcuate nucleus of the Siberian hamster. Endocrinology 146, 1930-
1939. 
Bartness, T.J., Hamilton, J.M., Wade, G.N., and Goldman, B.D. (1989). Regional differences in fat pad 
responses to short days in Siberian hamsters. Am J Physiol 257, R1533-1540. 
Bartolomucci, A., Bresciani, E., Bulgarelli, I., Rigamonti, A.E., Pascucci, T., Levi, A., Possenti, R., 
Torsello, A., Locatelli, V., Muller, E.E., et al. (2009). Chronic intracerebroventricular injection of 
TLQP-21 prevents high fat diet induced weight gain in fast weight-gaining mice. Genes & Nutrition 4, 
49-57. 
Bartolomucci, A., La Corte, G., Possenti, R., Locatelli, V., Rigamonti, A.E., Torsello, A., Bresciani, E., 
Bulgarelli, I., Rizzi, R., Pavone, F., et al. (2006). TLQP-21, a VGF-derived peptide, increases energy 
expenditure and prevents the early phase of diet-induced obesity. Proc Natl Acad Sci U S A 103, 
14584-14589. 
 199
Bartolomucci, A., Possenti, R., Levi, A., Pavone, F., and Moles, A. (2007). The role of the vgf gene 
and VGF-derived peptides in nutrition and metabolism. Genes & Nutrition 2, 169-180. 
Batchelor, P.E., Tan, S., Wills, T.E., Porritt, M.J., and Howells, D.W. (2008). Comparison of 
inflammation in the brain and spinal cord following mechanical injury. J Neurotrauma 25, 1217-1225. 
Baybis, M., and Salton, S.R. (1992). Nerve growth factor rapidly regulates VGF gene transcription 
through cycloheximide sensitive and insensitive pathways. FEBS Lett 308, 202-206. 
Berridge, M.J., Bootman, M.D., and Roderick, H.L. (2003). Calcium signalling: dynamics, homeostasis 
and remodelling. Nature reviews Molecular cell biology 4, 517-529. 
Berridge, M.J., Lipp, P., and Bootman, M.D. (2000). The versatility and universality of calcium 
signalling. Nat Rev Mol Cell Biol 1, 11-21. 
Bonni, A., Ginty, D.D., Dudek, H., and Greenberg, M.E. (1995). Serine 133-phosphorylated CREB 
induces transcription via a cooperative mechanism that may confer specificity to neurotrophin signals. 
Mol Cell Neurosci 6, 168-183. 
Bordin, S., Costa, L.G., and Tan, X. (1998). Fibroblast heterogeneity of signal transduction 
mechanisms to complement-C1q. Analyses of calcium mobilization, inositol phosphate accumulation, 
and protein kinases-C redistribution. J Periodontol 69, 642-649. 
Bozdagi, O., Rich, E., Tronel, S., Sadahiro, M., Patterson, K., Shapiro, M.L., Alberini, C.M., Huntley, 
G.W., and Salton, S.R. (2008). The neurotrophin-inducible gene Vgf regulates hippocampal function 
and behavior through a brain-derived neurotrophic factor-dependent mechanism. J Neurosci 28, 9857-
9869. 
Braun, L., Ghebrehiwet, B., and Cossart, P. (2000). gC1q-R/p32, a C1q-binding protein, is a receptor 
for the InlB invasion protein of Listeria monocytogenes. The EMBO journal 19, 1458-1466. 
Burchiel, S.W., Edwards, B.S., Kuckuck, F.W., Lauer, F.T., Prossnitz, E.R., Ransom, J.T., and Sklar, 
L.A. (2000). Analysis of free intracellular calcium by flow cytometry: multiparameter and 
pharmacologic applications. Methods 21, 221-230. 
Bustin, S.A. (2010). Why the need for qPCR publication guidelines?--The case for MIQE. Methods 50, 
217-226. 
Bustin, S.A., and Nolan, T. (2004). Pitfalls of quantitative real-time reverse-transcription polymerase 
chain reaction. J Biomol Tech 15, 155-166. 
Bylund, D.B., and Toews, M.L. (1993). Radioligand binding methods: practical guide and tips. The 
American journal of physiology 265, L421-429. 
Calabrese, E.J. (2001). Prostaglandins: biphasic dose responses. Crit Rev Toxicol 31, 475-487. 
Calvo, M., Zhu, N., Tsantoulas, C., Ma, Z., Grist, J., Loeb, J.A., and Bennett, D.L. (2010). Neuregulin-
ErbB signaling promotes microglial proliferation and chemotaxis contributing to microgliosis and pain 
after peripheral nerve injury. J Neurosci 30, 5437-5450. 
 200
Canu, N., Possenti, R., Ricco, A.S., Rocchi, M., and Levi, A. (1997a). Cloning, structural organization 
analysis, and chromosomal assignment of the human gene for the neurosecretory protein VGF. 
Genomics 45, 443-446. 
Canu, N., Possenti, R., Rinaldi, A.M., Trani, E., and Levi, A. (1997b). Molecular cloning and 
characterization of the human VGF promoter region. J Neurochem 68, 1390-1399. 
Cao, Y.Q. (2006). Voltage-gated calcium channels and pain. Pain 126, 5-9. 
Carafoli, E. (2010). The fateful encounter of mitochondria with calcium: how did it happen? 
Biochimica et biophysica acta 1797, 595-606. 
Carafoli, E., Santella, L., Branca, D., and Brini, M. (2001). Generation, control, and processing of 
cellular calcium signals. Crit Rev Biochem Mol Biol 36, 107-260. 
Carroll, M.C. (2004). The complement system in regulation of adaptive immunity. Nature immunology 
5, 981-986. 
Chatterjee, R. (2007). Cell biology. Cases of mistaken identity. Science 315, 928-931. 
Cho, H.J., Acharjee, S., Moon, M.J., Oh, D.Y., Vaudry, H., Kwon, H.B., and Seong, J.Y. (2007). 
Molecular evolution of neuropeptide receptors with regard to maintaining high affinity to their 
authentic ligands. Gen Comp Endocrinol 153, 98-107. 
Cho, I.H., Chung, Y.M., Park, C.K., Park, S.H., Li, H.Y., Kim, D., Piao, Z.G., Choi, S.Y., Lee, S.J., 
Park, K., et al. (2006). Systemic administration of minocycline inhibits formalin-induced inflammatory 
pain in rat. Brain research 1072, 208-214. 
Cho, K.O., Skarnes, W.C., Minsk, B., Palmieri, S., Jackson-Grusby, L., and Wagner, J.A. (1989). 
Nerve growth factor regulates gene expression by several distinct mechanisms. Mol Cell Biol 9, 135-
143. 
Clark, A.K., Gentry, C., Bradbury, E.J., McMahon, S.B., and Malcangio, M. (2007). Role of spinal 
microglia in rat models of peripheral nerve injury and inflammation. European journal of pain 11, 223-
230. 
Cornell-Bell, A.H., Finkbeiner, S.M., Cooper, M.S., and Smith, S.J. (1990). Glutamate induces calcium 
waves in cultured astrocytes: long-range glial signaling. Science 247, 470-473. 
Costigan, M., Befort, K., Karchewski, L., Griffin, R.S., D'Urso, D., Allchorne, A., Sitarski, J., 
Mannion, J.W., Pratt, R.E., and Woolf, C.J. (2002). Replicate high-density rat genome oligonucleotide 
microarrays reveal hundreds of regulated genes in the dorsal root ganglion after peripheral nerve injury. 
BMC Neurosci 3, 16. 
Coull, J.A., Beggs, S., Boudreau, D., Boivin, D., Tsuda, M., Inoue, K., Gravel, C., Salter, M.W., and 
De Koninck, Y. (2005). BDNF from microglia causes the shift in neuronal anion gradient underlying 
neuropathic pain. Nature 438, 1017-1021. 
D'Arcangelo, G., Habas, R., Wang, S., Halegoua, S., and Salton, S.R. (1996). Activation of 
codependent transcription factors is required for transcriptional induction of the vgf gene by nerve 
growth factor and Ras. Mol Cell Biol 16, 4621-4631. 
 201
Dai, J.N., Zong, Y., Zhong, L.M., Li, Y.M., Zhang, W., Bian, L.G., Ai, Q.L., Liu, Y.D., Sun, J., and 
Lu, D. (2011). Gastrodin Inhibits Expression of Inducible NO Synthase, Cyclooxygenase-2 and 
Proinflammatory Cytokines in Cultured LPS-Stimulated Microglia via MAPK Pathways. PLoS ONE 6, 
e21891. 
Daugherty, B.L., Siciliano, S.J., DeMartino, J.A., Malkowitz, L., Sirotina, A., and Springer, M.S. 
(1996). Cloning, expression, and characterization of the human eosinophil eotaxin receptor. The 
Journal of experimental medicine 183, 2349-2354. 
Davis, B.M., Albers, K.M., Seroogy, K.B., and Katz, D.M. (1994). Overexpression of nerve growth 
factor in transgenic mice induces novel sympathetic projections to primary sensory neurons. J Comp 
Neurol 349, 464-474. 
De Pinto, V., Messina, A., Lane, D.J., and Lawen, A. (2010). Voltage-dependent anion-selective 
channel (VDAC) in the plasma membrane. FEBS letters 584, 1793-1799. 
Dedio, J., Jahnen-Dechent, W., Bachmann, M., and Muller-Esterl, W. (1998). The multiligand-binding 
protein gC1qR, putative C1q receptor, is a mitochondrial protein. J Immunol 160, 3534-3542. 
Dejda, A., Sokolowska, P., and Nowak, J.Z. (2005). Neuroprotective potential of three neuropeptides 
PACAP, VIP and PHI. Pharmacol Rep 57, 307-320. 
Dheen, S.T., Jun, Y., Yan, Z., Tay, S.S., and Ling, E.A. (2005). Retinoic acid inhibits expression of 
TNF-alpha and iNOS in activated rat microglia. Glia 50, 21-31. 
Dheen, S.T., Kaur, C., and Ling, E.A. (2007). Microglial activation and its implications in the brain 
diseases. Curr Med Chem 14, 1189-1197. 
Dorf, M.E., Berman, M.A., Tanabe, S., Heesen, M., and Luo, Y. (2000). Astrocytes express functional 
chemokine receptors. Journal of neuroimmunology 111, 109-121. 
Dranovsky, A., and Hen, R. (2006). Hippocampal neurogenesis: regulation by stress and 
antidepressants. Biol Psychiatry 59, 1136-1143. 
Duan, Y., Sahley, C.L., and Muller, K.J. (2009). ATP and NO dually control migration of microglia to 
nerve lesions. Dev Neurobiol 69, 60-72. 
Dugas, J.C., Tai, Y.C., Speed, T.P., Ngai, J., and Barres, B.A. (2006). Functional genomic analysis of 
oligodendrocyte differentiation. The Journal of neuroscience : the official journal of the Society for 
Neuroscience 26, 10967-10983. 
Dunkelberger, J.R., and Song, W.C. (2010). Complement and its role in innate and adaptive immune 
responses. Cell Res 20, 34-50. 
Dworkin, R.H., Backonja, M., Rowbotham, M.C., Allen, R.R., Argoff, C.R., Bennett, G.J., Bushnell, 
M.C., Farrar, J.T., Galer, B.S., Haythornthwaite, J.A., et al. (2003). Advances in neuropathic pain: 
diagnosis, mechanisms, and treatment recommendations. Arch Neurol 60, 1524-1534. 
Echeverry, S., Shi, X.Q., and Zhang, J. (2008). Characterization of cell proliferation in rat spinal cord 
following peripheral nerve injury and the relationship with neuropathic pain. Pain 135, 37-47. 
 202
Eichhoff, G., Brawek, B., and Garaschuk, O. (2011). Microglial calcium signal acts as a rapid sensor of 
single neuron damage in vivo. Biochimica et biophysica acta 1813, 1014-1024. 
Farber, K., Cheung, G., Mitchell, D., Wallis, R., Weihe, E., Schwaeble, W., and Kettenmann, H. 
(2009). C1q, the recognition subcomponent of the classical pathway of complement, drives microglial 
activation. J Neurosci Res 87, 644-652. 
Farber, K., and Kettenmann, H. (2006). Functional role of calcium signals for microglial function. Glia 
54, 656-665. 
Farrar, M.A., and Schreiber, R.D. (1993). The molecular cell biology of interferon-gamma and its 
receptor. Annu Rev Immunol 11, 571-611. 
Feng, X., Tonnesen, M.G., Peerschke, E.I., and Ghebrehiwet, B. (2002). Cooperation of C1q receptors 
and integrins in C1q-mediated endothelial cell adhesion and spreading. Journal of immunology 168, 
2441-2448. 
Ferri, G.L., Gaudio, R.M., Cossu, M., Rinaldi, A.M., Polak, J.M., Berger, P., and Possenti, R. (1995). 
The "VGF" protein in rat adenohypophysis: sex differences and changes during the estrous cycle and 
after gonadectomy. Endocrinology 136, 2244-2251. 
Ferri, G.L., Levi, A., and Possenti, R. (1992). A novel neuroendocrine gene product: selective VGF8a 
gene expression and immuno-localisation of the VGF protein in endocrine and neuronal populations. 
Brain Res Mol Brain Res 13, 139-143. 
Ferri, G.L., Noli, B., Brancia, C., D'Amato, F., and Cocco, C. (2011). VGF: An inducible gene product, 
precursor of a diverse array of neuro-endocrine peptides and tissue-specific disease biomarkers. J 
Chem Neuroanat. 
Fleige, S., and Pfaffl, M.W. (2006). RNA integrity and the effect on the real-time qRT-PCR 
performance. Mol Aspects Med 27, 126-139. 
Fraser, D.A., Pisalyaput, K., and Tenner, A.J. (2010). C1q enhances microglial clearance of apoptotic 
neurons and neuronal blebs, and modulates subsequent inflammatory cytokine production. Journal of 
neurochemistry 112, 733-743. 
Fryer, M.W., and Zucker, R.S. (1993). Ca(2+)-dependent inactivation of Ca2+ current in Aplysia 
neurons: kinetic studies using photolabile Ca2+ chelators. The Journal of physiology 464, 501-528. 
Fu, K.Y., Light, A.R., and Maixner, W. (2001). Long-lasting inflammation and long-term hyperalgesia 
after subcutaneous formalin injection into the rat hindpaw. J Pain 2, 2-11. 
Fu, P., Layfield, S., Ferraro, T., Tomiyama, H., Hutson, J., Otvos, L., Jr., Tregear, G.W., Bathgate, 
R.A., and Wade, J.D. (2004). Synthesis, conformation, receptor binding and biological activities of 
monobiotinylated human insulin-like peptide 3. J Pept Res 63, 91-98. 
Futaki, S. (2005). Membrane-permeable arginine-rich peptides and the translocation mechanisms. Adv 
Drug Deliv Rev 57, 547-558. 
Galione, A., and Petersen, O.H. (2005). The NAADP receptor: new receptors or new regulation? Mol 
Interv 5, 73-79. 
 203
Gao, L.J., Gu, P.Q., Fan, W.M., Liu, Z., Qiu, F., Peng, Y.Z., and Guo, X.R. (2011). The role of gC1qR 
in regulating survival of human papillomavirus 16 oncogene-transfected cervical cancer cells. Int J 
Oncol 39, 1265-1272. 
Garcia-Zepeda, E.A., Rothenberg, M.E., Ownbey, R.T., Celestin, J., Leder, P., and Luster, A.D. (1996). 
Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to 
explain tissue eosinophilia. Nature medicine 2, 449-456. 
Ghebrehiwet, B., CebadaMora, C., Tantral, L., Jesty, J., and Peerschke, E.I. (2006). gC1qR/p33 serves 
as a molecular bridge between the complement and contact activation systems and is an important 
catalyst in inflammation. Adv Exp Med Biol 586, 95-105. 
Ghebrehiwet, B., Jesty, J., and Peerschke, E.I. (2002). gC1q-R/p33: structure-function predictions from 
the crystal structure. Immunobiology 205, 421-432. 
Ghebrehiwet, B., Lim, B.L., Kumar, R., Feng, X., and Peerschke, E.I. (2001). gC1q-R/p33, a member 
of a new class of multifunctional and multicompartmental cellular proteins, is involved in inflammation 
and infection. Immunol Rev 180, 65-77. 
Ghebrehiwet, B., Lim, B.L., Peerschke, E.I., Willis, A.C., and Reid, K.B. (1994). Isolation, cDNA 
cloning, and overexpression of a 33-kD cell surface glycoprotein that binds to the globular "heads" of 
C1q. J Exp Med 179, 1809-1821. 
Ghebrehiwet, B., Lu, P.D., Zhang, W., Keilbaugh, S.A., Leigh, L.E., Eggleton, P., Reid, K.B., and 
Peerschke, E.I. (1997). Evidence that the two C1q binding membrane proteins, gC1q-R and cC1q-R, 
associate to form a complex. J Immunol 159, 1429-1436. 
Ghebrehiwet, B., Lu, P.D., Zhang, W., Lim, B.L., Eggleton, P., Leigh, L.E., Reid, K.B., and Peerschke, 
E.I. (1996). Identification of functional domains on gC1Q-R, a cell surface protein that binds to the 
globular "heads" of C1Q, using monoclonal antibodies and synthetic peptides. Hybridoma 15, 333-342. 
Ghebrehiwet, B., and Peerschke, E.I. (2004). cC1q-R (calreticulin) and gC1q-R/p33: ubiquitously 
expressed multi-ligand binding cellular proteins involved in inflammation and infection. Mol Immunol 
41, 173-183. 
Ghebrehiwet, B., Tantral, L., Titmus, M.A., Panessa-Warren, B.J., Tortora, G.T., Wong, S.S., and 
Warren, J.B. (2007). The exosporium of B. cereus contains a binding site for gC1qR/p33: implication 
in spore attachment and/or entry. Advances in experimental medicine and biology 598, 181-197. 
Giulian, D., and Baker, T.J. (1986). Characterization of ameboid microglia isolated from developing 
mammalian brain. J Neurosci 6, 2163-2178. 
Giulietti, A., Overbergh, L., Valckx, D., Decallonne, B., Bouillon, R., and Mathieu, C. (2001). An 
overview of real-time quantitative PCR: applications to quantify cytokine gene expression. Methods 
25, 386-401. 
Grace, K.S., Bronson, R.A., and Ghebrehiwet, B. (2002). Surface expression of complement receptor 
gC1q-R/p33 is increased on the plasma membrane of human spermatozoa after capacitation. Biol 
Reprod 66, 823-829. 
Graeber, M.B. (2010). Changing face of microglia. Science 330, 783-788. 
 204
Greene, L.A., and Tischler, A.S. (1976). Establishment of a noradrenergic clonal line of rat adrenal 
pheochromocytoma cells which respond to nerve growth factor. Proc Natl Acad Sci U S A 73, 2424-
2428. 
Greenwood, B.N., Foley, T.E., Day, H.E., Campisi, J., Hammack, S.H., Campeau, S., Maier, S.F., and 
Fleshner, M. (2003). Freewheel running prevents learned helplessness/behavioral depression: role of 
dorsal raphe serotonergic neurons. J Neurosci 23, 2889-2898. 
Greer, S., Honeywell, R., Geletu, M., Arulanandam, R., and Raptis, L. (2010). Housekeeping genes; 
expression levels may change with density of cultured cells. J Immunol Methods 355, 76-79. 
Griesbeck, O., Baird, G.S., Campbell, R.E., Zacharias, D.A., and Tsien, R.Y. (2001). Reducing the 
environmental sensitivity of yellow fluorescent protein. Mechanism and applications. The Journal of 
biological chemistry 276, 29188-29194. 
Griffin, R.S., Costigan, M., Brenner, G.J., Ma, C.H., Scholz, J., Moss, A., Allchorne, A.J., Stahl, G.L., 
and Woolf, C.J. (2007). Complement induction in spinal cord microglia results in anaphylatoxin C5a-
mediated pain hypersensitivity. The Journal of neuroscience : the official journal of the Society for 
Neuroscience 27, 8699-8708. 
Grynkiewicz, G., Poenie, M., and Tsien, R.Y. (1985). A new generation of Ca2+ indicators with 
greatly improved fluorescence properties. The Journal of biological chemistry 260, 3440-3450. 
Guerini, D., Coletto, L., and Carafoli, E. (2005). Exporting calcium from cells. Cell Calcium 38, 281-
289. 
Guo, L.H., Trautmann, K., and Schluesener, H.J. (2005). Expression of P2X4 receptor by lesional 
activated microglia during formalin-induced inflammatory pain. Journal of neuroimmunology 163, 
120-127. 
Gustafsson, K., Ingelsten, M., Bergqvist, L., Nystrom, J., Andersson, B., and Karlsson-Parra, A. 
(2008). Recruitment and activation of natural killer cells in vitro by a human dendritic cell vaccine. 
Cancer research 68, 5965-5971. 
Hahm, S., Fekete, C., Mizuno, T.M., Windsor, J., Yan, H., Boozer, C.N., Lee, C., Elmquist, J.K., 
Lechan, R.M., Mobbs, C.V., et al. (2002). VGF is required for obesity induced by diet, gold 
thioglucose treatment, and agouti and is differentially regulated in pro-opiomelanocortin- and 
neuropeptide Y-containing arcuate neurons in response to fasting. J Neurosci 22, 6929-6938. 
Hahm, S., Mizuno, T.M., Wu, T.J., Wisor, J.P., Priest, C.A., Kozak, C.A., Boozer, C.N., Peng, B., 
McEvoy, R.C., Good, P., et al. (1999). Targeted deletion of the Vgf gene indicates that the encoded 
secretory peptide precursor plays a novel role in the regulation of energy balance. Neuron 23, 537-548. 
Hawley, R.J., Scheibe, R.J., and Wagner, J.A. (1992). NGF induces the expression of the VGF gene 
through a cAMP response element. J Neurosci 12, 2573-2581. 
Heapy, C.G., Jamieson, A., and Russell, N.J.W. (1987). Afferent C-fibre and A-delta activity in models 
of inflammation. British journal of pharmacology 90, 164P. 
Heim, N., Garaschuk, O., Friedrich, M.W., Mank, M., Milos, R.I., Kovalchuk, Y., Konnerth, A., and 
Griesbeck, O. (2007). Improved calcium imaging in transgenic mice expressing a troponin C-based 
biosensor. Nat Methods 4, 127-129. 
 205
Henn, A., Lund, S., Hedtjarn, M., Schrattenholz, A., Porzgen, P., and Leist, M. (2009). The suitability 
of BV2 cells as alternative model system for primary microglia cultures or for animal experiments 
examining brain inflammation. Altex 26, 83-94. 
Hermanson, G.T. (2008). Bioconjugate techniques, 2nd ed. edn (London, Academic). 
Hernandez-Vargas, H., Rodriguez-Pinilla, S.M., Julian-Tendero, M., Sanchez-Rovira, P., Cuevas, C., 
Anton, A., Rios, M.J., Palacios, J., and Moreno-Bueno, G. (2007). Gene expression profiling of breast 
cancer cells in response to gemcitabine: NF-kappaB pathway activation as a potential mechanism of 
resistance. Breast Cancer Res Treat 102, 157-172. 
Herwald, H., Dedio, J., Kellner, R., Loos, M., and Muller-Esterl, W. (1996). Isolation and 
characterization of the kininogen-binding protein p33 from endothelial cells. Identity with the gC1q 
receptor. The Journal of biological chemistry 271, 13040-13047. 
Hodgkin, A.L., and Keynes, R.D. (1957). Movements of labelled calcium in squid giant axons. The 
Journal of physiology 138, 253-281. 
Hoffmann, A., Kann, O., Ohlemeyer, C., Hanisch, U.K., and Kettenmann, H. (2003). Elevation of basal 
intracellular calcium as a central element in the activation of brain macrophages (microglia): 
suppression of receptor-evoked calcium signaling and control of release function. The Journal of 
neuroscience : the official journal of the Society for Neuroscience 23, 4410-4419. 
Hoogenboom, B.W., Suda, K., Engel, A., and Fotiadis, D. (2007). The supramolecular assemblies of 
voltage-dependent anion channels in the native membrane. J Mol Biol 370, 246-255. 
Hoppe, U.C. (2010). Mitochondrial calcium channels. FEBS letters 584, 1975-1981. 
Hunsberger, J.G., Newton, S.S., Bennett, A.H., Duman, C.H., Russell, D.S., Salton, S.R., and Duman, 
R.S. (2007). Antidepressant actions of the exercise-regulated gene VGF. Nat Med 13, 1476-1482. 
Inesi, G., Hua, S., Xu, C., Ma, H., Seth, M., Prasad, A.M., and Sumbilla, C. (2005). Studies of Ca2+ 
ATPase (SERCA) inhibition. J Bioenerg Biomembr 37, 365-368. 
Inoue, K., and Tsuda, M. (2009). Microglia and neuropathic pain. Glia 57, 1469-1479. 
Ishihama, Y., Oda, Y., Tabata, T., Sato, T., Nagasu, T., Rappsilber, J., and Mann, M. (2005). 
Exponentially modified protein abundance index (emPAI) for estimation of absolute protein amount in 
proteomics by the number of sequenced peptides per protein. Molecular & cellular proteomics : MCP 
4, 1265-1272. 
Jenkinson, K.M., Mann, P.T., Southwell, B.R., and Furness, J.B. (2000). Independent endocytosis of 
the NK(1) and NK(3) tachykinin receptors in neurons of the rat myenteric plexus. Neuroscience 100, 
191-199. 
Jethwa, P.H., and Ebling, F.J. (2008). Role of VGF-derived peptides in the control of food intake, body 
weight and reproduction. Neuroendocrinology 88, 80-87. 
Jethwa, P.H., Warner, A., Nilaweera, K.N., Brameld, J.M., Keyte, J.W., Carter, W.G., Bolton, N., 
Bruggraber, M., Morgan, P.J., Barrett, P., et al. (2007). VGF-derived peptide, TLQP-21, regulates food 
intake and body weight in Siberian hamsters. Endocrinology 148, 4044-4055. 
 206
Ji, R.R., Gereau, R.W.t., Malcangio, M., and Strichartz, G.R. (2009). MAP kinase and pain. Brain Res 
Rev 60, 135-148. 
Ji, R.R., and Suter, M.R. (2007). p38 MAPK, microglial signaling, and neuropathic pain. Mol Pain 3, 
33. 
Jiang, J., Zhang, Y., Krainer, A.R., and Xu, R.M. (1999). Crystal structure of human p32, a doughnut-
shaped acidic mitochondrial matrix protein. Proc Natl Acad Sci U S A 96, 3572-3577. 
Jin, S.X., Zhuang, Z.Y., Woolf, C.J., and Ji, R.R. (2003). p38 mitogen-activated protein kinase is 
activated after a spinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and 
contributes to the generation of neuropathic pain. J Neurosci 23, 4017-4022. 
Jose, P.J., Griffiths-Johnson, D.A., Collins, P.D., Walsh, D.T., Moqbel, R., Totty, N.F., Truong, O., 
Hsuan, J.J., and Williams, T.J. (1994). Eotaxin: a potent eosinophil chemoattractant cytokine detected 
in a guinea pig model of allergic airways inflammation. The Journal of experimental medicine 179, 
881-887. 
Joseph, K., Ghebrehiwet, B., Peerschke, E.I., Reid, K.B., and Kaplan, A.P. (1996). Identification of the 
zinc-dependent endothelial cell binding protein for high molecular weight kininogen and factor XII: 
identity with the receptor that binds to the globular "heads" of C1q (gC1q-R). Proc Natl Acad Sci U S 
A 93, 8552-8557. 
Kampen, G.T., Stafford, S., Adachi, T., Jinquan, T., Quan, S., Grant, J.A., Skov, P.S., Poulsen, L.K., 
and Alam, R. (2000). Eotaxin induces degranulation and chemotaxis of eosinophils through the 
activation of ERK2 and p38 mitogen-activated protein kinases. Blood 95, 1911-1917. 
Kandel, E.R., Schwartz, J.H., and Jessell, T.M. (2000). Principles of neural science, 4th edn (New 
York, McGraw-Hill, Health Professions Division). 
Kaplan, A.P., and Ghebrehiwet, B. (2010). The plasma bradykinin-forming pathways and its 
interrelationships with complement. Molecular immunology 47, 2161-2169. 
Kasai, H., and Aosaki, T. (1988). Divalent cation dependent inactivation of the high-voltage-activated 
Ca-channel current in chick sensory neurons. Pflugers Arch 411, 695-697. 
Kettenmann, H., Hanisch, U.K., Noda, M., and Verkhratsky, A. (2011). Physiology of microglia. 
Physiological reviews 91, 461-553. 
Kirichok, Y., Krapivinsky, G., and Clapham, D.E. (2004). The mitochondrial calcium uniporter is a 
highly selective ion channel. Nature 427, 360-364. 
Kishore, U., and Reid, K.B. (2000). C1q: structure, function, and receptors. Immunopharmacology 49, 
159-170. 
Kitazawa, S., Takenaka, A., Kondo, T., Mizoguchi, A., and Kitazawa, R. (2006). Protruding disordered 
loop of gC1qR is specifically exposed and related to antiapoptotic property in germ cell lineage. 
Histochemistry and cell biology 126, 665-677. 
Klingenspor, M., Dickopp, A., Heldmaier, G., and Klaus, S. (1996). Short photoperiod reduces leptin 
gene expression in white and brown adipose tissue of Djungarian hamsters. FEBS Lett 399, 290-294. 
 207
Korotzer, A.R., Watt, J., Cribbs, D., Tenner, A.J., Burdick, D., Glabe, C., and Cotman, C.W. (1995). 
Cultured rat microglia express C1q and receptor for C1q: implications for amyloid effects on microglia. 
Experimental neurology 134, 214-221. 
Lacroix-Fralish, M.L., Austin, J.S., Zheng, F.Y., Levitin, D.J., and Mogil, J.S. (2011). Patterns of pain: 
Meta-analysis of microarray studies of pain. Pain 152, 1888-1898. 
Laine, S., Thouard, A., Derancourt, J., Kress, M., Sitterlin, D., and Rossignol, J.M. (2003). In vitro and 
in vivo interactions between the hepatitis B virus protein P22 and the cellular protein gC1qR. J Virol 
77, 12875-12880. 
Lambert, D.G. (1999). Calcium signaling protocols (Totowa, N.J., Humana Press). 
Le Friec, G., and Kemper, C. (2009). Complement: coming full circle. Arch Immunol Ther Exp 
(Warsz) 57, 393-407. 
Leng, S.X., McElhaney, J.E., Walston, J.D., Xie, D., Fedarko, N.S., and Kuchel, G.A. (2008). ELISA 
and multiplex technologies for cytokine measurement in inflammation and aging research. J Gerontol 
A Biol Sci Med Sci 63, 879-884. 
Levi, A., Eldridge, J.D., and Paterson, B.M. (1985). Molecular cloning of a gene sequence regulated by 
nerve growth factor. Science 229, 393-395. 
Levi, A., Ferri, G.L., Watson, E., Possenti, R., and Salton, S.R. (2004). Processing, distribution, and 
function of VGF, a neuronal and endocrine peptide precursor. Cell Mol Neurobiol 24, 517-533. 
Levine, E.S., Dreyfus, C.F., Black, I.B., and Plummer, M.R. (1996). Selective role for trkB 
neurotrophin receptors in rapid modulation of hippocampal synaptic transmission. Brain research 
Molecular brain research 38, 300-303. 
Lewit-Bentley, A., and Rety, S. (2000). EF-hand calcium-binding proteins. Curr Opin Struct Biol 10, 
637-643. 
Li, K., Lin, T., Cao, Y., Light, A.R., and Fu, K.Y. (2010). Peripheral formalin injury induces 2 stages 
of microglial activation in the spinal cord. J Pain 11, 1056-1065. 
Li, M., Peake, P.W., Charlesworth, J.A., Tracey, D.J., and Moalem-Taylor, G. (2007). Complement 
activation contributes to leukocyte recruitment and neuropathic pain following peripheral nerve injury 
in rats. The European journal of neuroscience 26, 3486-3500. 
Lim, B.L., Reid, K.B., Ghebrehiwet, B., Peerschke, E.I., Leigh, L.A., and Preissner, K.T. (1996). The 
binding protein for globular heads of complement C1q, gC1qR. Functional expression and 
characterization as a novel vitronectin binding factor. The Journal of biological chemistry 271, 26739-
26744. 
Livak, K.J., and Schmittgen, T.D. (2001). Analysis of relative gene expression data using real-time 
quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402-408. 
Loetscher, P., Pellegrino, A., Gong, J.H., Mattioli, I., Loetscher, M., Bardi, G., Baggiolini, M., and 
Clark-Lewis, I. (2001). The ligands of CXC chemokine receptor 3, I-TAC, Mig, and IP10, are natural 
antagonists for CCR3. The Journal of biological chemistry 276, 2986-2991. 
 208
Lombardo, A., Rabacchi, S.A., Cremisi, F., Pizzorusso, T., Cenni, M.C., Possenti, R., Barsacchi, G., 
and Maffei, L. (1995). A developmentally regulated nerve growth factor-induced gene, VGF, is 
expressed in geniculocortical afferents during synaptogenesis. Neuroscience 65, 997-1008. 
Machelska, H. (2011). Dual peripheral actions of immune cells in neuropathic pain. Arch Immunol 
Ther Exp (Warsz) 59, 11-24. 
Mahata, M., Hortnagl, H., Mahata, S.K., Fischer-Colbrie, R., and Winkler, H. (1993a). Messenger 
RNA levels of chromogranin B, secretogranin II, and VGF in rat brain after AF64A-induced 
septohippocampal cholinergic lesions. J Neurochem 61, 1648-1656. 
Mahata, S.K., Mahata, M., Fischer-Colbrie, R., and Winkler, H. (1993b). In situ hybridization: mRNA 
levels of secretogranin II, VGF and peptidylglycine alpha-amidating monooxygenase in brain of salt-
loaded rats. Histochemistry 99, 287-293. 
Malinen, E., Kassinen, A., Rinttila, T., and Palva, A. (2003). Comparison of real-time PCR with SYBR 
Green I or 5'-nuclease assays and dot-blot hybridization with rDNA-targeted oligonucleotide probes in 
quantification of selected faecal bacteria. Microbiology 149, 269-277. 
Mannon, P.J., Taylor, I.L., Kaiser, L.M., and Nguyen, T.D. (1989). Cross-linking of neuropeptide Y to 
its receptor on rat brain membranes. Am J Physiol 256, G637-643. 
Maratou, K., Wallace, V.C., Hasnie, F.S., Okuse, K., Hosseini, R., Jina, N., Blackbeard, J., Pheby, T., 
Orengo, C., Dickenson, A.H., et al. (2009). Comparison of dorsal root ganglion gene expression in rat 
models of traumatic and HIV-associated neuropathic pain. Eur J Pain 13, 387-398. 
Martin, F.C., Anton, P.A., Gornbein, J.A., Shanahan, F., and Merrill, J.E. (1993). Production of 
interleukin-1 by microglia in response to substance P: role for a non-classical NK-1 receptor. Journal of 
neuroimmunology 42, 53-60. 
Masramon, L., Vendrell, E., Tarafa, G., Capella, G., Miro, R., Ribas, M., and Peinado, M.A. (2006). 
Genetic instability and divergence of clonal populations in colon cancer cells in vitro. Journal of cell 
science 119, 1477-1482. 
Mattson, G., Conklin, E., Desai, S., Nielander, G., Savage, M.D., and Morgensen, S. (1993). A 
practical approach to crosslinking. Mol Biol Rep 17, 167-183. 
McMahon, S.B. (1996). NGF as a mediator of inflammatory pain. Philos Trans R Soc Lond B Biol Sci 
351, 431-440. 
McNamara, C.R., Mandel-Brehm, J., Bautista, D.M., Siemens, J., Deranian, K.L., Zhao, M., Hayward, 
N.J., Chong, J.A., Julius, D., Moran, M.M., et al. (2007). TRPA1 mediates formalin-induced pain. 
Proceedings of the National Academy of Sciences of the United States of America 104, 13525-13530. 
Mercer, J.G., Moar, K.M., Logie, T.J., Findlay, P.A., Adam, C.L., and Morgan, P.J. (2001). Seasonally 
inappropriate body weight induced by food restriction: effect on hypothalamic gene expression in male 
Siberian hamsters. Endocrinology 142, 4173-4181. 
Merrill, G.F. (1998). Cell synchronization. Methods Cell Biol 57, 229-249. 
Michelangeli, F., Ogunbayo, O.A., and Wootton, L.L. (2005). A plethora of interacting organellar 
Ca2+ stores. Current opinion in cell biology 17, 135-140. 
 209
Middleton, R.J., and Kellam, B. (2005). Fluorophore-tagged GPCR ligands. Current opinion in 
chemical biology 9, 517-525. 
Min, G., and Sherwood, O.D. (1996). Identification of specific relaxin-binding cells in the cervix, 
mammary glands, nipples, small intestine, and skin of pregnant pigs. Biol Reprod 55, 1243-1252. 
Minelli, A., Lyons, S., Nolte, C., Verkhratsky, A., and Kettenmann, H. (2000). Ammonium triggers 
calcium elevation in cultured mouse microglial cells by initiating Ca(2+) release from thapsigargin-
sensitive intracellular stores. Pflugers Arch 439, 370-377. 
Mitchell, D.J., Kim, D.T., Steinman, L., Fathman, C.G., and Rothbard, J.B. (2000). Polyarginine enters 
cells more efficiently than other polycationic homopolymers. J Pept Res 56, 318-325. 
Mitra, A., Fillmore, R.A., Metge, B.J., Rajesh, M., Xi, Y., King, J., Ju, J., Pannell, L., Shevde, L.A., 
and Samant, R.S. (2008). Large isoform of MRJ (DNAJB6) reduces malignant activity of breast 
cancer. Breast Cancer Res 10, R22. 
Miyawaki, A. (2005). Innovations in the imaging of brain functions using fluorescent proteins. Neuron 
48, 189-199. 
Miyawaki, A., Llopis, J., Heim, R., McCaffery, J.M., Adams, J.A., Ikura, M., and Tsien, R.Y. (1997). 
Fluorescent indicators for Ca2+ based on green fluorescent proteins and calmodulin. Nature 388, 882-
887. 
Mizoguchi, Y., Monji, A., Kato, T., Seki, Y., Gotoh, L., Horikawa, H., Suzuki, S.O., Iwaki, T., 
Yonaha, M., Hashioka, S., et al. (2009). Brain-derived neurotrophic factor induces sustained elevation 
of intracellular Ca2+ in rodent microglia. Journal of immunology 183, 7778-7786. 
Moalem, G., and Tracey, D.J. (2006). Immune and inflammatory mechanisms in neuropathic pain. 
Brain research reviews 51, 240-264. 
Molander, C., Hongpaisan, J., Svensson, M., and Aldskogius, H. (1997). Glial cell reactions in the 
spinal cord after sensory nerve stimulation are associated with axonal injury. Brain research 747, 122-
129. 
Moller, T. (2002). Calcium signaling in microglial cells. Glia 40, 184-194. 
Moorman, J.P., Fitzgerald, S.M., Prayther, D.C., Lee, S.A., Chi, D.S., and Krishnaswamy, G. (2005). 
Induction of p38- and gC1qR-dependent IL-8 expression in pulmonary fibroblasts by soluble hepatitis 
C core protein. Respir Res 6, 105. 
Moss, A., Ingram, R., Koch, S., Theodorou, A., Low, L., Baccei, M., Hathway, G., Costigan, M., 
Salton, S.R., and Fitzgerald, M. (2008). Origins, actions and dynamic expression patterns of the 
neuropeptide VGF in rat peripheral and central sensory neurones following peripheral nerve injury. 
Mol Pain 4, 62. 
Mueller, M., Wacker, K., Ringelstein, E.B., Hickey, W.F., Imai, Y., and Kiefer, R. (2001). Rapid 
response of identified resident endoneurial macrophages to nerve injury. Am J Pathol 159, 2187-2197. 
Muller, M., Carter, S., Hofer, M.J., and Campbell, I.L. (2010). Review: The chemokine receptor 
CXCR3 and its ligands CXCL9, CXCL10 and CXCL11 in neuroimmunity--a tale of conflict and 
conundrum. Neuropathol Appl Neurobiol 36, 368-387. 
 210
Nakajima, K., Hamanoue, M., Shimojo, M., Takei, N., and Kohsaka, S. (1989). Characterization of 
microglia isolated from a primary culture of embryonic rat brain by a simplified method. Biomedical 
Research 10, 411-423. 
Nakajima, K., and Kohsaka, S. (2004). Microglia: neuroprotective and neurotrophic cells in the central 
nervous system. Curr Drug Targets Cardiovasc Haematol Disord 4, 65-84. 
Nakajima, K., Shimojo, M., Hamanoue, M., Ishiura, S., Sugita, H., and Kohsaka, S. (1992). 
Identification of elastase as a secretory protease from cultured rat microglia. J Neurochem 58, 1401-
1408. 
Nakamura, Y. (2002). Regulating factors for microglial activation. Biol Pharm Bull 25, 945-953. 
Nayak, A., Ferluga, J., Tsolaki, A.G., and Kishore, U. (2010). The non-classical functions of the 
classical complement pathway recognition subcomponent C1q. Immunol Lett 131, 139-150. 
Nesvizhskii, A.I. (2007). Protein identification by tandem mass spectrometry and sequence database 
searching. Methods in molecular biology 367, 87-119. 
Nguyen, T., Ghebrehiwet, B., and Peerschke, E.I. (2000). Staphylococcus aureus protein A recognizes 
platelet gC1qR/p33: a novel mechanism for staphylococcal interactions with platelets. Infect Immun 
68, 2061-2068. 
Nibuya, M., Morinobu, S., and Duman, R.S. (1995). Regulation of BDNF and trkB mRNA in rat brain 
by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 15, 7539-7547. 
Nimmerjahn, A., Kirchhoff, F., and Helmchen, F. (2005). Resting microglial cells are highly dynamic 
surveillants of brain parenchyma in vivo. Science 308, 1314-1318. 
Noda, M., Kariura, Y., Amano, T., Manago, Y., Nishikawa, K., Aoki, S., and Wada, K. (2003). 
Expression and function of bradykinin receptors in microglia. Life Sci 72, 1573-1581. 
Noda, M., Kariura, Y., Amano, T., Manago, Y., Nishikawa, K., Aoki, S., and Wada, K. (2004). Kinin 
receptors in cultured rat microglia. Neurochemistry international 45, 437-442. 
O'Connor, A.B., and Dworkin, R.H. (2009). Treatment of neuropathic pain: an overview of recent 
guidelines. Am J Med 122, S22-32. 
Ogilvie, P., Bardi, G., Clark-Lewis, I., Baggiolini, M., and Uguccioni, M. (2001). Eotaxin is a natural 
antagonist for CCR2 and an agonist for CCR5. Blood 97, 1920-1924. 
Okuse, K. (2007). Pain signalling pathways: from cytokines to ion channels. Int J Biochem Cell Biol 
39, 490-496. 
Olson, J.K. (2010). Immune response by microglia in the spinal cord. Annals of the New York 
Academy of Sciences 1198, 271-278. 
Palmer, S., Wiegand, A.P., Maldarelli, F., Bazmi, H., Mican, J.M., Polis, M., Dewar, R.L., Planta, A., 
Liu, S., Metcalf, J.A., et al. (2003). New real-time reverse transcriptase-initiated PCR assay with 
single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 41, 
4531-4536. 
 211
Pankratov, Y., Lalo, U., Krishtal, O.A., and Verkhratsky, A. (2009). P2X receptors and synaptic 
plasticity. Neuroscience 158, 137-148. 
Peerschke, E.I., and Ghebrehiwet, B. (2007). The contribution of gC1qR/p33 in infection and 
inflammation. Immunobiology 212, 333-342. 
Peerschke, E.I., Murphy, T.K., and Ghebrehiwet, B. (2003). Activation-dependent surface expression 
of gC1qR/p33 on human blood platelets. Thromb Haemost 89, 331-339. 
Peerschke, E.I., Yin, W., Grigg, S.E., and Ghebrehiwet, B. (2006). Blood platelets activate the classical 
pathway of human complement. J Thromb Haemost 4, 2035-2042. 
Peinnequin, A., Mouret, C., Birot, O., Alonso, A., Mathieu, J., Clarencon, D., Agay, D., Chancerelle, 
Y., and Multon, E. (2004). Rat pro-inflammatory cytokine and cytokine related mRNA quantification 
by real-time polymerase chain reaction using SYBR green. BMC Immunol 5, 3. 
Perkins, N.M., and Tracey, D.J. (2000). Hyperalgesia due to nerve injury: role of neutrophils. 
Neuroscience 101, 745-757. 
Perrin, F.E., Lacroix, S., Aviles-Trigueros, M., and David, S. (2005). Involvement of monocyte 
chemoattractant protein-1, macrophage inflammatory protein-1alpha and interleukin-1beta in Wallerian 
degeneration. Brain 128, 854-866. 
Petersen-Mahrt, S.K., Estmer, C., Ohrmalm, C., Matthews, D.A., Russell, W.C., and Akusjarvi, G. 
(1999). The splicing factor-associated protein, p32, regulates RNA splicing by inhibiting ASF/SF2 
RNA binding and phosphorylation. The EMBO journal 18, 1014-1024. 
Peterson, K.L., Zhang, W., Lu, P.D., Keilbaugh, S.A., Peerschke, E.I., and Ghebrehiwet, B. (1997). 
The C1q-binding cell membrane proteins cC1q-R and gC1q-R are released from activated cells: 
subcellular distribution and immunochemical characterization. Clin Immunol Immunopathol 84, 17-26. 
Pezet, S., and McMahon, S.B. (2006). Neurotrophins: mediators and modulators of pain. Annual 
review of neuroscience 29, 507-538. 
Pinilla, L., Pineda, R., Gaytan, F., Romero, M., Garcia-Galiano, D., Sanchez-Garrido, M.A., Ruiz-Pino, 
F., Tena-Sempere, M., and Aguilar, E. (2011). Characterization of the reproductive effects of the 
anorexigenic VGF-derived peptide TLQP-21: in vivo and in vitro studies in male rats. American 
journal of physiology Endocrinology and metabolism 300, E837-847. 
Ponath, P.D., Qin, S., Ringler, D.J., Clark-Lewis, I., Wang, J., Kassam, N., Smith, H., Shi, X., Gonzalo, 
J.A., Newman, W., et al. (1996). Cloning of the human eosinophil chemoattractant, eotaxin. 
Expression, receptor binding, and functional properties suggest a mechanism for the selective 
recruitment of eosinophils. The Journal of clinical investigation 97, 604-612. 
Porro, C.A., and Cavazzuti, M. (1993). Spatial and temporal aspects of spinal cord and brainstem 
activation in the formalin pain model. Prog Neurobiol 41, 565-607. 
Possenti, R., Di Rocco, G., Nasi, S., and Levi, A. (1992). Regulatory elements in the promoter region 
of vgf, a nerve growth factor-inducible gene. Proc Natl Acad Sci U S A 89, 3815-3819. 
 212
Possenti, R., Eldridge, J.D., Paterson, B.M., Grasso, A., and Levi, A. (1989). A protein induced by 
NGF in PC12 cells is stored in secretory vesicles and released through the regulated pathway. EMBO J 
8, 2217-2223. 
Possenti, R., Rinaldi, A.M., Ferri, G.L., Borboni, P., Trani, E., and Levi, A. (1999). Expression, 
processing, and secretion of the neuroendocrine VGF peptides by INS-1 cells. Endocrinology 140, 
3727-3735. 
Prakash, M., Kale, S., Ghosh, I., Kundu, G.C., and Datta, K. (2011). Hyaluronan-binding protein 1 
(HABP1/p32/gC1qR) induces melanoma cell migration and tumor growth by NF-kappa B dependent 
MMP-2 activation through integrin alpha(v)beta(3) interaction. Cellular signalling 23, 1563-1577. 
Prieto, D., Buus, C.L., Mulvany, M.J., and Nilsson, H. (2000). Neuropeptide Y regulates intracellular 
calcium through different signalling pathways linked to a Y(1)-receptor in rat mesenteric small arteries. 
British journal of pharmacology 129, 1689-1699. 
Raghavendra, V., Tanga, F.Y., and DeLeo, J.A. (2004). Complete Freunds adjuvant-induced peripheral 
inflammation evokes glial activation and proinflammatory cytokine expression in the CNS. The 
European journal of neuroscience 20, 467-473. 
Ricklin, D., Hajishengallis, G., Yang, K., and Lambris, J.D. (2010). Complement: a key system for 
immune surveillance and homeostasis. Nature immunology 11, 785-797. 
Riedl, M.S., Braun, P.D., Kitto, K.F., Roiko, S.A., Anderson, L.B., Honda, C.N., Fairbanks, C.A., and 
Vulchanova, L. (2009). Proteomic Analysis Uncovers Novel Actions of the Neurosecretory Protein 
VGF in Nociceptive Processing. J Neurosci 29, 13377-13388. 
Rindi, G., Licini, L., Necchi, V., Bottarelli, L., Campanini, N., Azzoni, C., Favret, M., Giordano, G., 
D'Amato, F., Brancia, C., et al. (2007). Peptide products of the neurotrophin-inducible gene vgf are 
produced in human neuroendocrine cells from early development and increase in hyperplasia and 
neoplasia. J Clin Endocrinol Metab 92, 2811-2815. 
Ririe, K.M., Rasmussen, R.P., and Wittwer, C.T. (1997). Product differentiation by analysis of DNA 
melting curves during the polymerase chain reaction. Analytical biochemistry 245, 154-160. 
Rizzi, R., Bartolomucci, A., Moles, A., D'Amato, F., Sacerdote, P., Levi, A., La Corte, G., Ciotti, M.T., 
Possenti, R., and Pavone, F. (2008). The VGF-derived peptide TLQP-21: a new modulatory peptide for 
inflammatory pain. Neurosci Lett 441, 129-133. 
Rogers, J., and Lue, L.F. (2001). Microglial chemotaxis, activation, and phagocytosis of amyloid beta-
peptide as linked phenomena in Alzheimer's disease. Neurochemistry international 39, 333-340. 
Rothenberg, M.E., Luster, A.D., and Leder, P. (1995). Murine eotaxin: an eosinophil chemoattractant 
inducible in endothelial cells and in interleukin 4-induced tumor suppression. Proceedings of the 
National Academy of Sciences of the United States of America 92, 8960-8964. 
Rozanov, D.V., Ghebrehiwet, B., Postnova, T.I., Eichinger, A., Deryugina, E.I., and Strongin, A.Y. 
(2002). The hemopexin-like C-terminal domain of membrane type 1 matrix metalloproteinase regulates 
proteolysis of a multifunctional protein, gC1qR. The Journal of biological chemistry 277, 9318-9325. 
Rubinstein, D.B., Stortchevoi, A., Boosalis, M., Ashfaq, R., Ghebrehiwet, B., Peerschke, E.I., Calvo, 
F., and Guillaume, T. (2004). Receptor for the globular heads of C1q (gC1q-R, p33, hyaluronan-
binding protein) is preferentially expressed by adenocarcinoma cells. Int J Cancer 110, 741-750. 
 213
Salton, S.R. (1991). Nucleotide sequence and regulatory studies of VGF, a nervous system-specific 
mRNA that is rapidly and relatively selectively induced by nerve growth factor. J Neurochem 57, 991-
996. 
Salton, S.R., Ferri, G.L., Hahm, S., Snyder, S.E., Wilson, A.J., Possenti, R., and Levi, A. (2000). VGF: 
a novel role for this neuronal and neuroendocrine polypeptide in the regulation of energy balance. 
Front Neuroendocrinol 21, 199-219. 
Salton, S.R., Fischberg, D.J., and Dong, K.W. (1991). Structure of the gene encoding VGF, a nervous 
system-specific mRNA that is rapidly and selectively induced by nerve growth factor in PC12 cells. 
Mol Cell Biol 11, 2335-2349. 
Sarma, J.V., and Ward, P.A. (2011). The complement system. Cell Tissue Res 343, 227-235. 
Sasaki, K., Takahashi, N., Satoh, M., Yamasaki, M., and Minamino, N. (2010). A peptidomics strategy 
for discovering endogenous bioactive peptides. J Proteome Res 9, 5047-5052. 
Sattayaprasert, P., Choi, H.B., Chongthammakun, S., and McLarnon, J.G. (2005). Platelet-activating 
factor enhancement of calcium influx and interleukin-6 expression, but not production, in human 
microglia. Journal of neuroinflammation 2, 11. 
Sawada, M. (2009). Neuroprotective and toxic changes in microglia in neurodegenerative disease. 
Parkinsonism Relat Disord 15 Suppl 1, S39-41. 
Schagger, H. (2006). Tricine-SDS-PAGE. Nat Protoc 1, 16-22. 
Schermann, S.M., Simmons, D.A., and Konermann, L. (2005). Mass spectrometry-based approaches to 
protein-ligand interactions. Expert Rev Proteomics 2, 475-485. 
Schild, D. (1996). Laser scanning microscopy and calcium imaging. Cell Calcium 19, 281-296. 
Schneider, J.E. (2004). Energy balance and reproduction. Physiol Behav 81, 289-317. 
Scholz, J., and Woolf, C.J. (2007). The neuropathic pain triad: neurons, immune cells and glia. Nat 
Neurosci 10, 1361-1368. 
Scopes, R.K. (1994). Protein purification : principles and practice, 3rd edn (New York, Springer-
Verlag). 
Seidah, N.G., and Chretien, M. (1999). Proprotein and prohormone convertases: a family of subtilases 
generating diverse bioactive polypeptides. Brain Res 848, 45-62. 
Sethi, S., Herrmann, M., Roller, J., von Muller, L., Peerschke, E.I., Ghebrehiwet, B., Bajric, I., Menger, 
M.D., and Laschke, M.W. (2011). Blockade of gC1qR/p33, a receptor for C1q, inhibits adherence of 
Staphylococcus aureus to the microvascular endothelium. Microvasc Res 82, 66-72. 
Severini, C., Ciotti, M.T., Biondini, L., Quaresima, S., Rinaldi, A.M., Levi, A., Frank, C., and Possenti, 
R. (2008). TLQP-21, a neuroendocrine VGF-derived peptide, prevents cerebellar granule cells death 
induced by serum and potassium deprivation. J Neurochem 104, 534-544. 
 214
Severini, C., La Corte, G., Improta, G., Broccardo, M., Agostini, S., Petrella, C., Sibilia, V., Pagani, F., 
Guidobono, F., Bulgarelli, I., et al. (2009). In vitro and in vivo pharmacological role of TLQP-21, a 
VGF-derived peptide, in the regulation of rat gastric motor functions. British journal of pharmacology 
157, 984-993. 
Shimazawa, M., Tanaka, H., Ito, Y., Morimoto, N., Tsuruma, K., Kadokura, M., Tamura, S., Inoue, T., 
Yamada, M., Takahashi, H., et al. (2010). An inducer of VGF protects cells against ER stress-induced 
cell death and prolongs survival in the mutant SOD1 animal models of familial ALS. PLoS ONE 5, 
e15307. 
Sibilia, V., Pagani, F., Bulgarelli, I., Mrak, E., Broccardo, M., Improta, G., Severini, C., Possenti, R., 
and Guidobono, F. (2010a). TLQP-21, a VGF-derived peptide, prevents ethanol-induced gastric 
lesions: insights into its mode of action. Neuroendocrinology 92, 189-197. 
Sibilia, V., Pagani, F., Bulgarelli, I., Tulipano, G., Possenti, R., and Guidobono, F. (2010b). 
Characterization of the mechanisms involved in the gastric antisecretory effect of TLQP-21, a vgf-
derived peptide, in rats. Amino Acids. 
Simmons, L.K., May, P.C., Tomaselli, K.J., Rydel, R.E., Fuson, K.S., Brigham, E.F., Wright, S., 
Lieberburg, I., Becker, G.W., Brems, D.N., et al. (1994). Secondary structure of amyloid beta peptide 
correlates with neurotoxic activity in vitro. Molecular pharmacology 45, 373-379. 
Skalnikova, H., Motlik, J., Gadher, S.J., and Kovarova, H. (2011). Mapping of the secretome of 
primary isolates of mammalian cells, stem cells and derived cell lines. Proteomics 11, 691-708. 
Smetters, D., Majewska, A., and Yuste, R. (1999). Detecting action potentials in neuronal populations 
with calcium imaging. Methods 18, 215-221. 
Smith, M.E., van der Maesen, K., and Somera, F.P. (1998). Macrophage and microglial responses to 
cytokines in vitro: phagocytic activity, proteolytic enzyme release, and free radical production. Journal 
of neuroscience research 54, 68-78. 
Snyder, S.E., Cheng, H.W., Murray, K.D., Isackson, P.J., McNeill, T.H., and Salton, S.R. (1998a). The 
messenger RNA encoding VGF, a neuronal peptide precursor, is rapidly regulated in the rat central 
nervous system by neuronal activity, seizure and lesion. Neuroscience 82, 7-19. 
Snyder, S.E., Pintar, J.E., and Salton, S.R. (1998b). Developmental expression of VGF mRNA in the 
prenatal and postnatal rat. J Comp Neurol 394, 64-90. 
Snyder, S.E., and Salton, S.R. (1998). Expression of VGF mRNA in the adult rat central nervous 
system. J Comp Neurol 394, 91-105. 
Soltys, B.J., Kang, D., and Gupta, R.S. (2000). Localization of P32 protein (gC1q-R) in mitochondria 
and at specific extramitochondrial locations in normal tissues. Histochem Cell Biol 114, 245-255. 
Song, G., Cechvala, C., Resnick, D.K., Dempsey, R.J., and Rao, V.L. (2001). GeneChip analysis after 
acute spinal cord injury in rat. J Neurochem 79, 804-815. 
Stark, M., Danielsson, O., Griffiths, W.J., Jornvall, H., and Johansson, J. (2001). Peptide repertoire of 
human cerebrospinal fluid: novel proteolytic fragments of neuroendocrine proteins. J Chromatogr B 
Biomed Sci Appl 754, 357-367. 
 215
Starkov, A.A. (2010). The molecular identity of the mitochondrial Ca2+ sequestration system. The 
FEBS journal 277, 3652-3663. 
Steiner, D.F. (1998). The proprotein convertases. Curr Opin Chem Biol 2, 31-39. 
Steranka, L.R., Manning, D.C., DeHaas, C.J., Ferkany, J.W., Borosky, S.A., Connor, J.R., Vavrek, 
R.J., Stewart, J.M., and Snyder, S.H. (1988). Bradykinin as a pain mediator: receptors are localized to 
sensory neurons, and antagonists have analgesic actions. Proceedings of the National Academy of 
Sciences of the United States of America 85, 3245-3249. 
Streit, W.J. (2002). Microglia as neuroprotective, immunocompetent cells of the CNS. Glia 40, 133-
139. 
Succu, S., Cocco, C., Mascia, M.S., Melis, T., Melis, M.R., Possenti, R., Levi, A., Ferri, G.L., and 
Argiolas, A. (2004). Pro-VGF-derived peptides induce penile erection in male rats: possible 
involvement of oxytocin. Eur J Neurosci 20, 3035-3040. 
Succu, S., Mascia, M.S., Melis, T., Sanna, F., Melis, M.R., Possenti, R., and Argiolas, A. (2005). Pro-
VGF-derived peptides induce penile erection in male rats: Involvement of paraventricular nitric oxide. 
Neuropharmacology 49, 1017-1025. 
Szabo, J., Cervenak, L., Toth, F.D., Prohaszka, Z., Horvath, L., Kerekes, K., Beck, Z., Bacsi, A., Erdei, 
A., Peerschke, E.I., et al. (2001). Soluble gC1q-R/p33, a cell protein that binds to the globular "heads" 
of C1q, effectively inhibits the growth of HIV-1 strains in cell cultures. Clin Immunol 99, 222-231. 
Takenouchi, T., Ogihara, K., Sato, M., and Kitani, H. (2005). Inhibitory effects of U73122 and U73343 
on Ca2+ influx and pore formation induced by the activation of P2X7 nucleotide receptors in mouse 
microglial cell line. Biochimica et biophysica acta 1726, 177-186. 
Talbot, S., Chahmi, E., Dias, J.P., and Couture, R. (2010). Key role for spinal dorsal horn microglial 
kinin B1 receptor in early diabetic pain neuropathy. Journal of neuroinflammation 7, 36. 
Tensen, C.P., Flier, J., Van Der Raaij-Helmer, E.M., Sampat-Sardjoepersad, S., Van Der Schors, R.C., 
Leurs, R., Scheper, R.J., Boorsma, D.M., and Willemze, R. (1999). Human IP-9: A keratinocyte-
derived high affinity CXC-chemokine ligand for the IP-10/Mig receptor (CXCR3). J Invest Dermatol 
112, 716-722. 
Thakker-Varia, S., Jean, Y.Y., Parikh, P., Sizer, C.F., Jernstedt Ayer, J., Parikh, A., Hyde, T.M., 
Buyske, S., and Alder, J. (2010). The Neuropeptide VGF Is Reduced in Human Bipolar Postmortem 
Brain and Contributes to Some of the Behavioral and Molecular Effects of Lithium. J Neurosci 30, 
9368-9380. 
Thakker-Varia, S., Krol, J.J., Nettleton, J., Bilimoria, P.M., Bangasser, D.A., Shors, T.J., Black, I.B., 
and Alder, J. (2007). The neuropeptide VGF produces antidepressant-like behavioral effects and 
enhances proliferation in the hippocampus. J Neurosci 27, 12156-12167. 
Tjolsen, A., Berge, O.G., Hunskaar, S., Rosland, J.H., and Hole, K. (1992). The formalin test: an 
evaluation of the method. Pain 51, 5-17. 
Toshinai, K., Yamaguchi, H., Kageyama, H., Matsuo, T., Koshinaka, K., Sasaki, K., Shioda, S., 
Minamino, N., and Nakazato, M. (2010). Neuroendocrine regulatory peptide-2 regulates feeding 
behavior via the orexin system in the hypothalamus. Am J Physiol Endocrinol Metab 299, E394-401. 
 216
Trani, E., Ciotti, T., Rinaldi, A.M., Canu, N., Ferri, G.L., Levi, A., and Possenti, R. (1995). Tissue-
specific processing of the neuroendocrine protein VGF. J Neurochem 65, 2441-2449. 
Trani, E., Giorgi, A., Canu, N., Amadoro, G., Rinaldi, A.M., Halban, P.A., Ferri, G.L., Possenti, R., 
Schinina, M.E., and Levi, A. (2002). Isolation and characterization of VGF peptides in rat brain. Role 
of PC1/3 and PC2 in the maturation of VGF precursor. J Neurochem 81, 565-574. 
Tschernitz, C., Laslop, A., Eiter, C., Kroesen, S., and Winkler, H. (1995). Biosynthesis of large dense-
core vesicles in PC12 cells: effects of depolarization and second messengers on the mRNA levels of 
their constituents. Brain Res Mol Brain Res 31, 131-140. 
Tsuda, M., Inoue, K., and Salter, M.W. (2005). Neuropathic pain and spinal microglia: a big problem 
from molecules in "small" glia. Trends Neurosci 28, 101-107. 
Tyler, W.J., Alonso, M., Bramham, C.R., and Pozzo-Miller, L.D. (2002). From acquisition to 
consolidation: on the role of brain-derived neurotrophic factor signaling in hippocampal-dependent 
learning. Learn Mem 9, 224-237. 
Urh, M., Simpson, D., and Zhao, K. (2009). Affinity chromatography: general methods. Methods in 
enzymology 463, 417-438. 
Valder, C.R., Liu, J.J., Song, Y.H., and Luo, Z.D. (2003). Coupling gene chip analyses and rat genetic 
variances in identifying potential target genes that may contribute to neuropathic allodynia 
development. J Neurochem 87, 560-573. 
Vallejo, R., Tilley, D.M., Vogel, L., and Benyamin, R. (2010). The role of glia and the immune system 
in the development and maintenance of neuropathic pain. Pain Pract 10, 167-184. 
van den Pol, A.N., Bina, K., Decavel, C., and Ghosh, P. (1994). VGF expression in the brain. J Comp 
Neurol 347, 455-469. 
van Leeuwen, H.C., and O'Hare, P. (2001). Retargeting of the mitochondrial protein p32/gC1Qr to a 
cytoplasmic compartment and the cell surface. Journal of cell science 114, 2115-2123. 
Van Scoy, S., Watakabe, I., Krainer, A.R., and Hearing, J. (2000). Human p32: a coactivator for 
Epstein-Barr virus nuclear antigen-1-mediated transcriptional activation and possible role in viral latent 
cycle DNA replication. Virology 275, 145-157. 
Vandesompele, J., De Paepe, A., and Speleman, F. (2002a). Elimination of primer-dimer artifacts and 
genomic coamplification using a two-step SYBR green I real-time RT-PCR. Analytical biochemistry 
303, 95-98. 
Vandesompele, J., De Preter, K., Pattyn, F., Poppe, B., Van Roy, N., De Paepe, A., and Speleman, F. 
(2002b). Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of 
multiple internal control genes. Genome biology 3, RESEARCH0034. 
Vegh, Z., Kew, R.R., Gruber, B.L., and Ghebrehiwet, B. (2006). Chemotaxis of human monocyte-
derived dendritic cells to complement component C1q is mediated by the receptors gC1qR and cC1qR. 
Molecular immunology 43, 1402-1407. 
Verkhratsky, A. (2005). Physiology and pathophysiology of the calcium store in the endoplasmic 
reticulum of neurons. Physiological reviews 85, 201-279. 
 217
Verkhratsky, A., and Kettenmann, H. (1996). Calcium signalling in glial cells. Trends in neurosciences 
19, 346-352. 
Verkhratsky, A., and Steinhauser, C. (2000). Ion channels in glial cells. Brain Res Brain Res Rev 32, 
380-412. 
Verkhratsky, A.N., and Petersen, O.H. (2010). Calcium measurement methods (New York ; London, 
Humana). 
Vinayek, R., and Gardner, J.D. (1990). Receptor identification. Methods Enzymol 191, 609-639. 
Wall, P.D., McMahon, S.B., and Koltzenburg, M. (2006). Wall and Melzack's textbook of pain, 5th 
edn (Philadelphia, Elsevier/Churchill Livingstone). 
Wang, A.L., Yu, A.C., He, Q.H., Zhu, X., and Tso, M.O. (2007). AGEs mediated expression and 
secretion of TNF alpha in rat retinal microglia. Experimental eye research 84, 905-913. 
Wang, T., and Brown, M.J. (1999). mRNA quantification by real time TaqMan polymerase chain 
reaction: validation and comparison with RNase protection. Analytical biochemistry 269, 198-201. 
Wang, W., Mei, X., Huang, J., Wei, Y., Wang, Y., Wu, S., and Li, Y. (2009). Crosstalk between spinal 
astrocytes and neurons in nerve injury-induced neuropathic pain. PLoS ONE 4, e6973. 
Watkins, L.R., and Maier, S.F. (2002). Beyond neurons: evidence that immune and glial cells 
contribute to pathological pain states. Physiological reviews 82, 981-1011. 
Webster, S.D., Yang, A.J., Margol, L., Garzon-Rodriguez, W., Glabe, C.G., and Tenner, A.J. (2000). 
Complement component C1q modulates the phagocytosis of Abeta by microglia. Experimental 
neurology 161, 127-138. 
Whitaker, M. (2010). Genetically encoded probes for measurement of intracellular calcium. Methods 
Cell Biol 99, 153-182. 
Wiesenfeld-Hallin, Z., Xu, X.J., Hakanson, R., Feng, D.M., Folkers, K., Kristensson, K., Villar, M.J., 
Fahrenkrug, J., and Hokfelt, T. (1991). On the role of substance P, galanin, vasoactive intestinal 
peptide, and calcitonin gene-related peptide in mediation of spinal reflex excitability in rats with intact 
and sectioned peripheral nerves. Annals of the New York Academy of Sciences 632, 198-211. 
Wiley, J.W., Gross, R.A., and MacDonald, R.L. (1993). Agonists for neuropeptide Y receptor subtypes 
NPY-1 and NPY-2 have opposite actions on rat nodose neuron calcium currents. J Neurophysiol 70, 
324-330. 
Winter, J., Bevan, S., and Campbell, E.A. (1995). Capsaicin and pain mechanisms. Br J Anaesth 75, 
157-168. 
Wisor, J.P., and Takahashi, J.S. (1997). Regulation of the vgf gene in the golden hamster 
suprachiasmatic nucleus by light and by the circadian clock. J Comp Neurol 378, 229-238. 
Wong, B.J., Tublitz, N.J., and Minson, C.T. (2005). Neurokinin-1 receptor desensitization to 
consecutive microdialysis infusions of substance P in human skin. The Journal of physiology 568, 
1047-1056. 
 218
Wong, M.L., and Medrano, J.F. (2005). Real-time PCR for mRNA quantitation. Biotechniques 39, 75-
85. 
Wood, J.N., Bevan, S.J., Coote, P.R., Dunn, P.M., Harmar, A., Hogan, P., Latchman, D.S., Morrison, 
C., Rougon, G., Theveniau, M., et al. (1990). Novel cell lines display properties of nociceptive sensory 
neurons. Proc Biol Sci 241, 187-194. 
Woolf, C., and Wiesenfeld-Hallin, Z. (1986). Substance P and calcitonin gene-related peptide 
synergistically modulate the gain of the nociceptive flexor withdrawal reflex in the rat. Neuroscience 
letters 66, 226-230. 
Wu, H.Y., Tomizawa, K., Matsushita, M., Lu, Y.F., Li, S.T., and Matsui, H. (2003). Poly-arginine-
fused calpastatin peptide, a living cell membrane-permeable and specific inhibitor for calpain. Neurosci 
Res 47, 131-135. 
Wu, Y., Willcockson, H.H., Maixner, W., and Light, A.R. (2004). Suramin inhibits spinal cord 
microglia activation and long-term hyperalgesia induced by formalin injection. J Pain 5, 48-55. 
Xanthou, G., Duchesnes, C.E., Williams, T.J., and Pease, J.E. (2003). CCR3 functional responses are 
regulated by both CXCR3 and its ligands CXCL9, CXCL10 and CXCL11. Eur J Immunol 33, 2241-
2250. 
Xiao, H.S., Huang, Q.H., Zhang, F.X., Bao, L., Lu, Y.J., Guo, C., Yang, L., Huang, W.J., Fu, G., Xu, 
S.H., et al. (2002). Identification of gene expression profile of dorsal root ganglion in the rat peripheral 
axotomy model of neuropathic pain. Proc Natl Acad Sci U S A 99, 8360-8365. 
Xu, Z., Hirasawa, A., Shinoura, H., and Tsujimoto, G. (1999). Interaction of the alpha(1B)-adrenergic 
receptor with gC1q-R, a multifunctional protein. The Journal of biological chemistry 274, 21149-
21154. 
Yamaguchi, H., Sasaki, K., Satomi, Y., Shimbara, T., Kageyama, H., Mondal, M.S., Toshinai, K., 
Date, Y., Gonzalez, L.J., Shioda, S., et al. (2007). Peptidomic identification and biological validation 
of neuroendocrine regulatory peptide-1 and -2. J Biol Chem 282, 26354-26360. 
Yao, Z.Q., Eisen-Vandervelde, A., Ray, S., and Hahn, Y.S. (2003). HCV core/gC1qR interaction 
arrests T cell cycle progression through stabilization of the cell cycle inhibitor p27Kip1. Virology 314, 
271-282. 
Yao, Z.Q., Nguyen, D.T., Hiotellis, A.I., and Hahn, Y.S. (2001). Hepatitis C virus core protein inhibits 
human T lymphocyte responses by a complement-dependent regulatory pathway. Journal of 
immunology 167, 5264-5272. 
Yin, W., Ghebrehiwet, B., Weksler, B., and Peerschke, E.I. (2007). Classical pathway complement 
activation on human endothelial cells. Molecular immunology 44, 2228-2234. 
Yuste, R., Maclean, J., Vogelstein, J., and Paninski, L. (2011). Imaging action potentials with calcium 
indicators. Cold Spring Harb Protoc 2011. 
Zhang, F.Y., Wan, Y., Zhang, Z.K., Light, A.R., and Fu, K.Y. (2007). Peripheral formalin injection 
induces long-lasting increases in cyclooxygenase 1 expression by microglia in the spinal cord. J Pain 8, 
110-117. 
 219
Zhang, J., and De Koninck, Y. (2006). Spatial and temporal relationship between monocyte 
chemoattractant protein-1 expression and spinal glial activation following peripheral nerve injury. 
Journal of neurochemistry 97, 772-783. 
Zhang, J., Hoffert, C., Vu, H.K., Groblewski, T., Ahmad, S., and O'Donnell, D. (2003). Induction of 
CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain 
models. The European journal of neuroscience 17, 2750-2754. 
Zhao, P., Waxman, S.G., and Hains, B.C. (2007). Extracellular signal-regulated kinase-regulated 
microglia-neuron signaling by prostaglandin E2 contributes to pain after spinal cord injury. The Journal 
of neuroscience : the official journal of the Society for Neuroscience 27, 2357-2368. 
Zhao, Z., Lange, D.J., Ho, L., Bonini, S., Shao, B., Salton, S.R., Thomas, S., and Pasinetti, G.M. 
(2008). Vgf is a novel biomarker associated with muscle weakness in amyotrophic lateral sclerosis 
(ALS), with a potential role in disease pathogenesis. Int J Med Sci 5, 92-99. 
Zhou, Z., Peng, X., Hagshenas, J., Insolera, R., Fink, D.J., and Mata, M. (2010). A novel cell-cell 
signaling by microglial transmembrane TNFalpha with implications for neuropathic pain. Pain 151, 
296-306. 
Zhuang, Z.Y., Gerner, P., Woolf, C.J., and Ji, R.R. (2005). ERK is sequentially activated in neurons, 
microglia, and astrocytes by spinal nerve ligation and contributes to mechanical allodynia in this 
neuropathic pain model. Pain 114, 149-159. 
Zhuang, Z.Y., Kawasaki, Y., Tan, P.H., Wen, Y.R., Huang, J., and Ji, R.R. (2007). Role of the 
CX3CR1/p38 MAPK pathway in spinal microglia for the development of neuropathic pain following 
nerve injury-induced cleavage of fractalkine. Brain Behav Immun 21, 642-651. 
Zieske, L.R. (2006). A perspective on the use of iTRAQ reagent technology for protein complex and 
profiling studies. J Exp Bot 57, 1501-1508. 
Zochodne, D.W., Levy, D., Zwiers, H., Sun, H., Rubin, I., Cheng, C., and Lauritzen, M. (1999). 
Evidence for nitric oxide and nitric oxide synthase activity in proximal stumps of transected peripheral 
nerves. Neuroscience 91, 1515-1527. 
 
 
 220
Appendix 
 
A1. Mass spectrometry data showing the full list of 136 proteins identified, from the 
~30 kDa protein band of the +TLQP-21 elution in the WCL (whole cell lysate) fraction (see 
Figure 3.4).  
 
Score Mass Sequences emPAI 
 
1012 29326 24 47.08 
RecName: Full=14-3-3 protein epsilon; Short=14-3-3E; AltName: Full=Mitochondrial import stimulation factor L 
subunit; Short=MSF L; 
162 28456 6 0.94 
RecName: Full=14-3-3 protein gamma; Contains: RecName: Full=14-3-3 protein gamma, N-terminally processed; 
124 27925 3 0.4 
RecName: Full=14-3-3 protein zeta/delta; AltName: Full=Mitochondrial import stimulation factor S1 subunit; 
AltName: Full=Protein kinase C inhibitor protein 1; Short=KCIP-1; 
89 28365 3 0.39 
RecName: Full=14-3-3 protein eta; 
514 26828 15 10.68 
RecName: Full=40S ribosomal protein S3; 
443 28718 13 4.18 
RecName: Full=Acidic leucine-rich nuclear phosphoprotein 32 family member A; AltName: Full=Leucine-rich acidic 
nuclear protein; Short=LANP; 
372 31497 9 2.68 
RecName: Full=40S ribosomal protein S2; 
311 30156 5 1.08 
RecName: Full=Microtubule-associated protein RP/EB family member 1; AltName: Full=APC-binding protein EB1; 
AltName: Full=End-binding protein 1; Short=EB1; 
82 32231 3 0.34 
RecName: Full=Microtubule-associated protein RP/EB family member 3; AltName: Full=EB1 protein family member 
3; Short=EBF3; AltName: Full=End-binding protein 3; Short=EB3; AltName: Full=RP3; 
277 28235 6 1.19 
RecName: Full=60S ribosomal protein L8; 
257 30148 11 2.16 
RecName: Full=60S ribosomal protein L7a; 
228 31320 3 0.66 
RecName: Full=Complement component 1 Q subcomponent-binding protein, mitochondrial; AltName: 
Full=GC1q-R protein; AltName: Full=Glycoprotein gC1qBP; Short=C1qBP; Flags: Precursor; 
227 32566 3 0.63 
RecName: Full=Purine nucleoside phosphorylase; Short=PNP; EC=2.4.2.1; AltName: Full=Inosine phosphorylase; 
223 28834 8 1.98 
RecName: Full=40S ribosomal protein S6; 
214 30952 9 1.5 
RecName: Full=F-actin-capping protein subunit beta; AltName: Full=CapZ beta; 
214 33689 6 0.93 
RecName: Full=Cell division protein kinase 5; EC=2.7.11.22; AltName: Full=Cyclin-dependent kinase 5; AltName: 
Full=Serine/threonine-protein kinase PSSALRE; AltName: Full=Tau protein kinase II catalytic subunit; Short=TPKII 
catalytic subunit; 
213 26169 6 1.61 
RecName: Full=V-type proton ATPase subunit E 1; Short=V-ATPase subunit E 1; AltName: Full=Vacuolar proton 
pump subunit E 1; 
187 30154 10 2.5 
RecName: Full=40S ribosomal protein S3a; AltName: Full=V-fos transformation effector protein; Contains: 
RecName: Full=40S ribosomal protein S3b; 
186 30367 9 1.29 
RecName: Full=60S ribosomal protein L7; 
172 32269 7 1.19 
RecName: Full=Serine/threonine-protein phosphatase PGAM5, mitochondrial; EC=3.1.3.16; AltName: 
Full=Phosphoglycerate mutase family member 5; 
163 29217 8 1.37 
RecName: Full=Tropomyosin alpha-3 chain; AltName: Full=Gamma-tropomyosin; AltName: Full=Tropomyosin-3; 
AltName: Full=Tropomyosin-5; 
117 28549 3 0.39 
RecName: Full=Tropomyosin alpha-4 chain; AltName: Full=Tropomyosin-4; Short=TM-4; 
157 30229 5 0.87 
RecName: Full=ATP synthase subunit gamma, mitochondrial; AltName: Full=F-ATPase gamma subunit; 
151 33493 6 0.94 
RecName: Full=Pyridoxal phosphate phosphatase; Short=PLP phosphatase; EC=3.1.3.74; AltName: Full=Reg I-
binding protein 1; 
142 34393 3 0.32 
RecName: Full=Mitochondrial 2-oxoglutarate/malate carrier protein; Short=OGCP; AltName: Full=Solute carrier 
family 25 member 11; 
141 29859 5 0.7 
RecName: Full=Prohibitin; 
141 30523 4 0.68 
RecName: Full=Toll-interacting protein; 
140 33821 2 0.21 
RecName: Full=Four and a half LIM domains protein 1; Short=FHL-1; 
133 59291 3 0.18 
RecName: Full=Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform; EC=3.1.3.16; AltName: 
Full=CAM-PRP catalytic subunit; AltName: Full=Calmodulin-dependent calcineurin A subunit alpha isoform; 
130 27002 2 0.26 
RecName: Full=Estradiol 17-beta-dehydrogenase 8; EC=1.1.1.62; AltName: Full=17-beta-hydroxysteroid 
dehydrogenase 8; Short=17-beta-HSD 8; AltName: Full=3-oxoacyl-[acyl-carrier-protein] reductase; EC=1.1.1.-; 
AltName: Full=Testosterone 17-beta-dehydro 
124 33108 5 0.61 
RecName: Full=ADP/ATP translocase 2; AltName: Full=ADP,ATP carrier protein 2; AltName: Full=Adenine nucleotide 
translocator 2; Short=ANT 2; AltName: Full=Solute carrier family 25 member 5; 
121 33196 5 0.61 
RecName: Full=ADP/ATP translocase 1; AltName: Full=ADP,ATP carrier protein 1; AltName: Full=Adenine nucleotide 
translocator 1; Short=ANT 1; AltName: Full=Solute carrier family 25 member 4; 
119 31178 5 0.66 
RecName: Full=Voltage-dependent anion-selective channel protein 3; Short=VDAC-3; Short=rVDAC3; AltName: 
Full=Outer mitochondrial membrane protein porin 3; 
118 24475 4 0.67 
RecName: Full=40S ribosomal protein S8; 
110 29784 4 0.7 
RecName: Full=Proteasome subunit alpha type-1; EC=3.4.25.1; AltName: Full=Macropain subunit C2; AltName: 
Full=Multicatalytic endopeptidase complex subunit C2; AltName: Full=Proteasome component C2; AltName: 
Full=Proteasome nu chain; 
108 50225 4 0.29 
RecName: Full=Tubulin beta-2C chain; 
104 30011 3 0.37 
RecName: Full=N 
103 33942 1 0.1 
RecName: Full=Translation initiation factor eIF-2B subunit alpha; AltName: Full=eIF-2B GDP-GTP exchange factor 
subunit alpha; 
102 26560 3 0.43 
RecName: Full=RING finger protein 114; AltName: Full=Zinc finger protein 313; 
98 29628 4 0.53 
RecName: Full=Acidic leucine-rich nuclear phosphoprotein 32 family member E; 
92 31768 4 0.49 
RecName: Full=39S ribosomal protein L46, mitochondrial; Short=L46mt; Short=MRP-L46; Flags: Precursor; 
91 39876 3 0.27 
RecName: Full=Phosphate carrier protein, mitochondrial; AltName: Full=Phosphate transport protein; Short=PTP; 
AltName: Full=Solute carrier family 25 member 3; Flags: Precursor; 
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90 32781 2 0.21 
RecName: Full=Enoyl-CoA hydratase domain-containing protein 1; 
89 
27053
2 1 0.01 
RecName: Full=Microtubule-associated protein 1B; Short=MAP-1B; AltName: Full=Neuraxin; Contains: RecName: 
Full=MAP1 light chain LC1; 
88 34818 2 0.2 
RecName: Full=NAD-dependent deacetylase sirtuin-5; EC=3.5.1.-; Flags: Precursor; 
87 29053 2 0.24 
RecName: Full=Synaptosomal-associated protein 29; Short=SNAP-29; AltName: Full=Golgi SNARE of 32 kDa; 
Short=Gs32; AltName: Full=Soluble 29 kDa NSF attachment protein; AltName: Full=Vesicle-membrane fusion 
protein SNAP-29; 
83 61105 3 0.17 
RecName: Full=Calcium/calmodulin-dependent protein kinase type II subunit beta; Short=CaM kinase II subunit 
beta; Short=CaMK-II subunit beta; EC=2.7.11.17; 
82 40420 2 0.17 
RecName: Full=BAG family molecular chaperone regulator 1; Short=BAG-1; AltName: Full=Bcl-2-associated 
athanogene 1; 
82 37512 5 0.53 
RecName: Full=Heterogeneous nuclear ribonucleoproteins A2/B1; Short=hnRNP A2/B1; 
62 39856 2 0.17 
RecName: Full=Heterogeneous nuclear ribonucleoprotein A3; Short=hnRNP A3; 
79 21974 3 0.53 
RecName: Full=Histone H1.2; AltName: Full=H1d; 
79 18282 2 0.4 
RecName: Full=Ubiquitin-40S ribosomal protein S27a; AltName: Full=Ubiquitin carboxyl extension protein 80; 
Contains: RecName: Full=Ubiquitin; Contains: RecName: Full=40S ribosomal protein S27a; Flags: Precursor; 
76 34170 1 0.1 
RecName: Full=Cell division protein kinase 1; EC=2.7.11.22; EC=2.7.11.23; AltName: Full=Cell division control 
protein 2 homolog; AltName: Full=Cyclin-dependent kinase 1; Short=CDK1; AltName: Full=p34 protein kinase; 
73 23438 1 0.14 
RecName: Full=60S ribosomal protein L14; 
72 38576 3 0.28 
RecName: Full=D-beta-hydroxybutyrate dehydrogenase, mitochondrial; Short=BDH; EC=1.1.1.30; AltName: Full=3-
hydroxybutyrate dehydrogenase; Flags: Precursor; 
72 29807 4 0.7 
RecName: Full=40S ribosomal protein S4, X isoform; 
70 23565 2 0.3 
RecName: Full=60S ribosomal protein L19; 
69 30053 2 0.23 
RecName: Full=Tumor protein p63-regulated gene 1-like protein; AltName: Full=Mossy fiber terminal-associated 
vertebrate-specific presynaptic protein; 
67 30803 3 0.36 
RecName: Full=Integral membrane protein 2C; Contains: RecName: Full=CT-BRI3; 
66 29960 2 0.23 
RecName: Full=Transmembrane protein 111; 
66 31941 1 0.1 
RecName: Full=tRNA 
64 58576 3 0.18 
RecName: Full=T-complex protein 1 subunit delta; Short=TCP-1-delta; AltName: Full=CCT-delta; 
63 28932 4 0.55 
RecName: Full=Haloacid dehalogenase-like hydrolase domain-containing protein 2; 
63 20548 1 0.16 
RecName: Full=Uncharacterized protein C12orf68 homolog; 
60 38339 1 0.09 
RecName: Full=Heterogeneous nuclear ribonucleoprotein D0; Short=hnRNP D0; AltName: Full=AU-rich element 
RNA-binding protein 1; 
59 34990 3 0.31 
RecName: Full=Estradiol 17-beta-dehydrogenase 12; EC=1.1.1.62; AltName: Full=17-beta-hydroxysteroid 
dehydrogenase 12; Short=17-beta-HSD 12; AltName: Full=3-ketoacyl-CoA reductase; Short=KAR; EC=1.3.1.-; 
58 30834 1 0.11 
RecName: Full=Inositol monophosphatase 1; Short=IMP 1; Short=IMPase 1; EC=3.1.3.25; AltName: Full=Inositol-1 
57 42052 2 0.16 
RecName: Full=Actin, cytoplasmic 1; AltName: Full=Beta-actin; Contains: RecName: Full=Actin, cytoplasmic 1, N-
terminally processed; 
56 28629 1 0.12 
RecName: Full=Proteasome subunit alpha type-3; EC=3.4.25.1; AltName: Full=Macropain subunit C8; AltName: 
Full=Multicatalytic endopeptidase complex subunit C8; AltName: Full=Proteasome component C8; AltName: 
Full=Proteasome subunit K; 
52 25461 3 0.45 
RecName: Full=Serine/arginine-rich splicing factor 2; AltName: Full=Splicing component, 35 kDa; AltName: 
Full=Splicing factor SC35; Short=SC-35; AltName: Full=Splicing factor, arginine/serine-rich 2; 
51 21751 1 0.15 
RecName: Full=Small nuclear ribonucleoprotein-associated protein B; Short=snRNP-B; Short=snRPB; AltName: 
Full=SM11; AltName: Full=Sm protein B; Short=Sm-B; Short=SmB; Flags: Fragment; 
51 23647 1 0.14 
RecName: Full=SAP domain-containing ribonucleoprotein; AltName: Full=Nuclear protein Hcc-1; 
51 39153 3 0.28 
RecName: Full=Etoposide-induced protein 2.4 homolog; 
49 40819 1 0.08 
RecName: Full=Neuronal migration protein doublecortin; 
49 29722 1 0.11 
RecName: Full=Signal recognition particle receptor subunit beta; Short=SR-beta; 
48 
14146
3 1 0.02 
RecName: Full=CLIP-associating protein 2; AltName: Full=Cytoplasmic linker-associated protein 2; 
48 34243 3 0.32 
RecName: Full=Thioredoxin-related transmembrane protein 2; AltName: Full=Thioredoxin domain-containing 
protein 14; Flags: Precursor; 
47 29457 1 0.11 
RecName: Full=Phospholysine phosphohistidine inorganic pyrophosphate phosphatase; EC=3.1.3.-; EC=3.6.1.1; 
46 35705 1 0.09 
RecName: Full=Aminoacyl tRNA synthase complex-interacting multifunctional protein 2; AltName: 
Full=Multisynthase complex auxiliary component p38; AltName: Full=Protein JTV-1; 
45 28514 1 0.12 
RecName: Full=Protein YIF1B; AltName: Full=YIP1-interacting factor homolog B; 
45 64045 1 0.11 
RecName: Full=Protein LYRIC; AltName: Full=Lysine-rich CEACAM1 co-isolated protein; AltName: Full=Metadherin; 
AltName: Full=Metastasis adhesion protein; 
43 23575 2 0.3 
RecName: Full=60S ribosomal protein L13a; 
43 35779 1 0.09 
RecName: Full=Annexin A5; AltName: Full=Anchorin CII; AltName: Full=Annexin V; AltName: Full=Annexin-5; 
AltName: Full=Calphobindin I; Short=CBP-I; AltName: Full=Endonexin II; AltName: Full=Lipocortin V; AltName: 
Full=Placental anticoagulant protein 
43 50804 1 0.06 
RecName: Full=Tubulin alpha-1B chain; AltName: Full=Alpha-tubulin 2; AltName: Full=Tubulin alpha-2 chain; 
43 31213 1 0.11 
RecName: Full=Acidic leucine-rich nuclear phosphoprotein 32 family member B; AltName: Full=Proliferation-related 
acidic leucine-rich protein PAL31; 
42 
30083
1 1 0.01 
RecName: Full=Microtubule-associated protein 1A; Short=MAP-1A; Contains: RecName: Full=MAP1 light chain LC2; 
42 34156 1 0.1 
RecName: Full=Tricarboxylate transport protein, mitochondrial; AltName: Full=Citrate transport protein; Short=CTP; 
AltName: Full=Solute carrier family 25 member 1; AltName: Full=Tricarboxylate carrier protein; Flags: Precursor; 
42 25736 1 0.13 
RecName: Full=Platelet-activating factor acetylhydrolase IB subunit beta; EC=3.1.1.47; AltName: Full=PAF 
acetylhydrolase 30 kDa subunit; Short=PAF-AH 30 kDa subunit; AltName: Full=PAF-AH subunit beta; Short=PAFAH 
subunit beta; AltName: Full=Platelet 
41 
10489
1 1 0.03 
RecName: Full=AP-2 complex subunit alpha-2; AltName: Full=100 kDa coated vesicle protein C; AltName: 
Full=Adapter-related protein complex 2 alpha-2 subunit; AltName: Full=Adaptor protein complex AP-2 subunit 
alpha-2; AltName: Full=Alpha-adaptin C; A 
40 34372 1 0.1 
RecName: Full=NADH-cytochrome b5 reductase 1; Short=b5R.1; EC=1.6.2.2; 
40 30295 1 0.11 
RecName: Full=ZW10 interactor; AltName: Full=SNAP25-interacting protein 30; AltName: Full=Scoilin; AltName: 
Full=ZW10-interacting protein 1; Short=Zwint-1; 
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39 32251 1 0.1 
RecName: Full=Mortality factor 4-like protein 2; AltName: Full=Liver regeneration-related protein LRRG00119; 
AltName: Full=MORF-related gene X protein; AltName: Full=Transcription factor-like protein MRGX; 
39 30007 1 0.11 
RecName: Full=Proteasome inhibitor PI31 subunit; 
39 30844 1 0.11 
RecName: Full=Carbonyl reductase [NADPH] 1; EC=1.1.1.184; AltName: Full=15-hydroxyprostaglandin 
dehydrogenase [NADP+]; EC=1.1.1.197; AltName: Full=20-beta-hydroxysteroid dehydrogenase; AltName: 
Full=NADPH-dependent carbonyl reductase 1; AltName: Ful 
39 30307 1 0.11 
RecName: Full=ATP-binding domain-containing protein 4; 
38 28501 1 0.12 
RecName: Full=Adaptin ear-binding coat-associated protein 2; Short=NECAP-2; 
37 29089 1 0.11 
RecName: Full=Transmembrane protein 55A; EC=3.1.3.78; AltName: Full=PtdIns-4,5-P2 4-Ptase II; AltName: 
Full=Type II phosphatidylinositol 4,5-bisphosphate 4-phosphatase; 
37 83635 1 0.04 
RecName: Full=Zinc transporter ZIP6; AltName: Full=Solute carrier family 39 member 6; AltName: Full=Zrt- and Irt-
like protein 6; Short=ZIP-6; Flags: Precursor; 
37 26938 1 0.12 
RecName: Full=Survival of motor neuron-related-splicing factor 30; AltName: Full=Survival motor neuron domain-
containing protein 1; 
37 22885 1 0.15 
RecName: Full=DnaJ homolog subfamily C member 5; AltName: Full=Cysteine string protein; Short=CSP; 
37 28730 2 0.25 
RecName: Full=Proteasome activator complex subunit 1; AltName: Full=11S regulator complex subunit alpha; 
Short=REG-alpha; AltName: Full=Activator of multicatalytic protease subunit 1; AltName: Full=Proteasome activator 
28 subunit alpha; Short=PA28a; 
36 34544 1 0.1 
RecName: Full=Hydroxyacylglutathione hydrolase, mitochondrial; EC=3.1.2.6; AltName: Full=Glyoxalase II; 
Short=Glx II; AltName: Full=Round spermatid protein RSP29; Flags: Precursor; 
36 33743 1 0.1 
RecName: Full=Armadillo repeat-containing protein 10; 
35 27569 1 0.12 
RecName: Full=RNA-binding protein PNO1; 
35 30221 1 0.11 
RecName: Full=Peflin; AltName: Full=PEF protein with a long N-terminal hydrophobic domain; AltName: Full=Penta-
EF hand domain-containing protein 1; 
34 26025 1 0.13 
RecName: Full=RING finger protein 141; 
33 
12676
6 1 0.03 
RecName: Full=Reticulon-4; AltName: Full=Foocen; AltName: Full=Glut4 vesicle 20 kDa protein; AltName: 
Full=Neurite outgrowth inhibitor; Short=Nogo protein; 
31 65756 1 0.05 
RecName: Full=Putative phospholipase B-like 2; EC=3.1.1.-; AltName: Full=LAMA-like protein 2; AltName: 
Full=Lamina ancestor homolog 2; AltName: Full=Phospholipase B domain-containing protein 2; Flags: Precursor; 
31 32413 3 0.34 
RecName: Full=Protein rogdi homolog; 
30 34484 3 0.32 
RecName: Full=Actin-related protein 2/3 complex subunit 2; AltName: Full=Arp2/3 complex 34 kDa subunit; 
Short=p34-ARC; 
30 35511 2 0.2 
RecName: Full=Guanine nucleotide-binding protein subunit beta-2-like 1; AltName: Full=Receptor for activated C 
kinase; AltName: Full=Receptor of activated protein kinase C 1; Short=RACK1; 
30 36210 1 0.09 
RecName: Full=NADH-ubiquinone oxidoreductase chain 1; EC=1.6.5.3; AltName: Full=NADH dehydrogenase subunit 
1; 
29 24617 1 0.14 
RecName: Full=Charged multivesicular body protein 5; AltName: Full=Chromatin-modifying protein 5; 
29 27870 1 0.12 
RecName: Full=OCIA domain-containing protein 1; 
28 72506 1 0.05 
RecName: Full=Beta-galactosidase-1-like protein 3; EC=3.2.1.-; 
28 24758 1 0.14 
RecName: Full=Zinc finger CCHC-type and RNA-binding motif-containing protein 1; AltName: Full=U11/U12 small 
nuclear ribonucleoprotein 31 kDa protein; Short=U11/U12 snRNP 31 kDa protein; 
28 25422 1 0.13 
RecName: Full=Transmembrane emp24 domain-containing protein 1; AltName: Full=Interleukin-1 receptor-like 1 
ligand; Flags: Precursor; 
27 26627 1 0.13 
RecName: Full=Anionic trypsin-1; EC=3.4.21.4; AltName: Full=Anionic trypsin I; AltName: Full=Pretrypsinogen I; 
AltName: Full=Serine protease 1; Flags: Precursor; 
27 
53774
0 1 0.01 
RecName: Full=Apolipoprotein B-100; Short=Apo B-100; Contains: RecName: Full=Apolipoprotein B-48; Short=Apo 
B-48; Flags: Precursor; 
27 38367 1 0.09 
RecName: Full=Magnesium transporter protein 1; Short=MagT1; AltName: Full=Implantation-associated protein; 
Short=IAP; Flags: Precursor; 
26 29499 3 0.38 
RecName: Full=Replication protein A 32 kDa subunit; Short=RP-A p32; AltName: Full=Replication factor A protein 2; 
Short=RF-A protein 2; 
25 28051 2 0.25 
RecName: Full=Vesicle-associated membrane protein-associated protein A; Short=VAMP-A; Short=VAMP-
associated protein A; Short=VAP-A; AltName: Full=33 kDa VAMP-associated protein; Short=VAP-33; 
25 38474 1 0.09 
RecName: Full=DNA polymerase beta; EC=2.7.7.7; EC=4.2.99.-; 
25 24920 1 0.13 
RecName: Full=LysM and putative peptidoglycan-binding domain-containing protein 1; 
25 26186 1 0.13 
RecName: Full=Complement C1q subcomponent subunit A; Flags: Precursor; 
25 14097 1 0.24 
RecName: Full=Histone H2A type 1-C; 
25 47380 1 0.07 
RecName: Full=Choline/ethanolaminephosphotransferase 1; EC=2.7.8.1; EC=2.7.8.2; 
24 27936 1 0.12 
RecName: Full=Glutathione S-transferase omega-1; Short=GSTO-1; EC=2.5.1.18; AltName: Full=Glutathione-
dependent dehydroascorbate reductase; 
23 33316 1 0.1 
RecName: Full=Estradiol 17-beta-dehydrogenase 11; EC=1.1.1.-; AltName: Full=17-beta-hydroxysteroid 
dehydrogenase 11; Short=17-beta-HSD 11; Short=17bHSD11; Short=17betaHSD11; AltName: Full=17-beta-
hydroxysteroid dehydrogenase XI; Short=17-beta-HSD XI 
23 51937 1 0.13 
RecName: Full=NADH-ubiquinone oxidoreductase chain 4; EC=1.6.5.3; AltName: Full=NADH dehydrogenase subunit 
4; 
23 30575 1 0.11 
RecName: Full=Transmembrane protein 192; 
22 46043 1 0.07 
RecName: Full=Heterogeneous nuclear ribonucleoprotein F; Short=hnRNP F; Contains: RecName: 
Full=Heterogeneous nuclear ribonucleoprotein F, N-terminally processed; 
21 24351 1 0.14 
RecName: Full=60S ribosomal protein L13; 
20 0 1 0.06 
RecName: Full=F-box/LRR-repeat protein 16; AltName: Full=F-box and leucine-rich repeat protein 16; AltName: 
Full=Spinal cord injury and regeneration-related protein 1; 
20 46952 1 0.07 
RecName: Full=Blood group Rh 
19 22113 1 0.15 
RecName: Full=40S ribosomal protein S7; AltName: Full=S8; 
18 
20274
4 1 0.02 
RecName: Full=Microtubule-associated protein 2; Short=MAP-2; 
18 17372 1 0.19 
RecName: Full=60S ribosomal protein L29; AltName: Full=P23; 
18 15964 1 0.21 
RecName: Full=60S ribosomal protein L32; 
18 22635 1 0.15 
RecName: Full=40S ribosomal protein S9; 
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16 73987 1 0.04 
RecName: Full=Sodium/glucose cotransporter 1; Short=Na 
14 34006 1 0.1 
RecName: Full=Cell division protein kinase 4; EC=2.7.11.22; AltName: Full=Cyclin-dependent kinase 4; AltName: 
Full=PSK-J3; 
14 23765 1 0.14 
RecName: Full=ATP synthase subunit s, mitochondrial; AltName: Full=ATP synthase-coupling factor B; AltName: 
Full=Mitochondrial ATP synthase regulatory component factor B; Flags: Precursor; 
1012 29326 24 47.08 
RecName: Full=14-3-3 protein epsilon; Short=14-3-3E; AltName: Full=Mitochondrial import stimulation factor L 
subunit; Short=MSF L; 
162 28456 6 0.94 
RecName: Full=14-3-3 protein gamma; Contains: RecName: Full=14-3-3 protein gamma, N-terminally processed; 
124 27925 3 0.4 
RecName: Full=14-3-3 protein zeta/delta; AltName: Full=Mitochondrial import stimulation factor S1 subunit; 
AltName: Full=Protein kinase C inhibitor protein 1; Short=KCIP-1; 
89 28365 3 0.39 
RecName: Full=14-3-3 protein eta; 
514 26828 15 10.68 
RecName: Full=40S ribosomal protein S3; 
443 28718 13 4.18 
RecName: Full=Acidic leucine-rich nuclear phosphoprotein 32 family member A; AltName: Full=Leucine-rich acidic 
nuclear protein; Short=LANP; 
372 31497 9 2.68 
RecName: Full=40S ribosomal protein S2; 
311 30156 5 1.08 
RecName: Full=Microtubule-associated protein RP/EB family member 1; AltName: Full=APC-binding protein EB1; 
AltName: Full=End-binding protein 1; Short=EB1; 
82 32231 3 0.34 
RecName: Full=Microtubule-associated protein RP/EB family member 3; AltName: Full=EB1 protein family member 
3; Short=EBF3; AltName: Full=End-binding protein 3; Short=EB3; AltName: Full=RP3; 
277 28235 6 1.19 
RecName: Full=60S ribosomal protein L8; 
257 30148 11 2.16 
RecName: Full=60S ribosomal protein L7a; 
228 31320 3 0.66 
RecName: Full=Complement component 1 Q subcomponent-binding protein, mitochondrial; AltName: Full=GC1q-R 
protein; AltName: Full=Glycoprotein gC1qBP; Short=C1qBP; Flags: Precursor; 
227 32566 3 0.63 
RecName: Full=Purine nucleoside phosphorylase; Short=PNP; EC=2.4.2.1; AltName: Full=Inosine phosphorylase; 
223 28834 8 1.98 
RecName: Full=40S ribosomal protein S6; 
214 30952 9 1.5 
RecName: Full=F-actin-capping protein subunit beta; AltName: Full=CapZ beta; 
214 33689 6 0.93 
RecName: Full=Cell division protein kinase 5; EC=2.7.11.22; AltName: Full=Cyclin-dependent kinase 5; AltName: 
Full=Serine/threonine-protein kinase PSSALRE; AltName: Full=Tau protein kinase II catalytic subunit; Short=TPKII 
catalytic subunit; 
213 26169 6 1.61 
RecName: Full=V-type proton ATPase subunit E 1; Short=V-ATPase subunit E 1; AltName: Full=Vacuolar proton 
pump subunit E 1; 
187 30154 10 2.5 
RecName: Full=40S ribosomal protein S3a; AltName: Full=V-fos transformation effector protein; Contains: 
RecName: Full=40S ribosomal protein S3b; 
186 30367 9 1.29 
RecName: Full=60S ribosomal protein L7; 
172 32269 7 1.19 
RecName: Full=Serine/threonine-protein phosphatase PGAM5, mitochondrial; EC=3.1.3.16; AltName: 
Full=Phosphoglycerate mutase family member 5; 
163 29217 8 1.37 
RecName: Full=Tropomyosin alpha-3 chain; AltName: Full=Gamma-tropomyosin; AltName: Full=Tropomyosin-3; 
AltName: Full=Tropomyosin-5; 
117 28549 3 0.39 
RecName: Full=Tropomyosin alpha-4 chain; AltName: Full=Tropomyosin-4; Short=TM-4; 
157 30229 5 0.87 
RecName: Full=ATP synthase subunit gamma, mitochondrial; AltName: Full=F-ATPase gamma subunit; 
151 33493 6 0.94 
RecName: Full=Pyridoxal phosphate phosphatase; Short=PLP phosphatase; EC=3.1.3.74; AltName: Full=Reg I-
binding protein 1; 
142 34393 3 0.32 
RecName: Full=Mitochondrial 2-oxoglutarate/malate carrier protein; Short=OGCP; AltName: Full=Solute carrier 
family 25 member 11; 
141 29859 5 0.7 
RecName: Full=Prohibitin; 
141 30523 4 0.68 
RecName: Full=Toll-interacting protein; 
140 33821 2 0.21 
RecName: Full=Four and a half LIM domains protein 1; Short=FHL-1; 
133 59291 3 0.18 
RecName: Full=Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform; EC=3.1.3.16; AltName: 
Full=CAM-PRP catalytic subunit; AltName: Full=Calmodulin-dependent calcineurin A subunit alpha isoform; 
130 27002 2 0.26 
RecName: Full=Estradiol 17-beta-dehydrogenase 8; EC=1.1.1.62; AltName: Full=17-beta-hydroxysteroid 
dehydrogenase 8; Short=17-beta-HSD 8; AltName: Full=3-oxoacyl-[acyl-carrier-protein] reductase; EC=1.1.1.-; 
AltName: Full=Testosterone 17-beta-dehydro 
124 33108 5 0.61 
RecName: Full=ADP/ATP translocase 2; AltName: Full=ADP,ATP carrier protein 2; AltName: Full=Adenine nucleotide 
translocator 2; Short=ANT 2; AltName: Full=Solute carrier family 25 member 5; 
121 33196 5 0.61 
RecName: Full=ADP/ATP translocase 1; AltName: Full=ADP,ATP carrier protein 1; AltName: Full=Adenine nucleotide 
translocator 1; Short=ANT 1; AltName: Full=Solute carrier family 25 member 4; 
119 31178 5 0.66 
RecName: Full=Voltage-dependent anion-selective channel protein 3; Short=VDAC-3; Short=rVDAC3; AltName: 
Full=Outer mitochondrial membrane protein porin 3; 
118 24475 4 0.67 
RecName: Full=40S ribosomal protein S8; 
110 29784 4 0.7 
RecName: Full=Proteasome subunit alpha type-1; EC=3.4.25.1; AltName: Full=Macropain subunit C2; AltName: 
Full=Multicatalytic endopeptidase complex subunit C2; AltName: Full=Proteasome component C2; AltName: 
Full=Proteasome nu chain; 
108 50225 4 0.29 
RecName: Full=Tubulin beta-2C chain; 
104 30011 3 0.37 
RecName: Full=N 
103 33942 1 0.1 
RecName: Full=Translation initiation factor eIF-2B subunit alpha; AltName: Full=eIF-2B GDP-GTP exchange factor 
subunit alpha; 
102 26560 3 0.43 
RecName: Full=RING finger protein 114; AltName: Full=Zinc finger protein 313; 
98 29628 4 0.53 
RecName: Full=Acidic leucine-rich nuclear phosphoprotein 32 family member E; 
92 31768 4 0.49 
RecName: Full=39S ribosomal protein L46, mitochondrial; Short=L46mt; Short=MRP-L46; Flags: Precursor; 
91 39876 3 0.27 
RecName: Full=Phosphate carrier protein, mitochondrial; AltName: Full=Phosphate transport protein; Short=PTP; 
AltName: Full=Solute carrier family 25 member 3; Flags: Precursor; 
90 32781 2 0.21 
RecName: Full=Enoyl-CoA hydratase domain-containing protein 1; 
89 
27053
2 1 0.01 
RecName: Full=Microtubule-associated protein 1B; Short=MAP-1B; AltName: Full=Neuraxin; Contains: RecName: 
Full=MAP1 light chain LC1; 
88 34818 2 0.2 
RecName: Full=NAD-dependent deacetylase sirtuin-5; EC=3.5.1.-; Flags: Precursor; 
87 29053 2 0.24 
RecName: Full=Synaptosomal-associated protein 29; Short=SNAP-29; AltName: Full=Golgi SNARE of 32 kDa; 
Short=Gs32; AltName: Full=Soluble 29 kDa NSF attachment protein; AltName: Full=Vesicle-membrane fusion 
protein SNAP-29; 
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83 61105 3 0.17 
RecName: Full=Calcium/calmodulin-dependent protein kinase type II subunit beta; Short=CaM kinase II subunit 
beta; Short=CaMK-II subunit beta; EC=2.7.11.17; 
82 40420 2 0.17 
RecName: Full=BAG family molecular chaperone regulator 1; Short=BAG-1; AltName: Full=Bcl-2-associated 
athanogene 1; 
82 37512 5 0.53 
RecName: Full=Heterogeneous nuclear ribonucleoproteins A2/B1; Short=hnRNP A2/B1; 
62 39856 2 0.17 
RecName: Full=Heterogeneous nuclear ribonucleoprotein A3; Short=hnRNP A3; 
79 21974 3 0.53 
RecName: Full=Histone H1.2; AltName: Full=H1d; 
79 18282 2 0.4 
RecName: Full=Ubiquitin-40S ribosomal protein S27a; AltName: Full=Ubiquitin carboxyl extension protein 80; 
Contains: RecName: Full=Ubiquitin; Contains: RecName: Full=40S ribosomal protein S27a; Flags: Precursor; 
76 34170 1 0.1 
RecName: Full=Cell division protein kinase 1; EC=2.7.11.22; EC=2.7.11.23; AltName: Full=Cell division control 
protein 2 homolog; AltName: Full=Cyclin-dependent kinase 1; Short=CDK1; AltName: Full=p34 protein kinase; 
73 23438 1 0.14 
RecName: Full=60S ribosomal protein L14; 
72 38576 3 0.28 
RecName: Full=D-beta-hydroxybutyrate dehydrogenase, mitochondrial; Short=BDH; EC=1.1.1.30; AltName: Full=3-
hydroxybutyrate dehydrogenase; Flags: Precursor; 
72 29807 4 0.7 
RecName: Full=40S ribosomal protein S4, X isoform; 
70 23565 2 0.3 
RecName: Full=60S ribosomal protein L19; 
69 30053 2 0.23 
RecName: Full=Tumor protein p63-regulated gene 1-like protein; AltName: Full=Mossy fiber terminal-associated 
vertebrate-specific presynaptic protein; 
67 30803 3 0.36 
RecName: Full=Integral membrane protein 2C; Contains: RecName: Full=CT-BRI3; 
66 29960 2 0.23 
RecName: Full=Transmembrane protein 111; 
66 31941 1 0.1 
RecName: Full=tRNA 
64 58576 3 0.18 
RecName: Full=T-complex protein 1 subunit delta; Short=TCP-1-delta; AltName: Full=CCT-delta; 
63 28932 4 0.55 
RecName: Full=Haloacid dehalogenase-like hydrolase domain-containing protein 2; 
63 20548 1 0.16 
RecName: Full=Uncharacterized protein C12orf68 homolog; 
60 38339 1 0.09 
RecName: Full=Heterogeneous nuclear ribonucleoprotein D0; Short=hnRNP D0; AltName: Full=AU-rich element 
RNA-binding protein 1; 
59 34990 3 0.31 
RecName: Full=Estradiol 17-beta-dehydrogenase 12; EC=1.1.1.62; AltName: Full=17-beta-hydroxysteroid 
dehydrogenase 12; Short=17-beta-HSD 12; AltName: Full=3-ketoacyl-CoA reductase; Short=KAR; EC=1.3.1.-; 
58 30834 1 0.11 
RecName: Full=Inositol monophosphatase 1; Short=IMP 1; Short=IMPase 1; EC=3.1.3.25; AltName: Full=Inositol-1 
57 42052 2 0.16 
RecName: Full=Actin, cytoplasmic 1; AltName: Full=Beta-actin; Contains: RecName: Full=Actin, cytoplasmic 1, N-
terminally processed; 
56 28629 1 0.12 
RecName: Full=Proteasome subunit alpha type-3; EC=3.4.25.1; AltName: Full=Macropain subunit C8; AltName: 
Full=Multicatalytic endopeptidase complex subunit C8; AltName: Full=Proteasome component C8; AltName: 
Full=Proteasome subunit K; 
52 25461 3 0.45 
RecName: Full=Serine/arginine-rich splicing factor 2; AltName: Full=Splicing component, 35 kDa; AltName: 
Full=Splicing factor SC35; Short=SC-35; AltName: Full=Splicing factor, arginine/serine-rich 2; 
51 21751 1 0.15 
RecName: Full=Small nuclear ribonucleoprotein-associated protein B; Short=snRNP-B; Short=snRPB; AltName: 
Full=SM11; AltName: Full=Sm protein B; Short=Sm-B; Short=SmB; Flags: Fragment; 
51 23647 1 0.14 
RecName: Full=SAP domain-containing ribonucleoprotein; AltName: Full=Nuclear protein Hcc-1; 
51 39153 3 0.28 
RecName: Full=Etoposide-induced protein 2.4 homolog; 
49 40819 1 0.08 
RecName: Full=Neuronal migration protein doublecortin; 
49 29722 1 0.11 
RecName: Full=Signal recognition particle receptor subunit beta; Short=SR-beta; 
48 
14146
3 1 0.02 
RecName: Full=CLIP-associating protein 2; AltName: Full=Cytoplasmic linker-associated protein 2; 
48 34243 3 0.32 
RecName: Full=Thioredoxin-related transmembrane protein 2; AltName: Full=Thioredoxin domain-containing 
protein 14; Flags: Precursor; 
47 29457 1 0.11 
RecName: Full=Phospholysine phosphohistidine inorganic pyrophosphate phosphatase; EC=3.1.3.-; EC=3.6.1.1; 
46 35705 1 0.09 
RecName: Full=Aminoacyl tRNA synthase complex-interacting multifunctional protein 2; AltName: 
Full=Multisynthase complex auxiliary component p38; AltName: Full=Protein JTV-1; 
45 28514 1 0.12 
RecName: Full=Protein YIF1B; AltName: Full=YIP1-interacting factor homolog B; 
45 64045 1 0.11 
RecName: Full=Protein LYRIC; AltName: Full=Lysine-rich CEACAM1 co-isolated protein; AltName: Full=Metadherin; 
AltName: Full=Metastasis adhesion protein; 
43 23575 2 0.3 
RecName: Full=60S ribosomal protein L13a; 
43 35779 1 0.09 
RecName: Full=Annexin A5; AltName: Full=Anchorin CII; AltName: Full=Annexin V; AltName: Full=Annexin-5; 
AltName: Full=Calphobindin I; Short=CBP-I; AltName: Full=Endonexin II; AltName: Full=Lipocortin V; AltName: 
Full=Placental anticoagulant protein 
43 50804 1 0.06 
RecName: Full=Tubulin alpha-1B chain; AltName: Full=Alpha-tubulin 2; AltName: Full=Tubulin alpha-2 chain; 
43 31213 1 0.11 
RecName: Full=Acidic leucine-rich nuclear phosphoprotein 32 family member B; AltName: Full=Proliferation-related 
acidic leucine-rich protein PAL31; 
42 
30083
1 1 0.01 
RecName: Full=Microtubule-associated protein 1A; Short=MAP-1A; Contains: RecName: Full=MAP1 light chain LC2; 
42 34156 1 0.1 
RecName: Full=Tricarboxylate transport protein, mitochondrial; AltName: Full=Citrate transport protein; Short=CTP; 
AltName: Full=Solute carrier family 25 member 1; AltName: Full=Tricarboxylate carrier protein; Flags: Precursor; 
42 25736 1 0.13 
RecName: Full=Platelet-activating factor acetylhydrolase IB subunit beta; EC=3.1.1.47; AltName: Full=PAF 
acetylhydrolase 30 kDa subunit; Short=PAF-AH 30 kDa subunit; AltName: Full=PAF-AH subunit beta; Short=PAFAH 
subunit beta; AltName: Full=Platelet 
41 
10489
1 1 0.03 
RecName: Full=AP-2 complex subunit alpha-2; AltName: Full=100 kDa coated vesicle protein C; AltName: 
Full=Adapter-related protein complex 2 alpha-2 subunit; AltName: Full=Adaptor protein complex AP-2 subunit 
alpha-2; AltName: Full=Alpha-adaptin C; A 
40 34372 1 0.1 
RecName: Full=NADH-cytochrome b5 reductase 1; Short=b5R.1; EC=1.6.2.2; 
40 30295 1 0.11 
RecName: Full=ZW10 interactor; AltName: Full=SNAP25-interacting protein 30; AltName: Full=Scoilin; AltName: 
Full=ZW10-interacting protein 1; Short=Zwint-1; 
39 32251 1 0.1 
RecName: Full=Mortality factor 4-like protein 2; AltName: Full=Liver regeneration-related protein LRRG00119; 
AltName: Full=MORF-related gene X protein; AltName: Full=Transcription factor-like protein MRGX; 
39 30007 1 0.11 
RecName: Full=Proteasome inhibitor PI31 subunit; 
39 30844 1 0.11 
RecName: Full=Carbonyl reductase [NADPH] 1; EC=1.1.1.184; AltName: Full=15-hydroxyprostaglandin 
dehydrogenase [NADP+]; EC=1.1.1.197; AltName: Full=20-beta-hydroxysteroid dehydrogenase; AltName: 
Full=NADPH-dependent carbonyl reductase 1; AltName: Ful 
39 30307 1 0.11 
RecName: Full=ATP-binding domain-containing protein 4; 
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38 28501 1 0.12 
RecName: Full=Adaptin ear-binding coat-associated protein 2; Short=NECAP-2; 
37 29089 1 0.11 
RecName: Full=Transmembrane protein 55A; EC=3.1.3.78; AltName: Full=PtdIns-4,5-P2 4-Ptase II; AltName: 
Full=Type II phosphatidylinositol 4,5-bisphosphate 4-phosphatase; 
37 83635 1 0.04 
RecName: Full=Zinc transporter ZIP6; AltName: Full=Solute carrier family 39 member 6; AltName: Full=Zrt- and Irt-
like protein 6; Short=ZIP-6; Flags: Precursor; 
37 26938 1 0.12 
RecName: Full=Survival of motor neuron-related-splicing factor 30; AltName: Full=Survival motor neuron domain-
containing protein 1; 
37 22885 1 0.15 
RecName: Full=DnaJ homolog subfamily C member 5; AltName: Full=Cysteine string protein; Short=CSP; 
37 28730 2 0.25 
RecName: Full=Proteasome activator complex subunit 1; AltName: Full=11S regulator complex subunit alpha; 
Short=REG-alpha; AltName: Full=Activator of multicatalytic protease subunit 1; AltName: Full=Proteasome activator 
28 subunit alpha; Short=PA28a; 
36 34544 1 0.1 
RecName: Full=Hydroxyacylglutathione hydrolase, mitochondrial; EC=3.1.2.6; AltName: Full=Glyoxalase II; 
Short=Glx II; AltName: Full=Round spermatid protein RSP29; Flags: Precursor; 
36 33743 1 0.1 
RecName: Full=Armadillo repeat-containing protein 10; 
35 27569 1 0.12 
RecName: Full=RNA-binding protein PNO1; 
35 30221 1 0.11 
RecName: Full=Peflin; AltName: Full=PEF protein with a long N-terminal hydrophobic domain; AltName: Full=Penta-
EF hand domain-containing protein 1; 
34 26025 1 0.13 
RecName: Full=RING finger protein 141; 
33 
12676
6 1 0.03 
RecName: Full=Reticulon-4; AltName: Full=Foocen; AltName: Full=Glut4 vesicle 20 kDa protein; AltName: 
Full=Neurite outgrowth inhibitor; Short=Nogo protein; 
31 65756 1 0.05 
RecName: Full=Putative phospholipase B-like 2; EC=3.1.1.-; AltName: Full=LAMA-like protein 2; AltName: 
Full=Lamina ancestor homolog 2; AltName: Full=Phospholipase B domain-containing protein 2; Flags: Precursor; 
31 32413 3 0.34 
RecName: Full=Protein rogdi homolog; 
30 34484 3 0.32 
RecName: Full=Actin-related protein 2/3 complex subunit 2; AltName: Full=Arp2/3 complex 34 kDa subunit; 
Short=p34-ARC; 
30 35511 2 0.2 
RecName: Full=Guanine nucleotide-binding protein subunit beta-2-like 1; AltName: Full=Receptor for activated C 
kinase; AltName: Full=Receptor of activated protein kinase C 1; Short=RACK1; 
30 36210 1 0.09 
RecName: Full=NADH-ubiquinone oxidoreductase chain 1; EC=1.6.5.3; AltName: Full=NADH dehydrogenase subunit 
1; 
29 24617 1 0.14 
RecName: Full=Charged multivesicular body protein 5; AltName: Full=Chromatin-modifying protein 5; 
29 27870 1 0.12 
RecName: Full=OCIA domain-containing protein 1; 
28 72506 1 0.05 
RecName: Full=Beta-galactosidase-1-like protein 3; EC=3.2.1.-; 
28 24758 1 0.14 
RecName: Full=Zinc finger CCHC-type and RNA-binding motif-containing protein 1; AltName: Full=U11/U12 small 
nuclear ribonucleoprotein 31 kDa protein; Short=U11/U12 snRNP 31 kDa protein; 
28 25422 1 0.13 
RecName: Full=Transmembrane emp24 domain-containing protein 1; AltName: Full=Interleukin-1 receptor-like 1 
ligand; Flags: Precursor; 
27 26627 1 0.13 
RecName: Full=Anionic trypsin-1; EC=3.4.21.4; AltName: Full=Anionic trypsin I; AltName: Full=Pretrypsinogen I; 
AltName: Full=Serine protease 1; Flags: Precursor; 
27 
53774
0 1 0.01 
RecName: Full=Apolipoprotein B-100; Short=Apo B-100; Contains: RecName: Full=Apolipoprotein B-48; Short=Apo 
B-48; Flags: Precursor; 
27 38367 1 0.09 
RecName: Full=Magnesium transporter protein 1; Short=MagT1; AltName: Full=Implantation-associated protein; 
Short=IAP; Flags: Precursor; 
26 29499 3 0.38 
RecName: Full=Replication protein A 32 kDa subunit; Short=RP-A p32; AltName: Full=Replication factor A protein 2; 
Short=RF-A protein 2; 
25 28051 2 0.25 
RecName: Full=Vesicle-associated membrane protein-associated protein A; Short=VAMP-A; Short=VAMP-
associated protein A; Short=VAP-A; AltName: Full=33 kDa VAMP-associated protein; Short=VAP-33; 
25 38474 1 0.09 
RecName: Full=DNA polymerase beta; EC=2.7.7.7; EC=4.2.99.-; 
25 24920 1 0.13 
RecName: Full=LysM and putative peptidoglycan-binding domain-containing protein 1; 
25 26186 1 0.13 
RecName: Full=Complement C1q subcomponent subunit A; Flags: Precursor; 
25 14097 1 0.24 
RecName: Full=Histone H2A type 1-C; 
25 47380 1 0.07 
RecName: Full=Choline/ethanolaminephosphotransferase 1; EC=2.7.8.1; EC=2.7.8.2; 
24 27936 1 0.12 
RecName: Full=Glutathione S-transferase omega-1; Short=GSTO-1; EC=2.5.1.18; AltName: Full=Glutathione-
dependent dehydroascorbate reductase; 
23 33316 1 0.1 
RecName: Full=Estradiol 17-beta-dehydrogenase 11; EC=1.1.1.-; AltName: Full=17-beta-hydroxysteroid 
dehydrogenase 11; Short=17-beta-HSD 11; Short=17bHSD11; Short=17betaHSD11; AltName: Full=17-beta-
hydroxysteroid dehydrogenase XI; Short=17-beta-HSD XI 
23 51937 1 0.13 
RecName: Full=NADH-ubiquinone oxidoreductase chain 4; EC=1.6.5.3; AltName: Full=NADH dehydrogenase subunit 
4; 
23 30575 1 0.11 
RecName: Full=Transmembrane protein 192; 
22 46043 1 0.07 
RecName: Full=Heterogeneous nuclear ribonucleoprotein F; Short=hnRNP F; Contains: RecName: 
Full=Heterogeneous nuclear ribonucleoprotein F, N-terminally processed; 
21 24351 1 0.14 
RecName: Full=60S ribosomal protein L13; 
20 0 1 0.06 
RecName: Full=F-box/LRR-repeat protein 16; AltName: Full=F-box and leucine-rich repeat protein 16; AltName: 
Full=Spinal cord injury and regeneration-related protein 1; 
20 46952 1 0.07 
RecName: Full=Blood group Rh 
19 22113 1 0.15 
RecName: Full=40S ribosomal protein S7; AltName: Full=S8; 
18 
20274
4 1 0.02 
RecName: Full=Microtubule-associated protein 2; Short=MAP-2; 
18 17372 1 0.19 
RecName: Full=60S ribosomal protein L29; AltName: Full=P23; 
18 15964 1 0.21 
RecName: Full=60S ribosomal protein L32; 
18 22635 1 0.15 
RecName: Full=40S ribosomal protein S9; 
16 73987 1 0.04 
RecName: Full=Sodium/glucose cotransporter 1; Short=Na 
14 34006 1 0.1 
RecName: Full=Cell division protein kinase 4; EC=2.7.11.22; AltName: Full=Cyclin-dependent kinase 4; AltName: 
Full=PSK-J3; 
14 23765 1 0.14 
RecName: Full=ATP synthase subunit s, mitochondrial; AltName: Full=ATP synthase-coupling factor B; AltName: 
Full=Mitochondrial A 
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A2. Full list of genes included in the Rat Inflammatory Cytokines and Receptors PCR Array 
(SABiosciences; # PARN-011C). Housekeeping genes are indicated in red (wells H1-H5).  
 
 
 
 
Position Symbol Description Gene Name 
A01 Abcf1 ATP-binding cassette, sub-family F (GCN20), member 1 Abc50 
A02 Bcl6 B-cell CLL/lymphoma 6 - 
A03 Cxcr5 Chemokine (C-X-C motif) receptor 5 Blr1, NLR 
A04 C3 Complement component 3 - 
A05 RGD1561905_predicted Complement component 5 C5a, Hc, RGD1561905 
A06 Casp1 Caspase 1 Ice, Il1bc 
A07 Ccl11 Chemokine (C-C motif) ligand 11 Scya11 
A08 Ccl12 Chemokine (C-C motif) ligand 12 - 
A09 Ccl17 Chemokine (C-C motif) ligand 17 Scya17, Tarc 
A10 Ccl19 Chemokine (C-C motif) ligand 19 - 
A11 Ccl2 Chemokine (C-C motif) ligand 2 MCP-1, Scya2, Sigje 
A12 Ccl20 Chemokine (C-C motif) ligand 20 ST38, Scya20 
B01 Ccl21b Chemokine (C-C motif) ligand 21b (serine) MGC105669 
B02 Ccl22 Chemokine (C-C motif) ligand 22 MGC108943, Mdc, Scya22 
B03 Ccl24 Chemokine (C-C motif) ligand 24 - 
B04 Ccl25 Chemokine (C-C motif) ligand 25 MGC125074 
B05 Ccl3 Chemokine (C-C motif) ligand 3 MIP-1a, Scya3 
B06 Ccl4 Chemokine (C-C motif) ligand 4 Mip1-b, Scya4 
B07 Ccl5 Chemokine (C-C motif) ligand 5 Rantes, Scya5 
B08 Ccl6 Chemokine (C-C motif) ligand 6 Mrp-1, Scay6 
B09 Ccl7 Chemokine (C-C motif) ligand 7 - 
B10 Ccl9 Chemokine (C-C motif) ligand 9 MGC108969 
B11 Ccr1 Chemokine (C-C motif) receptor 1 - 
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B12 Ccr2 Chemokine (C-C motif) receptor 2 - 
C01 Ccr3 Chemokine (C-C motif) receptor 3 Cmkbr3 
C02 Ccr4 Chemokine (C-C motif) receptor 4 Cmkbr4 
C03 Ccr5 Chemokine (C-C motif) receptor 5 Ckr5, Cmkbr5 
C04 Ccr6 Chemokine (C-C motif) receptor 6 MGC108876 
C05 Ccr7 Chemokine (C-C motif) receptor 7 MGC108519 
C06 Ccr8 Chemokine (C-C motif) receptor 8 - 
C07 Ccr9 Chemokine (C-C motif) receptor 9 - 
C08 Crp C-reactive protein, pentraxin-related 
Aa1249, Ab1-341, 
Ab2-196, Ac1-114, 
Ac1262, Ac2-069, 
Ba2-693 
C09 Cx3cl1 Chemokine (C-X3-C motif) ligand 1 Cx3c, Scyd1 
C10 Cx3cr1 Chemokine (C-X3-C motif) receptor 1 Rbs11 
C11 Cxcl1 
Chemokine (C-X-C motif) ligand 1 
(melanoma growth stimulating activity, 
alpha) 
CINC-1, Gro1 
C12 Cxcl10 Chemokine (C-X-C motif) ligand 10 IP-10, Scyb10 
D01 Cxcl11 Chemokine (C-X-C motif) ligand 11 SCYB11 
D02 Cxcl12 Chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1) Sdf1 
D03 Cxcl2 Chemokine (C-X-C motif) ligand 2 Mip-2, Scyb2 
D04 Cxcl6 Chemokine (C-X-C motif) ligand 6 (granulocyte chemotactic protein 2) Cxcl5 
D05 Cxcl9 Chemokine (C-X-C motif) ligand 9 MGC105312, Mig, Scyb9 
D06 Cxcr3 Chemokine (C-X-C motif) receptor 3 Gpr9 
D07 Ccr10 Chemokine (C-C motif) receptor 10 Gpr2 
D08 Ifng Interferon gamma IFNG2 
D09 Il10 Interleukin 10 IL10X 
D10 Il10ra Interleukin 10 receptor, alpha - 
D11 Il11 Interleukin 11 - 
D12 Il13 Interleukin 13 - 
E01 Il13ra1 Interleukin 13 receptor, alpha 1 MGC105309 
E02 Il15 Interleukin 15 - 
E03 Il16 Interleukin 16 - 
E04 Il17b Interleukin 17B - 
E05 Il18 Interleukin 18 IL-18 
E06 Il1a Interleukin 1 alpha IL-1 alpha 
E07 Il1b Interleukin 1 beta - 
E08 Il1f5 Interleukin 1 family, member 5 (delta) - 
E09 Il1f6 Interleukin 1 family, member 6 - 
E10 Il1r1 Interleukin 1 receptor, type I - 
E11 Il1r2 Interleukin 1 receptor, type II - 
E12 Il2rb Interleukin 2 receptor, beta IL2RBC 
F01 Il2rg Interleukin 2 receptor, gamma Ab2-183, Cd132 
F02 Il3 Interleukin 3 - 
F03 Il4 Interleukin 4 Il4e12 
F04 Il5 Interleukin 5 - 
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F05 Il5ra Interleukin 5 receptor, alpha - 
F06 Il6ra Interleukin 6 receptor, alpha IL6R1, Il6r 
F07 Il6st Interleukin 6 signal transducer Ac1055 
F08 Il8ra Interleukin 8 receptor, alpha - 
F09 Il8rb Interleukin 8 receptor, beta Cmkar2 
F10 Itgam Integrin alpha M Cd11b 
F11 Itgb2 Integrin beta 2 Cd18, MGC116306 
F12 Lta Lymphotoxin alpha (TNF superfamily, member 1) Tnfb 
G01 Ltb Lymphotoxin beta (TNF superfamily, member 3) MGC108924 
G02 Mif Macrophage migration inhibitory factor MGC72801 
G03 Pf4 Platelet factor 4 Cxcl4, PF-4, Pf4a, RATPF4A 
G04 Scye1 Small inducible cytokine subfamily E, member 1 Emap2, MGC112632 
G05 Spp1 Secreted phosphoprotein 1 OSP 
G06 Tgfb1 Transforming growth factor, beta 1 - 
G07 Tnf Tumor necrosis factor (TNF superfamily, member 2) 
MGC124630, 
RATTNF, TNF-alpha, 
Tnfa 
G08 Tnfrsf1a Tumor necrosis factor receptor superfamily, member 1a MGC105478, Tnfr1 
G09 Tnfrsf1b Tumor necrosis factor receptor superfamily, member 1b Tnfr2 
G10 Cd40lg CD40 ligand Tnfsf5 
G11 Tollip Toll interacting protein - 
G12 Xcr1 Chemokine (C motif) receptor 1 - 
H01 Rplp1 Ribosomal protein, large, P1 MGC72935 
H02 Hprt1 Hypoxanthine phosphoribosyltransferase 1 
Hgprtase, Hprt, 
MGC112554 
H03 Rpl13a Ribosomal protein L13A - 
H04 Ldha Lactate dehydrogenase A Ldh1 
H05 Actb Actin, beta Actx 
H06 RGDC Rat Genomic DNA Contamination RGDC 
H07 RTC Reverse Transcription Control RTC 
H08 RTC Reverse Transcription Control RTC 
H09 RTC Reverse Transcription Control RTC 
H10 PPC Positive PCR Control PPC 
H11 PPC Positive PCR Control PPC 
H12 PPC Positive PCR Control PPC 
 
 
